| Symbol | AMGN |
|---|---|
| Name | AMGEN INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA 91320 |
| Telephone | (805)447-1000 |
| Fax | — |
| — | |
| Website | https://www.amgen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000318154 |
| Description | Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firms therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgens biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira). Additional info from NASDAQ: |
2026-06-11 17:24
New Form 11-K - AMGEN INC <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0000318154-26-000114 <b>Size:</b> 2 MB
Read more
2026-06-11 17:22
New Form 11-K - AMGEN INC <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0000318154-26-000113 <b>Size:</b> 3 MB
Read more
2026-06-04 20:01
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Read more
2026-05-27 13:00
Ember LifeSciences announces new strategic investments boosting Series A to $27M
Read more
2026-05-21 23:08
Director MILES AMY E 🟢 acquired 665 shares of AMGEN INC (AMGN) Transaction Date: May 19, 2026 | Filing ID: 000108
Read more
2026-05-21 23:07
Director Kullman Ellen Jamison 🟢 acquired 665 shares of AMGEN INC (AMGN) Transaction Date: May 19, 2026 | Filing ID: 000107
Read more
2026-05-21 23:05
Director Klotman Mary E. 🟢 acquired 665 shares of AMGEN INC (AMGN) Transaction Date: May 19, 2026 | Filing ID: 000106
Read more
2026-05-21 23:04
Director Jacks Tyler 🟢 acquired 665 shares of AMGEN INC (AMGN) Transaction Date: May 19, 2026 | Filing ID: 000105
Read more
2026-05-21 23:02
Director ISHRAK OMAR 🟢 acquired 665 shares of AMGEN INC (AMGN) Transaction Date: May 19, 2026 | Filing ID: 000104
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00751894 | Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) | Phase2 | Solid Malignancies | Unknown | — | — | ClinicalTrials.gov |
| NCT00001059 | Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin… | Phase2 | Sarcoma, Kaposi | Completed | — | 1998-08-01 | ClinicalTrials.gov |
| NCT00002037 | Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients Wit… | Na | Mycobacterium Avium-Intracellulare Infection | Completed | — | — | ClinicalTrials.gov |
| NCT00002126 | A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methiony… | Phase2 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002255 | An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Fa… | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002281 | A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoieti… | Na | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002433 | The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS | Na | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00000626 | Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associat… | Phase2 | HIV Infections | Completed | — | 1999-02-01 | ClinicalTrials.gov |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | Phase2 | Lymphoma | Completed | — | — | ClinicalTrials.gov |
| NCT00041665 | Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hemato… | Phase3 | Stomatitis | Completed | — | — | ClinicalTrials.gov |
| NCT00044902 | Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade) | Phase2 | Non-Hodgkin's Lymphoma | Completed | — | — | ClinicalTrials.gov |
| NCT00102830 | Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors | Phase1 | Tumors | Completed | — | — | ClinicalTrials.gov |
| NCT00110903 | Treatment for Subjects With Active Rheumatoid Arthritis (RA) | Phase3 | Rheumatoid Arthritis | Completed | — | — | ClinicalTrials.gov |
| NCT00111111 | An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis | Phase3 | Psoriasis | Completed | — | — | ClinicalTrials.gov |
| NCT00111124 | Enbrel® in Psoriatic Arthritis | Phase4 | Psoriasis | Completed | — | — | ClinicalTrials.gov |
| NCT00111410 | Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse i… | Phase4 | Rheumatoid Arthritis | Completed | — | 2003-11-01 | ClinicalTrials.gov |
| NCT00111462 | Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceivi… | Phase2 | Anemia | Completed | — | — | ClinicalTrials.gov |
| NCT00113776 | Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer | Phase2 | Colorectal Cancer | Completed | — | — | ClinicalTrials.gov |
| NCT00113958 | Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) L… | Phase2 | End Stage Renal Disease | Completed | — | — | ClinicalTrials.gov |
| NCT00115414 | Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemother… | Phase2 | Breast Cancer | Completed | — | — | ClinicalTrials.gov |
| NCT07079267 | Olpasiran Expanded Access Program | — | — | Available | — | — | ClinicalTrials.gov |
| NCT00117065 | Study of Transplant Related Anemia Treated With Aranesp® (STRATA) | Phase4 | Anemia | Completed | — | — | ClinicalTrials.gov |
| NCT00117078 | Aranesp® Monthly Preference Study - 2 | Phase4 | Kidney Disease | Completed | — | — | ClinicalTrials.gov |
| NCT00117091 | Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs … | Phase3 | Rheumatoid Arthritis | Completed | — | — | ClinicalTrials.gov |
| NCT00117104 | Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodial… | Phase4 | End Stage Renal Disease | Completed | — | — | ClinicalTrials.gov |
| NCT00117130 | Study to Evaluate Effectiveness of Aranesp® | Phase4 | Kidney Disease | Completed | — | — | ClinicalTrials.gov |
| NCT00117455 | A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy… | Phase2 | Non-Hodgkin's Lymphoma | Completed | — | — | ClinicalTrials.gov |
| NCT06590051 | AMG 335 Expanded Access Program for IgG4-Related Disease | — | — | Available | — | — | ClinicalTrials.gov |
| NCT00119600 | A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of … | Phase1 | Anemia | Terminated | — | — | ClinicalTrials.gov |
| NCT00121043 | Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSel… | Phase4 | Rheumatoid Arthritis | Completed | — | — | ClinicalTrials.gov |
| NCT00124098 | An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD) | Phase3 | Kidney Disease | Completed | — | — | ClinicalTrials.gov |
| NCT00124111 | A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrasti… | Phase2 | Breast Cancer | Completed | — | — | ClinicalTrials.gov |
| NCT06064500 | Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Canc… | — | Small Cell Lung Cancer | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00148421 | Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Rec… | Phase3 | Anemia | Completed | — | — | ClinicalTrials.gov |
| NCT00189670 | Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer | Phase2 | Node Positive Breast Cancer | Completed | — | — | ClinicalTrials.gov |
| NCT05256446 | AMG 701 Expanded Access Program | — | — | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04667234 | Expanded Access of Sotorasib | — | Non Small-cell Lung Cancer | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04040894 | Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thy… | — | Thyroid Eye Disease | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT03740516 | Expanded Access for CC-10004 | — | Bechet's Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03439475 | AMG 714 Expanded Access Program | — | Celiac Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02297529 | Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects Wit… | — | Unresected Stage IIIB to IVM1c Melanoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02187354 | Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With… | — | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02147951 | Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresect… | — | Unresected Stage IIIb to IVM1c Melanoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01410500 | Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapse… | — | Multiple Myeloma | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT01351038 | Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecita… | Phase2 | KRAS Wild Type | Terminated | — | — | ClinicalTrials.gov |
| NCT00786058 | A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003 | — | Pancreatic Cancer | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07637513 | Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lun… | Phase3 | Limited Stage Small-Cell Lung Cancer | Not_Yet_Recruiting | 2027-01-01 | 2038-06-01 | ClinicalTrials.gov |
| NCT06081153 | Mechanistic Clinical Trial of PCSK9 Inhibition for AAA | Early_Phase1 | Abdominal Aortic Aneurysm | Not_Yet_Recruiting | 2026-12-01 | 2029-02-28 | ClinicalTrials.gov |
| NCT07283640 | A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for… | Phase1 | Blinatumomab | Not_Yet_Recruiting | 2026-11-18 | 2031-08-31 | ClinicalTrials.gov |
| NCT07192237 | Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in… | Phase2 | Phase 2 Study | Not_Yet_Recruiting | 2026-09-27 | 2032-10-12 | ClinicalTrials.gov |
| NCT07598825 | A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | Phase3 | Autoimmune Hepatitis | Not_Yet_Recruiting | 2026-09-07 | 2034-02-11 | ClinicalTrials.gov |
| NCT06987539 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerabi… | Phase2 | Generalized Myasthenia Gravis | Recruiting | 2026-08-31 | 2030-03-13 | ClinicalTrials.gov |
| NCT07178912 | Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatin… | Phase2 | Phase II Clinical Trial | Not_Yet_Recruiting | 2026-08-27 | 2033-09-30 | ClinicalTrials.gov |
| NCT07684235 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of… | Phase3 | Obesity | Not_Yet_Recruiting | 2026-07-29 | 2028-03-19 | ClinicalTrials.gov |
| NCT07684144 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of… | Phase3 | Obesity | Not_Yet_Recruiting | 2026-07-29 | 2028-03-19 | ClinicalTrials.gov |
| NCT07176546 | TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis | Phase2 | Granulomatosis With Polyangiitis | Not_Yet_Recruiting | 2026-07-01 | 2030-10-01 | ClinicalTrials.gov |
| NCT06973109 | Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes | Phase2 | Osteoporosis, Post-menopausal | Withdrawn | 2026-06-20 | 2027-06-01 | ClinicalTrials.gov |
| NCT07590193 | A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2… | Phase1 | Diabetes Mellitus, Type 2 | Recruiting | 2026-06-11 | 2027-10-02 | ClinicalTrials.gov |
| NCT07223190 | A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagno… | Phase3 | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Not_Yet_Recruiting | 2026-06-11 | 2033-08-09 | ClinicalTrials.gov |
| NCT07313852 | A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblasti… | Phase1 | B-cell Acute Lymphoblastic Leukemia | Not_Yet_Recruiting | 2026-06-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT07614776 | A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Vers… | Phase3 | Neovascular Age-related Macular Degeneration | Recruiting | 2026-05-27 | 2028-01-12 | ClinicalTrials.gov |
| NCT07575399 | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Rec… | Phase3 | Obesity or Overweight | Recruiting | 2026-05-11 | 2028-02-28 | ClinicalTrials.gov |
| NCT07438405 | An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in… | Phase2 | Thyroid Eye Disease | Recruiting | 2026-05-07 | 2028-07-14 | ClinicalTrials.gov |
| NCT07355894 | Health Enhanced Artery Risk Tracking With Widespread Implementation and Screeni… | Na | Atherosclerotic Cardiovascular Disease (ASCVD) | Not_Yet_Recruiting | 2026-05-01 | 2028-03-01 | ClinicalTrials.gov |
| NCT07493512 | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Ca… | Phase1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting | 2026-04-28 | 2030-07-30 | ClinicalTrials.gov |
| NCT07545226 | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available i… | Phase1 | Healthy Participants | Active_Not_Recruiting | 2026-04-21 | 2026-09-03 | ClinicalTrials.gov |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) i… | Phase1 | Small Cell Lung Cancer | Recruiting | 2026-04-21 | 2031-05-21 | ClinicalTrials.gov |
| NCT07203053 | A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lu… | Phase2 | Extensive Stage Lung Small Cell Cancer | Recruiting | 2026-04-15 | 2029-10-01 | ClinicalTrials.gov |
| NCT05909761 | Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder… | — | Neuromyelitis Optica Spectrum Disorder | Recruiting | 2026-04-15 | 2032-10-31 | ClinicalTrials.gov |
| NCT07523711 | Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and P… | Phase1 | Overweight | Active_Not_Recruiting | 2026-04-09 | 2026-11-18 | ClinicalTrials.gov |
| NCT07403721 | AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR … | Phase1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | Recruiting | 2026-04-08 | 2028-06-28 | ClinicalTrials.gov |
| NCT07297979 | Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or … | Phase1 | Ewing Sarcoma | Recruiting | 2026-04-08 | 2030-05-26 | ClinicalTrials.gov |
| NCT07222553 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerabil… | Phase2 | Immunoglobulin G4-related Disease | Not_Yet_Recruiting | 2026-04-03 | 2031-06-10 | ClinicalTrials.gov |
| NCT07526298 | Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder:… | — | Neuromyelitis Optica Spectrum Disorders | Not_Yet_Recruiting | 2026-04-01 | 2027-04-01 | ClinicalTrials.gov |
| NCT07293260 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Corona… | Phase3 | Cardiovascular Disease | Recruiting | 2026-03-23 | 2028-06-15 | ClinicalTrials.gov |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | Phase2 | Extensive Stage Lung Small Cell Carcinoma | Recruiting | 2026-03-20 | 2027-12-31 | ClinicalTrials.gov |
| NCT07366086 | Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteog… | Phase3 | Osteogenesis Imperfecta | Recruiting | 2026-03-18 | 2028-04-19 | ClinicalTrials.gov |
| NCT07441252 | A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Li… | Phase2 | Overweight or Obesity and Elevated Liver Fat | Recruiting | 2026-03-05 | 2027-12-22 | ClinicalTrials.gov |
| NCT07301424 | Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | Phase2 | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | Not_Yet_Recruiting | 2026-03-01 | 2031-12-01 | ClinicalTrials.gov |
| NCT07388498 | A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety… | Phase3 | Uncontrolled Gout | Recruiting | 2026-02-09 | 2028-06-18 | ClinicalTrials.gov |
| NCT07102394 | Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofib… | Phase1 | NF1 | Recruiting | 2026-02-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT07153796 | A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab … | Phase2 | B-cell Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2026-01-30 | 2033-09-30 | ClinicalTrials.gov |
| NCT07422285 | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available i… | Phase1 | Healthy Participants | Active_Not_Recruiting | 2026-01-16 | 2026-07-24 | ClinicalTrials.gov |
| NCT07222579 | Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mi… | Phase2 | CD19 Positive | Recruiting | 2026-01-15 | 2031-08-01 | ClinicalTrials.gov |
| NCT07172919 | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participan… | Phase2 | Advanced Solid Tumors | Recruiting | 2026-01-02 | 2028-07-01 | ClinicalTrials.gov |
| NCT07225686 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive S… | Phase3 | Obesity | Recruiting | 2025-12-19 | 2028-09-13 | ClinicalTrials.gov |
| NCT07061080 | Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | Phase2 | Advanced Neuroendocrine Carcinomas of The Digestive System | Recruiting | 2025-12-18 | 2028-12-01 | ClinicalTrials.gov |
| NCT07313761 | A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Mad… | Phase1 | Overweight and Obesity | Completed | 2025-12-15 | 2026-06-26 | ClinicalTrials.gov |
| NCT07134088 | A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell P… | Phase1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2025-12-08 | 2030-06-18 | ClinicalTrials.gov |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Partici… | Phase3 | Metastatic Castration-resistant Prostate Cancer | Recruiting | 2025-11-28 | 2032-08-30 | ClinicalTrials.gov |
| NCT07226765 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive S… | Phase3 | Obstructive Sleep Apnea | Recruiting | 2025-11-25 | 2028-09-13 | ClinicalTrials.gov |
| NCT07243470 | Combination of Tarlatamab and Temozolomide in Patients With Central Nervous Sys… | Phase1 | Glioma | Recruiting | 2025-11-04 | 2030-10-01 | ClinicalTrials.gov |
| NCT07229157 | Effect of Maridebart Cafraglutide on the Heart's Electrical Activity | Phase1 | Overweight | Active_Not_Recruiting | 2025-10-22 | 2026-08-26 | ClinicalTrials.gov |
| NCT07226778 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Availab… | Phase1 | Overweight | Completed | 2025-10-10 | 2026-05-28 | ClinicalTrials.gov |
| NCT07140900 | Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combi… | Phase1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Recruiting | 2025-10-07 | 2030-03-30 | ClinicalTrials.gov |
| NCT07037758 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive … | Phase1 | Extensive Stage Small Cell Lung Cancer | Recruiting | 2025-09-16 | 2031-01-18 | ClinicalTrials.gov |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors | Phase1 | Melanoma | Recruiting | 2025-09-08 | 2030-05-01 | ClinicalTrials.gov |
| NCT07142642 | A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab … | Phase1 | Healthy Volunteers | Completed | 2025-08-26 | 2026-01-15 | ClinicalTrials.gov |
| NCT07136012 | OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a… | Phase3 | Cardiovascular Disease | Recruiting | 2025-08-22 | 2031-10-20 | ClinicalTrials.gov |
| NCT07005128 | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Dur… | Phase3 | Small-cell Lung Cancer | Recruiting | 2025-08-18 | 2029-07-15 | ClinicalTrials.gov |
| NCT06776250 | Study of How Safe and Effective Tarlatamab is in Brain Cancers | Phase2 | Astrocytic Tumor | Recruiting | 2025-08-18 | 2028-03-03 | ClinicalTrials.gov |
| NCT07143513 | Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Pat… | — | Non-Small Cell Lung Cancer | Completed | 2025-08-11 | 2025-12-07 | ClinicalTrials.gov |
| NCT07160257 | A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivit… | Phase1 | Type 2 Diabetes Mellitus | Active_Not_Recruiting | 2025-08-05 | 2027-03-04 | ClinicalTrials.gov |
| NCT07111507 | A Study of Tarlatamab for People With Prostate Cancer | Phase2 | Metastatic Prostate Cancer | Recruiting | 2025-07-31 | 2027-08-31 | ClinicalTrials.gov |
| NCT07094113 | AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Al… | Phase1 | KRAS Altered Advanced or Metastatic Solid Tumors | Recruiting | 2025-07-31 | 2031-04-20 | ClinicalTrials.gov |
| NCT07037433 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in … | Phase3 | Atherosclerotic Cardiovascular Disease | Recruiting | 2025-07-25 | 2030-09-29 | ClinicalTrials.gov |
| NCT07013578 | TIDHI Mental Health in IBD Patients Study | Na | Crohn Disease (CD) | Recruiting | 2025-07-22 | 2027-07-01 | ClinicalTrials.gov |
| NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune… | Phase2 | Systemic Lupus Erythematosus | Recruiting | 2025-07-16 | 2028-08-06 | ClinicalTrials.gov |
| NCT07016230 | Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Ad… | Phase2 | Metastatic/Locally Advanced Small-Cell Lung Cancer | Recruiting | 2025-07-02 | 2030-01-15 | ClinicalTrials.gov |
| NCT07085117 | Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among… | — | Thyroid Eye Disease | Completed | 2025-07-02 | 2025-08-10 | ClinicalTrials.gov |
| NCT07037459 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Eject… | Phase3 | Heart Failure With Preserved Ejection Fraction | Recruiting | 2025-06-25 | 2030-09-29 | ClinicalTrials.gov |
| NCT07478887 | Impact of the Corrie Lipids Digital Health Program on Lipid Optimization | Na | Cardiovascular Risk | Recruiting | 2025-06-20 | 2027-12-01 | ClinicalTrials.gov |
| NCT06987695 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan W… | Phase3 | Obesity Disease | Active_Not_Recruiting | 2025-06-13 | 2027-07-21 | ClinicalTrials.gov |
| NCT05601492 | Adherence to Otezla | Early_Phase1 | Psoriasis | Withdrawn | 2025-06-01 | 2026-02-01 | ClinicalTrials.gov |
| NCT06588153 | A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants Wi… | Phase4 | Glucocorticoid-induced Osteoporosis | Active_Not_Recruiting | 2025-05-24 | 2027-04-27 | ClinicalTrials.gov |
| NCT06898957 | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed D… | Phase1 | Small Cell Lung Cancer | Active_Not_Recruiting | 2025-05-16 | 2031-06-23 | ClinicalTrials.gov |
| NCT06816394 | Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine … | Phase2 | Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | Not_Yet_Recruiting | 2025-05-15 | 2029-04-30 | ClinicalTrials.gov |
| NCT07429032 | The Effect of AMG 133 on Gastric Emptying | Phase1 | Overweight or Obesity | Completed | 2025-04-17 | 2025-11-26 | ClinicalTrials.gov |
| NCT06910709 | Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants | Phase1 | Healthy Volunteers | Terminated | 2025-04-08 | 2025-12-02 | ClinicalTrials.gov |
| NCT06788938 | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroend… | Phase2 | DLL3-expressing Tumors | Recruiting | 2025-03-21 | 2029-04-24 | ClinicalTrials.gov |
| NCT06858878 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type … | Phase3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Active_Not_Recruiting | 2025-03-17 | 2027-04-16 | ClinicalTrials.gov |
| NCT07428525 | A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Imp… | Phase1 | Hepatic Impairment | Completed | 2025-03-14 | 2026-02-26 | ClinicalTrials.gov |
| NCT06858839 | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diab… | Phase3 | Obesity | Active_Not_Recruiting | 2025-03-12 | 2027-04-16 | ClinicalTrials.gov |
| NCT07429045 | A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, B… | Phase1 | Overweight and Obesity | Completed | 2025-03-11 | 2025-11-21 | ClinicalTrials.gov |
| NCT06660810 | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | Phase2 | Soft Tissue Sarcoma | Active_Not_Recruiting | 2025-03-03 | 2031-02-24 | ClinicalTrials.gov |
| NCT06680622 | Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of… | Phase2 | Metastatic Gastro-esophageal Adenocarcinoma | Active_Not_Recruiting | 2025-03-03 | 2028-03-01 | ClinicalTrials.gov |
| NCT06068153 | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KR… | Phase2 | Metastatic Non Small Cell Lung Cancer | Withdrawn | 2025-03-01 | 2026-12-30 | ClinicalTrials.gov |
| NCT06745323 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regim… | Phase2 | Small Cell Lung Cancer (SCLC) | Active_Not_Recruiting | 2025-02-26 | 2029-02-09 | ClinicalTrials.gov |
| NCT06747949 | A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndr… | Phase3 | Sjögren's Syndrome | Recruiting | 2025-02-25 | 2029-12-11 | ClinicalTrials.gov |
| NCT06807619 | A Study of Sotorasib in People With Brain Tumors | Phase1 | Brain Tumor | Recruiting | 2025-01-29 | 2028-01-01 | ClinicalTrials.gov |
| NCT06700343 | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | Phase3 | Relapsing-remitting Multiple Sclerosis (RRMS) | Active_Not_Recruiting | 2025-01-13 | 2027-12-17 | ClinicalTrials.gov |
| NCT06649006 | Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants Wi… | Phase1 | B-precursor Acute Lymphoblastic Leukemia | Completed | 2025-01-08 | 2025-12-04 | ClinicalTrials.gov |
| NCT07444190 | Psychological Burden of Thyroid Eye Disease | — | Thyroid Eye Disease, TED | Completed | 2025-01-01 | 2025-12-31 | ClinicalTrials.gov |
| NCT06593522 | A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCL… | Phase2 | MTAP-deleted NSCLC | Active_Not_Recruiting | 2024-12-26 | 2026-11-30 | ClinicalTrials.gov |
| NCT07310563 | A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in P… | Phase1 | Overweight | Completed | 2024-12-10 | 2025-05-09 | ClinicalTrials.gov |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directe… | Phase3 | Metastatic Castration-resistant Prostate Cancer | Active_Not_Recruiting | 2024-12-09 | 2029-07-30 | ClinicalTrials.gov |
| NCT07717814 | A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or… | Phase1 | Overweight and Obesity | Completed | 2024-11-26 | 2025-06-02 | ClinicalTrials.gov |
| NCT06613100 | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Phase1 | Prostate Cancer | Recruiting | 2024-11-25 | 2030-01-23 | ClinicalTrials.gov |
| NCT06761703 | A Study to Determine the Feasibility of Online Recruitment of People Using an A… | — | Obesity | Completed | 2024-11-14 | 2025-01-06 | ClinicalTrials.gov |
| NCT06660173 | A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes M… | Phase2 | Type 2 Diabetes Mellitus (T2DM) | Active_Not_Recruiting | 2024-11-07 | 2026-11-10 | ClinicalTrials.gov |
| NCT06321601 | Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-… | Phase3 | Vasculitis | Active_Not_Recruiting | 2024-10-22 | 2027-07-18 | ClinicalTrials.gov |
| NCT06637371 | A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 69… | Phase1 | Asthma | Active_Not_Recruiting | 2024-10-16 | 2027-04-10 | ClinicalTrials.gov |
| NCT06471036 | Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in P… | Na | ASCVD | Recruiting | 2024-10-08 | 2027-02-28 | ClinicalTrials.gov |
| NCT06598306 | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Ca… | Phase1 | Extensive Stage Small Cell Lung Cancer | Recruiting | 2024-10-07 | 2030-04-24 | ClinicalTrials.gov |
| NCT06529731 | Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myel… | Phase2 | Acute Myeloid Leukemia | Recruiting | 2024-09-23 | 2027-10-31 | ClinicalTrials.gov |
| NCT06555796 | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic… | Phase1 | Prostate Cancer | Active_Not_Recruiting | 2024-09-23 | 2028-12-02 | ClinicalTrials.gov |
| NCT06333951 | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Adva… | Phase1 | Thoracic Tumors | Active_Not_Recruiting | 2024-09-17 | 2026-11-30 | ClinicalTrials.gov |
| NCT06430866 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | Phase3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2024-09-12 | 2026-12-14 | ClinicalTrials.gov |
| NCT06411860 | A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Partic… | Phase1 | Basic Science | Completed | 2024-09-12 | 2024-12-11 | ClinicalTrials.gov |
| NCT06311721 | A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With A… | Phase3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2024-09-09 | 2028-05-29 | ClinicalTrials.gov |
| NCT06585462 | Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity | Phase1 | Cardiometabolic Disease | Recruiting | 2024-09-09 | 2026-10-01 | ClinicalTrials.gov |
| NCT06502977 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lu… | Phase2 | Extensive Stage Small Cell Lung Cancer | Active_Not_Recruiting | 2024-08-27 | 2027-09-10 | ClinicalTrials.gov |
| NCT06976372 | A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Ov… | Phase1 | Overweight | Completed | 2024-08-20 | 2024-12-27 | ClinicalTrials.gov |
| NCT06438263 | A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in He… | Phase1 | Atopic Dermatitis | Completed | 2024-08-06 | 2025-07-02 | ClinicalTrials.gov |
| NCT06332014 | Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in… | Phase4 | Osteoporosis | Active_Not_Recruiting | 2024-08-06 | 2027-01-23 | ClinicalTrials.gov |
| NCT06054113 | Study of Blinatumomab Administration in Chinese Pediatric Participants With Rel… | Phase2 | B Precursor Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2024-07-23 | 2027-10-14 | ClinicalTrials.gov |
| NCT06527404 | A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Pru… | Phase3 | Prurigo Nodularis | Active_Not_Recruiting | 2024-07-18 | 2027-01-17 | ClinicalTrials.gov |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Beva… | Phase3 | Metastatic Colorectal Cancer | Recruiting | 2024-07-17 | 2032-04-25 | ClinicalTrials.gov |
| NCT06061523 | A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib i… | Phase1 | Healthy Participants | Withdrawn | 2024-07-15 | 2024-09-09 | ClinicalTrials.gov |
| NCT06248619 | A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With P… | Phase3 | Thyroid Eye Disease | Active_Not_Recruiting | 2024-07-05 | 2026-11-13 | ClinicalTrials.gov |
| NCT06468826 | A Study of Avacopan in Participants With Normal Renal Function and Participants… | Phase1 | End-Stage Renal Disease (ESRD) | Completed | 2024-06-18 | 2024-10-05 | ClinicalTrials.gov |
| NCT06211036 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line… | Phase3 | Extensive-Stage Small-Cell Lung Cancer | Active_Not_Recruiting | 2024-06-05 | 2028-09-30 | ClinicalTrials.gov |
| NCT06401044 | A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Di… | Phase1 | Thyroid Eye Disease | Recruiting | 2024-05-30 | 2027-08-13 | ClinicalTrials.gov |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Particip… | Phase1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | Active_Not_Recruiting | 2024-05-29 | 2026-11-30 | ClinicalTrials.gov |
| NCT06376045 | A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asth… | Phase2 | Asthma | Completed | 2024-05-24 | 2026-06-23 | ClinicalTrials.gov |
| NCT06312020 | A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants … | Phase2 | Sjogren's Syndrome | Active_Not_Recruiting | 2024-05-09 | 2026-11-24 | ClinicalTrials.gov |
| NCT06352892 | A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight | Phase1 | Obesity | Completed | 2024-04-25 | 2024-08-27 | ClinicalTrials.gov |
| NCT05972551 | Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphona… | Phase3 | Osteogenesis Imperfecta | Active_Not_Recruiting | 2024-04-22 | 2027-07-30 | ClinicalTrials.gov |
| NCT06245408 | A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndr… | Phase3 | Sjögren's Syndrome (SS) | Active_Not_Recruiting | 2024-04-08 | 2026-12-17 | ClinicalTrials.gov |
| NCT06180278 | Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spe… | Phase4 | Neuromyelitis Optica Spectrum Disorder | Active_Not_Recruiting | 2024-04-02 | 2028-06-26 | ClinicalTrials.gov |
| NCT06224192 | A Study With Self-administered Rocatinlimab in Adolescent and Adult Participant… | Phase3 | Atopic Dermatitis | Completed | 2024-04-02 | 2026-03-16 | ClinicalTrials.gov |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung … | Phase2 | Non-Small Cell Lung Cancer | Completed | 2024-03-20 | 2026-01-27 | ClinicalTrials.gov |
| NCT06229145 | A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 … | Phase4 | Gout | Completed | 2024-03-18 | 2026-03-11 | ClinicalTrials.gov |
| NCT06131398 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants … | Phase1 | Advanced Solid Tumors | Active_Not_Recruiting | 2024-03-07 | 2026-07-21 | ClinicalTrials.gov |
| NCT06117774 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell… | Phase3 | Limited Stage Small Cell Lung Cancer | Active_Not_Recruiting | 2024-02-20 | 2030-04-20 | ClinicalTrials.gov |
| NCT06268860 | A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled … | Phase1 | Atopic Dermatitis | Completed | 2024-02-15 | 2024-10-08 | ClinicalTrials.gov |
| NCT06072482 | A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis | Phase4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Recruiting | 2024-02-07 | 2036-12-31 | ClinicalTrials.gov |
| NCT06140095 | Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Chole… | Early_Phase1 | Acute Metabolic Effects of Evolocumab and Atorvastatin | Unknown | 2024-02-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT06104124 | A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With… | Phase3 | Sjogren's Syndrome | Active_Not_Recruiting | 2024-01-24 | 2026-08-19 | ClinicalTrials.gov |
| NCT06214481 | A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants | Phase1 | Atopic Dermatitis | Completed | 2024-01-23 | 2024-06-05 | ClinicalTrials.gov |
| NCT05669014 | A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdili… | Phase2 | Idiopathic Inflammatory Myositis | Completed | 2023-12-04 | 2025-07-02 | ClinicalTrials.gov |
| NCT06122649 | A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID… | Phase3 | Plaque Psoriasis | Completed | 2023-11-27 | 2025-12-05 | ClinicalTrials.gov |
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab … | Phase3 | Non-Small Cell Lung Cancer (NSCLC) | Recruiting | 2023-11-16 | 2032-06-29 | ClinicalTrials.gov |
| NCT06314763 | Rivaroxaban Sotorasib Interaction Study | Phase4 | Drug Drug Interaction Study | Completed | 2023-11-09 | 2024-03-21 | ClinicalTrials.gov |
| NCT05848687 | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Phase1 | Lymphoblastic Leukemia | Recruiting | 2023-11-03 | 2033-12-01 | ClinicalTrials.gov |
| NCT06054555 | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With … | Phase3 | Melanoma | Active_Not_Recruiting | 2023-11-02 | 2028-01-25 | ClinicalTrials.gov |
| NCT06079476 | A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteopo… | Phase4 | Postmenopausal Osteoporosis | Completed | 2023-10-30 | 2025-10-18 | ClinicalTrials.gov |
| NCT06088199 | A Study of Apremilast in Pediatric Participants in Children With Mild to Modera… | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2023-10-24 | 2026-08-06 | ClinicalTrials.gov |
| NCT06127940 | K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With … | Phase1 | Non-small Cell Lung Cancer Metastatic | Unknown | 2023-10-15 | 2026-01-01 | ClinicalTrials.gov |
| NCT05323617 | Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With… | Phase2 | Severe Aplastic Anemia (SAA) | Withdrawn | 2023-08-31 | 2025-02-25 | ClinicalTrials.gov |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractor… | Phase1 | Relapsed/Refractory Multiple Myeloma | Withdrawn | 2023-08-29 | 2025-08-28 | ClinicalTrials.gov |
| NCT04586660 | Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents… | Phase4 | Giant Cell Tumor of Bone | Active_Not_Recruiting | 2023-08-17 | 2028-03-07 | ClinicalTrials.gov |
| NCT05975073 | A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants Wi… | Phase1 | MTAP-null Non-Small-Cell Lung Cancer | Completed | 2023-08-01 | 2026-03-26 | ClinicalTrials.gov |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in … | Phase3 | Melanoma | Completed | 2023-07-26 | 2025-10-31 | ClinicalTrials.gov |
| NCT05549258 | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum … | Phase2 | Neuromyelitis Optica Spectrum Disorder | Recruiting | 2023-07-03 | 2027-04-13 | ClinicalTrials.gov |
| NCT05885607 | Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure | — | Heart Failure NYHA Class II | Active_Not_Recruiting | 2023-06-27 | 2027-06-30 | ClinicalTrials.gov |
| NCT05800964 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in S… | Phase1 | Advanced Solid Tumors | Completed | 2023-06-13 | 2026-01-22 | ClinicalTrials.gov |
| NCT05899816 | A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-seve… | Phase3 | Atopic Dermatitis | Completed | 2023-06-07 | 2024-11-14 | ClinicalTrials.gov |
| NCT05891119 | Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokineti… | Early_Phase1 | Atopic Dermatitis | Completed | 2023-06-03 | 2025-02-12 | ClinicalTrials.gov |
| NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small… | Phase3 | Small Cell Lung Cancer (SCLC) | Active_Not_Recruiting | 2023-05-31 | 2028-03-26 | ClinicalTrials.gov |
| NCT05882877 | A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab … | Phase3 | Atopic Dermatitis | Terminated | 2023-05-31 | 2026-07-01 | ClinicalTrials.gov |
| NCT05789303 | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone… | Phase2 | Multiple Myeloma | Recruiting | 2023-05-30 | 2028-07-01 | ClinicalTrials.gov |
| NCT05672199 | Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderate… | Phase2 | Ulcerative Colitis | Terminated | 2023-04-28 | 2024-10-31 | ClinicalTrials.gov |
| NCT05540665 | Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus … | Phase2 | Lupus Nephritis | Terminated | 2023-04-26 | 2024-01-04 | ClinicalTrials.gov |
| NCT05704738 | A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Mode… | Phase3 | Atopic Dermatitis | Completed | 2023-04-20 | 2025-11-25 | ClinicalTrials.gov |
| NCT06674941 | A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneo… | Phase1 | Healthy Volunteers | Completed | 2023-03-24 | 2023-11-14 | ClinicalTrials.gov |
| NCT05767047 | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Dis… | Phase3 | Behçet's Disease | Recruiting | 2023-03-23 | 2036-03-17 | ClinicalTrials.gov |
| NCT03904069 | Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 i… | Phase1 | Relapsed/Refractory Acute Myeloid Leukemia | Withdrawn | 2023-03-13 | 2030-08-07 | ClinicalTrials.gov |
| NCT05317078 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Clau… | Phase1 | Non-squamous Non-small Cell Lung Cancer | Terminated | 2023-02-28 | 2024-04-01 | ClinicalTrials.gov |
| NCT05724199 | A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/o… | Phase3 | Atopic Dermatitis | Completed | 2023-02-21 | 2024-12-04 | ClinicalTrials.gov |
| NCT05633355 | A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Ado… | Phase3 | Atopic Dermatitis | Completed | 2023-01-30 | 2025-07-31 | ClinicalTrials.gov |
| NCT05565560 | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric P… | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2023-01-25 | 2026-09-03 | ClinicalTrials.gov |
| NCT05704725 | A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chori… | Phase3 | Chorioretinal Vascular Disease | Completed | 2023-01-23 | 2023-03-24 | ClinicalTrials.gov |
| NCT05669599 | Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 13… | Phase2 | Obesity | Completed | 2023-01-18 | 2025-12-16 | ClinicalTrials.gov |
| NCT05591222 | Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary … | Phase2 | Discoid Lupus Erythematosus | Terminated | 2022-12-29 | 2025-05-08 | ClinicalTrials.gov |
| NCT06295679 | A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared … | — | Major Cardiovascular Event | Recruiting | 2022-12-19 | 2028-12-19 | ClinicalTrials.gov |
| NCT05581303 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a… | Phase3 | Atherosclerotic Cardiovascular Disease | Active_Not_Recruiting | 2022-12-14 | 2028-03-31 | ClinicalTrials.gov |
| NCT05651711 | A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atop… | Phase3 | Atopic Dermatitis | Completed | 2022-12-14 | 2024-08-27 | ClinicalTrials.gov |
| NCT05669040 | mHealth to Improve the Experience, Adherence to Drug Treatment and Positive Men… | Na | Fracture of Femur | Unknown | 2022-11-21 | 2023-04-01 | ClinicalTrials.gov |
| NCT05245851 | Clinical Deployment and Validation of Rho | Na | Low Bone Density | Completed | 2022-11-21 | 2023-10-01 | ClinicalTrials.gov |
| NCT05209152 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Mye… | Phase1 | Higher Risk Myelodysplastic Syndrome | Terminated | 2022-11-14 | 2023-12-19 | ClinicalTrials.gov |
| NCT05583227 | Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis | Phase3 | Eosinophilic Esophagitis | Active_Not_Recruiting | 2022-11-10 | 2027-03-23 | ClinicalTrials.gov |
| NCT05626751 | An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Di… | Phase2 | Diffuse Cutaneous Systemic Sclerosis | Terminated | 2022-11-04 | 2025-02-24 | ClinicalTrials.gov |
| NCT05284747 | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | Phase4 | Cardiovascular Disease | Active_Not_Recruiting | 2022-10-26 | 2027-05-29 | ClinicalTrials.gov |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor … | Phase1 | Solid Tumors | Terminated | 2022-09-23 | 2026-01-28 | ClinicalTrials.gov |
| NCT05325034 | Guideline Oriented Approach To Lipid Lowering In Asia-Pacific | Na | Cardiovascular Diseases | Recruiting | 2022-09-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT04933942 | Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at Firs… | Phase2 | First Progression of MGMT Promoter-methylated Glioblastoma | Withdrawn | 2022-09-13 | 2022-12-19 | ClinicalTrials.gov |
| NCT05489614 | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpas… | Phase1 | Renal Impairment | Completed | 2022-09-13 | 2023-12-19 | ClinicalTrials.gov |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Panc… | Phase1 | Pancreatic Cancer | Withdrawn | 2022-09-13 | 2023-01-31 | ClinicalTrials.gov |
| NCT05481411 | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpas… | Phase1 | Hepatic Impairment | Completed | 2022-09-13 | 2023-05-31 | ClinicalTrials.gov |
| NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inh… | Phase1 | Extensive Stage Small Cell Lung Cancer | Active_Not_Recruiting | 2022-08-24 | 2028-08-28 | ClinicalTrials.gov |
| NCT05542719 | Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of… | — | Secondary Prevention | Unknown | 2022-08-04 | 2024-12-31 | ClinicalTrials.gov |
| NCT05495620 | Long-term KRd in Relapsed and/or Refractory Multiple Myeloma | — | Multiple Myeloma in Relapse | Unknown | 2022-08-01 | 2023-09-30 | ClinicalTrials.gov |
| NCT05406115 | Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Partici… | Phase1 | Obesity | Completed | 2022-07-26 | 2023-08-21 | ClinicalTrials.gov |
| NCT06389578 | A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease | Phase1 | Thyroid Eye Disease | Completed | 2022-07-14 | 2023-09-12 | ClinicalTrials.gov |
| NCT05497557 | A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotoras… | Phase1 | Healthy Volunteers | Completed | 2022-07-14 | 2022-09-08 | ClinicalTrials.gov |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced … | Phase1 | Solid Tumor, Adult | Terminated | 2022-07-06 | 2024-08-22 | ClinicalTrials.gov |
| NCT06207682 | Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Sin… | Phase1 | Healthy Volunteers | Completed | 2022-06-28 | 2022-08-11 | ClinicalTrials.gov |
| NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanc… | Phase1 | Non Small Cell Lung Cancer | Withdrawn | 2022-06-15 | 2023-01-31 | ClinicalTrials.gov |
| NCT05430854 | Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosu… | Phase2 | Systemic Lupus Erythematosus | Terminated | 2022-06-01 | 2023-10-31 | ClinicalTrials.gov |
| NCT05398445 | A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET… | Phase3 | Atopic Dermatitis | Completed | 2022-05-31 | 2025-01-13 | ClinicalTrials.gov |
| NCT05142228 | Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. | Phase2 | Trigeminal Neuropathy | Terminated | 2022-05-31 | 2022-10-27 | ClinicalTrials.gov |
| NCT05162027 | Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody REl… | Phase2 | Temporomandibular Disorders | Terminated | 2022-05-26 | 2023-01-03 | ClinicalTrials.gov |
| NCT05322577 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapie… | Phase1 | Gastric Cancer | Active_Not_Recruiting | 2022-05-17 | 2026-08-12 | ClinicalTrials.gov |
| NCT05368103 | Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata | Phase2 | Alopecia Areata | Completed | 2022-04-27 | 2024-01-26 | ClinicalTrials.gov |
| NCT05198934 | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Ki… | Phase3 | Colorectal Cancer (CRC) | Completed | 2022-04-19 | 2026-04-14 | ClinicalTrials.gov |
| NCT05378529 | A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented Hi… | Na | Atherosclerotic Cardiovascular Disease | Completed | 2022-04-19 | 2023-12-30 | ClinicalTrials.gov |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactini… | Phase1 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2022-04-12 | 2027-04-01 | ClinicalTrials.gov |
| NCT05118854 | A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carb… | Phase2 | Lung Cancer | Active_Not_Recruiting | 2022-03-30 | 2027-10-20 | ClinicalTrials.gov |
| NCT05267470 | A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer The… | Phase1 | Squamous-Cell Non-Small-Cell Lung Cancer | Terminated | 2022-03-29 | 2024-05-28 | ClinicalTrials.gov |
| NCT05327491 | A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Admi… | Phase1 | Healthy Participants | Completed | 2022-03-21 | 2022-07-17 | ClinicalTrials.gov |
| NCT04804553 | Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis | Phase3 | Active Juvenile Psoriatic Arthritis | Recruiting | 2022-03-17 | 2028-12-29 | ClinicalTrials.gov |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab… | Phase3 | Gastric Cancer | Terminated | 2022-03-14 | 2025-10-29 | ClinicalTrials.gov |
| NCT05174065 | Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplan… | Phase3 | Palmoplantar Pustulosis | Completed | 2022-03-08 | 2024-06-01 | ClinicalTrials.gov |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast G… | Phase3 | Gastric Cancer | Completed | 2022-03-07 | 2026-04-26 | ClinicalTrials.gov |
| NCT05273047 | RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC | — | Nsclc | Unknown | 2022-03-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT04604691 | Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minima… | Phase1 | Pediatric ALL, B Cell | Unknown | 2022-02-18 | 2024-12-01 | ClinicalTrials.gov |
| NCT05094336 | A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (M… | Phase1 | Advanced MTAP-null Solid Tumors | Active_Not_Recruiting | 2022-02-01 | 2026-11-30 | ClinicalTrials.gov |
| NCT04987307 | Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Seve… | Phase2 | Ulcerative Colitis | Terminated | 2022-01-31 | 2024-10-22 | ClinicalTrials.gov |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors… | Phase2 | Non-small Cell Lung Cancer | Completed | 2022-01-28 | 2025-05-27 | ClinicalTrials.gov |
| NCT06576050 | WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise | — | Heart Failure | Active_Not_Recruiting | 2022-01-25 | 2024-11-01 | ClinicalTrials.gov |
| NCT05032066 | A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-82… | Phase2 | Idiopathic Pulmonary Fibrosis | Terminated | 2022-01-20 | 2025-01-02 | ClinicalTrials.gov |
| NCT05347745 | Therascreen® KRAS RGQ PCR Kit | Na | Colo-rectal Cancer | Completed | 2022-01-07 | 2023-04-30 | ClinicalTrials.gov |
| NCT04448834 | Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | Phase2 | B-cell Acute Lymphoblastic Leukemia | Withdrawn | 2022-01-01 | 2023-06-01 | ClinicalTrials.gov |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mu… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2021-12-30 | 2024-08-29 | ClinicalTrials.gov |
| NCT04934475 | MInimal Residual Disease Adapted Strategy | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2021-12-08 | 2028-09-30 | ClinicalTrials.gov |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) | Phase2 | Relapsed/Refractory Small Cell Lung Cancer | Active_Not_Recruiting | 2021-12-01 | 2027-12-30 | ClinicalTrials.gov |
| NCT05152238 | ITP Registry and Accompanying Biospecimen Collection | — | Immune Thrombocytopenia | Recruiting | 2021-11-29 | 2027-04-01 | ClinicalTrials.gov |
| NCT04478994 | A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcS… | Phase1 | Diffuse Cutaneous Systemic Sclerosis | Terminated | 2021-11-17 | 2022-12-08 | ClinicalTrials.gov |
| NCT04884763 | Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder | Phase2 | Temporomandibular Disorder | Completed | 2021-11-15 | 2024-01-04 | ClinicalTrials.gov |
| NCT04781543 | A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmaco… | Phase2 | Diffuse Cutaneous Systemic Sclerosis | Terminated | 2021-11-05 | 2025-02-24 | ClinicalTrials.gov |
| NCT04994717 | Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus… | Phase3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Active_Not_Recruiting | 2021-11-02 | 2031-06-30 | ClinicalTrials.gov |
| NCT04956809 | Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure | Phase2 | HFrEF | Completed | 2021-10-22 | 2023-06-01 | ClinicalTrials.gov |
| NCT05073315 | A Comparative Study Between ABP 501 and Humira® in Participants With Moderate t… | Phase3 | Plaque Psoriasis | Completed | 2021-10-04 | 2022-12-19 | ClinicalTrials.gov |
| NCT04951856 | Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Inf… | Phase4 | STEMI - ST Elevation Myocardial Infarction | Active_Not_Recruiting | 2021-09-29 | 2028-05-22 | ClinicalTrials.gov |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | Phase1 | Small Cell Lung Cancer | Completed | 2021-09-27 | 2024-09-11 | ClinicalTrials.gov |
| NCT04779216 | Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa | Phase3 | Bone Density, Low | Completed | 2021-09-20 | 2025-11-17 | ClinicalTrials.gov |
| NCT05002998 | TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study | Phase4 | Thyroid Eye Disease | Completed | 2021-09-16 | 2025-12-19 | ClinicalTrials.gov |
| NCT05056246 | Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian … | Phase1 | Healthy Participants | Completed | 2021-09-10 | 2022-04-08 | ClinicalTrials.gov |
| NCT04528082 | Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With … | Phase3 | Behçet Disease | Recruiting | 2021-09-09 | 2030-12-17 | ClinicalTrials.gov |
| NCT04583735 | A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyro… | Phase4 | Thyroid Eye Disease | Completed | 2021-09-02 | 2023-10-12 | ClinicalTrials.gov |
| NCT04822298 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | Phase1 | Non-small Cell Lung Cancer | Terminated | 2021-08-31 | 2022-01-26 | ClinicalTrials.gov |
| NCT04506086 | Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal … | Phase4 | B-precursor Acute Lymphoblastic Leukemia | Terminated | 2021-08-26 | 2024-09-16 | ClinicalTrials.gov |
| NCT05062759 | Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza V… | Phase3 | Moderate to Severe Asthma | Completed | 2021-08-23 | 2022-07-18 | ClinicalTrials.gov |
| NCT05045638 | Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin… | Phase1 | Healthy Participants | Completed | 2021-08-20 | 2021-10-10 | ClinicalTrials.gov |
| NCT04263480 | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib i… | Phase2 | Waldenstrom Macroglobulinemia | Active_Not_Recruiting | 2021-08-18 | 2028-05-01 | ClinicalTrials.gov |
| NCT05048784 | A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib i… | Phase1 | Healthy Participants | Completed | 2021-08-16 | 2022-02-18 | ClinicalTrials.gov |
| NCT05135312 | Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging | Phase4 | Psoriasis | Unknown | 2021-08-09 | 2022-08-08 | ClinicalTrials.gov |
| NCT04987333 | Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participa… | Phase1 | Inflammatory Diseases | Completed | 2021-08-09 | 2022-10-03 | ClinicalTrials.gov |
| NCT04987320 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerabi… | Phase1 | Elevated Serum Lipoprotein(a) | Completed | 2021-07-28 | 2022-03-18 | ClinicalTrials.gov |
| NCT05909852 | A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HC… | Phase1 | Adalimumab | Completed | 2021-07-23 | 2021-11-24 | ClinicalTrials.gov |
| NCT05171270 | AsseSSing Impact in pSoriatic Treatment | — | Psoriatic Arthritis | Completed | 2021-07-12 | 2022-03-22 | ClinicalTrials.gov |
| NCT04948099 | A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases | Phase1 | Dendritic Cell -Mediated Rheumatic Diseases | Completed | 2021-07-06 | 2023-07-03 | ClinicalTrials.gov |
| NCT04825678 | A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With M… | Phase4 | Migraine | Completed | 2021-06-11 | 2023-09-28 | ClinicalTrials.gov |
| NCT04702737 | A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer | Phase1 | Neuroendocrine Prostate Cancer | Completed | 2021-06-10 | 2024-07-22 | ClinicalTrials.gov |
| NCT04859309 | Activating Older People After a Hip Fracture | Na | Hip Fractures | Unknown | 2021-06-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT04925934 | Study of VIB7734 for the Treatment of Moderate to Severely Active SLE | Phase2 | Lupus Erythematosus, Systemic | Completed | 2021-05-28 | 2023-06-09 | ClinicalTrials.gov |
| NCT04857606 | Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver… | Phase1 | Non-alcoholic Fatty Liver Disease | Completed | 2021-05-24 | 2023-07-19 | ClinicalTrials.gov |
| NCT04822337 | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in M… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-05-19 | 2032-11-01 | ClinicalTrials.gov |
| NCT04466917 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squ… | Phase3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 2021-05-15 | 2022-11-13 | ClinicalTrials.gov |
| NCT04680637 | Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus … | Phase2 | Active Systemic Lupus Erythematosus | Terminated | 2021-05-06 | 2023-05-22 | ClinicalTrials.gov |
| NCT04748354 | Reducing Fall Risk Post Hip Fracture in Mild Cognitive Impairment | Na | Hip Fractures | Completed | 2021-05-03 | 2024-05-09 | ClinicalTrials.gov |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carc… | Phase1 | Metastatic Castration-resistant Prostate Cancer | Terminated | 2021-04-29 | 2024-06-24 | ClinicalTrials.gov |
| NCT04727554 | Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Par… | Phase1 | Advanced Solid Tumors | Completed | 2021-04-29 | 2023-06-05 | ClinicalTrials.gov |
| NCT04573777 | Reducing Intracranial atheroSclErosis With Repatha | Phase4 | Ischemic Stroke | Terminated | 2021-04-23 | 2021-12-16 | ClinicalTrials.gov |
| NCT04851964 | Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosin… | Phase3 | Chronic Rhinosinusitis With Nasal Polyps | Completed | 2021-04-22 | 2024-12-11 | ClinicalTrials.gov |
| NCT04887064 | Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Mod… | Phase1 | Hepatic Impairment | Completed | 2021-04-22 | 2022-03-09 | ClinicalTrials.gov |
| NCT04833855 | Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria | Phase2 | Chronic Spontaneous Urticaria | Completed | 2021-04-15 | 2023-04-13 | ClinicalTrials.gov |
| NCT04761627 | A Study to Investigate Interchangeability of ABP 654 for the Treatment of Parti… | Phase3 | Psoriasis | Completed | 2021-03-24 | 2023-02-28 | ClinicalTrials.gov |
| NCT05001087 | A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) | — | Multiple Myeloma | Recruiting | 2021-03-16 | 2027-03-31 | ClinicalTrials.gov |
| NCT04800367 | Romosozumab/Denosumab Study for Premenopausal IOP | Phase2 | Premenopausal Idiopathic Osteoporosis | Active_Not_Recruiting | 2021-03-12 | 2028-03-01 | ClinicalTrials.gov |
| NCT04772313 | Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled … | Phase4 | Uncontrolled Gout | Completed | 2021-03-08 | 2023-04-24 | ClinicalTrials.gov |
| NCT04708886 | Romosozumab in Women With Chronic SCI | Phase2 | Osteoporosis | Completed | 2021-03-01 | 2024-06-10 | ClinicalTrials.gov |
| NCT04673630 | Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma | Phase1 | Asthma | Completed | 2021-02-23 | 2022-09-27 | ClinicalTrials.gov |
| NCT04608474 | Lipid Management in Renal Transplant Recipients Using Evolocumab. | Phase4 | Hyperlipidemias | Completed | 2021-02-17 | 2025-05-14 | ClinicalTrials.gov |
| NCT04249427 | Erenumab for Idiosyncratic Facial Pain | Phase4 | Facial Pain | Completed | 2021-02-10 | 2023-07-11 | ClinicalTrials.gov |
| NCT04746209 | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | Phase2 | B-cell Acute Lymphoblastic Leukemia | Recruiting | 2021-02-01 | 2029-12-31 | ClinicalTrials.gov |
| NCT06150781 | Aimovig Pregnancy Exposure Registry | — | Migraine | Recruiting | 2021-01-27 | 2027-10-28 | ClinicalTrials.gov |
| NCT04762498 | A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Me… | Phase4 | Uncontrolled Gout | Completed | 2021-01-26 | 2023-12-20 | ClinicalTrials.gov |
| NCT04545554 | Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imp… | Phase1 | Osteogenesis Imperfecta | Completed | 2021-01-21 | 2023-03-30 | ClinicalTrials.gov |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate C… | Phase1 | Metastatic Castration-resistant Prostate Cancer | Terminated | 2021-01-15 | 2023-10-23 | ClinicalTrials.gov |
| NCT04098250 | Multidisciplinary Translational Approach to Investigate Mechanisms Predictors &… | Phase2 | Post-Traumatic Headache | Completed | 2021-01-04 | 2024-01-10 | ClinicalTrials.gov |
| NCT04521231 | A Study of Subcutaneous Blinatumomab Administration in Participants With R/R an… | Phase1 | B Cell Precursor Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2021-01-04 | 2029-05-25 | ClinicalTrials.gov |
| NCT04556084 | Blinatumomab Bridging Therapy for BALL | Phase2 | B-cell Acute Lymphoblastic Leukemia | Terminated | 2021-01-01 | 2022-10-01 | ClinicalTrials.gov |
| NCT04785547 | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | Phase2 | ALL, Childhood | Terminated | 2020-12-17 | 2022-01-22 | ClinicalTrials.gov |
| NCT04673266 | Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People Wi… | Phase2 | Lymphoma Patients | Completed | 2020-12-14 | 2026-04-07 | ClinicalTrials.gov |
| NCT04338581 | Evaluation of AMG 714 for Vitiligo | Phase2 | Vitiligo | Completed | 2020-12-11 | 2025-04-02 | ClinicalTrials.gov |
| NCT04540497 | A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease | Phase3 | IgG4 Related Disease | Active_Not_Recruiting | 2020-12-04 | 2028-10-31 | ClinicalTrials.gov |
| NCT04590586 | Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalize… | Phase3 | COVID-19 | Completed | 2020-11-24 | 2021-08-03 | ClinicalTrials.gov |
| NCT04645420 | Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients | Na | Psoriatic Arthritis | Completed | 2020-11-12 | 2023-02-10 | ClinicalTrials.gov |
| NCT04607980 | A Study to Investigate ABP 654 for the Treatment of Participants With Moderate … | Phase3 | Plaque Psoriasis | Completed | 2020-11-11 | 2022-06-03 | ClinicalTrials.gov |
| NCT04141579 | Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction Wi… | Na | Coronary Artery Disease | Completed | 2020-11-10 | 2023-11-09 | ClinicalTrials.gov |
| NCT04265755 | Biomarker and Genetic Predictors of Erenumab Treatment Response | Phase4 | Migraine | Completed | 2020-10-26 | 2023-01-18 | ClinicalTrials.gov |
| NCT04524273 | Myasthenia Gravis Inebilizumab Trial | Phase3 | Myasthenia Gravis | Active_Not_Recruiting | 2020-10-15 | 2029-06-07 | ClinicalTrials.gov |
| NCT04511702 | Infusion Duration Study To Assess Tolerability of Pegloticase Administered With… | Phase4 | Chronic Uncontrolled Gout | Completed | 2020-10-02 | 2024-03-25 | ClinicalTrials.gov |
| NCT04524455 | Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relap… | Phase1 | Acute Lymphoblastic Leukemia | Completed | 2020-10-02 | 2023-01-24 | ClinicalTrials.gov |
| NCT04478695 | Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Re… | Phase1 | Relapsed or Refractory Acute Myeloid Leukemia | Terminated | 2020-09-29 | 2020-10-23 | ClinicalTrials.gov |
| NCT06563856 | A Study of TEPEZZA Subcutaneous Administration in Healthy Adults | Phase1 | Bioavailability | Completed | 2020-09-22 | 2021-05-27 | ClinicalTrials.gov |
| NCT04252742 | Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Mi… | Phase4 | Migraine | Completed | 2020-09-15 | 2023-10-26 | ClinicalTrials.gov |
| NCT04362748 | Study of AMG 256 in Adult Subjects With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2020-09-15 | 2023-09-21 | ClinicalTrials.gov |
| NCT04735900 | lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Me… | Na | Metastatic Colorectal Cancer | Unknown | 2020-09-14 | 2022-03-01 | ClinicalTrials.gov |
| NCT04599062 | TVEC and Preop Radiation for Sarcoma (8 ml Dose) | Phase1 | Soft Tissue Sarcoma | Active_Not_Recruiting | 2020-09-10 | 2028-02-16 | ClinicalTrials.gov |
| NCT04369729 | Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traum… | — | Post-Traumatic Headache | Completed | 2020-09-09 | 2025-08-31 | ClinicalTrials.gov |
| NCT04330430 | Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metasta… | Phase2 | Melanoma Stage III | Completed | 2020-09-08 | 2025-01-29 | ClinicalTrials.gov |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant | Phase2 | B-cell Adult Acute Lymphoblastic Leukemia | Terminated | 2020-09-08 | 2022-02-02 | ClinicalTrials.gov |
| NCT04287855 | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexame… | Phase2 | Multiple Myeloma in Relapse | Unknown | 2020-08-28 | 2026-04-15 | ClinicalTrials.gov |
| NCT04539223 | A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior… | Phase4 | Carotid Artery Stenosis | Unknown | 2020-08-28 | 2022-05-01 | ClinicalTrials.gov |
| NCT04478227 | TPO-Mimetic Use in Children for Hematopoietic Failure | Early_Phase1 | Bone Marrow Failure Disorders | Completed | 2020-08-18 | 2024-01-18 | ClinicalTrials.gov |
| NCT04177940 | Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteop… | Phase4 | Osteoporosis | Completed | 2020-08-17 | 2025-01-14 | ClinicalTrials.gov |
| NCT05826756 | Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-Worl… | — | Lung Cancer Patients | Unknown | 2020-08-15 | 2025-12-01 | ClinicalTrials.gov |
| NCT04478708 | Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity | Phase1 | Obesity | Completed | 2020-08-07 | 2022-11-18 | ClinicalTrials.gov |
| NCT04191616 | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzo… | Phase2 | Relapsed or Refractory Multiple Myeloma | Completed | 2020-08-06 | 2024-10-01 | ClinicalTrials.gov |
| NCT04306965 | Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab | Phase2 | Atopic Dermatitis | Completed | 2020-08-01 | 2022-08-18 | ClinicalTrials.gov |
| NCT04270760 | Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE F… | Phase2 | Cardiovascular Disease | Completed | 2020-07-28 | 2022-11-08 | ClinicalTrials.gov |
| NCT05599828 | A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics … | Phase1 | Healthy Participants | Completed | 2020-07-17 | 2020-09-13 | ClinicalTrials.gov |
| NCT04478123 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autol… | Phase2 | Multiple Myeloma | Completed | 2020-07-14 | 2023-06-08 | ClinicalTrials.gov |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic… | Phase3 | Leukemia, Acute Lymphoblastic | Recruiting | 2020-07-13 | 2033-06-01 | ClinicalTrials.gov |
| NCT04430894 | KRDI in Transplant-Eligible MM | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2020-07-10 | 2026-12-30 | ClinicalTrials.gov |
| NCT04231682 | A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatme… | Phase2 | Osteoporosis | Withdrawn | 2020-07-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT04260191 | Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophagea… | Phase1 | Gastric and Gastroesophageal Junction Adenocarcinoma | Terminated | 2020-06-29 | 2022-06-02 | ClinicalTrials.gov |
| NCT04270747 | A Study to Understand Effectiveness and Safety of ABP 938 Compared to Afliberce… | Phase3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | Completed | 2020-06-22 | 2023-01-30 | ClinicalTrials.gov |
| NCT04303780 | Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small C… | Phase3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | Completed | 2020-06-04 | 2026-06-24 | ClinicalTrials.gov |
| NCT04427306 | Neoadjuvant T-VEC in High Risk Early Melanoma | Phase2 | Melanoma | Suspended | 2020-05-21 | 2024-05-21 | ClinicalTrials.gov |
| NCT04176718 | Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2020-05-18 | 2028-05-01 | ClinicalTrials.gov |
| NCT04362410 | Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects | Phase1 | Healthy Subjects | Completed | 2020-05-18 | 2020-10-09 | ClinicalTrials.gov |
| NCT04380753 | AMG 510 Ethnic Sensitivity Study (CodeBreaK 105). | Phase1 | Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation | Completed | 2020-04-28 | 2026-02-09 | ClinicalTrials.gov |
| NCT05360225 | Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRA… | — | Non Small Cell Lung Cancer | Completed | 2020-04-02 | 2022-05-26 | ClinicalTrials.gov |
| NCT04329325 | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia … | Phase2 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2020-03-30 | 2027-03-01 | ClinicalTrials.gov |
| NCT05347797 | Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using t… | Na | Non-small Cell Lung Cancer | Completed | 2020-03-13 | 2021-04-22 | ClinicalTrials.gov |
| NCT05578859 | A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following… | Phase1 | Healthy Subjects | Completed | 2020-03-11 | 2020-03-24 | ClinicalTrials.gov |
| NCT04293094 | Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2020-03-11 | 2023-02-15 | ClinicalTrials.gov |
| NCT05571163 | A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tab… | Phase1 | Healthy Participants | Completed | 2020-03-06 | 2020-06-14 | ClinicalTrials.gov |
| NCT04292275 | Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-D… | Na | Heart Failure | Terminated | 2020-03-06 | 2021-10-01 | ClinicalTrials.gov |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate … | Phase1 | Prostate Cancer | Recruiting | 2020-03-04 | 2032-03-21 | ClinicalTrials.gov |
| NCT03937154 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subject… | Phase3 | Chemotherapy-induced Thrombocytopenia | Active_Not_Recruiting | 2020-02-26 | 2027-02-23 | ClinicalTrials.gov |
| NCT04306471 | Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI) | Phase4 | Critical Limb Ischemia | Unknown | 2020-02-24 | 2022-02-04 | ClinicalTrials.gov |
| NCT04058028 | Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythemat… | Phase2 | Systemic Lupus Erythematosus (SLE) | Completed | 2020-02-19 | 2023-07-25 | ClinicalTrials.gov |
| NCT03751709 | Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+… | Phase1 | B-Cell Acute Lymphoblastic Leukaemia | Completed | 2020-02-14 | 2024-11-12 | ClinicalTrials.gov |
| NCT04268498 | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patient… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2020-02-11 | 2027-02-01 | ClinicalTrials.gov |
| NCT03554044 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2… | Phase1 | Anatomic Stage III Breast Cancer AJCC v8 | Completed | 2020-02-05 | 2023-12-31 | ClinicalTrials.gov |
| NCT04128475 | Observational Study of Cardiovascular Disease. | — | Cardiovascular Diseases | Terminated | 2020-02-05 | 2021-04-26 | ClinicalTrials.gov |
| NCT04068181 | Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression o… | Phase2 | Melanoma | Completed | 2020-01-22 | 2024-02-26 | ClinicalTrials.gov |
| NCT04117958 | Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric… | Phase1 | MUC17-positive Solid Tumors | Terminated | 2020-01-20 | 2023-06-01 | ClinicalTrials.gov |
| NCT04151342 | CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Ob… | — | Cancer | Recruiting | 2020-01-17 | 2029-12-01 | ClinicalTrials.gov |
| NCT04113018 | Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone … | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2020-01-10 | 2027-10-01 | ClinicalTrials.gov |
| NCT05581992 | Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmac… | Phase1 | Healthy Participants | Completed | 2020-01-06 | 2020-01-26 | ClinicalTrials.gov |
| NCT04220164 | Observation of Blood Lipid Outcomes in Lipid Clinic | — | Dyslipidemias | Unknown | 2020-01-03 | 2025-12-31 | ClinicalTrials.gov |
| NCT04174677 | Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly … | Phase2 | Highly Sensitized Patients on Waiting List for Kidney Transplantation | Withdrawn | 2019-12-27 | 2022-04-01 | ClinicalTrials.gov |
| NCT03969329 | A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism… | Phase3 | Secondary Hyperparathyroidism | Recruiting | 2019-12-20 | 2027-06-30 | ClinicalTrials.gov |
| NCT04175613 | A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From… | Phase3 | Psoriasis | Completed | 2019-12-20 | 2025-12-12 | ClinicalTrials.gov |
| NCT03925532 | Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant | Phase2 | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Completed | 2019-12-19 | 2022-11-16 | ClinicalTrials.gov |
| NCT04185883 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Muta… | Phase1 | Advanced Solid Tumors | Active_Not_Recruiting | 2019-12-17 | 2027-12-05 | ClinicalTrials.gov |
| NCT04199351 | Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity | Phase1 | Obesity | Terminated | 2019-12-13 | 2021-09-10 | ClinicalTrials.gov |
| NCT04129164 | A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjö… | Phase2 | Sjögren's Syndrome | Completed | 2019-12-09 | 2023-03-10 | ClinicalTrials.gov |
| NCT04163991 | A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rhe… | Phase2 | Rheumatoid Arthritis | Completed | 2019-12-09 | 2021-12-28 | ClinicalTrials.gov |
| NCT04197453 | The Cardiovascular Multi-dimensional Observational Investigation of the Use of … | — | ASCVD | Terminated | 2019-12-06 | 2020-12-21 | ClinicalTrials.gov |
| NCT03993847 | CLassification of Axial SpondyloarthritiS Inception Cohort | — | Spondyloarthritis | Completed | 2019-12-04 | 2022-08-22 | ClinicalTrials.gov |
| NCT03912337 | Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subject… | Phase4 | Migraine | Terminated | 2019-12-04 | 2021-07-28 | ClinicalTrials.gov |
| NCT05568082 | A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pha… | Phase1 | Healthy Participants | Completed | 2019-12-03 | 2019-12-17 | ClinicalTrials.gov |
| NCT04169347 | FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal C… | Phase2 | Colorectal Cancer Metastatic | Unknown | 2019-12-02 | 2025-01-01 | ClinicalTrials.gov |
| NCT05581758 | A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in… | Phase1 | Healthy Participants | Completed | 2019-11-14 | 2019-12-09 | ClinicalTrials.gov |
| NCT04403698 | The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase… | Phase2 | Erosive Osteoarthritis | Completed | 2019-11-13 | 2022-03-09 | ClinicalTrials.gov |
| NCT05550129 | Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in H… | Phase1 | Healthy Volunteers | Completed | 2019-11-13 | 2019-11-25 | ClinicalTrials.gov |
| NCT05988034 | A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Do… | Phase1 | Electrocardiography | Completed | 2019-11-08 | 2020-03-31 | ClinicalTrials.gov |
| NCT05577624 | A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmac… | Phase1 | Healthy Participants | Completed | 2019-11-05 | 2019-12-01 | ClinicalTrials.gov |
| NCT05598281 | Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin… | Phase1 | Healthy Participants | Completed | 2019-11-05 | 2019-11-19 | ClinicalTrials.gov |
| NCT04046549 | A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With… | Phase2 | Allografts | Completed | 2019-10-30 | 2023-03-22 | ClinicalTrials.gov |
| NCT03636373 | Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout | Phase4 | Gout Attack | Terminated | 2019-10-25 | 2021-08-13 | ClinicalTrials.gov |
| NCT04057937 | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanes… | Phase2 | Palmoplantaris Pustulosis | Completed | 2019-10-16 | 2021-06-07 | ClinicalTrials.gov |
| NCT03971071 | A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medicati… | Phase4 | Migraine Headache | Completed | 2019-10-07 | 2023-06-13 | ClinicalTrials.gov |
| NCT03792763 | Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients | Phase2 | Multiple Myeloma | Completed | 2019-09-30 | 2023-09-14 | ClinicalTrials.gov |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subject… | Phase3 | Chemotherapy-induced Thrombocytopenia | Completed | 2019-09-30 | 2025-01-09 | ClinicalTrials.gov |
| NCT03620149 | Reduced Dose-density of Denosumab for Unresectable GCTB | Phase2 | Bone Giant Cell Tumor | Terminated | 2019-09-26 | 2020-07-30 | ClinicalTrials.gov |
| NCT03656666 | The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Geni… | Phase2 | Lichen Planus of Vulva | Unknown | 2019-09-24 | 2023-12-31 | ClinicalTrials.gov |
| NCT03934684 | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in R… | Phase4 | Relapsed Refractory Multiple Myeloma | Completed | 2019-09-16 | 2025-06-27 | ClinicalTrials.gov |
| NCT04087720 | Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidn… | Phase4 | Uncontrolled Gout | Completed | 2019-09-09 | 2021-09-07 | ClinicalTrials.gov |
| NCT03832998 | Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | Phase3 | Migraine | Completed | 2019-09-05 | 2026-01-07 | ClinicalTrials.gov |
| NCT04082442 | Evolocumab in Patients With Acute MI | Phase2 | Acute Coronary Syndrome | Completed | 2019-09-01 | 2024-10-25 | ClinicalTrials.gov |
| NCT03851263 | Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfu… | Phase4 | Coronary Artery Disease | Withdrawn | 2019-08-30 | 2023-02-24 | ClinicalTrials.gov |
| NCT04139226 | A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodyna… | Phase1 | Healthy Volunteers | Completed | 2019-08-28 | 2020-02-27 | ClinicalTrials.gov |
| NCT04034173 | Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | Phase2 | Treatment Related Cancer | Not_Yet_Recruiting | 2019-08-01 | 2026-08-01 | ClinicalTrials.gov |
| NCT04039113 | Tezepelumab COPD Exacerbation Study | Phase2 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2019-07-30 | 2024-01-31 | ClinicalTrials.gov |
| NCT04031027 | A Study to Describe the Characteristics of Patients Treated With Apremilast for… | — | Plaque Psoriasis | Completed | 2019-07-22 | 2021-01-27 | ClinicalTrials.gov |
| NCT03836040 | Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | Phase3 | Migraine | Active_Not_Recruiting | 2019-07-19 | 2026-11-19 | ClinicalTrials.gov |
| NCT03944577 | Impact of Evolocumab in Cardiac Transplant Patients With CAV | Phase2 | Heart Transplant | Completed | 2019-07-15 | 2023-03-28 | ClinicalTrials.gov |
| NCT03931642 | BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transform… | Phase2 | Richter Syndrome | Completed | 2019-07-05 | 2022-10-21 | ClinicalTrials.gov |
| NCT04386629 | Health Economy Register | — | Breast Neoplasms | Completed | 2019-07-05 | 2020-12-31 | ClinicalTrials.gov |
| NCT05348187 | Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit | Na | Non-Small Cell Lung Cancer | Completed | 2019-07-01 | 2020-11-23 | ClinicalTrials.gov |
| NCT03970902 | Quality of Life in Postmenopausal Women With Osteoporosis | — | Postmenopausal Osteoporosis | Completed | 2019-07-01 | 2022-04-01 | ClinicalTrials.gov |
| NCT03815279 | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myel… | Phase2 | Multiple Myeloma | Enrolling_By_Invitation | 2019-06-24 | 2028-01-01 | ClinicalTrials.gov |
| NCT03989544 | A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered b… | Phase1 | Asthma | Completed | 2019-06-19 | 2019-12-30 | ClinicalTrials.gov |
| NCT03930186 | A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremila… | Phase3 | Plaque Psoriasis | Completed | 2019-06-17 | 2020-09-25 | ClinicalTrials.gov |
| NCT03927157 | Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma | Phase3 | Asthma | Completed | 2019-06-14 | 2024-08-13 | ClinicalTrials.gov |
| NCT03994731 | Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncont… | Phase4 | Gout | Completed | 2019-06-13 | 2022-04-11 | ClinicalTrials.gov |
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myoc… | Phase3 | Coronary Heart Disease (CHD) | Completed | 2019-06-11 | 2025-07-25 | ClinicalTrials.gov |
| NCT04048343 | Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controll… | Phase3 | Severe Asthma | Completed | 2019-06-10 | 2021-03-18 | ClinicalTrials.gov |
| NCT03829046 | The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascula… | Phase4 | Atherosclerotic Vascular Disease | Completed | 2019-06-03 | 2021-11-15 | ClinicalTrials.gov |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | Phase2 | B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation | Withdrawn | 2019-06-01 | 2021-11-30 | ClinicalTrials.gov |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transpl… | Phase1 | Multiple Myeloma | Unknown | 2019-05-22 | 2023-11-01 | ClinicalTrials.gov |
| NCT03968978 | Tezepelumab Home Use Study | Phase3 | Asthma | Completed | 2019-05-21 | 2020-06-05 | ClinicalTrials.gov |
| NCT03927144 | Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients | Phase4 | Episodic Migraine | Completed | 2019-05-15 | 2022-09-30 | ClinicalTrials.gov |
| NCT03433755 | Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Stat… | Phase3 | Primary Hypercholesterolemia | Terminated | 2019-05-09 | 2020-05-09 | ClinicalTrials.gov |
| NCT03859427 | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With L… | Phase3 | Relapsed or Refractory Multiple Myeloma | Completed | 2019-05-08 | 2023-03-31 | ClinicalTrials.gov |
| NCT03795558 | A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv… | Phase2 | End Stage Renal Disease | Completed | 2019-05-01 | 2022-03-01 | ClinicalTrials.gov |
| NCT03633708 | A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyr… | Phase3 | Secondary Hyperparathyroidism | Recruiting | 2019-04-29 | 2029-01-31 | ClinicalTrials.gov |
| NCT03839459 | Denosumab for Smoldering Multiple Myeloma | Phase2 | Smoldering Multiple Myeloma | Completed | 2019-04-19 | 2025-01-30 | ClinicalTrials.gov |
| NCT03780504 | Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece | — | Psoriatic Arthritis | Unknown | 2019-04-15 | 2022-12-31 | ClinicalTrials.gov |
| NCT04004338 | Carfilzomib in Combination for the Treatment of RR MM | — | Multiple Myeloma | Unknown | 2019-04-14 | 2021-04-14 | ClinicalTrials.gov |
| NCT03812224 | A Controlled Trial of Erenumab in Migraine Prevention | Phase3 | Migraine | Completed | 2019-04-12 | 2020-11-25 | ClinicalTrials.gov |
| NCT03974360 | Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persiste… | Phase2 | Post-Traumatic Headache | Completed | 2019-04-05 | 2019-12-31 | ClinicalTrials.gov |
| NCT03861533 | GOAL International QuERI - Protocol CHRC 2019 GOAL INTERNATIONAL | — | Dyslipidemia | Completed | 2019-04-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT03774875 | A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, an… | Phase4 | Psoriasis | Completed | 2019-03-28 | 2021-11-03 | ClinicalTrials.gov |
| NCT03689946 | Effect of Evolocumab on Coronary Atherosclerosis | Phase3 | Cardiovascular Disease | Completed | 2019-03-19 | 2023-05-30 | ClinicalTrials.gov |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematolo… | Phase1 | Acute Myeloid Leukemia | Terminated | 2019-03-18 | 2019-12-30 | ClinicalTrials.gov |
| NCT03809663 | A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and… | Phase2 | Atopic Dermatitis | Terminated | 2019-03-15 | 2020-12-22 | ClinicalTrials.gov |
| NCT03721172 | Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus P… | Phase3 | Psoriasis | Completed | 2019-03-11 | 2020-07-24 | ClinicalTrials.gov |
| NCT03597009 | A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pl… | Phase1 | Malignant Pleural Effusion | Terminated | 2019-03-06 | 2020-02-12 | ClinicalTrials.gov |
| NCT03853109 | AMG 404 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2019-03-05 | 2023-11-02 | ClinicalTrials.gov |
| NCT03836053 | Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myel… | Phase1 | Relapsed and/or Refractory Multiple Myeloma | Terminated | 2019-03-04 | 2022-04-21 | ClinicalTrials.gov |
| NCT03500445 | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in New… | Phase2 | Myeloma | Active_Not_Recruiting | 2019-02-13 | 2026-06-01 | ClinicalTrials.gov |
| NCT03777436 | An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate… | Phase3 | Psoriasis | Completed | 2019-02-11 | 2022-02-09 | ClinicalTrials.gov |
| NCT03783026 | A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI… | Phase4 | Psoriatic Arthritis | Completed | 2019-02-06 | 2022-05-11 | ClinicalTrials.gov |
| NCT03828045 | A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis,… | — | Arthritis, Psoriatic | Completed | 2019-02-06 | 2021-10-20 | ClinicalTrials.gov |
| NCT03792841 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects … | Phase1 | Metastatic Castration-resistant Prostate Cancer | Terminated | 2019-02-05 | 2023-06-29 | ClinicalTrials.gov |
| NCT05885451 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in… | Phase1 | Chronic Graft-versus-Host Disease (cGVHD) | Completed | 2019-01-29 | 2019-04-11 | ClinicalTrials.gov |
| NCT03756896 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Ris… | Phase2 | Plasma Cell Myeloma | Active_Not_Recruiting | 2019-01-25 | 2026-06-30 | ClinicalTrials.gov |
| NCT03818607 | A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab … | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2019-01-22 | 2022-07-12 | ClinicalTrials.gov |
| NCT03706079 | Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adult… | Phase3 | Asthma | Completed | 2019-01-07 | 2022-05-18 | ClinicalTrials.gov |
| NCT03773107 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory … | Phase1 | Multiple Myeloma | Completed | 2019-01-03 | 2024-02-21 | ClinicalTrials.gov |
| NCT03812367 | Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women T… | — | Osteoporosis, Postmenopausal | Withdrawn | 2019-01-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT03811418 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuz… | Phase3 | Advanced Breast Cancer | Withdrawn | 2019-01-01 | 2019-04-01 | ClinicalTrials.gov |
| NCT03747939 | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarti… | Phase4 | Arthritis, Psoriatic | Completed | 2018-12-31 | 2023-07-05 | ClinicalTrials.gov |
| NCT03852472 | Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Seve… | Phase2 | Hidradenitis Suppurativa | Completed | 2018-12-21 | 2021-03-09 | ClinicalTrials.gov |
| NCT03714828 | Study of TVEC in Patients With Cutaneous Squamous Cell Cancer | Phase2 | Squamous Cell Carcinoma | Completed | 2018-12-20 | 2023-07-19 | ClinicalTrials.gov |
| NCT03620188 | Treatment Goals in Psoriatic Arthritis | — | Psoriatic Arthritis | Completed | 2018-12-20 | 2022-06-30 | ClinicalTrials.gov |
| NCT03701763 | Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6… | Phase3 | Psoriasis | Completed | 2018-12-19 | 2023-03-27 | ClinicalTrials.gov |
| NCT03817424 | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (… | Phase1 | Systemic Lupus Erythematosus | Completed | 2018-12-13 | 2020-07-20 | ClinicalTrials.gov |
| NCT03802604 | Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer | Early_Phase1 | Breast Cancer | Completed | 2018-12-10 | 2025-03-18 | ClinicalTrials.gov |
| NCT03757130 | Multiple Ascending Dose Study of AMG 598 in Adults With Obesity | Phase1 | Obesity | Completed | 2018-11-26 | 2019-12-16 | ClinicalTrials.gov |
| NCT03570697 | Imaging of Coronary Plaques in Participants Treated With Evolocumab | Phase3 | Coronary Artery Disease (CAD) | Completed | 2018-11-19 | 2021-01-21 | ClinicalTrials.gov |
| NCT03331666 | Impact of LDL-cholesterol Lowering on Platelet Activation | Phase4 | Familial Hypercholesterolemia | Terminated | 2018-11-16 | 2020-02-04 | ClinicalTrials.gov |
| NCT03751176 | Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Col… | Phase2 | Colorectal Cancer Metastatic | Unknown | 2018-11-08 | 2022-11-30 | ClinicalTrials.gov |
| NCT03619187 | An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capaci… | Phase3 | Heart Transplantation, Elevated Resting Heart Rate | Withdrawn | 2018-11-02 | 2020-02-19 | ClinicalTrials.gov |
| NCT03688074 | Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolle… | Phase2 | Asthma | Completed | 2018-11-02 | 2020-11-16 | ClinicalTrials.gov |
| NCT03571828 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of A… | Phase1 | Diffuse Large B-cell Lymphoma(DLBCL) | Terminated | 2018-10-29 | 2022-01-12 | ClinicalTrials.gov |
| NCT05918666 | National Register of Actionable Mutations | — | Solid Tumours in Advanced Stages | Active_Not_Recruiting | 2018-10-27 | 2026-10-27 | ClinicalTrials.gov |
| NCT03635021 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Be… | Phase3 | Colorectal Cancer | Active_Not_Recruiting | 2018-10-15 | 2025-06-28 | ClinicalTrials.gov |
| NCT03703908 | A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome | Phase2 | Focal Segmental Glomerulosclerosis | Terminated | 2018-10-01 | 2020-06-24 | ClinicalTrials.gov |
| NCT03635957 | Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontroll… | Phase4 | Gout | Completed | 2018-09-26 | 2020-10-26 | ClinicalTrials.gov |
| NCT03757013 | A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Ch… | — | Psoriasis | Completed | 2018-09-25 | 2021-09-10 | ClinicalTrials.gov |
| NCT03541369 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed… | Phase1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Terminated | 2018-09-14 | 2023-02-21 | ClinicalTrials.gov |
| NCT03392064 | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in … | Phase1 | Small Cell Lung Cancer | Suspended | 2018-09-10 | 2028-01-14 | ClinicalTrials.gov |
| NCT03620019 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | Phase2 | Melanoma Stage Iii | Completed | 2018-09-10 | 2023-08-15 | ClinicalTrials.gov |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients… | Phase2 | Urothelial Carcinoma | Completed | 2018-09-04 | 2020-12-01 | ClinicalTrials.gov |
| NCT03600883 | A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sot… | Phase1 | KRAS p.G12C Mutant Advanced Solid Tumors | Completed | 2018-08-27 | 2026-05-29 | ClinicalTrials.gov |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With… | Phase1 | Multiple Myeloma | Terminated | 2018-08-17 | 2019-07-25 | ClinicalTrials.gov |
| NCT03621605 | A Phase1 Study of VIB9600 | Phase1 | Safety Issues | Terminated | 2018-08-14 | 2019-04-08 | ClinicalTrials.gov |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable H… | Phase2 | HER2-positive Breast Cancer | Active_Not_Recruiting | 2018-08-06 | 2027-09-01 | ClinicalTrials.gov |
| NCT03403374 | Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Ho… | Phase4 | Homozygous Familial Hypercholesterolemia HoFH | Completed | 2018-08-04 | 2019-11-27 | ClinicalTrials.gov |
| NCT03608657 | Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Trea… | — | Arthritis, Psoriatic | Completed | 2018-07-31 | 2022-03-30 | ClinicalTrials.gov |
| NCT03626662 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in… | Phase1 | Cardiovascular Disease | Completed | 2018-07-30 | 2023-04-18 | ClinicalTrials.gov |
| NCT03638128 | Open-label Extension of Study 20130173 of Denosumab in Children and Young Adult… | Phase3 | Osteogenesis Imperfecta (OI) | Terminated | 2018-07-26 | 2022-03-28 | ClinicalTrials.gov |
| NCT03751072 | Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, … | — | Acute Lymphoblastic Leukemia, in Relapse | Completed | 2018-07-16 | 2019-01-30 | ClinicalTrials.gov |
| NCT03691311 | Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative … | Early_Phase1 | Breast Neoplasm Female | Unknown | 2018-07-05 | 2023-02-05 | ClinicalTrials.gov |
| NCT03512353 | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory… | Phase2 | Relapsed or Refractory Multiple Myeloma | Terminated | 2018-07-05 | 2020-01-16 | ClinicalTrials.gov |
| NCT03168529 | Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the O… | Phase4 | Heart Failure | Terminated | 2018-07-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT03619993 | Patient Preference for Pegfilgrastim (Neulasta®) Application Forms | Na | Non Hodgkin Lymphoma | Completed | 2018-06-25 | 2019-09-10 | ClinicalTrials.gov |
| NCT03605199 | Denosumab in Subjects With Giant Cell Rich Tumors of Bone | Phase2 | Aneurysmal Bone Cysts | Unknown | 2018-06-18 | 2023-06-01 | ClinicalTrials.gov |
| NCT03539419 | Study to Evaluate the Benefits for the Patient Associated With the Treatment of… | — | Psoriasis | Completed | 2018-06-12 | 2020-10-31 | ClinicalTrials.gov |
| NCT03430687 | Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder … | Phase1 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7 | Withdrawn | 2018-06-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT03289299 | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transpla… | Phase2 | Smoldering Multiple Myeloma | Active_Not_Recruiting | 2018-05-25 | 2031-11-15 | ClinicalTrials.gov |
| NCT03298412 | Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cel… | Phase2 | High-risk Diffuse Large B-cell Lymphoma | Terminated | 2018-05-23 | 2019-09-30 | ClinicalTrials.gov |
| NCT03410056 | Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arth… | Phase1 | Rheumatoid Arthritis RA | Terminated | 2018-05-22 | 2020-05-13 | ClinicalTrials.gov |
| NCT03515304 | Evolocumab in Acute Coronary Syndrome | Phase2 | Acute Coronary Syndrome | Completed | 2018-05-20 | 2025-03-25 | ClinicalTrials.gov |
| NCT03536754 | A Study of CCX140-B in Subjects With FSGS | Phase2 | FSGS | Completed | 2018-05-17 | 2020-02-19 | ClinicalTrials.gov |
| NCT03299244 | Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patien… | Phase3 | Secondary Hyperparathyroidism | Completed | 2018-05-15 | 2020-04-08 | ClinicalTrials.gov |
| NCT03448731 | Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-E… | Phase2 | Skin Toxicity | Completed | 2018-05-10 | 2020-04-06 | ClinicalTrials.gov |
| NCT03164928 | Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-in… | Phase3 | Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With | Completed | 2018-05-07 | 2023-12-20 | ClinicalTrials.gov |
| NCT03499119 | AMG 334 20160172 Pediatric Migraine PK Study. | Phase1 | Migraine | Completed | 2018-05-04 | 2021-11-23 | ClinicalTrials.gov |
| NCT03422627 | Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chr… | Phase1 | Chronic Graft Versus Host Disease cGVHD | Terminated | 2018-04-27 | 2022-10-13 | ClinicalTrials.gov |
| NCT03584711 | FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroductio… | Phase2 | Metastatic Colorectal Cancer | Completed | 2018-04-26 | 2025-03-30 | ClinicalTrials.gov |
| NCT03469661 | Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Sy… | — | Immune Thrombocytopenia | Completed | 2018-04-25 | 2021-04-19 | ClinicalTrials.gov |
| NCT03296696 | Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma | Phase1 | Glioblastoma or Malignant Glioma | Terminated | 2018-04-18 | 2021-08-28 | ClinicalTrials.gov |
| NCT06004934 | A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants W… | Phase1 | Hepatic Impairment | Completed | 2018-04-17 | 2018-09-18 | ClinicalTrials.gov |
| NCT03461211 | Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusion… | Phase3 | Thyroid Eye Disease | Completed | 2018-04-16 | 2021-02-17 | ClinicalTrials.gov |
| NCT03451422 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of… | Phase1 | Systemic Lupus Erythematosus | Completed | 2018-04-10 | 2021-10-12 | ClinicalTrials.gov |
| NCT03951220 | The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myel… | — | Myeloma | Completed | 2018-03-29 | 2020-12-30 | ClinicalTrials.gov |
| NCT03311750 | Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With… | Phase2 | Advanced Colorectal Cancer | Terminated | 2018-03-26 | 2021-05-20 | ClinicalTrials.gov |
| NCT03446157 | Palbociclib and Cetuximab in Metastatic Colorectal Cancer | Phase2 | Cancer of the Colon | Completed | 2018-03-23 | 2026-01-26 | ClinicalTrials.gov |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast … | Phase1 | Metastatic Triple Negative Breast Cancer | Completed | 2018-03-19 | 2021-12-03 | ClinicalTrials.gov |
| NCT03340766 | Study Investigating the Safety and Efficacy of Blinatumomab in Combination With… | Phase1 | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Completed | 2018-03-16 | 2023-08-14 | ClinicalTrials.gov |
| NCT03387605 | Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine | Phase4 | Heart Failure | Unknown | 2018-03-15 | 2020-06-01 | ClinicalTrials.gov |
| NCT03224507 | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Mye… | Phase2 | Multiple Myeloma | Completed | 2018-03-14 | 2023-06-30 | ClinicalTrials.gov |
| NCT03442569 | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS R… | Phase2 | Colon Cancer | Completed | 2018-03-09 | 2024-12-02 | ClinicalTrials.gov |
| NCT03406078 | Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corti… | Phase3 | Asthma | Completed | 2018-03-05 | 2020-09-25 | ClinicalTrials.gov |
| NCT03283098 | A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 | Phase1 | Secondary Hyperparathyroidism | Completed | 2018-03-01 | 2019-02-04 | ClinicalTrials.gov |
| NCT03137537 | Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With T… | Phase2 | Lymphoma | Terminated | 2018-02-27 | 2020-11-18 | ClinicalTrials.gov |
| NCT03300609 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer Af… | Phase3 | Colorectal Adenocarcinoma | Terminated | 2018-02-27 | 2019-10-03 | ClinicalTrials.gov |
| NCT03335488 | Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïv… | Phase4 | Urea Cycle Disorder | Completed | 2018-02-20 | 2022-12-20 | ClinicalTrials.gov |
| NCT03182725 | Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome | Phase3 | Postural Orthostatic Tachycardia Syndrome | Completed | 2018-02-06 | 2020-05-08 | ClinicalTrials.gov |
| NCT03432533 | A Comparison of Subject-administered Romosozumab With Healthcare Provider-admin… | Phase3 | Post-Menopausal Osteoporosis | Completed | 2018-02-06 | 2020-01-08 | ClinicalTrials.gov |
| NCT03532087 | Study to Identify the Impact of Denosumab on the Immune System in Patients With… | Phase2 | Breast Neoplasms | Withdrawn | 2018-02-01 | 2023-06-01 | ClinicalTrials.gov |
| NCT03396315 | Bisphosphonates for Prevention of Post-Denosumab Bone Loss | Phase2 | IOP | Completed | 2018-01-29 | 2023-06-09 | ClinicalTrials.gov |
| NCT03343847 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subject… | Phase3 | Chemotherapy-induced Thrombocytopenia | Withdrawn | 2018-01-27 | 2021-07-17 | ClinicalTrials.gov |
| NCT03287609 | EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute… | Phase3 | Acute Coronary Syndrome | Completed | 2018-01-23 | 2019-08-07 | ClinicalTrials.gov |
| NCT03398954 | a Prospective Pilot Study of Screening Out Rate and Clinical Management of Fami… | — | Familial Hypercholesterolemia | Unknown | 2018-01-18 | 2019-12-30 | ClinicalTrials.gov |
| NCT03319940 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab i… | Phase1 | Small Cell Lung Carcinoma | Active_Not_Recruiting | 2017-12-26 | 2027-12-31 | ClinicalTrials.gov |
| NCT04306081 | Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Pe… | Phase4 | Peripheral Arterial Disease | Unknown | 2017-12-14 | 2021-03-30 | ClinicalTrials.gov |
| NCT03318809 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Admi… | Phase1 | Heart Failure | Completed | 2017-12-12 | 2018-04-05 | ClinicalTrials.gov |
| NCT03280667 | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma | Phase2 | Renal Cell Carcinoma, Clear Cell | Unknown | 2017-12-12 | 2023-06-04 | ClinicalTrials.gov |
| NCT03161756 | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Pat… | Phase1 | Melanoma Stage Iv | Unknown | 2017-12-07 | 2023-12-01 | ClinicalTrials.gov |
| NCT03263572 | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With… | Phase2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recruiting | 2017-11-29 | 2027-11-30 | ClinicalTrials.gov |
| NCT03347279 | Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled … | Phase3 | Asthma | Completed | 2017-11-23 | 2020-11-12 | ClinicalTrials.gov |
| NCT03086642 | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | Phase1 | Pancreatic Cancer | Completed | 2017-11-16 | 2022-12-31 | ClinicalTrials.gov |
| NCT03287908 | A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2017-11-13 | 2023-06-30 | ClinicalTrials.gov |
| NCT03301857 | Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated Wi… | Phase4 | Giant Cell Tumor of Bone | Completed | 2017-11-13 | 2023-07-27 | ClinicalTrials.gov |
| NCT03142516 | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectabl… | Phase2 | Colorectal Neoplasms | Completed | 2017-10-31 | 2021-01-21 | ClinicalTrials.gov |
| NCT03292146 | Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A … | Phase3 | Bone Density | Completed | 2017-10-25 | 2021-07-22 | ClinicalTrials.gov |
| NCT05988008 | A Study of CCX168 in Japanese and Caucasian Healthy Adult Males | Phase1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Completed | 2017-10-23 | 2018-09-20 | ClinicalTrials.gov |
| NCT03070002 | Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metast… | Phase2 | Breast Carcinoma Metastatic in the Bone | Terminated | 2017-10-19 | 2018-04-24 | ClinicalTrials.gov |
| NCT03476239 | Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects… | Phase3 | Acute Lymphoblastic Leukemia | Completed | 2017-10-18 | 2021-04-08 | ClinicalTrials.gov |
| NCT03298867 | Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With… | Phase3 | Thyroid Eye Disease | Completed | 2017-10-04 | 2020-11-30 | ClinicalTrials.gov |
| NCT03096288 | Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Tre… | Phase4 | Atherosclerotic Cardiovascular Disease | Completed | 2017-10-03 | 2020-11-02 | ClinicalTrials.gov |
| NCT03182699 | Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients | Phase4 | Secondary Hyperparathyroidism | Completed | 2017-10-01 | 2019-12-20 | ClinicalTrials.gov |
| NCT03301467 | Controlled Trial Evaluating Avacopan in C3 Glomerulopathy | Phase2 | C3 Glomerulopathy (C3G) | Completed | 2017-09-29 | 2021-10-27 | ClinicalTrials.gov |
| NCT03456856 | A Study of Ivabradine in African-American/ Black Subjects With Heart Failure an… | Phase4 | Heart Failure (HF) | Completed | 2017-09-28 | 2019-05-20 | ClinicalTrials.gov |
| NCT02961881 | A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Ad… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2017-09-18 | 2021-09-02 | ClinicalTrials.gov |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid… | Early_Phase1 | Acute Myeloid Leukemia | Terminated | 2017-09-07 | 2020-12-28 | ClinicalTrials.gov |
| NCT03238781 | Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention | Phase2 | Chronic Migraine or Episodic Migraine | Completed | 2017-09-06 | 2019-02-04 | ClinicalTrials.gov |
| NCT03114865 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-… | Phase1 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2017-09-05 | 2026-10-30 | ClinicalTrials.gov |
| NCT03284879 | Post-Marketing Surveillance Study of OTEZLA | — | Psoriasis | Completed | 2017-09-05 | 2022-03-20 | ClinicalTrials.gov |
| NCT02756845 | Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors | Phase1 | Advanced Non CNS Tumors | Completed | 2017-08-16 | 2022-11-29 | ClinicalTrials.gov |
| NCT03156023 | Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid… | Phase1 | Rheumatoid Arthritis | Completed | 2017-08-14 | 2020-06-12 | ClinicalTrials.gov |
| NCT02910557 | Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to C… | — | Melanoma | Completed | 2017-08-10 | 2026-01-30 | ClinicalTrials.gov |
| NCT03155100 | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-… | Phase2 | Multiple Myeloma in Relapse | Completed | 2017-08-07 | 2023-08-31 | ClinicalTrials.gov |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL Wit… | Phase1 | B-Cell Acute Lymphoblastic Leukemia, Adult | Completed | 2017-08-04 | 2023-06-23 | ClinicalTrials.gov |
| NCT03131453 | A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clini… | Phase2 | Alzheimers Disease | Terminated | 2017-08-03 | 2020-03-26 | ClinicalTrials.gov |
| NCT03072771 | Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patient… | Phase1 | Diffuse Large B Cell Lymphoma | Completed | 2017-08-01 | 2023-10-30 | ClinicalTrials.gov |
| NCT04741906 | Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medic… | — | Missing Teeth | Recruiting | 2017-08-01 | 2025-12-31 | ClinicalTrials.gov |
| NCT02969837 | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexam… | Phase2 | Multiple Myeloma | Completed | 2017-07-10 | 2025-12-01 | ClinicalTrials.gov |
| NCT03088176 | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated… | Phase1 | Melanoma | Unknown | 2017-06-25 | 2021-06-30 | ClinicalTrials.gov |
| NCT03121534 | Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation | Phase2 | Hematopoietic/Lymphoid Cancer | Terminated | 2017-06-22 | 2022-02-11 | ClinicalTrials.gov |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed … | Phase3 | Relapsed Multiple Myeloma | Completed | 2017-06-13 | 2022-04-15 | ClinicalTrials.gov |
| NCT05913115 | A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients W… | Phase1 | Gastric or Gastroesophageal Cancer | Completed | 2017-06-12 | 2018-06-19 | ClinicalTrials.gov |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexametha… | Phase1 | Multiple Myeloma | Withdrawn | 2017-06-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT03000374 | Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple W… | Phase2 | Rectal Cancer | Completed | 2017-05-30 | 2021-12-15 | ClinicalTrials.gov |
| NCT02833844 | Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C… | Phase3 | Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | Completed | 2017-05-22 | 2020-01-27 | ClinicalTrials.gov |
| NCT03123471 | A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mo… | Phase3 | Psoriasis | Completed | 2017-05-16 | 2019-01-09 | ClinicalTrials.gov |
| NCT03170193 | AMG 529 First in Human Study | Phase1 | Cardiovascular | Completed | 2017-05-15 | 2017-11-17 | ClinicalTrials.gov |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple… | Phase1 | Breast Cancer | Completed | 2017-05-02 | 2025-08-26 | ClinicalTrials.gov |
| NCT02976818 | Lp(a) and Aortic Valve Calcification | — | Heterozygous Familial Hypercholesterolemia | Completed | 2017-04-30 | 2020-02-19 | ClinicalTrials.gov |
| NCT03096990 | A Study of the Real-life Management of Psoriatic Arthritis Patients Treated Wit… | — | Arthritis, Psoriatic | Completed | 2017-04-21 | 2018-12-27 | ClinicalTrials.gov |
| NCT03097003 | A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® … | — | Psoriasis | Completed | 2017-04-06 | 2018-12-20 | ClinicalTrials.gov |
| NCT03029234 | Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Rel… | Phase3 | Relapsed and Refractory Multiple Myeloma | Completed | 2017-03-31 | 2021-06-04 | ClinicalTrials.gov |
| NCT03117621 | Observational Study of Blinatumomab | — | Blincyto Use in Routine Clinical Practice | Completed | 2017-03-22 | 2024-03-20 | ClinicalTrials.gov |
| NCT02994927 | A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated … | Phase3 | ANCA-Associated Vasculitis | Completed | 2017-03-15 | 2019-11-01 | ClinicalTrials.gov |
| NCT03091127 | Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe | — | Multiple Myeloma | Completed | 2017-03-14 | 2020-03-17 | ClinicalTrials.gov |
| NCT02833857 | A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Se… | Phase1 | Chronic Kidney Disease, Secondary Hyperparathyroidism | Completed | 2017-03-14 | 2018-10-31 | ClinicalTrials.gov |
| NCT03080935 | Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiova… | Phase3 | Dyslipidemia | Terminated | 2017-03-13 | 2022-03-04 | ClinicalTrials.gov |
| NCT03087851 | Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis | Phase4 | Osteoporosis | Completed | 2017-03-13 | 2020-08-01 | ClinicalTrials.gov |
| NCT03023878 | Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Di… | Phase2 | High-risk Diffuse Large B-Cell Lymphoma | Completed | 2017-03-13 | 2019-10-28 | ClinicalTrials.gov |
| NCT02891811 | Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction … | Phase2 | Multiple Myeloma | Completed | 2017-03-10 | 2024-03-28 | ClinicalTrials.gov |
| NCT03064763 | Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unres… | Phase1 | Unresectable Stage IIIB-IV Malignant Melanoma | Completed | 2017-03-07 | 2023-01-12 | ClinicalTrials.gov |
| NCT02875184 | A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthriti… | — | Arthritis, Psoriatic | Completed | 2017-03-06 | 2022-06-30 | ClinicalTrials.gov |
| NCT03069378 | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab i… | Phase2 | Sarcoma | Active_Not_Recruiting | 2017-03-03 | 2027-03-01 | ClinicalTrials.gov |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX) | Phase2 | Breast Cancer Female NOS | Completed | 2017-02-13 | 2020-12-31 | ClinicalTrials.gov |
| NCT02954081 | APremilast After FumaRic Acid Ester Treatment | — | Psoriasis | Completed | 2017-01-26 | 2022-08-15 | ClinicalTrials.gov |
| NCT03043950 | Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC… | — | Metastatic Colorectal Cancer | Completed | 2017-01-25 | 2024-01-17 | ClinicalTrials.gov |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed… | Phase2 | B-Cell Non Hodgkin Lymphoma | Completed | 2017-01-23 | 2020-03-12 | ClinicalTrials.gov |
| NCT02939183 | Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma | Phase1 | Relapsed or Refractory Multiple Myeloma | Completed | 2017-01-17 | 2022-10-06 | ClinicalTrials.gov |
| NCT02791516 | A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean W… | Phase3 | Postmenopausal Osteoporosis | Completed | 2017-01-16 | 2018-12-21 | ClinicalTrials.gov |
| NCT02906124 | Study to Evaluate the Safety of Repatha® in Pregnancy | — | Hypercholesterolaemia | Terminated | 2017-01-12 | 2020-11-06 | ClinicalTrials.gov |
| NCT02957604 | Evolocumab Pregnancy Exposure Registry | — | Hypercholesterolemia; ASCVD; Pregnancy | Terminated | 2016-12-22 | 2020-09-02 | ClinicalTrials.gov |
| NCT02993120 | Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and… | — | Medical Conditions to be Studied | Completed | 2016-12-06 | 2021-08-06 | ClinicalTrials.gov |
| NCT02986139 | Study to Assess the Injection Site Pain Associated With a New Etanercept Formul… | Phase3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | Completed | 2016-11-29 | 2017-10-09 | ClinicalTrials.gov |
| NCT02990104 | First Report, Five Years Experience of the Acute Leukemia Work Group | — | Acute Leukemia (Category) | Unknown | 2016-11-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02970747 | Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamet… | — | Multiple Myeloma in Relapse | Completed | 2016-10-25 | 2025-04-26 | ClinicalTrials.gov |
| NCT02937701 | Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rh… | Phase3 | Arthritis, Rheumatoid | Completed | 2016-10-10 | 2018-08-13 | ClinicalTrials.gov |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients Wit… | Phase2 | Breast Carcinoma | Active_Not_Recruiting | 2016-10-06 | 2027-10-31 | ClinicalTrials.gov |
| NCT02624869 | Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inhe… | Phase3 | Familial Hypercholesterolemia | Completed | 2016-09-10 | 2021-06-01 | ClinicalTrials.gov |
| NCT02867813 | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With… | Phase3 | Dyslipidemia | Completed | 2016-09-02 | 2022-03-21 | ClinicalTrials.gov |
| NCT02851732 | Brazilian inteRvention to Increase eviDence usaGe in practicE - Cardiovascular … | Na | Cardiovascular Diseases | Completed | 2016-08-26 | 2018-09-01 | ClinicalTrials.gov |
| NCT02780674 | A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases | Phase1 | Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc | Completed | 2016-08-26 | 2017-11-27 | ClinicalTrials.gov |
| NCT02777554 | A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilas… | Phase1 | Healthy Volunteers | Completed | 2016-08-17 | 2016-11-22 | ClinicalTrials.gov |
| NCT03276728 | Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers … | Phase1 | Heart Failure | Terminated | 2016-08-12 | 2019-04-18 | ClinicalTrials.gov |
| NCT02833610 | A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency | Phase2 | Multiple Myeloma | Completed | 2016-08-01 | 2023-03-20 | ClinicalTrials.gov |
| NCT02807883 | Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantatio… | Phase2 | Acute Lymphoblastic Leukemia | Completed | 2016-08-01 | 2022-02-01 | ClinicalTrials.gov |
| NCT02925234 | The Drug Rediscovery Protocol (DRUP Trial) | Phase2 | Cancer | Recruiting | 2016-08-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02811679 | A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent No… | Phase2 | Non-Hodgkin Lymphoma | Terminated | 2016-08-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT02597062 | High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Tre… | Phase2 | Multiple Myeloma | Completed | 2016-07-05 | 2022-02-01 | ClinicalTrials.gov |
| NCT02827500 | Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME… | Phase4 | Heart Failure | Completed | 2016-07-01 | 2018-10-15 | ClinicalTrials.gov |
| NCT02740218 | A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast … | — | Psoriasis | Completed | 2016-06-30 | 2021-10-27 | ClinicalTrials.gov |
| NCT02783651 | An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute … | — | Relapsed/Refractory Acute Lymphoblastic Leukemia | Completed | 2016-06-30 | 2020-03-31 | ClinicalTrials.gov |
| NCT02797080 | Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children an… | Phase3 | Friedreich's Ataxia | Completed | 2016-06-28 | 2017-03-31 | ClinicalTrials.gov |
| NCT02808403 | Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Jap… | — | Hypercholesterolemia | Completed | 2016-06-24 | 2023-03-30 | ClinicalTrials.gov |
| NCT02802735 | Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremila… | Phase1 | Pharmacokinetics | Completed | 2016-06-22 | 2016-08-05 | ClinicalTrials.gov |
| NCT02819843 | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Me… | Phase2 | Melanoma | Completed | 2016-06-21 | 2024-02-22 | ClinicalTrials.gov |
| NCT02675452 | AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multip… | Phase1 | Relapsed or Refractory Multiple Myeloma | Terminated | 2016-06-13 | 2024-05-27 | ClinicalTrials.gov |
| NCT02747043 | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma … | Phase3 | Lymphoma, Non-Hodgkin | Completed | 2016-05-25 | 2019-06-28 | ClinicalTrials.gov |
| NCT02749370 | Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed The… | Phase4 | Plaque Psoriasis | Completed | 2016-05-18 | 2017-12-06 | ClinicalTrials.gov |
| NCT02792699 | Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe R… | Phase3 | Arthritis, Rheumatoid | Completed | 2016-05-17 | 2018-10-08 | ClinicalTrials.gov |
| NCT02739984 | Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholes… | Phase3 | Hypercholesterolemia | Completed | 2016-05-17 | 2017-08-03 | ClinicalTrials.gov |
| NCT02780388 | A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthri… | Phase1 | Adult Onset Rheumatoid Arthritis | Completed | 2016-05-12 | 2018-08-09 | ClinicalTrials.gov |
| NCT02792478 | Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wi… | — | RAS Wild Type mCRC | Completed | 2016-05-06 | 2021-05-31 | ClinicalTrials.gov |
| NCT02770131 | Chart Review of Repatha® in Subjects With Hyperlipidaemia | — | Hypercholesterolaemia | Completed | 2016-05-04 | 2021-06-30 | ClinicalTrials.gov |
| NCT02662569 | Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults … | Phase3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | Completed | 2016-04-14 | 2017-12-06 | ClinicalTrials.gov |
| NCT02729025 | Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on … | Phase3 | Subjects With Hyperlipidemia, Dyslipidemia | Completed | 2016-04-14 | 2018-04-05 | ClinicalTrials.gov |
| NCT02637141 | A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With C… | Phase2 | Celiac Disease | Completed | 2016-04-13 | 2017-03-14 | ClinicalTrials.gov |
| NCT02633020 | Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Typ… | Phase2 | Type II Refractory Celiac Disease (RCD-II) | Completed | 2016-04-13 | 2017-05-02 | ClinicalTrials.gov |
| NCT02626000 | Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous C… | Phase1 | Carcinoma of the Head and Neck | Completed | 2016-04-06 | 2020-08-28 | ClinicalTrials.gov |
| NCT01428154 | Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chr… | Phase1 | Anemia | Withdrawn | 2016-04-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02618967 | Single Ascending Dose Study of AMG 570 in Healthy Subjects | Phase1 | Systemic Lupus Erythematosus | Completed | 2016-03-28 | 2018-12-03 | ClinicalTrials.gov |
| NCT02392559 | Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subt… | Phase3 | Heterozygous Familial Hypercholesterolemia | Completed | 2016-03-24 | 2019-11-25 | ClinicalTrials.gov |
| NCT02771860 | RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalang… | Phase2 | Hand Osteoarthritis | Completed | 2016-03-01 | 2021-04-28 | ClinicalTrials.gov |
| NCT03139630 | COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in … | — | HIV Seropositivity | Completed | 2016-03-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02634580 | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Su… | Phase3 | Hypercholesterolemia | Completed | 2016-02-27 | 2018-05-26 | ClinicalTrials.gov |
| NCT02652494 | Observational Study of Apremilast in Patients With Psoriasis in The Netherlands | — | Psoriasis | Completed | 2016-02-22 | 2020-06-30 | ClinicalTrials.gov |
| NCT02741310 | Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomita… | Phase1 | Healthy Subjects | Completed | 2016-02-22 | 2016-08-11 | ClinicalTrials.gov |
| NCT03106051 | Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Condit… | — | Arthritis, Psoriatic | Completed | 2016-02-18 | 2020-08-12 | ClinicalTrials.gov |
| NCT02512926 | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children | Phase1 | Relapsed Solid Tumors | Completed | 2016-02-16 | 2023-11-07 | ClinicalTrials.gov |
| NCT02792517 | Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in H… | Phase1 | Headache, Migraine | Completed | 2016-02-12 | 2016-09-09 | ClinicalTrials.gov |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors A… | Phase1 | Hepatocellular Carcinoma | Completed | 2016-02-05 | 2023-07-11 | ClinicalTrials.gov |
| NCT06004947 | A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential o… | Phase1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Completed | 2016-01-14 | 2016-06-10 | ClinicalTrials.gov |
| NCT02630459 | A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention | Phase2 | Migraine | Completed | 2016-01-06 | 2019-06-05 | ClinicalTrials.gov |
| NCT02641353 | Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tab… | Phase1 | Healthy Volunteers | Completed | 2016-01-05 | 2016-02-27 | ClinicalTrials.gov |
| NCT02537535 | Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada | — | Dyslipidemia | Completed | 2016-01-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT02624895 | ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EG… | — | Metastatic Colorectal Cancer | Completed | 2015-12-30 | 2020-12-31 | ClinicalTrials.gov |
| NCT02593773 | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's… | Phase3 | Friedreich's Ataxia | Completed | 2015-12-25 | 2017-03-21 | ClinicalTrials.gov |
| NCT02576652 | Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Under… | Phase4 | Osteoporosis | Completed | 2015-12-22 | 2017-12-18 | ClinicalTrials.gov |
| NCT02585895 | Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Pr… | Phase3 | Hypercholesterolemia | Completed | 2015-12-21 | 2017-01-20 | ClinicalTrials.gov |
| NCT02293109 | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymp… | Phase1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | Completed | 2015-12-17 | 2018-01-11 | ClinicalTrials.gov |
| NCT02392039 | Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggres… | Early_Phase1 | Lymphoma | Terminated | 2015-12-14 | 2018-04-04 | ClinicalTrials.gov |
| NCT05988021 | A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and C… | Phase1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Completed | 2015-12-03 | 2016-05-25 | ClinicalTrials.gov |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (No… | — | Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2015-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02565511 | A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Ons… | Phase2 | Alzheimers Disease | Terminated | 2015-11-30 | 2020-04-30 | ClinicalTrials.gov |
| NCT02575833 | Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) | Phase2 | Stable Angina | Completed | 2015-11-23 | 2017-04-13 | ClinicalTrials.gov |
| NCT02561962 | A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Completed | 2015-11-20 | 2022-04-21 | ClinicalTrials.gov |
| NCT02542605 | To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like A… | Phase1 | Migraine | Completed | 2015-11-11 | 2017-11-08 | ClinicalTrials.gov |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects Wi… | Phase3 | Leukemia, Acute Lymphoblastic | Completed | 2015-11-10 | 2022-11-21 | ClinicalTrials.gov |
| NCT02613416 | Denosumab and MRI Breast Imaging | Phase2 | Breast Cancer | Completed | 2015-11-01 | 2021-08-20 | ClinicalTrials.gov |
| NCT05873907 | A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics,… | Phase1 | Chronic Graft-versus-host Disease (cGVHD) | Completed | 2015-10-19 | 2017-07-28 | ClinicalTrials.gov |
| NCT02576678 | A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) i… | Phase2 | Psoriasis | Completed | 2015-10-13 | 2019-07-29 | ClinicalTrials.gov |
| NCT02512900 | A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents W… | Phase1 | Asthma | Completed | 2015-09-10 | 2016-05-17 | ClinicalTrials.gov |
| NCT02412878 | Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone i… | Phase3 | Multiple Myeloma | Completed | 2015-09-09 | 2019-01-07 | ClinicalTrials.gov |
| NCT02520427 | A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies | Phase1 | Relapsed/Refractory AML | Terminated | 2015-08-31 | 2022-01-09 | ClinicalTrials.gov |
| NCT02525094 | Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With A… | Phase2 | Atopic Dermatitis | Completed | 2015-08-15 | 2016-07-15 | ClinicalTrials.gov |
| NCT02626793 | A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions | — | Psoriasis | Completed | 2015-08-03 | 2018-06-14 | ClinicalTrials.gov |
| NCT02504476 | Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of … | Phase1 | Schizophrenia or Schizoaffective Disorder | Completed | 2015-08-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02567370 | Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581 | Phase1 | Schizophrenia or Schizoaffective Disorder | Completed | 2015-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02301962 | Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer | Phase4 | Cancer | Unknown | 2015-07-28 | 2022-01-31 | ClinicalTrials.gov |
| NCT02483585 | Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Pla… | Phase3 | Migraine | Completed | 2015-07-20 | 2017-03-20 | ClinicalTrials.gov |
| NCT02456740 | Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Pre… | Phase3 | Migraine | Completed | 2015-07-17 | 2017-06-19 | ClinicalTrials.gov |
| NCT02318784 | Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers | Phase2 | Neuroendocrine Cancer | Completed | 2015-07-15 | 2021-05-15 | ClinicalTrials.gov |
| NCT02453191 | TVEC and Preop Radiation for Sarcoma (4 ml Dose) | Phase1 | Soft Tissue Sarcoma | Completed | 2015-07-13 | 2023-03-10 | ClinicalTrials.gov |
| NCT03141203 | Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refract… | Phase1 | Peripheral T Cell Lymphoma | Completed | 2015-07-13 | 2021-09-23 | ClinicalTrials.gov |
| NCT02352753 | Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics o… | Phase3 | Osteogenesis Imperfecta | Terminated | 2015-06-24 | 2022-03-26 | ClinicalTrials.gov |
| NCT02315716 | Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Mult… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2015-06-16 | 2029-11-01 | ClinicalTrials.gov |
| NCT02347865 | Characteristics and Management of Postmenopausal Women With Osteoporosis Treate… | — | Post Menopausal Osteoporosis | Completed | 2015-06-16 | 2018-09-27 | ClinicalTrials.gov |
| NCT02341417 | Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (S… | Phase3 | Secondary Hyperparathyroidism, Chronic Kidney Disease | Completed | 2015-06-10 | 2017-03-15 | ClinicalTrials.gov |
| NCT02334306 | A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Ef… | Phase2 | Primary Sjögren's Syndrome | Completed | 2015-06-08 | 2018-08-13 | ClinicalTrials.gov |
| NCT02464891 | Complement Inhibition in aHUS Dialysis Patients | Phase2 | Atypical Hemolytic Uremic Syndrome | Terminated | 2015-06-04 | 2017-07-13 | ClinicalTrials.gov |
| NCT02412306 | Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor… | Phase1 | Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia | Completed | 2015-06-04 | 2019-07-04 | ClinicalTrials.gov |
| NCT02415127 | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's… | Phase3 | Friedreich's Ataxia | Completed | 2015-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02335268 | Validation of a Predictive Model of Response to Romiplostim in Patients With IP… | Phase2 | Myelodysplastic Syndromes | Completed | 2015-05-21 | 2021-07-01 | ClinicalTrials.gov |
| NCT02473445 | A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamin… | Phase2 | Mitochondrial Diseases | Terminated | 2015-05-19 | 2017-03-06 | ClinicalTrials.gov |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Mult… | Phase2 | Smoldering Multiple Myeloma | Active_Not_Recruiting | 2015-05-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT02429882 | Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects Wi… | Phase2 | Axial Spondyloarthritis | Withdrawn | 2015-05-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02335983 | Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexam… | Phase1 | Multiple Myeloma | Completed | 2015-04-30 | 2019-10-28 | ClinicalTrials.gov |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | Phase1 | Advanced Malignancy | Terminated | 2015-04-21 | 2016-12-12 | ClinicalTrials.gov |
| NCT02269085 | Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/R… | Phase1 | Lymphoma | Terminated | 2015-04-20 | 2018-05-29 | ClinicalTrials.gov |
| NCT02425826 | A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate … | Phase4 | Parapsoriasis | Completed | 2015-04-20 | 2016-11-22 | ClinicalTrials.gov |
| NCT02366195 | Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Lahe… | Phase2 | Unresected Stage IIIb to IVM1c Melanoma | Completed | 2015-04-07 | 2020-12-25 | ClinicalTrials.gov |
| NCT02435147 | Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength I… | — | Osteoporosis | Completed | 2015-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02253654 | Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidne… | Phase4 | Renal Insufficiency, Chronic | Completed | 2015-04-01 | 2016-05-25 | ClinicalTrials.gov |
| NCT02499315 | Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females Wi… | Phase1 | Rheumatoid Arthritis | Terminated | 2015-04-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02346877 | Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adu… | Phase4 | Persistence to Enbrel | Terminated | 2015-04-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02384317 | Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA… | Phase2 | Immunoglobulin A Nephropathy | Completed | 2015-03-27 | 2018-06-01 | ClinicalTrials.gov |
| NCT02376790 | Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthr… | Phase3 | Psoriatic Arthritis | Completed | 2015-03-03 | 2018-07-06 | ClinicalTrials.gov |
| NCT02273570 | Optimal Anemia Treatment in End Stage Renal Disease (ERSD) | Na | Hyperparathyroidism, Secondary | Unknown | 2015-03-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02373813 | Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of … | Phase3 | Rheumatoid Arthritis | Completed | 2015-02-20 | 2019-12-06 | ClinicalTrials.gov |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children Wit… | Phase1 | Acute Lymphoblastic Leukemia (ALL) | Completed | 2015-02-16 | 2024-06-28 | ClinicalTrials.gov |
| NCT01952054 | Denosumab for Breast Cancer With Bone Mets | Phase2 | Breast Cancer | Terminated | 2015-02-09 | 2018-10-10 | ClinicalTrials.gov |
| NCT02222155 | Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vas… | Phase2 | ANCA-associated Vasculitis | Completed | 2015-02-04 | 2016-07-19 | ClinicalTrials.gov |
| NCT02211131 | Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surg… | Phase2 | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma | Completed | 2015-02-03 | 2022-04-28 | ClinicalTrials.gov |
| NCT02345408 | Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma | Phase1 | Pancreatic Cancer | Completed | 2015-02-01 | 2020-05-06 | ClinicalTrials.gov |
| NCT02332850 | Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Re… | Phase1 | Multiple Myeloma | Completed | 2015-01-21 | 2025-12-31 | ClinicalTrials.gov |
| NCT02289417 | Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis | Phase2 | Ulcerative Colitis | Completed | 2015-01-08 | 2019-06-03 | ClinicalTrials.gov |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy | Phase3 | Lung Cancer Non-small Cell Stage IV | Terminated | 2015-01-06 | 2020-02-29 | ClinicalTrials.gov |
| NCT02274792 | Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Mo… | Phase4 | Plaque Psoriasis | Completed | 2015-01-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02246218 | A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate… | Phase4 | Urea Cycle Disorder | Completed | 2014-12-31 | 2017-07-17 | ClinicalTrials.gov |
| NCT02307513 | A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of… | Phase3 | Behçet's Syndrome | Completed | 2014-12-30 | 2020-07-17 | ClinicalTrials.gov |
| NCT02279173 | Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immu… | Phase3 | Immune Thrombocytopenia | Completed | 2014-12-10 | 2019-08-08 | ClinicalTrials.gov |
| NCT02303522 | Historical Data Analysis of Complete Remission in Children With R/R Acute Lymph… | — | B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Completed | 2014-12-09 | 2015-01-22 | ClinicalTrials.gov |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma | Phase3 | Melanoma | Terminated | 2014-12-08 | 2021-03-11 | ClinicalTrials.gov |
| NCT02215200 | ATG-GCSF in New Onset Type 1 Diabetes | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2014-12-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC an… | Phase3 | Tubular Breast Cancer Stage II | Completed | 2014-12-01 | 2017-01-30 | ClinicalTrials.gov |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Ad… | Phase1 | Advanced Hepatocellular Carcinoma | Withdrawn | 2014-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m… | Phase2 | Multiple Myeloma | Terminated | 2014-12-01 | 2020-09-22 | ClinicalTrials.gov |
| NCT02442648 | B-Cell Targeted Carfilzomib Desensitization | Phase1 | Transplants and Implants | Unknown | 2014-12-01 | 2021-09-01 | ClinicalTrials.gov |
| NCT02291614 | A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer | Phase1 | GI Adenocarcinoma | Terminated | 2014-11-27 | 2018-01-09 | ClinicalTrials.gov |
| NCT05995691 | Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adali… | Phase1 | Healthy Volunteers | Completed | 2014-11-24 | 2015-12-04 | ClinicalTrials.gov |
| NCT02304484 | Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab | Phase3 | Hypercholesterolemia | Completed | 2014-11-24 | 2018-03-09 | ClinicalTrials.gov |
| NCT02322736 | Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCR… | — | Metastatic Colorectal Cancer | Completed | 2014-11-21 | 2018-08-03 | ClinicalTrials.gov |
| NCT02138838 | Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperpar… | Phase3 | Chronic Kidney Disease, Secondary Hyperparathyroidism | Terminated | 2014-11-07 | 2016-06-23 | ClinicalTrials.gov |
| NCT02101164 | Evaluate Time Associated With the Preparation & Administration of Denosumab/Pam… | Phase4 | Solid Tumor | Withdrawn | 2014-11-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02287610 | A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis | — | Rheumatoid Arthritis | Completed | 2014-11-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02235740 | A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); t… | Phase1 | Cancer | Terminated | 2014-11-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02517944 | MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CH… | — | Familial Hypercholesterolemia - Heterozygous | Unknown | 2014-11-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT06004960 | A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metaboli… | Phase1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Completed | 2014-10-20 | 2014-12-05 | ClinicalTrials.gov |
| NCT02420587 | AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Canc… | Phase2 | Prostate Cancer | Withdrawn | 2014-10-01 | — | ClinicalTrials.gov |
| NCT02103283 | A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular E… | Phase1 | Diabetic Macular Edema | Completed | 2014-10-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02207634 | Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiov… | Phase3 | Dyslipidemia | Completed | 2014-09-10 | 2016-11-11 | ClinicalTrials.gov |
| NCT02275156 | Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage … | Phase1 | Hyperlipidemia | Completed | 2014-08-19 | 2014-12-19 | ClinicalTrials.gov |
| NCT02257476 | Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced So… | Phase1 | Neoplasms | Completed | 2014-08-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02244112 | A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With … | Phase1 | Advanced Non-Central Nervous System (CNS) Malignancies | Terminated | 2014-08-01 | 2019-07-10 | ClinicalTrials.gov |
| NCT01999335 | A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Re… | Phase1 | Multiple Myeloma | Terminated | 2014-07-30 | 2019-04-25 | ClinicalTrials.gov |
| NCT02178475 | Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim P… | — | Chemotherapy-induced Febrile Neutropenia | Completed | 2014-07-18 | 2016-10-28 | ClinicalTrials.gov |
| NCT02189837 | Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal … | Phase3 | Primary Hyperlipidemia and Mixed Dyslipidemia | Completed | 2014-07-08 | 2015-03-05 | ClinicalTrials.gov |
| NCT02170337 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Chronic Rhinosinusitis With Nasal Polyps | Completed | 2014-07-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02085993 | Study of Patients With ITP Estimating the Proportion Administering Romiplostim … | — | Immune Thrombocytopenic Purpura | Completed | 2014-07-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02137343 | A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) a… | Phase3 | Gastric Cancer | Terminated | 2014-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02174861 | A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Ch… | Phase2 | Treatment for Prevention of Chronic Migraine | Completed | 2014-06-30 | 2017-05-26 | ClinicalTrials.gov |
| NCT01926665 | Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (A… | Phase1 | Lymphoma | Completed | 2014-06-17 | 2017-09-17 | ClinicalTrials.gov |
| NCT02186171 | A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Plac… | Phase3 | Osteoporosis in Men | Completed | 2014-06-16 | 2016-04-20 | ClinicalTrials.gov |
| NCT02175277 | Darbepoetin Alfa MDS Companion Protocol | Phase3 | Myelodysplastic Syndrome (MDS) | Completed | 2014-06-12 | 2017-03-20 | ClinicalTrials.gov |
| NCT02128230 | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining… | Phase2 | Multiple Myeloma | Terminated | 2014-06-10 | 2019-02-19 | ClinicalTrials.gov |
| NCT02185911 | Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing… | — | Anaemia | Completed | 2014-06-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02087943 | Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Ato… | Phase2 | Dermatitis, Atopic Dermatitis | Completed | 2014-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02191150 | Study of Haemodialysis Patients Switching From Aranesp to Biosimilar | — | Anaemia | Completed | 2014-06-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02157948 | A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by… | Phase3 | Postmenopausal Osteoporosis | Completed | 2014-05-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02023866 | Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of … | Phase2 | Inherited Mitochondrial Disease, Including Leigh Syndrome | Completed | 2014-05-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02132429 | Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, … | Phase1 | Migraine | Terminated | 2014-05-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01959698 | Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Pati… | Phase1 | CD20 Positive | Active_Not_Recruiting | 2014-04-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT02096666 | A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects | Phase1 | Stomach Neoplasms | Completed | 2014-04-15 | 2018-12-07 | ClinicalTrials.gov |
| NCT02014441 | Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Lah… | Phase2 | Melanoma | Completed | 2014-04-07 | 2018-04-19 | ClinicalTrials.gov |
| NCT02114931 | Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rh… | Phase3 | Arthritis, Rheumatoid | Completed | 2014-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02099461 | Effect of Denosumab on Cellular Biomarkers in the Human Breast | Phase1 | Healthy Volunteer, Female, Breast | Completed | 2014-04-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01991873 | Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior… | Phase2 | Metastatic Colorectal Cancer | Completed | 2014-04-01 | 2023-02-18 | ClinicalTrials.gov |
| NCT02047253 | Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cance… | Phase2 | Metastatic Castration-resistant Prostate Cancer | Completed | 2014-04-01 | 2017-07-14 | ClinicalTrials.gov |
| NCT02102204 | Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism… | Phase3 | Hyperparathyroidism, Secondary | Completed | 2014-03-25 | 2017-06-26 | ClinicalTrials.gov |
| NCT01971346 | The Immunological Basis for Treatment Resistance to Anti-TNF Treatments | Phase4 | Psoriasis | Completed | 2014-03-13 | 2017-11-01 | ClinicalTrials.gov |
| NCT02066415 | A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Mi… | Phase2 | Treatment for Prevention of Chronic Migraine | Completed | 2014-03-05 | 2016-04-28 | ClinicalTrials.gov |
| NCT02054572 | Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With… | Phase1 | Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis | Completed | 2014-02-07 | 2014-08-15 | ClinicalTrials.gov |
| NCT02126449 | DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative… | Phase2 | Fasting Mimicking Diet | Completed | 2014-02-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT02016534 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or … | Phase2 | Stomach Neoplasms | Terminated | 2014-02-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carc… | Phase2 | Urothelial Carcinoma | Withdrawn | 2014-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02053753 | Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available D… | Phase1 | Healthy Volunteer | Completed | 2014-02-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02052882 | Study of Romiplostim for Chemotherapy Induced Thrombocytopenia | Phase2 | Isolated Chemotherapy-induced Thrombocytopenia | Completed | 2014-01-30 | 2023-11-13 | ClinicalTrials.gov |
| NCT02302495 | Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptoma… | Phase2 | Multiple Myeloma | Completed | 2014-01-08 | 2021-07-31 | ClinicalTrials.gov |
| NCT02236988 | Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations O… | Phase1 | Healthy Volunteers | Completed | 2014-01-07 | 2014-09-11 | ClinicalTrials.gov |
| NCT02000427 | Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precurs… | Phase2 | Relapsed/Refractory Philadelphia Positive B-precursor ALL | Completed | 2014-01-03 | 2017-01-06 | ClinicalTrials.gov |
| NCT02013167 | Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or … | Phase3 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Terminated | 2014-01-03 | 2017-03-14 | ClinicalTrials.gov |
| NCT01949532 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multip… | Phase1 | Relapsed Multiple Myeloma | Completed | 2014-01-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02066805 | Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databa… | — | XGEVA Off-label Use | Completed | 2014-01-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patien… | Phase1 | Multiple Myeloma | Completed | 2014-01-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02208869 | Russian Familial Hypercholesterolemia Registry | — | Familial Hypercholesterolemia | Recruiting | 2014-01-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT01951586 | Denosumab in Combination With Chemotherapy as First-line Treatment of Metastati… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2013-12-31 | 2017-11-28 | ClinicalTrials.gov |
| NCT02054130 | Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjec… | Phase2 | Asthma | Completed | 2013-12-13 | 2017-03-01 | ClinicalTrials.gov |
| NCT01984424 | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Su… | Phase3 | Hyperlipidemia | Completed | 2013-12-10 | 2017-11-21 | ClinicalTrials.gov |
| NCT02016716 | A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postm… | Phase3 | Postmenopausal Osteoporosis | Completed | 2013-12-03 | 2014-12-08 | ClinicalTrials.gov |
| NCT01926158 | Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Wo… | Phase4 | Hip Osteoarthritis | Completed | 2013-12-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT01349088 | Investigational Drug in Combination With Two Chemotherapy Drugs in Women With L… | Phase1 | Breast Cancer | Withdrawn | 2013-12-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT01966003 | Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With… | Phase3 | Non-small Cell Lung Cancer Metastatic | Completed | 2013-11-11 | 2015-07-23 | ClinicalTrials.gov |
| NCT01987232 | Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Pr… | Phase1 | Extensive-Stage Small-Cell Lung Cancer | Completed | 2013-11-05 | 2017-05-04 | ClinicalTrials.gov |
| NCT02009345 | Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada | — | Familial Hypercholesterolemia | Recruiting | 2013-11-01 | 2028-11-01 | ClinicalTrials.gov |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosp… | Phase1 | Multiple Myeloma | Terminated | 2013-10-28 | 2019-09-23 | ClinicalTrials.gov |
| NCT01970488 | Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adu… | Phase3 | Psoriasis | Completed | 2013-10-18 | 2015-03-18 | ClinicalTrials.gov |
| NCT01953328 | Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab… | Phase3 | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | Completed | 2013-10-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01953341 | Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Mi… | Phase1 | Migraine | Completed | 2013-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02003612 | Historical Data Analysis of Hematological Remission and Survival in Adults With… | — | Acute Lymphoblastic Leukemia | Completed | 2013-10-01 | 2014-04-28 | ClinicalTrials.gov |
| NCT01949545 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanc… | Phase1 | Solid Tumors | Completed | 2013-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01970475 | Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Mo… | Phase3 | Arthritis, Rheumatoid | Completed | 2013-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01948427 | Observational Study That Will Collect Information on Patients With Urea Cycle D… | — | Urea Cycle Disorder | Terminated | 2013-09-25 | 2020-02-24 | ClinicalTrials.gov |
| NCT01925768 | Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis | Phase3 | Psoriatic Arthritis | Completed | 2013-09-04 | 2016-11-17 | ClinicalTrials.gov |
| NCT01775553 | Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed… | Phase2 | Relapse Multiple Myeloma | Completed | 2013-09-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02010931 | Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Le… | — | Acute Lymphoblastic Leukemia | Completed | 2013-09-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01896232 | Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet | Phase3 | Secondary Hyperparathyroidism | Completed | 2013-08-13 | 2015-01-08 | ClinicalTrials.gov |
| NCT01932970 | Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Se… | Phase3 | Hyperparathyroidism, Secondary | Completed | 2013-08-12 | 2017-02-14 | ClinicalTrials.gov |
| NCT01952574 | Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Pre… | Phase2 | Migraine | Completed | 2013-08-06 | 2019-11-12 | ClinicalTrials.gov |
| NCT01920568 | A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metasta… | Phase3 | Fractures, Bone | Completed | 2013-08-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01916109 | Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemot… | Phase2 | Bladder Cancer | Terminated | 2013-08-01 | — | ClinicalTrials.gov |
| NCT01928368 | A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subje… | Phase1 | Asthma | Completed | 2013-08-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01980589 | A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and … | Phase1 | Multiple Myeloma | Completed | 2013-08-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01785875 | Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroid… | Phase3 | Hyperparathyroidism, Secondary | Completed | 2013-07-31 | 2015-07-01 | ClinicalTrials.gov |
| NCT01879319 | Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either… | Phase3 | Primary Hypercholesterolemia | Completed | 2013-07-11 | — | ClinicalTrials.gov |
| NCT01988103 | Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Pat… | Phase2 | Psoriasis | Completed | 2013-07-09 | 2015-12-15 | ClinicalTrials.gov |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, P… | Phase3 | Multiple Myeloma | Completed | 2013-07-08 | 2016-11-04 | ClinicalTrials.gov |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Pat… | Phase1 | Multiple Myeloma | Terminated | 2013-07-02 | 2019-06-25 | ClinicalTrials.gov |
| NCT01868997 | Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease | Phase2 | Thyroid Associated Ophthalmopathies | Completed | 2013-07-01 | 2017-02-22 | ClinicalTrials.gov |
| NCT01172717 | Study of Panitumumab in the Treatment of Carcinoid Syndrome | Phase2 | Carcinoid Syndrome | Withdrawn | 2013-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01901185 | Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriati… | Phase3 | Rheumatoid Arthritis | Completed | 2013-06-11 | 2013-12-30 | ClinicalTrials.gov |
| NCT01875991 | Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and … | Phase4 | Rheumatoid Arthritis | Completed | 2013-06-05 | 2014-03-04 | ClinicalTrials.gov |
| NCT01869686 | Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Me… | Phase1 | Healthy Volunteer | Completed | 2013-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01508000 | Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab i… | Phase2 | Colorectal Cancer Metastatic | Terminated | 2013-06-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01902290 | Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With… | Phase2 | Asthma | Terminated | 2013-05-22 | 2015-05-15 | ClinicalTrials.gov |
| NCT01890109 | Study of Erenumab (AMG 334) in Women With Hot Flashes | Phase1 | Vasomotor Symptoms; Hot Flashes | Completed | 2013-05-13 | 2014-03-11 | ClinicalTrials.gov |
| NCT01927757 | Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthri… | Phase4 | Moderate to Severe Rheumatoid Arthritis | Terminated | 2013-05-06 | 2015-06-11 | ClinicalTrials.gov |
| NCT01901146 | Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HE… | Phase3 | Breast Cancer | Completed | 2013-04-29 | 2017-01-27 | ClinicalTrials.gov |
| NCT01854918 | Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemi… | Phase3 | Hyperlipidemia and Mixed Dyslipidemia | Completed | 2013-04-23 | 2018-05-31 | ClinicalTrials.gov |
| NCT01833754 | Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patient… | Phase1 | Osteoporosis | Completed | 2013-04-22 | 2014-02-19 | ClinicalTrials.gov |
| NCT01813422 | GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by int… | Phase3 | Hypercholesterolemia | Completed | 2013-04-18 | 2016-07-29 | ClinicalTrials.gov |
| NCT01849497 | Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe o… | Phase3 | Primary Hypercholesterolemia | Completed | 2013-04-18 | — | ClinicalTrials.gov |
| NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib f… | Phase1 | Multiple Myeloma | Unknown | 2013-04-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01890577 | Study of South African Dialysis Patients | — | Chronic Kidney Disease, Receiving Dialysis | Terminated | 2013-04-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01738594 | Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T… | Phase1 | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Terminated | 2013-03-22 | 2016-10-11 | ClinicalTrials.gov |
| NCT01788046 | Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hy… | Phase3 | Hyperparathyroidism, Secondary | Completed | 2013-03-12 | 2014-05-09 | ClinicalTrials.gov |
| NCT01785849 | Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hy… | Phase3 | Hyperparathyroidism, Secondary | Completed | 2013-03-12 | 2014-06-12 | ClinicalTrials.gov |
| NCT01842776 | Care Transitions in Renal Disease Patients | — | Renal Disease | Unknown | 2013-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01856881 | Multiple Ascending Dose Study in Subjects With Type 2 Diabetes | Phase1 | Diabetes Mellitus | Terminated | 2013-03-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01764633 | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With… | Phase3 | Dyslipidemia | Completed | 2013-02-08 | 2016-11-11 | ClinicalTrials.gov |
| NCT01763918 | Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholeste… | Phase3 | Hyperlipidemia | Completed | 2013-02-07 | 2013-12-19 | ClinicalTrials.gov |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | Phase1 | Melanoma | Completed | 2013-02-07 | 2021-03-09 | ClinicalTrials.gov |
| NCT01998607 | Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summa… | — | Solid Tumours | Completed | 2013-02-04 | 2015-05-15 | ClinicalTrials.gov |
| NCT01789242 | A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Ligh… | Phase1 | Amyloidosis | Completed | 2013-02-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After … | Phase2 | Mucinous Adenocarcinoma of the Colon | Completed | 2013-02-01 | 2018-08-06 | ClinicalTrials.gov |
| NCT01733316 | Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate De… | Phase3 | Cystinosis | Completed | 2013-01-31 | 2017-07-10 | ClinicalTrials.gov |
| NCT01796301 | An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Ter… | Phase3 | Postmenopausal Osteoporosis | Completed | 2013-01-31 | 2015-05-14 | ClinicalTrials.gov |
| NCT01763905 | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Su… | Phase3 | Hyperlipidemia | Completed | 2013-01-24 | 2013-11-19 | ClinicalTrials.gov |
| NCT01763827 | Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currentl… | Phase3 | Hyperlipidemia | Completed | 2013-01-21 | 2013-10-29 | ClinicalTrials.gov |
| NCT01752907 | Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Rec… | Phase2 | Breast Cancer | Completed | 2013-01-17 | 2014-12-15 | ClinicalTrials.gov |
| NCT01763866 | LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin… | Phase3 | Hyperlipidemia | Completed | 2013-01-15 | 2013-12-04 | ClinicalTrials.gov |
| NCT01660750 | A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT i… | Phase1 | Multiple Myeloma | Completed | 2013-01-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01745068 | Partnership for Applied Research in Fracture Prevention Programs for the Elderly | Na | Osteoporosis With Current Fragility Fracture | Unknown | 2013-01-01 | 2019-06-01 | ClinicalTrials.gov |
| NCT01744782 | Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (R… | Phase3 | Cystinosis | Completed | 2012-12-20 | 2016-12-13 | ClinicalTrials.gov |
| NCT01732783 | Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Can… | — | Wild-type RAS Metastatic Colorectal Cancer | Completed | 2012-12-10 | 2016-11-30 | ClinicalTrials.gov |
| NCT01696396 | Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2012-12-04 | 2018-04-10 | ClinicalTrials.gov |
| NCT01813721 | Study Investigating How Physicians Assess the Risk of Patients Developing Febri… | — | Chemotherapy-induced Febrile Neutropenia | Completed | 2012-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01694485 | Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis | Phase2 | Ulcerative Colitis | Completed | 2012-11-16 | 2018-04-10 | ClinicalTrials.gov |
| NCT01723514 | Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migrain… | Phase1 | Migraine | Completed | 2012-11-14 | 2014-07-10 | ClinicalTrials.gov |
| NCT01732770 | Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid i… | Phase4 | Post Menopausal Osteoporosis | Completed | 2012-11-07 | 2015-01-07 | ClinicalTrials.gov |
| NCT01755442 | Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Le… | Phase1 | Diabetes Mellitus | Terminated | 2012-11-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01791374 | Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors… | Phase1 | Part 1- Advanced Solid Tumors | Completed | 2012-11-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01712009 | NOLAN: Naproxen or Loratadine and Neulasta | Phase2 | Bone Pain in Stage I - III Breast Cancer | Completed | 2012-11-01 | 2015-03-18 | ClinicalTrials.gov |
| NCT01545648 | Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DT… | Phase2 | Early Stage Breast Cancer | Terminated | 2012-11-01 | 2016-06-09 | ClinicalTrials.gov |
| NCT01479179 | Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing… | Phase1 | Breast Cancer | Withdrawn | 2012-11-01 | — | ClinicalTrials.gov |
| NCT01992159 | Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese W… | Phase2 | Postmenopausal Osteoporosis (PMO) | Completed | 2012-10-12 | 2015-06-17 | ClinicalTrials.gov |
| NCT01690299 | Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Pl… | Phase3 | Psoriasis | Completed | 2012-10-01 | 2016-04-04 | ClinicalTrials.gov |
| NCT01666106 | Osteonecrosis of the Jaw (ONJ) Case Registry | — | Osteonecrosis of the Jaw | Completed | 2012-10-01 | 2020-12-16 | ClinicalTrials.gov |
| NCT01695876 | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Ph… | Phase1 | Inflammatory Disease | Completed | 2012-10-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01692912 | Psoriatic Arthritis Treat to Target vs. Usual Care | Na | Psoriatic Arthritis (PsA) | Withdrawn | 2012-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial … | Phase3 | Gastric Cancer | Terminated | 2012-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01737879 | Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Rece… | Phase4 | Anemia | Terminated | 2012-10-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01791361 | Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Us… | — | Metastatic Colorectal Cancer | Completed | 2012-09-19 | 2015-06-02 | ClinicalTrials.gov |
| NCT01690702 | Study of Nab-Paclitaxel in High Risk Early Breast Cancer | Phase3 | Breast Cancer | Completed | 2012-09-01 | 2020-07-20 | ClinicalTrials.gov |
| NCT01936376 | A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In… | — | Head and Neck Cancer | Unknown | 2012-09-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lu… | Phase1 | Non Small Cell Lung Cancer | Completed | 2012-08-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01997892 | TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Unio… | — | Anemia | Completed | 2012-08-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01652872 | Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disea… | Phase3 | Anemia in Chronic Kidney Disease Patients Not on Dialysis | Completed | 2012-07-30 | 2017-10-19 | ClinicalTrials.gov |
| NCT01652703 | A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japane… | Phase2 | Hypercholesterolemia and High Risk for Cardiovascular Events | Completed | 2012-07-10 | — | ClinicalTrials.gov |
| NCT01677858 | A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive… | Phase1 | Multiple Myeloma | Completed | 2012-07-04 | 2018-10-31 | ClinicalTrials.gov |
| NCT01992341 | AMG 386 Drug-Drug Interaction Study With Paclitaxel | Phase1 | Advanced Solid Tumors | Completed | 2012-07-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01652690 | Prospective Observational Study to Describe Characteristics and Management of P… | — | Osteoporosis, Postmenopausal | Completed | 2012-06-26 | 2015-05-15 | ClinicalTrials.gov |
| NCT01439867 | Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney D… | Phase2 | Chronic Kidney Disease | Terminated | 2012-06-22 | 2016-06-03 | ClinicalTrials.gov |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexameth… | Phase3 | Multiple Myeloma | Completed | 2012-06-20 | 2018-02-05 | ClinicalTrials.gov |
| NCT01683695 | Safety Study of AMG 557 in Subjects With Lupus Arthritis | Phase1 | Lupus Arthritis, Systemic Lupus Erythematosus | Completed | 2012-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01624142 | Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL … | Phase2 | Severe Familial Hypercholesterolemia | Completed | 2012-06-01 | 2018-05-11 | ClinicalTrials.gov |
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patie… | Phase3 | Cancer | Completed | 2012-05-17 | 2019-03-29 | ClinicalTrials.gov |
| NCT01631214 | Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of P… | Phase3 | Postmenopausal Women With Osteoporosis | Completed | 2012-05-04 | 2017-06-29 | ClinicalTrials.gov |
| NCT01583374 | Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis | Phase3 | Ankylosing Spondyloarthritis | Completed | 2012-05-02 | 2018-10-25 | ClinicalTrials.gov |
| NCT01250405 | Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in H… | Phase4 | Chronic Kidney Disease | Completed | 2012-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01627379 | Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or … | Phase3 | Esophageal Squamous Cell Cancer | Terminated | 2012-05-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT01690143 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematop… | Phase1 | Multiple Myeloma | Completed | 2012-05-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT01568216 | 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Sym… | Phase2 | Schizophrenia | Terminated | 2012-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01568229 | 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Sym… | Phase2 | Schizophrenia | Terminated | 2012-05-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01588496 | Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities | Phase2 | Homozygous Familial Hypercholesterolemia | Completed | 2012-04-05 | 2014-01-31 | ClinicalTrials.gov |
| NCT01563185 | Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidin… | Phase4 | Juvenile Idiopathic Arthritis | Completed | 2012-04-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01544114 | A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) | Phase4 | Juvenile Idiopathic Arthritis (JIA) | Completed | 2012-04-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01588509 | Transition From Alendronate to Romosozumab (AMG 785) | Phase1 | Osteoporosis | Completed | 2012-03-30 | 2012-11-21 | ClinicalTrials.gov |
| NCT01575873 | Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Takin… | Phase3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | Completed | 2012-03-28 | 2017-06-29 | ClinicalTrials.gov |
| NCT01575834 | Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteo… | Phase3 | Postmenopausal Osteoporosis | Completed | 2012-03-15 | 2016-12-28 | ClinicalTrials.gov |
| NCT01688739 | Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Pat… | Phase1 | Migraine | Completed | 2012-03-13 | 2013-03-27 | ClinicalTrials.gov |
| NCT01701076 | Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Ther… | Phase2 | Multiple Myeloma | Completed | 2012-03-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT03315468 | French Clinical Datbase of Melanoma Patients (RIC-Mel) | — | Melanoma (Skin) | Recruiting | 2012-03-01 | 2030-03-01 | ClinicalTrials.gov |
| NCT01652833 | European Physician Survey of EGFR Inhibitor Prescribing Patterns | — | Metastatic Colorectal Cancer | Completed | 2012-03-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01543620 | Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephro… | — | Cystic Fibrosis | Unknown | 2012-02-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01634191 | Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults | Phase1 | Healthy Volunteer | Completed | 2012-02-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01634178 | Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adul… | Phase1 | Healthy Volunteer | Completed | 2012-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01561963 | A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmac… | Phase1 | Healthy Subjects | Completed | 2012-02-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01543204 | Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who L… | Phase4 | Psoriasis | Terminated | 2012-02-01 | 2015-05-29 | ClinicalTrials.gov |
| NCT01541072 | Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrast… | Na | Non Hodgkin Lymphoma | Terminated | 2012-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01475006 | AMG 595 First-in-Human in Recurrent Gliomas | Phase1 | Advanced Malignant Glioma | Completed | 2012-02-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01516879 | Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study | Phase3 | Hypercholesterolemia | Completed | 2012-01-05 | 2013-10-14 | ClinicalTrials.gov |
| NCT01967160 | Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treat… | — | Osteonecrosis of the Jaw | Completed | 2012-01-02 | 2019-08-05 | ClinicalTrials.gov |
| NCT01497821 | AMG 172 First in Human Study in Patients With Kidney Cancer | Phase1 | Renal Cell Adenocarcinoma | Completed | 2012-01-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01444417 | Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP)… | Phase3 | Idiopathic Thrombocytopenic Purpura | Completed | 2012-01-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01558115 | Denosumab in Primary Hyperparathyroidism | Phase4 | Primary Hyperparathyroidism | Terminated | 2012-01-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01549431 | Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapse… | Phase1 | Multiple Myeloma | Completed | 2012-01-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02922192 | Incidence of Hospitalizations for Serious Infections in Patients Receiving Biol… | — | Rheumatoid Arthritis | Completed | 2012-01-01 | 2020-06-01 | ClinicalTrials.gov |
| NCT01493505 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel… | Phase3 | Fallopian Tube Cancer | Terminated | 2012-01-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01362140 | Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodyspla… | Phase3 | MDS | Completed | 2011-12-21 | 2017-09-14 | ClinicalTrials.gov |
| NCT01358669 | Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Art… | Phase2 | Revision Surgery of Total Hip Arthroplasty | Completed | 2011-12-14 | 2021-12-31 | ClinicalTrials.gov |
| NCT01514981 | AMG 761 in Adults With Asthma | Phase1 | Asthma | Terminated | 2011-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01312493 | Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Pan… | Phase2 | Head and Neck Cancer | Withdrawn | 2011-12-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01668589 | Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteopo… | — | Postmenopausal Osteoporosis | Completed | 2011-11-28 | 2015-08-31 | ClinicalTrials.gov |
| NCT01419717 | Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer | Phase3 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Completed | 2011-11-22 | 2018-08-10 | ClinicalTrials.gov |
| NCT01412957 | Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supp… | Phase3 | Metastatic Colorectal Cancer | Completed | 2011-11-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01492465 | Single Ascending Dose Trial in Patients With Type 2 Diabetes | Phase1 | Diabetes Mellitus | Terminated | 2011-11-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01464931 | Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 m… | Phase1 | Renal Impairment | Completed | 2011-11-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01516619 | Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Th… | Phase2 | Non-Hodgkin Lymphoma | Completed | 2011-11-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01464034 | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone … | Phase1 | Multiple Myeloma | Terminated | 2011-11-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT01493518 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects … | Phase1 | Psoriasis | Terminated | 2011-11-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01555268 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute … | Phase1 | Adult Acute Megakaryoblastic Leukemia (M7) | Completed | 2011-10-31 | 2016-08-03 | ClinicalTrials.gov |
| NCT01405963 | Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild … | Phase1 | Asthma | Completed | 2011-10-31 | 2013-04-05 | ClinicalTrials.gov |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hemat… | Phase1 | Multiple Myeloma | Terminated | 2011-10-15 | 2019-08-12 | ClinicalTrials.gov |
| NCT01439880 | Open Label Study of Long Term Evaluation Against LDL-C Trial | Phase2 | Hypercholesterolemia | Completed | 2011-10-07 | 2018-06-20 | ClinicalTrials.gov |
| NCT01380756 | Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myelo… | Phase1 | Cancer | Completed | 2011-10-04 | 2014-09-04 | ClinicalTrials.gov |
| NCT01447147 | A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabet… | Phase2 | Diabetic Nephropathy | Completed | 2011-10-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01470196 | Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2011-10-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01444456 | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced… | — | Anemia | Completed | 2011-10-01 | — | ClinicalTrials.gov |
| NCT01389895 | Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus | Phase1 | Cutaneous Lupus | Terminated | 2011-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01331941 | A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired … | Phase1 | Advanced Solid Tumors | Completed | 2011-09-19 | — | ClinicalTrials.gov |
| NCT01568203 | First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With … | Phase1 | Schizophrenia | Terminated | 2011-09-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01363388 | A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Ass… | Phase2 | Vasculitis | Completed | 2011-09-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01440257 | A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subj… | Phase2 | Diabetic Nephropathy | Completed | 2011-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01464437 | AMG 151 Amgen Protocol Number 20100761 | Phase2 | Diabetes Mellitus | Completed | 2011-09-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01375751 | Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition … | Phase2 | Hypercholesterolemia, Familial | Completed | 2011-08-02 | 2012-05-16 | ClinicalTrials.gov |
| NCT01233687 | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2011-08-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT00984217 | Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies | Phase2 | Adenoma, Pleomorphic | Withdrawn | 2011-08-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01510951 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects … | Phase1 | Psoriasis | Completed | 2011-08-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01384994 | Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS … | Phase2 | Colorectal Cancer | Unknown | 2011-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01375764 | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Su… | Phase2 | Hyperlipidemia | Completed | 2011-07-28 | 2012-05-08 | ClinicalTrials.gov |
| NCT02732210 | Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis | — | Osteoporosis, Age-Related | Completed | 2011-07-06 | 2014-04-14 | ClinicalTrials.gov |
| NCT01375777 | Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Ch… | Phase2 | Hyperlipidemia | Completed | 2011-07-06 | 2012-03-02 | ClinicalTrials.gov |
| NCT01380730 | LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PC… | Phase2 | Hyperlipidemia | Completed | 2011-07-01 | 2012-04-05 | ClinicalTrials.gov |
| NCT01347073 | Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Sub… | Phase3 | Urea Cycle Disorders | Completed | 2011-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01277510 | Pediatric Chronic Kidney Disease Safety and Efficacy | Phase3 | Chronic Kidney Disease | Terminated | 2011-06-28 | — | ClinicalTrials.gov |
| NCT01336920 | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | Phase1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Completed | 2011-06-21 | 2018-03-01 | ClinicalTrials.gov |
| NCT01395485 | Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma | Phase1 | Asthma | Withdrawn | 2011-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01671319 | Dose Dense TC + Pegfilgrastim Support for Breast Cancer | Phase2 | Female Breast Cancer | Completed | 2011-06-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01351623 | Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2011-05-09 | 2016-01-26 | ClinicalTrials.gov |
| NCT01365559 | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory … | Phase1 | Multiple Myeloma | Completed | 2011-05-02 | 2016-03-01 | ClinicalTrials.gov |
| NCT01313884 | Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ew… | Phase2 | Bone Cancer | Terminated | 2011-05-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | Phase3 | Fallopian Tube Cancer | Terminated | 2011-04-18 | 2017-04-19 | ClinicalTrials.gov |
| NCT01300026 | AMG 319 Lymphoid Malignancy FIH | Phase1 | Cancer | Completed | 2011-04-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01182610 | Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Re… | Phase2 | Gastroesophageal Adenocarcinoma | Terminated | 2011-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01313221 | Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agen… | Phase3 | Psoriasis | Completed | 2011-04-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01328171 | FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) | Phase2 | Metastatic Colorectal Cancer | Completed | 2011-04-01 | 2022-01-01 | ClinicalTrials.gov |
| NCT01264328 | Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment… | Phase2 | Head and Neck Cancer | Completed | 2011-03-09 | 2014-09-29 | ClinicalTrials.gov |
| NCT01312857 | Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovo… | Phase2 | Metastatic Colorectal Cancer | Completed | 2011-03-07 | 2024-07-15 | ClinicalTrials.gov |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | Phase2 | Advanced Solid Tumors | Completed | 2011-03-03 | 2020-02-05 | ClinicalTrials.gov |
| NCT01325194 | CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis | Phase2 | Primary Disease | Completed | 2011-03-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT01313208 | Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel) | Phase4 | Rheumatoid Arthritis | Completed | 2011-03-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01294397 | Effects of Denosumab on the Pharmacokinetics of Etanercept | Phase1 | Postmenopausal | Terminated | 2011-03-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01199302 | Long-term Safety Study of Brodalumab in Adults With Crohn's Disease | Phase2 | Crohn's Disease | Terminated | 2011-02-02 | 2011-10-18 | ClinicalTrials.gov |
| NCT01296035 | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | Phase2 | Ovarian Cancer | Terminated | 2011-02-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01290042 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o… | Phase1 | Ulcerative Colitis | Completed | 2011-02-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01161498 | Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Rad… | Phase3 | Squamous Cell Carcinoma | Terminated | 2011-02-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01290029 | Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | Phase1 | Chronic Kidney Disease | Completed | 2011-01-25 | 2015-09-23 | ClinicalTrials.gov |
| NCT01270347 | Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosi… | Phase3 | Cystic Fibrosis | Completed | 2011-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01824342 | Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refr… | Phase3 | Castrate-resistant Prostate Cancer | Completed | 2011-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01305772 | Identification of Gene Expression Signature for Panitumumab Sensitivity in Untr… | Phase2 | Squamous Cell Carcinoma of the Head and Neck | Terminated | 2011-01-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT02922179 | Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics | — | Diabetes | Completed | 2011-01-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT01307423 | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (Ps… | Phase3 | Psoriatic Arthritis | Completed | 2010-12-09 | 2017-08-16 | ClinicalTrials.gov |
| NCT01285310 | Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With … | Phase2 | Rheumatoid Arthritis | Terminated | 2010-12-09 | 2012-09-10 | ClinicalTrials.gov |
| NCT01253707 | A Study of AMG 337 in Subjects With Advanced Solid Tumors | Phase1 | Advanced Malignancy | Completed | 2010-12-08 | 2016-12-13 | ClinicalTrials.gov |
| NCT01226719 | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal C… | Phase2 | Colorectal Cancer | Completed | 2010-12-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01308840 | Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track … | Phase2 | Biliary Tract Cancer | Completed | 2010-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01379807 | Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a F… | Phase2 | Gastric Adenocarcinoma | Unknown | 2010-12-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | Phase1 | Glioblastoma Multiforme | Completed | 2010-12-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01143038 | Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Recei… | Phase2 | Idiopathic Thrombocytopenic Purpura | Completed | 2010-11-30 | 2013-12-26 | ClinicalTrials.gov |
| NCT01015625 | Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer | Na | Synchronous Metastasized Breast Cancer | Completed | 2010-11-24 | 2022-07-01 | ClinicalTrials.gov |
| NCT01232283 | Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Pat… | Phase3 | Plaque Psoriasis | Completed | 2010-11-22 | 2016-11-30 | ClinicalTrials.gov |
| NCT01150890 | Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease | Phase2 | Crohn's Disease | Terminated | 2010-11-09 | 2011-10-15 | ClinicalTrials.gov |
| NCT01288339 | Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Can… | Phase2 | Metastatic Colorectal Cancer | Completed | 2010-11-08 | 2015-02-13 | ClinicalTrials.gov |
| NCT01180634 | MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis | Phase3 | Cystic Fibrosis | Completed | 2010-11-04 | 2012-05-07 | ClinicalTrials.gov |
| NCT01202409 | CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla o… | Phase2 | Gastrointestinal Cancer | Completed | 2010-11-02 | 2018-07-03 | ClinicalTrials.gov |
| NCT01191385 | GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Th… | — | Carcinoma, Hepatocellular | Withdrawn | 2010-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT02983097 | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dex… | Phase1 | Diffuse Large B-cell Lymphoma (DLBCL) | Terminated | 2010-11-01 | 2015-04-28 | ClinicalTrials.gov |
| NCT01036087 | Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Brea… | Phase2 | Breast Cancer | Completed | 2010-11-01 | 2022-08-09 | ClinicalTrials.gov |
| NCT01253681 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects Wit… | Phase1 | Carcinoma | Completed | 2010-11-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01196715 | Comparison Study of Standard Care Against Combination of Growth Factors Agents … | Phase3 | Myelodysplastic Syndrome | Completed | 2010-11-01 | 2015-10-31 | ClinicalTrials.gov |
| NCT01204749 | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel… | Phase3 | Fallopian Tube Cancer | Completed | 2010-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01221727 | The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam | Phase1 | Postmenopausal Osteoporosis | Completed | 2010-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00943943 | Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for… | Phase1 | Acute Myelogenous Leukemia | Completed | 2010-10-29 | 2017-03-23 | ClinicalTrials.gov |
| NCT01199289 | A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Contro… | Phase2 | Asthma | Completed | 2010-10-04 | 2011-12-21 | ClinicalTrials.gov |
| NCT01257737 | To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cy… | Phase4 | Urea Cycle Disorders | Completed | 2010-10-04 | 2017-02-16 | ClinicalTrials.gov |
| NCT01181531 | Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyper… | Phase4 | Hyperparathyroidism, Secondary | Completed | 2010-10-01 | 2012-08-14 | ClinicalTrials.gov |
| NCT01212380 | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic L… | Phase1 | B-cell Chronic Lymphocytic Leukemia | Completed | 2010-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01234324 | ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of… | Phase2 | Stomach Neoplasms | Completed | 2010-10-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT01300208 | To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodyn… | Phase2 | Cutaneous Lupus Erythematosus | Completed | 2010-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01285778 | Vectibix for the Treatment of Anal Cancer | Phase2 | Anal Squamous Cell Carcinoma | Completed | 2010-10-01 | 2017-03-24 | ClinicalTrials.gov |
| NCT01212770 | PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Art… | Phase3 | Psoriatic Arthritis | Completed | 2010-09-30 | 2017-02-09 | ClinicalTrials.gov |
| NCT01212757 | PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Art… | Phase3 | Psoriatic Arthritis | Completed | 2010-09-27 | 2017-01-25 | ClinicalTrials.gov |
| NCT01194219 | Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Pat… | Phase3 | Plaque Psoriasis | Completed | 2010-09-09 | 2016-11-22 | ClinicalTrials.gov |
| NCT01242917 | A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheuma… | Phase2 | Rheumatoid Arthritis | Completed | 2010-09-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01302392 | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Re… | Phase3 | Multiple Myeloma | Completed | 2010-09-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01235442 | Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects Wit… | Phase3 | Psoriasis | Completed | 2010-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01197378 | Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsu… | Phase3 | Cystinosis | Completed | 2010-08-27 | 2017-06-26 | ClinicalTrials.gov |
| NCT01113398 | AMG 102 and Avastin for Recurrent Malignant Glioma | Phase2 | Glioblastoma Multiforme | Completed | 2010-08-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01989689 | Etanercept and Vascular Function in Psoriasis | Phase2 | PSORIASIS | Completed | 2010-08-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01164917 | Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus | Phase1 | Cutaneous Lupus | Terminated | 2010-08-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01080391 | Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidom… | Phase3 | Relapsed Multiple Myeloma | Completed | 2010-07-14 | 2017-12-05 | ClinicalTrials.gov |
| NCT01175733 | Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients Wi… | Phase1 | Pancreatic Cancer | Completed | 2010-07-08 | 2016-05-01 | ClinicalTrials.gov |
| NCT01163669 | A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathy… | — | Hyperparathyroidism | Completed | 2010-07-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01164904 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healt… | Phase1 | Ulcerative Colitis | Terminated | 2010-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01081678 | Study To Assess FRacTure Healing With SclerosTin Antibody - Hip | Phase2 | Fracture Healing | Completed | 2010-06-20 | 2013-05-10 | ClinicalTrials.gov |
| NCT00953446 | Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation… | Na | Renal Cell Carcinoma | Terminated | 2010-06-15 | 2011-09-13 | ClinicalTrials.gov |
| NCT01059448 | Safety and Efficacy of AMG 827 in Subjects With RA | Phase2 | Rheumatoid Arthritis | Terminated | 2010-06-03 | 2011-04-05 | ClinicalTrials.gov |
| NCT01172938 | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis | Phase3 | Psoriatic Arthritis | Completed | 2010-06-02 | 2016-10-27 | ClinicalTrials.gov |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast … | Phase3 | Breast Cancer | Terminated | 2010-06-02 | 2018-03-26 | ClinicalTrials.gov |
| NCT01156090 | A Retrospective Cohort Study of Infusion Reactions Due to Vectibix | — | Infusion Reaction | Completed | 2010-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01717989 | Study to Evaluate the Prospective Payment System | — | Chronic Kidney Disease | Completed | 2010-06-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01194869 | Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Pacli… | Phase2 | Breast Cancer | Terminated | 2010-06-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01139918 | Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Mod… | — | Psoriatic Arthritis | Completed | 2010-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01139138 | Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in th… | Phase1 | Colorectal Cancer | Completed | 2010-06-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01137565 | Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma | Phase1 | Asthma | Completed | 2010-06-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01137552 | A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Soli… | Phase1 | Advanced Solid Tumors | Terminated | 2010-06-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01133522 | Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokin… | Phase1 | Hyperlipidemia | Completed | 2010-06-01 | 2011-09-14 | ClinicalTrials.gov |
| NCT01101048 | An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmeno… | Phase1 | Osteopenia | Completed | 2010-06-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01042288 | Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous… | Phase2 | Non-Small-Cell Lung Cancer | Completed | 2010-06-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01000961 | Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cyst… | Phase3 | Cystinosis | Completed | 2010-06-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT02520362 | Denosumab Safety Assessment in Multiple Observational Databases | — | Osteoporosis | Completed | 2010-05-31 | 2023-07-21 | ClinicalTrials.gov |
| NCT01122199 | Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors | Phase1 | Neoplasm Metastases | Completed | 2010-05-14 | 2015-01-19 | ClinicalTrials.gov |
| NCT01101061 | A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal … | Phase1 | Osteopenia | Completed | 2010-05-03 | 2010-11-01 | ClinicalTrials.gov |
| NCT01126112 | Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Adv… | Phase2 | Colorectal Cancer | Completed | 2010-05-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01124279 | Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects | Phase1 | Healthy Volunteers | Completed | 2010-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01128387 | Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophage… | Phase1 | Cancer | Terminated | 2010-05-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01554852 | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the… | Phase3 | Multiple Myeloma | Unknown | 2010-05-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT01135680 | Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of … | Phase1 | Drug Toxicity | Completed | 2010-05-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT02173171 | Registry Study for Talimogene Laherparepvec | — | Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial | Completed | 2010-04-27 | 2021-09-23 | ClinicalTrials.gov |
| NCT00130117 | Study of Leptin for the Treatment of Hypothalamic Amenorrhea | Phase2 | Amenorrhea | Completed | 2010-04-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01129349 | Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refrac… | Phase1 | Solid Tumors | Completed | 2010-04-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00975104 | AMG 745 in Subjects With Age-associated Muscle Loss | Phase2 | Age-associated Muscle Loss | Withdrawn | 2010-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01099436 | Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER… | Phase3 | Breast Cancer | Completed | 2010-04-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01132235 | An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With … | Phase4 | Psoriasis | Unknown | 2010-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01122095 | Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in C… | — | Psoriasis | Unknown | 2010-04-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00975221 | Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in P… | Phase3 | Hyperparathyroidism, Primary | Completed | 2010-03-10 | 2012-12-21 | ClinicalTrials.gov |
| NCT00947544 | Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyra… | Phase2 | Urea Cycle Disorders | Completed | 2010-03-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | Phase2 | Neuroendocrine Tumor | Completed | 2010-03-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Pa… | Phase3 | Metastatic Colorectal Cancer | Completed | 2010-02-02 | 2017-03-07 | ClinicalTrials.gov |
| NCT06585189 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | — | Metastatic Non Small Cell Lung Cancer | Completed | 2010-02-01 | 2023-04-13 | ClinicalTrials.gov |
| NCT06607393 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | — | Metastatic Nonsmall Cell Lung Cancer | Completed | 2010-02-01 | 2023-06-28 | ClinicalTrials.gov |
| NCT06607601 | CARE Initiative: Real-world Emulation of the PALOMA-2 Trial | — | Metastatic Breast Cancer | Completed | 2010-02-01 | 2023-07-20 | ClinicalTrials.gov |
| NCT01017653 | Panitumumab and Irinotecan for Malignant Gliomas | Phase2 | Malignant Glioma of Brain | Terminated | 2010-02-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00894504 | Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast C… | Phase2 | Metastatic Breast Cancer | Completed | 2010-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00940316 | Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab… | Phase2 | Colorectal Cancer | Completed | 2010-01-18 | 2015-01-01 | ClinicalTrials.gov |
| NCT01028963 | A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2010-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00950989 | Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate … | Phase2 | Rheumatoid Arthritis | Completed | 2009-12-30 | 2011-02-11 | ClinicalTrials.gov |
| NCT01071954 | A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim i… | Phase3 | Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP | Completed | 2009-12-30 | 2017-01-12 | ClinicalTrials.gov |
| NCT05984251 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in… | Phase1 | Vasculitis | Completed | 2009-12-21 | 2011-04-11 | ClinicalTrials.gov |
| NCT00975000 | Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients | Phase3 | Chronic Allograft Nephropathy | Completed | 2009-12-03 | 2013-04-16 | ClinicalTrials.gov |
| NCT01027728 | Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid … | Phase1 | Rheumatoid Arthritis | Completed | 2009-12-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00879385 | KRAS Wild-type Metastatic Colorectal Cancer Trial | Phase1 | Colorectal Cancer | Completed | 2009-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00999167 | A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episod… | Phase2 | Cirrhosis | Completed | 2009-12-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00925600 | Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic P… | Phase3 | Cancer | Completed | 2009-11-30 | 2016-05-12 | ClinicalTrials.gov |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects … | Phase2 | Breast Cancer | Completed | 2009-11-16 | 2013-08-21 | ClinicalTrials.gov |
| NCT00911170 | PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation … | Phase3 | Cancer | Completed | 2009-11-03 | 2015-01-02 | ClinicalTrials.gov |
| NCT01001208 | The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis | Phase3 | Psoriasis | Completed | 2009-11-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01009879 | Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigran… | Phase4 | Rheumatoid Arthritis | Withdrawn | 2009-11-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00947297 | Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea C… | Phase3 | Urea Cycle Disorders | Completed | 2009-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00984282 | Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Different… | Phase3 | Thyroid Neoplasms | Completed | 2009-10-15 | 2017-08-30 | ClinicalTrials.gov |
| NCT00992459 | Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Diso… | Phase3 | Urea Cycle Disorders | Completed | 2009-10-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01018550 | AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma | Phase2 | Asthma | Completed | 2009-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00980174 | Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males W… | Phase3 | Low Bone Mass | Completed | 2009-10-01 | 2012-05-23 | ClinicalTrials.gov |
| NCT00928408 | PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinac… | — | Hyperparathyroidism, Primary | Completed | 2009-10-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00972179 | Safety Study of Tezepelumab (AMG 157) in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2009-09-15 | 2011-01-09 | ClinicalTrials.gov |
| NCT00907296 | Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intra… | Phase2 | Fracture Healing | Completed | 2009-09-02 | 2013-05-10 | ClinicalTrials.gov |
| NCT01144195 | A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Sec… | Phase2 | Metastatic Colorectal Cancer | Unknown | 2009-09-01 | — | ClinicalTrials.gov |
| NCT00967538 | Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Resp… | Phase4 | Psoriasis | Completed | 2009-09-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT00984815 | Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal A… | Phase3 | Osteoarthritis | Completed | 2009-09-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01002703 | Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With… | Phase1 | Multiple Myeloma | Unknown | 2009-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT00919711 | Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Men… | Phase3 | Osteoporosis | Completed | 2009-09-01 | 2012-03-05 | ClinicalTrials.gov |
| NCT00950950 | A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the … | Phase1 | Osteopenia | Completed | 2009-08-18 | 2010-08-19 | ClinicalTrials.gov |
| NCT00907478 | Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment o… | Phase4 | Thrombocytopenia | Completed | 2009-08-11 | 2014-01-14 | ClinicalTrials.gov |
| NCT00858377 | A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | Phase1 | Advanced Malignancy | Completed | 2009-08-10 | 2019-04-03 | ClinicalTrials.gov |
| NCT00958386 | Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) … | Phase2 | Metastatic Colorectal Cancer | Completed | 2009-08-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT00872014 | A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advan… | Phase2 | Advanced Hepatocellular Carcinoma | Completed | 2009-08-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT00866359 | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Tre… | Phase2 | Behcet Syndrome | Completed | 2009-08-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Recei… | Phase3 | Non-Small Cell Lung Cancer | Terminated | 2009-07-17 | 2017-06-07 | ClinicalTrials.gov |
| NCT00890981 | A High-resolution Peripheral Quantitative Computed Tomography Study in Postmeno… | Phase3 | Low Bone Mass | Completed | 2009-07-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00915252 | Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients… | Phase2 | Acute Myeloid Leukemia | Completed | 2009-07-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00936897 | A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Pos… | Phase3 | Postmenopausal Osteoporosis | Completed | 2009-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00950911 | Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only | Phase3 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Completed | 2009-07-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00896532 | Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density | Phase2 | Low Bone Mineral Density | Completed | 2009-06-03 | 2016-02-18 | ClinicalTrials.gov |
| NCT00848354 | Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirhe… | Phase4 | Rheumatoid Arthritis | Completed | 2009-06-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00887965 | A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal … | Phase2 | Low Bone Mass | Completed | 2009-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00926380 | Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis | Phase2 | Osteoporosis | Completed | 2009-06-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00925821 | Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Tra… | Phase2 | Multiple Myeloma | Completed | 2009-06-01 | — | ClinicalTrials.gov |
| NCT00925587 | Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-d… | Phase3 | Anemia | Completed | 2009-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00853372 | AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After C… | Phase2 | Advanced Renal Cell Carcinoma | Completed | 2009-05-28 | 2019-06-25 | ClinicalTrials.gov |
| NCT00997022 | Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | Phase1 | Hepatocellular Cancer | Completed | 2009-05-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02090088 | Nplate® Pregnancy Exposure Registry | — | Birth Defect | Terminated | 2009-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00902356 | A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Wom… | Phase1 | Osteopenia | Completed | 2009-05-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00885885 | Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subj… | Phase2 | Colorectal Cancer | Completed | 2009-05-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01386866 | Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tum… | Phase1 | Advanced Solid Tumors | Completed | 2009-05-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00872729 | Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103… | Phase1 | Cystinosis | Completed | 2009-05-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00842257 | Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer | Phase2 | Colorectal Cancer | Completed | 2009-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00836277 | Phase II Study of Irinotecan and Panitumumab | Phase2 | Esophageal Cancer | Completed | 2009-05-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT00819780 | PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Tr… | Phase2 | Colon Cancer | Completed | 2009-04-24 | 2016-07-07 | ClinicalTrials.gov |
| NCT00884312 | A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Car… | Phase2 | Multiple Myeloma | Completed | 2009-04-09 | 2017-05-17 | ClinicalTrials.gov |
| NCT00840333 | "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days t… | Phase1 | Cystic Fibrosis | Completed | 2009-04-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00769704 | Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte M… | Phase3 | Melanoma | Completed | 2009-04-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00930592 | Peds Metabolic Syndrome in Psoriasis | — | Psoriasis | Completed | 2009-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00807859 | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic … | Phase1 | Breast Cancer | Completed | 2009-03-09 | 2015-10-19 | ClinicalTrials.gov |
| NCT00818948 | Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and … | Phase1 | Nephritis | Completed | 2009-03-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00841789 | A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children … | Phase2 | Mucocutaneous Lymph Node Syndrome | Completed | 2009-03-01 | 2018-08-30 | ClinicalTrials.gov |
| NCT00639717 | Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft… | Phase2 | Graft Versus Host Disease | Completed | 2009-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT00865709 | Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colore… | Phase2 | Metastatic Colorectal Cancer | Completed | 2009-03-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01525654 | Patient Rheumatoid Arthritis Social Support Study | Na | Rheumatoid Arthritis | Terminated | 2009-03-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT01049425 | Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative… | Phase3 | Primary Breast Cancer | Completed | 2009-02-05 | 2018-05-15 | ClinicalTrials.gov |
| NCT00838201 | Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoin… | Phase3 | Cancer | Completed | 2009-02-01 | 2012-05-03 | ClinicalTrials.gov |
| NCT00803712 | 20070360 Incident Dialysis | Phase4 | Chronic Kidney Disease | Completed | 2009-02-01 | 2011-07-05 | ClinicalTrials.gov |
| NCT00719550 | AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Eso… | Phase1 | Esophagogastric Junction Adenocarcinoma | Completed | 2009-02-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00833729 | The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responde… | Phase4 | Plaque Psoriasis | Completed | 2009-02-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00757172 | Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating P… | Phase2 | Adenocarcinoma of the Gastroesophageal Junction | Completed | 2009-01-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00770536 | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. … | Phase1 | Cancer | Completed | 2009-01-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT00774943 | A Study of AMG 557 in Adults With Systemic Lupus Erythematosus | Phase1 | Systemic Lupus Erythematosus | Completed | 2008-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00808639 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Uro… | Phase2 | Bladder Cancer | Completed | 2008-12-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT00813384 | A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors | Phase1 | Cancer | Completed | 2008-12-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00752570 | A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Com… | Phase2 | Cancer | Completed | 2008-11-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00770848 | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previo… | Phase1 | Cancer | Completed | 2008-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00721734 | Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relaps… | Phase2 | Multiple Myeloma | Completed | 2008-11-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00771030 | Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rhe… | Phase1 | Rheumatoid Arthritis | Completed | 2008-10-27 | 2010-05-25 | ClinicalTrials.gov |
| NCT00756444 | A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Pani… | Phase2 | Squamous Cell Carcinoma of Head and Neck | Completed | 2008-10-21 | 2012-03-30 | ClinicalTrials.gov |
| NCT00863460 | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Res… | Phase2 | Primary Central Nervous System Lymphoma | Active_Not_Recruiting | 2008-10-03 | 2026-05-01 | ClinicalTrials.gov |
| NCT00739648 | A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive… | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2008-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT02075697 | Spanish Registry of Systemic Treatments in Psoriasis | — | Psoriasis | Unknown | 2008-10-01 | 2025-10-01 | ClinicalTrials.gov |
| NCT00791765 | Moderate to Severe Plaque Psoriasis With Scalp Involvement | Phase4 | Psoriasis | Completed | 2008-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00757042 | Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic … | Phase1 | Atopic Dermatitis | Completed | 2008-09-18 | 2011-01-05 | ClinicalTrials.gov |
| NCT00436748 | Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatr… | Phase3 | Anemia | Terminated | 2008-09-16 | 2014-03-03 | ClinicalTrials.gov |
| NCT00680992 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | Phase2 | Cancer | Completed | 2008-09-09 | 2018-05-17 | ClinicalTrials.gov |
| NCT00773734 | Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to… | Phase2 | Psoriasis | Completed | 2008-09-01 | 2015-05-20 | ClinicalTrials.gov |
| NCT00794261 | Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma | Phase2 | Lymphoma | Completed | 2008-09-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00614523 | Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-… | Phase2 | MDS | Completed | 2008-07-21 | 2015-11-30 | ClinicalTrials.gov |
| NCT00752414 | A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive… | Phase1 | Chronic Obstructive Pulmonary Disease | Completed | 2008-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00686335 | A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients … | Phase2 | Asthma | Completed | 2008-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00654368 | CAMEO: Canadian Methotrexate and Etanercept Outcome Study | Phase4 | Rheumatoid Arthritis | Completed | 2008-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00661921 | A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients Wi… | Phase2 | Diabetes Mellitus | Withdrawn | 2008-06-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00677365 | Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosi… | Phase2 | Cystic Fibrosis (CF) | Completed | 2008-06-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00603447 | Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone i… | Phase1 | Relapsed Multiple Myeloma | Completed | 2008-05-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT00883415 | Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease | — | Cardiomyopathy | Completed | 2008-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00704652 | Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patien… | — | Diabetic Retinopathy | Terminated | 2008-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00640393 | Safety and Efficacy of Combining nbUVB to Etanercept in Patients | Phase4 | Psoriasis Vulgaris | Completed | 2008-04-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00661141 | Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure … | Phase2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | Completed | 2008-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00563316 | Effect of Panitumumab on the Pharmacokinetics of Irinotecan | Phase1 | Metastatic Colorectal Cancer | Completed | 2008-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00530114 | Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease… | Phase2 | End Stage Renal Disease | Completed | 2008-03-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00658658 | Panitumumab in Children With Solid Tumors | Phase1 | Solid Tumors | Completed | 2008-03-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00650078 | Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra… | Phase3 | Rheumatoid Arthritis | Completed | 2008-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00791011 | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | Phase1 | Hodgkin's Lymphoma | Completed | 2008-02-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00570999 | Palifermin After Haploidentical PBSCT | Phase2 | Non-Hodgkin's Lymphoma or Hodgkin's Disease | Withdrawn | 2008-02-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00838097 | European Union Registry in Paediatric Chronic Kidney Disease Patients Looking a… | — | Chronic Kidney Disease | Completed | 2008-02-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00534027 | A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin fo… | Phase1 | Non-Small Cell Lung Cancer | Completed | 2008-01-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00615901 | Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 an… | Na | Breast Cancer | Completed | 2008-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01013181 | Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Re… | — | Thrombopenia | Completed | 2008-01-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT02921191 | Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, … | — | Breast Cancer | Completed | 2008-01-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT01848028 | PsoBest - The German Psoriasis Registry | — | Psoriasis | Recruiting | 2008-01-01 | 2032-12-01 | ClinicalTrials.gov |
| NCT00630786 | Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study | Phase1 | Colon Cancer | Completed | 2008-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00578071 | Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esopha… | Phase1 | Cancer of the Esophagus | Completed | 2007-12-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00679419 | Coronary Artery Disease and Renal Failure Registry | — | Coronary Artery Disease | Unknown | 2007-12-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT02291588 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Systemic Lupus Erythematosus | Completed | 2007-12-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00597909 | Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Enc… | Phase2 | Hepatic Encephalopathy | Terminated | 2007-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00583674 | Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabin… | Phase2 | Gastrointestinal Cancer | Completed | 2007-12-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01825785 | A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics an… | Phase1 | Postmenopausal | Completed | 2007-11-14 | 2008-12-02 | ClinicalTrials.gov |
| NCT00626704 | Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Un… | Phase1 | Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma | Completed | 2007-11-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00798655 | Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advance… | Phase2 | Cancer of Head | Completed | 2007-11-01 | 2016-11-09 | ClinicalTrials.gov |
| NCT00586443 | BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) | Phase1 | Solid Tumors | Completed | 2007-11-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00547157 | Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Lo… | Phase2 | Cancer | Completed | 2007-11-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00562523 | Sorafenib/Docetaxel Dose Escalation Trial | Phase1 | Neoplasms | Completed | 2007-11-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00446446 | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | Phase2 | Cancer | Completed | 2007-10-30 | 2017-11-29 | ClinicalTrials.gov |
| NCT00500760 | Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Loc… | Phase2 | Head and Neck Cancer | Completed | 2007-10-01 | 2011-04-26 | ClinicalTrials.gov |
| NCT00603642 | P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanes… | Phase3 | Idiopathic Thrombocytopenic Purpura | Completed | 2007-10-01 | 2009-04-13 | ClinicalTrials.gov |
| NCT00551200 | Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders | Phase2 | Urea Cycle Disorders | Completed | 2007-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00625651 | Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metast… | Phase1 | Metastatic Colorectal Cancer | Completed | 2007-10-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00632541 | A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | Phase2 | Metastatic Breast Cancer | Terminated | 2007-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00540657 | A Phase II Study of CCX282-B in Patients With Celiac Disease | Phase2 | Celiac Disease | Completed | 2007-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00540332 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Loca… | Phase1 | Head and Neck Cancer | Withdrawn | 2007-10-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or … | Phase1 | Ovarian Cancer | Completed | 2007-09-01 | 2017-05-22 | ClinicalTrials.gov |
| NCT01053819 | Can We Miss Pigmented Lesions in Psoriasis Patients? | Phase4 | Psoriasis | Completed | 2007-09-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00518531 | Denosumab Adherence Preference Satisfaction Study | Phase3 | Osteoporosis | Completed | 2007-09-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00613106 | Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.… | Phase3 | Osteoarthritis | Completed | 2007-09-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00530816 | Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2007-09-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00523341 | Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in t… | Phase3 | Osteopenia | Completed | 2007-08-07 | 2015-07-19 | ClinicalTrials.gov |
| NCT00511238 | Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2007-08-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00521339 | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Phase2 | Psoriasis-Type Psoriasis | Completed | 2007-08-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00479817 | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithe… | Phase2 | Ovarian Cancer | Completed | 2007-07-05 | 2019-12-09 | ClinicalTrials.gov |
| NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | Phase3 | Non-Small Cell Lung Cancer | Terminated | 2007-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT00515203 | Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Su… | Phase1 | Idiopathic Thrombocytopenic Purpura | Completed | 2007-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00511459 | Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First L… | Phase2 | Locally Recurrent and Metastatic Breast Cancer | Completed | 2007-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00503490 | Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cy… | Phase1 | Cystic Fibrosis | Completed | 2007-06-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00417248 | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoper… | Phase1 | Non-Small Cell Lung Cancer | Terminated | 2007-06-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00499525 | Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Bre… | Phase2 | Breast Cancer | Unknown | 2007-06-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT00493636 | 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizum… | Phase2 | Breast Cancer | Completed | 2007-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00508404 | Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer | Phase2 | Metastatic Colorectal Cancer | Completed | 2007-05-09 | 2012-06-12 | ClinicalTrials.gov |
| NCT00585650 | Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in P… | Phase1 | Psoriasis | Completed | 2007-05-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00477191 | Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syn… | Na | Psoriasis | Terminated | 2007-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00460265 | Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head… | Phase3 | Recurrent and/or Metastatic Head and Neck Cancer | Completed | 2007-05-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00443430 | Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis | Phase4 | Juvenile Chronic Polyarthritis | Completed | 2007-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00515463 | A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and S… | Phase3 | Low Bone Mineral Density | Completed | 2007-05-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00467025 | AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib | Phase2 | Advanced Renal Cell Carcinoma | Completed | 2007-05-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00475293 | Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in … | Phase2 | Metastatic Colorectal Cancer | Completed | 2007-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00472290 | Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in … | Na | Hematology | Completed | 2007-04-01 | 2011-12-26 | ClinicalTrials.gov |
| NCT00456092 | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis | Phase2 | Psoriatic Arthritis | Completed | 2007-03-05 | 2009-05-09 | ClinicalTrials.gov |
| NCT00450216 | Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-In… | Phase3 | Ulcer | Completed | 2007-03-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00436670 | Phase II Study to Evaluate the Efficacy of AMG 317 | Phase2 | Asthma | Completed | 2007-03-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00443326 | AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects | Phase2 | Psoriasis | Completed | 2007-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00450658 | Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associat… | Phase3 | Peptic Ulcer | Completed | 2007-03-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00456716 | Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma | Phase2 | Lung Cancer | Completed | 2007-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00448786 | Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors | Phase1 | Solid Tumors | Completed | 2007-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00903812 | IMPACT Non Hodgkins Lymphoma (NHL) Study | — | Non-Hodgkin's Lymphoma | Completed | 2007-02-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00512499 | Strategies to Treat Osteoporosis Following a Fragility Fracture | Na | Osteoporosis | Completed | 2007-02-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT00369070 | A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advance… | Phase2 | Advanced Non-squamous NSCLC | Terminated | 2007-01-31 | 2011-08-03 | ClinicalTrials.gov |
| NCT00534456 | An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin … | Phase3 | Anemia | Terminated | 2007-01-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00613730 | Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen… | Phase2 | Cancer of Pancreas | Terminated | 2007-01-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00454779 | PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Eva… | Phase2 | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | Completed | 2007-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00422019 | A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma | Phase2 | Advanced Renal Cell Carcinoma | Completed | 2007-01-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00556374 | Study to Determine Treatment Effects of Denosumab in Patients With Breast Cance… | Phase3 | Breast Cancer | Completed | 2006-12-18 | 2022-07-26 | ClinicalTrials.gov |
| NCT01059435 | A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Post… | Phase1 | Osteopenia | Completed | 2006-12-13 | 2007-07-06 | ClinicalTrials.gov |
| NCT00413452 | Etanercept SFP in RA Patients | Phase3 | Rheumatoid Arthritis | Completed | 2006-12-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00413400 | Study of TNF-Antagonism in the Metabolic Syndrome (II) | Na | Metabolic Syndrome | Completed | 2006-12-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00439894 | Ancillary Study to Protocol 20060104 | — | Rheumatoid Arthritis | Completed | 2006-12-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT02318407 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in… | Phase1 | Osteoarthritis | Completed | 2006-12-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00401544 | Darbepoetin Alfa With or Without Intravenous (IV) Iron | Phase2 | Anemia | Completed | 2006-12-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00356681 | A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy,… | Phase2 | Breast Neoplasms | Terminated | 2006-12-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00413283 | Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocyt… | Phase2 | Lung Cancer | Completed | 2006-12-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00418665 | A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelo… | Phase2 | Myelodysplastic Syndromes | Completed | 2006-12-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00415532 | Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) T… | Phase3 | Idiopathic Thrombocytopenic Purpura | Completed | 2006-12-01 | 2009-05-11 | ClinicalTrials.gov |
| NCT00418938 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | Phase2 | Cancer | Completed | 2006-11-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT02391259 | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 55… | Phase1 | Systemic Lupus Erythematosus | Completed | 2006-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00427440 | A Phase II Study to Treat Advanced Malignant Glioma | Phase2 | Advanced Malignant Glioma | Completed | 2006-11-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00883181 | A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Rece… | — | Breast Cancer | Completed | 2006-11-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00411450 | Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Respons… | Phase2 | Colon Cancer | Completed | 2006-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00405366 | Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or S… | Early_Phase1 | Kidney Cancer | Completed | 2006-11-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT00381836 | Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormo… | Phase2 | Prostatic Neoplasms | Terminated | 2006-10-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00321711 | Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects W… | Phase2 | MDS | Completed | 2006-10-01 | 2009-10-19 | ClinicalTrials.gov |
| NCT00379899 | ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calci… | Phase4 | Chronic Kidney Disease | Completed | 2006-09-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00727571 | LEARN-6™: A Prospective, Observational Nursing Home Study | — | Anemia | Completed | 2006-09-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00431496 | A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidn… | Phase4 | Anemia | Completed | 2006-09-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00377819 | Study of Transitioning From Alendronate to Denosumab | Phase3 | Postmenopausal Osteoporosis | Completed | 2006-09-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00375310 | Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unres… | Phase1 | Pancreatic Cancer | Completed | 2006-09-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT00369473 | Long-Term Assessment of Safety and Physical Function With AMG 108 in RA | Phase2 | Rheumatoid Arthritis | Completed | 2006-09-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00364845 | STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) O… | Phase3 | Anemia | Terminated | 2006-09-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00361634 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Respo… | Phase1 | Rheumatoid Arthritis | Completed | 2006-09-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00986895 | A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose… | Phase1 | Hepatic Encephalopathy | Completed | 2006-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00345839 | E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lo… | Phase3 | Secondary Hyperparathyroidism | Completed | 2006-08-22 | 2012-04-10 | ClinicalTrials.gov |
| NCT00364013 | PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metast… | Phase3 | Metastatic Colorectal Cancer | Completed | 2006-08-01 | 2013-03-22 | ClinicalTrials.gov |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectab… | Phase2 | GCT | Completed | 2006-07-10 | 2011-02-01 | ClinicalTrials.gov |
| NCT00339183 | Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy… | Phase3 | Metastatic Colorectal Cancer | Completed | 2006-06-30 | 2010-11-01 | ClinicalTrials.gov |
| NCT00330759 | Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects Wit… | Phase3 | Bone Metastases | Completed | 2006-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00346099 | Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and … | Phase2 | Rectal Cancer | Withdrawn | 2006-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00333034 | Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Sub… | Phase3 | Psoriasis | Completed | 2006-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00355407 | Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation | Na | Hematologic Malignancies | Completed | 2006-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00508625 | A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Sm… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2006-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00358215 | RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial | Phase3 | Heart Failure | Completed | 2006-06-01 | 2012-10-11 | ClinicalTrials.gov |
| NCT00400764 | A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular… | Phase1 | Non-Hodgkin's Lymphoma | Terminated | 2006-06-01 | — | ClinicalTrials.gov |
| NCT00293813 | A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate th… | Phase2 | Postmenopausal Osteoporosis | Completed | 2006-05-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00322439 | Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis | — | Psoriasis | Completed | 2006-05-01 | 2013-02-08 | ClinicalTrials.gov |
| NCT00325468 | An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of D… | Phase3 | Low Bone Mineral Density | Completed | 2006-05-01 | 2012-08-02 | ClinicalTrials.gov |
| NCT00330460 | A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Deno… | Phase3 | Osteoporosis | Completed | 2006-05-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00454857 | Retrospective & Prospective Observational Study of Patients With Immune (Idiopa… | — | Idiopathic Thrombocytopenic Purpura | Completed | 2006-05-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00261950 | Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of E… | Phase2 | Secondary Hyperparathyroidism | Completed | 2006-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00332163 | Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receivi… | Phase2 | Metastatic Colorectal Cancer | Completed | 2006-04-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00436995 | Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration … | Phase3 | Chronic Kidney Disease | Completed | 2006-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00513383 | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and … | Phase1 | Squamous Cell Carcinoma of the Head and Neck | Completed | 2006-04-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00321464 | A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metas… | Phase3 | Bone Metastases | Completed | 2006-04-01 | 2012-04-04 | ClinicalTrials.gov |
| NCT00327119 | Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal C… | Phase2 | Metastatic Colorectal Cancer | Completed | 2006-04-01 | — | ClinicalTrials.gov |
| NCT00353119 | A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercep… | Phase3 | Palmoplantaris Pustulosis | Completed | 2006-04-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00606450 | Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects… | Phase2 | Psoriasis | Completed | 2006-04-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00321620 | Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hor… | Phase3 | Bone Metastases | Completed | 2006-04-01 | 2012-02-24 | ClinicalTrials.gov |
| NCT00112385 | A Pilot Study of Etanercept in Dermatomyositis | Phase1 | Dermatomyositis | Completed | 2006-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00299182 | Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin… | Phase1 | Lymphoma | Completed | 2006-03-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00300001 | Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Pat… | — | Cancer | Unknown | 2006-03-01 | — | ClinicalTrials.gov |
| NCT00306215 | A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Modera… | Phase2 | Crohn's Disease | Completed | 2006-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00293826 | A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumat… | Phase2 | Rheumatoid Arthritis | Completed | 2006-03-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00322400 | Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxe… | Phase1 | Locally Recurrent and Metastatic Breast Cancer | Completed | 2006-03-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00332332 | Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel… | Phase4 | Psoriasis | Completed | 2006-03-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00352950 | Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung … | Phase1 | Oncology | Withdrawn | 2006-03-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00314977 | Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Lar… | Phase3 | Breast Cancer | Completed | 2006-02-01 | — | ClinicalTrials.gov |
| NCT00303472 | Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodyspl… | Phase2 | Thrombocytopenia | Completed | 2006-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00286091 | Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractor… | Phase3 | Hormone Refractory Prostate Cancer | Completed | 2006-01-24 | 2014-04-09 | ClinicalTrials.gov |
| NCT00695370 | Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children | Phase2 | Solid Malignancies | Terminated | 2006-01-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00306189 | A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 … | Phase2 | Osteoporosis | Completed | 2006-01-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00346294 | An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) Su… | Phase4 | Rheumatoid Arthritis | Completed | 2006-01-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00861419 | To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used … | Phase1 | Advanced Solid Tumors | Completed | 2005-12-01 | — | ClinicalTrials.gov |
| NCT00189488 | Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Diseas… | Phase2 | Graft Versus Host Disease | Completed | 2005-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT00360867 | An Open Label Treatment Extension Study of AMG 706 | Phase2 | Solid Tumors | Terminated | 2005-12-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00418743 | Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC) | — | Small Cell Lung Cancer | Unknown | 2005-12-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00261313 | ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfil… | Phase2 | Breast Cancer | Completed | 2005-12-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00445042 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | Phase2 | Carcinoma, Renal Cell | Completed | 2005-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00259740 | Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab | Phase2 | Relapsed or Plateau-Phase Multiple Myeloma | Completed | 2005-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00254267 | Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tum… | Phase2 | Advanced Gastrointestinal Stromal Tumor | Completed | 2005-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00562380 | AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma | Phase1 | Lymphoma | Completed | 2005-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00249041 | Enbrel Liquid Immunogenicity Protocol | Phase3 | Rheumatoid Arthritis | Completed | 2005-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00283439 | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombo… | Phase1 | Chemotherapy-Induced Thrombocytopenia | Completed | 2005-10-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00965666 | Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia | Early_Phase1 | Fanconi Anemia | Completed | 2005-10-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01235416 | A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemci… | Phase1 | Histologically or Cytologically Documented Solid Tumors | Completed | 2005-09-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00146224 | Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chro… | Phase3 | Nephrology | Completed | 2005-09-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00150462 | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in … | Phase1 | Waldenstrom's Macroglobulinemia | Completed | 2005-09-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00141921 | Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psor… | Phase3 | Pediatric Plaque Psoriasis | Completed | 2005-08-11 | 2017-08-16 | ClinicalTrials.gov |
| NCT00393822 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stag… | Phase2 | Colon Cancer | Completed | 2005-08-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00127842 | REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel… | Phase4 | Psoriatic Arthritis | Completed | 2005-08-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00239239 | Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment… | Phase2 | Non-Myeloid Malignancies | Completed | 2005-08-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00135304 | ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism | Phase4 | Secondary Hyperparathyroidism | Completed | 2005-08-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00144131 | Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withN… | Phase2 | Anemia | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00861224 | Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology | — | Idiopathic Thrombocytopenic Purpura | Completed | 2005-08-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00147225 | AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplat… | Phase1 | Solid Tumors | Completed | 2005-08-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00101582 | Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advance… | Phase3 | Mucositis | Completed | 2005-08-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT00395902 | Post Transplant Study | — | Kidney Tansplant | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00626639 | A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Loca… | Phase1 | Mucositis | Completed | 2005-07-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT00121628 | A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced … | Phase2 | Thyroid Cancer | Completed | 2005-07-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00148369 | A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parki… | — | Idiopathic Parkinson's Disease | Completed | 2005-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00240097 | Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carbopla… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2005-06-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00115765 | PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study | Phase3 | Colorectal Cancer | Completed | 2005-06-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00204334 | Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transpl… | Phase4 | Kidney Transplantation | Completed | 2005-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00115219 | Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheuma… | Phase4 | Rheumatoid Arthritis | Completed | 2005-05-01 | — | ClinicalTrials.gov |
| NCT00116701 | Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis | Phase3 | Kidney Disease | Completed | 2005-05-01 | — | ClinicalTrials.gov |
| NCT02411136 | A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623… | Phase1 | Systemic Lupus Erythematosus | Completed | 2005-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00111007 | A Treatment Combination for Patients With Unresectable Stage III or Stage IV Me… | Phase3 | Melanoma | Completed | 2005-05-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00102336 | AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombo… | Phase3 | Thrombocytopenia | Completed | 2005-04-07 | 2007-04-01 | ClinicalTrials.gov |
| NCT00156962 | Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD) | Phase3 | Chronic Kidney Disease | Terminated | 2005-04-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00949546 | Treatment of Hidradenitis Suppurativa Using Etanercept | — | Hidradenitis Suppurativa | Completed | 2005-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00110994 | Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma | Phase2 | Cancer | Completed | 2005-04-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00116272 | Organization of Teratology Information Services (OTIS) Autoimmune Diseases in P… | — | Pregnancy | Completed | 2005-04-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00156949 | EPO Deep Tank in Dialysis Subjects | Phase3 | Chronic Kidney Disease | Completed | 2005-04-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00802815 | Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months … | Early_Phase1 | Inclusion Body Myositis | Completed | 2005-04-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00102323 | AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombo… | Phase3 | Thrombocytopenia | Completed | 2005-03-29 | 2007-03-01 | ClinicalTrials.gov |
| NCT00121602 | Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With C… | Phase3 | Anemia | Completed | 2005-03-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00110981 | Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for… | Phase4 | Psoriasis | Completed | 2005-03-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00977600 | A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) | Phase1 | Healthy | Completed | 2005-03-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00110942 | Treatment for Patients With Osteoarthritis (OA) | Phase2 | Osteoarthritis | Completed | 2005-02-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00309556 | Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitab… | Phase3 | Breast Cancer | Completed | 2005-02-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00508820 | An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP | Phase3 | Idiopathic Thrombocytopenic Purpura | Completed | 2005-02-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT02348879 | A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403… | Phase1 | Chronic Pain | Completed | 2005-01-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00094835 | Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumum… | Phase1 | Lung Cancer | Completed | 2005-01-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00094861 | Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Loc… | Phase2 | Dysphagia | Completed | 2005-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00293202 | Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients | Phase2 | End Stage Renal Disease | Terminated | 2005-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00104650 | Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With … | Phase2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Completed | 2005-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00109031 | Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMI… | Phase3 | Cancer | Completed | 2005-01-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00604682 | Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokin… | Phase2 | Psoriasis | Completed | 2005-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00131638 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Adva… | Phase3 | Head and Neck Cancer | Completed | 2005-01-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT00591851 | Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By … | Phase2 | Breast Cancer | Completed | 2004-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00101907 | Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment … | Phase1 | Lung Cancer | Terminated | 2004-12-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00189501 | A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyr… | — | Nephrology | Completed | 2004-12-01 | — | ClinicalTrials.gov |
| NCT00101894 | Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjec… | Phase1 | Rectal Cancer | Completed | 2004-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00617370 | Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breas… | Na | Breast Cancer | Completed | 2004-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT01502982 | Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell … | Phase2 | Diffuse Large B-Cell Lymphoma | Completed | 2004-11-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00135317 | AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects W… | Phase3 | Cancer | Completed | 2004-11-01 | — | ClinicalTrials.gov |
| NCT00094341 | Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-I… | Phase4 | Rheumatoid Arthritis | Completed | 2004-10-01 | — | ClinicalTrials.gov |
| NCT00093977 | Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease | Phase3 | Kidney Disease | Completed | 2004-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00089960 | Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GIS… | Phase2 | Gastrointestinal Cancer | Completed | 2004-10-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00089661 | AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibito… | Phase3 | Breast Cancer | Completed | 2004-10-01 | 2009-05-27 | ClinicalTrials.gov |
| NCT00095264 | A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Sy… | Phase2 | Myelodysplastic Syndromes | Completed | 2004-10-01 | — | ClinicalTrials.gov |
| NCT00096915 | Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD)… | Phase3 | Kidney Disease | Completed | 2004-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT02443506 | A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single … | Phase1 | Systemic Lupus Erythematosus | Completed | 2004-10-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00095277 | Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects W… | Phase2 | Anemia | Completed | 2004-10-01 | — | ClinicalTrials.gov |
| NCT00094484 | Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyro… | Phase3 | Kidney Disease | Completed | 2004-10-01 | — | ClinicalTrials.gov |
| NCT00116181 | Study to Help Understand the Action of the Drug Etanercept for the Adult Patien… | Phase3 | Psoriasis | Completed | 2004-10-01 | — | ClinicalTrials.gov |
| NCT00121615 | Study of Etanercept in the Treatment of Psoriasis in Adult Subjects | Phase3 | Inflammation | Completed | 2004-10-01 | — | ClinicalTrials.gov |
| NCT00078819 | Etanercept (Enbrel®) in Psoriasis - Pediatrics | Phase3 | Psoriasis | Completed | 2004-09-08 | 2007-06-01 | ClinicalTrials.gov |
| NCT00231582 | High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Progno… | Phase2 | Testicular Neoplasms | Completed | 2004-09-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00117052 | SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients Wit… | Phase3 | Secondary Hyperparathyroidism | Completed | 2004-09-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00091832 | Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer | Phase2 | Breast Cancer | Completed | 2004-09-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00121433 | Leptin and Endothelial Function | Phase4 | Healthy | Completed | 2004-09-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00509600 | Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | Phase2 | Leukemia | Terminated | 2004-09-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00095498 | Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid A… | Phase2 | Rheumatoid Arthritis | Completed | 2004-08-11 | 2007-04-01 | ClinicalTrials.gov |
| NCT00116688 | Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patient… | Phase3 | Thrombocytopenia | Completed | 2004-08-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT02588534 | Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Th… | Phase1 | Healthy Men and Women | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00594620 | Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Thera… | Phase2 | Prostate Cancer | Terminated | 2004-08-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00115167 | A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who H… | Phase3 | Anemia | Completed | 2004-08-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00102921 | Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Cro… | Phase2 | Crohn Disease | Completed | 2004-08-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00093015 | Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) | Phase3 | Kidney Disease | Completed | 2004-08-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00091806 | Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors | Phase1 | Tumors | Completed | 2004-08-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00091793 | Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis | Phase3 | Postmenopausal Osteoporosis | Completed | 2004-08-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00089791 | A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis | Phase3 | Osteoporosis | Completed | 2004-08-01 | 2008-06-17 | ClinicalTrials.gov |
| NCT00089674 | AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivati… | Phase3 | Prostate Cancer | Completed | 2004-08-01 | 2010-05-11 | ClinicalTrials.gov |
| NCT00089635 | Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer | Phase2 | Colorectal Cancer | Completed | 2004-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00132431 | START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney D… | Phase4 | Kidney Disease | Completed | 2004-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00110916 | Treatment for Patients With Osteoarthritis (OA) of the Knee | Phase2 | Osteoarthritis | Completed | 2004-06-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00112008 | Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis | Phase3 | Chronic Kidney Disease | Completed | 2004-05-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00125723 | FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles … | Phase4 | Neutropenia | Completed | 2004-05-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00099554 | Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjec… | Phase4 | Rheumatoid Arthritis | Completed | 2004-05-01 | — | ClinicalTrials.gov |
| NCT00169143 | Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large … | Phase2 | Untreated CD20-positive Large B-cell Lymphoma | Completed | 2004-05-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00259610 | Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) | Phase4 | Rheumatoid Arthritis | Completed | 2004-05-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00110890 | A Research Study for Patients With End-Stage Renal Disease (ESRD) | Phase4 | End Stage Renal Disease | Completed | 2004-05-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00101413 | BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) | Phase2 | Cancer | Completed | 2004-04-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00409318 | Study of TNF-Antagonism in Metabolic Syndrome | Na | Metabolic Syndrome | Completed | 2004-04-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00091858 | Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer | Phase3 | Anemia | Completed | 2004-04-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00785421 | Chemotherapy With or Without Enoxaparin in Pancreatic Cancer | Phase2 | Pancreatic Cancer | Completed | 2004-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00110656 | Study To Evaluate the Status of Subjects That Discontinued Participation in a Q… | — | Kidney Transplantation | Completed | 2004-03-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00118638 | A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-My… | Phase3 | Anemia | Completed | 2004-03-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00083616 | Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colore… | Phase2 | Colorectal Cancer | Completed | 2004-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00557817 | Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell… | Phase2 | Hematological Malignancies | Completed | 2004-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00111098 | Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis | Phase3 | Kidney Disease | Completed | 2004-03-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00425204 | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | Phase2 | Colorectal Cancer | Completed | 2004-03-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00110955 | Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycl… | Phase3 | Anemia | Completed | 2004-02-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00113763 | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supporti… | Phase3 | Colorectal Cancer | Completed | 2004-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00129896 | Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breas… | Phase1 | Breast Cancer | Completed | 2004-01-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00117039 | A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anem… | Phase4 | Anemia | Completed | 2004-01-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00067639 | Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple M… | Phase2 | Multiple Myeloma | Completed | 2003-12-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00140595 | ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large … | Phase3 | Diffuse Large-Cell Lymphoma | Completed | 2003-12-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00140660 | ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Ly… | Phase3 | Diffuse Large Cell Lymphoma | Terminated | 2003-12-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00144755 | R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years W… | Phase3 | Diffuse Large Cell Lymphoma | Completed | 2003-12-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00111982 | Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Contin… | Phase1 | Parkinson's Disease | Completed | 2003-12-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00115128 | Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Fil… | — | Normal PBPC Donors | Completed | 2003-11-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00280787 | Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | Phase2 | Non Small Cell Lung Cancer | Completed | 2003-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00073307 | Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell … | Phase3 | Carcinoma, Renal Cell | Completed | 2003-11-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT02799498 | Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Aut… | Phase1 | Healthy Men and Women | Completed | 2003-10-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00153868 | A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Pati… | Phase4 | Anemia | Completed | 2003-10-01 | 2007-08-17 | ClinicalTrials.gov |
| NCT00113789 | Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Rel… | Phase2 | Ovarian Cancer | Completed | 2003-10-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT03822078 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Osteoporosis | Completed | 2003-09-30 | 2004-12-24 | ClinicalTrials.gov |
| NCT00682383 | Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-sm… | Phase2 | Unresectable Locally Advanced NSCLC | Completed | 2003-09-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00072319 | Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treatin… | Phase2 | Breast Cancer | Completed | 2003-08-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00086086 | Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Hear… | Phase2 | Congestive Heart Failure | Completed | 2003-08-01 | — | ClinicalTrials.gov |
| NCT00657644 | Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction | Phase3 | Erectile Dysfunction | Completed | 2003-08-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00070382 | Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Rece… | Phase3 | Anemia | Completed | 2003-08-01 | — | ClinicalTrials.gov |
| NCT00094822 | Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advan… | — | Lung Cancer | Completed | 2003-07-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00093873 | Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors | Phase1 | Tumors | Completed | 2003-07-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00113945 | Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease … | Phase2 | End Stage Renal Disease | Completed | 2003-07-01 | — | ClinicalTrials.gov |
| NCT00283621 | Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfami… | Na | Sarcoma | Completed | 2003-06-02 | 2006-04-12 | ClinicalTrials.gov |
| NCT00359047 | Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme | Na | Osteoporosis | Unknown | 2003-06-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT00111449 | Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psorias… | Phase3 | Psoriasis | Completed | 2003-06-01 | — | ClinicalTrials.gov |
| NCT00122720 | The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery | Phase4 | Colorectal Cancer | Completed | 2003-06-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00101920 | ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) | Phase2 | Non-small Cell Lung Cancer | Completed | 2003-06-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00111436 | Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subj… | Phase3 | Psoriasis | Completed | 2003-04-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00245895 | Study of Aranesp to Treat Anemia in Prostate Cancer Patients. | Phase2 | Prostate Cancer | Completed | 2003-04-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00193479 | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab… | Phase2 | Non-Hodgkins Lymphoma | Completed | 2003-04-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00066092 | Pegfilgrastim PBPC Mobilization Study | Phase2 | Lymphoma | Completed | 2003-04-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00114764 | Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for… | Phase2 | Myeloid Leukemia | Completed | 2003-03-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00115427 | Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu)… | Phase1 | Idiopathic Parkinson's Disease | Completed | 2003-03-01 | — | ClinicalTrials.gov |
| NCT00111137 | Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy | Phase3 | Cancer | Completed | 2003-02-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00115193 | Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lym… | Phase2 | Non-Hodgkin's Lymphoma | Completed | 2003-02-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00094809 | Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjec… | Phase2 | Colon Cancer | Completed | 2003-02-01 | 2008-01-23 | ClinicalTrials.gov |
| NCT00501228 | Tissue Repair in Stem Cell Transplant Recipients | Na | Graft-Versus-Host Disease | Terminated | 2003-02-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00425035 | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | Phase2 | Advanced Renal Cell Carcinoma | Completed | 2003-02-01 | — | ClinicalTrials.gov |
| NCT00117143 | Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Im… | Phase1 | Thrombocytopenic Purpura | Completed | 2002-12-02 | 2004-07-19 | ClinicalTrials.gov |
| NCT00119613 | A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung C… | Phase3 | Small Cell Lung Cancer | Completed | 2002-12-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00433875 | Phase 2 AMG 714 in Rheumatoid Arthritis | Phase2 | Rheumatoid Arthritis | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00117624 | A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-… | Phase3 | Anemia | Completed | 2002-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00120705 | Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemother… | Phase2 | Neoplasms | Completed | 2002-11-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00110929 | Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Di… | Phase2 | End Stage Renal Disease | Completed | 2002-11-01 | — | ClinicalTrials.gov |
| NCT00120679 | Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2002-10-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00120692 | Treatment for Patients Suffering From Anemia Due to Chemotherapy | Phase2 | Breast Cancer | Completed | 2002-10-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00121030 | Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia D… | Phase2 | Gynecological Malignancies | Completed | 2002-10-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00117910 | Treatment for Elderly Patients With High Risk Breast Cancer | Phase3 | Breast Cancer | Completed | 2002-10-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00730392 | Etanercept in New Onset Type 1 Diabetes | Phase1 | Type 1 Diabetes | Completed | 2002-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00140231 | Role of Leptin in the Neuroendocrine and Immune Response to Fasting | Phase1 | Fasting | Completed | 2002-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00116727 | Rheumatoid Arthritis DMARD Intervention and UtilizationStudy | — | Rheumatoid Arthritis | Completed | 2002-10-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00117117 | A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Recei… | Phase4 | Anemia | Completed | 2002-09-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00121056 | REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Ev… | — | Rheumatoid Arthritis | Completed | 2002-09-01 | — | ClinicalTrials.gov |
| NCT00079612 | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory … | Phase2 | Carcinoma, Renal Cell | Completed | 2002-09-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00210249 | Development of an Evaluation Method of Elderly Condition in Patient Receiving C… | — | Lymphoma | Completed | 2002-09-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00117234 | Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure… | Na | Congestive Heart Failure | Completed | 2002-09-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00544765 | Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine… | Phase3 | Breast Cancer | Completed | 2002-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00111423 | Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in S… | Phase2 | Rheumatoid Arthritis | Completed | 2002-08-01 | — | ClinicalTrials.gov |
| NCT00117442 | A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoieti… | Phase2 | Breast Cancer | Completed | 2002-08-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00119587 | Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects | Phase3 | Anemia | Completed | 2002-08-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00544232 | Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) | Phase3 | Breast Cancer | Completed | 2002-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00941863 | Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sora… | Phase1 | Carcinoma | Completed | 2002-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00169104 | Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vino… | Phase2 | Metastatic Breast Cancer | Terminated | 2002-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00040651 | Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scle… | Phase1 | Scleroderma | Terminated | 2002-07-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00049985 | Heart Failure and Anemia | Phase2 | Heart Failure | Completed | 2002-07-01 | — | ClinicalTrials.gov |
| NCT00117897 | Treatment for Subjects With Non-Hodgkin's Lymphoma | Phase2 | Non-Hodgkin's Lymphoma | Completed | 2002-07-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00111475 | Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic… | Phase2 | Idiopathic Thrombocytopenic Purpura | Completed | 2002-07-01 | 2004-06-17 | ClinicalTrials.gov |
| NCT00111761 | Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer | Phase2 | Colorectal Cancer | Completed | 2002-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00115206 | Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During C… | Phase4 | Non-Small Cell Lung Cancer | Completed | 2002-07-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00277160 | A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary P… | Phase4 | Neutropenia | Completed | 2002-06-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00117247 | A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestiv… | Phase1 | Anemia | Completed | 2002-06-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00042432 | Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients | Phase2 | Secondary Hyperparathyroidism | Completed | 2002-06-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00042653 | A Study of an Investigational Medication for the Treatment of Secondary Hyperpa… | Phase3 | Secondary Hyperparathyroidism | Completed | 2002-05-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00111995 | Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects Wi… | Phase4 | Chronic Renal Failure | Completed | 2002-05-01 | — | ClinicalTrials.gov |
| NCT00989092 | Darbepoetin Alfa and Anemia of Cancer | Phase2 | Anemia | Terminated | 2002-05-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00369733 | STAAR-3 Clinical Study | Phase4 | Chronic Kidney Disease | Completed | 2002-05-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00043186 | Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the T… | Phase2 | Low Bone Mineral Density | Completed | 2002-05-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00356356 | 16.0040 Ankylosing Spondylitis Study | Phase3 | Ankylosing Spondylitis | Completed | 2002-04-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00038298 | A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People W… | Phase2 | Rheumatoid Arthritis | Completed | 2002-04-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00527215 | Phase 2 Study of Darbepoetin Alfa Extended Dosing | Phase2 | Pre-Dialysis | Completed | 2002-03-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00111774 | Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma | Phase2 | Colorectal Cancer | Completed | 2002-03-01 | — | ClinicalTrials.gov |
| NCT00035594 | Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemother… | Phase3 | Neutropenia | Completed | 2002-02-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00230321 | A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | Phase1 | Blood Cancer | Completed | 2002-02-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00369772 | STAAR-1 Clinical Study | Phase4 | Chronic Kidney Disease | Completed | 2002-02-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00527267 | Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects | Phase3 | Hyperparathyroidism | Completed | 2002-02-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00038064 | Anemia in Patients With a Non-Myeloid Malignancy | Phase3 | Neoplasms | Completed | 2002-01-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00368901 | STAAR-2 Clinical Study | Phase4 | Chronic Kidney Disease | Completed | 2002-01-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00034346 | ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Adv… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2002-01-01 | — | ClinicalTrials.gov |
| NCT00140244 | Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodys… | Phase2 | HAART-induced Lipodystrophy and Metabolic Syndrome | Completed | 2001-12-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00070616 | Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and… | Phase1 | Leukemia | Completed | 2001-12-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00194753 | Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxa… | Phase2 | Breast Neoplasm | Completed | 2001-12-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00035607 | Chemotherapy Related Anemia | Phase2 | Anemia | Completed | 2001-12-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00037635 | A Study of an Investigational Medication for the Treatment of Secondary Hyperpa… | Phase3 | Secondary Hyperparathyroidism | Completed | 2001-12-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00050674 | Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanc… | Phase2 | Non-small Cell Lung Cancer | Completed | 2001-11-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00116714 | Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy | — | Rheumatoid Arthritis | Completed | 2001-10-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00527085 | 12-month Study of AMG 073 in Renal Osteodystrophy | Phase2 | Renal Osteodystrophy | Completed | 2001-10-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00540696 | Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects Wi… | Phase2 | Anemia | Completed | 2001-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00537667 | The SPECTRA Study | Phase2 | Rheumatoid Arthritis | Terminated | 2001-08-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00078806 | Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Ons… | Phase3 | Juvenile Rheumatoid Arthritis | Terminated | 2001-06-04 | 2004-05-06 | ClinicalTrials.gov |
| NCT00037700 | Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunerc… | Phase2 | Rheumatoid Arthritis | Completed | 2001-05-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00037518 | A Study of an Investigational Medication for Severe Primary Hyperparathyroidism… | Phase4 | Hyperparathyroidism | Completed | 2001-04-01 | — | ClinicalTrials.gov |
| NCT00041470 | Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I -… | Phase1 | Breast Cancer | Terminated | 2001-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT01710722 | The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weigh… | Na | Obesity | Completed | 2001-02-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00140205 | Pharmacokinetics of Leptin Administration During Fasting | Phase1 | Energy Deficiency Due to Short-term Fasting | Completed | 2001-02-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00997529 | Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors | Na | Metastatic Solid Tumor | Completed | 2000-11-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00936988 | A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Ef… | Phase2 | Hyperparathyroidism, Primary | Completed | 2000-11-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00398372 | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving An… | Na | Lymphoma, Non-Hodgkin | Completed | 2000-11-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00038792 | Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestina… | Phase1 | Acute Graft Versus Host Disease | Terminated | 2000-10-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT03781375 | Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyart… | Phase3 | Juvenile Rheumatoid Arthritis | Terminated | 2000-08-24 | 2002-06-24 | ClinicalTrials.gov |
| NCT00527137 | NESP Pediatric Study | Phase3 | Pre-dialysis | Completed | 2000-08-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT01277419 | German Spondyloarthritis Inception Cohort | — | Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA) | Recruiting | 2000-07-01 | 2030-07-01 | ClinicalTrials.gov |
| NCT00186602 | Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breas… | — | Breast Cancer | Completed | 2000-07-01 | 2006-11-30 | ClinicalTrials.gov |
| NCT00037648 | Juvenile Rheumatoid Arthritis | Phase2 | Juvenile Chronic Arthritis | Completed | 2000-07-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT03776058 | Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (… | Phase2 | Primary Hyperparathyroidism | Completed | 2000-06-15 | 2000-12-26 | ClinicalTrials.gov |
| NCT00078793 | Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis | — | Juvenile Rheumatoid Arthritis | Completed | 2000-06-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00526929 | Fixed Dose NESP Study in Subjects With CRI | Phase2 | Pre-Dialysis | Completed | 2000-05-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00132418 | Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders | Phase4 | Rheumatoid Arthritis | Completed | 2000-04-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00317499 | Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the… | Phase3 | Psoriatic Arthritis | Completed | 2000-04-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00035620 | Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy | Phase2 | Sarcoma | Completed | 2000-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00005959 | Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-… | Phase2 | Lymphoma | Unknown | 1999-12-01 | — | ClinicalTrials.gov |
| NCT00936650 | A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Or… | Phase2 | Hyperparathyroidism, Primary | Completed | 1999-11-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00005958 | Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recu… | Phase2 | Bladder Cancer | Unknown | 1999-10-01 | — | ClinicalTrials.gov |
| NCT00005960 | Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not… | Phase2 | Pain | Unknown | 1999-10-01 | — | ClinicalTrials.gov |
| NCT00006215 | Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB … | Phase2 | Lung Cancer | Unknown | 1999-10-01 | — | ClinicalTrials.gov |
| NCT03776032 | A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Tre… | Phase3 | Anemia | Completed | 1999-09-14 | 2002-02-27 | ClinicalTrials.gov |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | Phase2 | AML | Completed | 1999-07-01 | — | ClinicalTrials.gov |
| NCT00540384 | Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the T… | Phase1 | Anemia | Completed | 1999-07-01 | 2002-06-01 | ClinicalTrials.gov |
| NCT00724386 | Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granul… | Phase1 | Breast Cancer | Completed | 1999-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01016795 | Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant … | Phase2 | Malignant Lymphoma | Terminated | 1999-01-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00356590 | Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Pati… | Phase3 | Rheumatoid Arthritis | Completed | 1998-12-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT03774771 | Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Prima… | Phase2 | Primary Hyperparathyroidism | Completed | 1998-09-29 | 1999-12-13 | ClinicalTrials.gov |
| NCT00100477 | Use of Topotecan in Patients With Refractory Acute Leukemia | Phase2 | Non-Hodgkin's Lymphoma | Completed | 1998-08-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT01207934 | Recombinant Human Leptin Therapy Effects on Insulin Action | Na | Type Two Diabetes Mellitus | Completed | 1998-08-01 | 2000-07-01 | ClinicalTrials.gov |
| NCT00007813 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients Wit… | Phase1 | Brain and Central Nervous System Tumors | Completed | 1997-05-31 | 2005-02-01 | ClinicalTrials.gov |
| NCT03780959 | Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Rece… | Phase2 | Juvenile Rheumatoid Arthritis | Completed | 1997-05-01 | 1998-07-08 | ClinicalTrials.gov |
| NCT00357903 | Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Pati… | Phase3 | Rheumatoid Arthritis | Completed | 1997-04-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT01020175 | Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplan… | Phase3 | Acute Leukemia | Completed | 1995-01-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00869284 | Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell… | Phase2 | Lymphoma | Completed | 1994-10-01 | 2009-02-01 | ClinicalTrials.gov |
Total clinical trials: 1563
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05633355 |
| Placebo | Other | Phase PHASE3 | Behçet Disease | RECRUITING | NCT04528082 |
| Apremilast | Other | Phase PHASE3 | Behçet Disease | RECRUITING | NCT04528082 |
| Placebo | Other | Phase PHASE3 | Active Juvenile Psoriatic Arthritis | RECRUITING | NCT04804553 |
| Apremilast | Other | Phase PHASE3 | Active Juvenile Psoriatic Arthritis | RECRUITING | NCT04804553 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05398445 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05398445 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Obesity or Overweight | RECRUITING | NCT07575399 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05899816 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05899816 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| Methotrexate | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Pegloticase | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Blinatumomab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | RECRUITING | NCT06570798 |
| Inebilizumab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | RECRUITING | NCT06570798 |
| Docetaxel | Other | Phase PHASE3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | COMPLETED | NCT04303780 |
| AMG 510 | Other | Phase PHASE3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | COMPLETED | NCT04303780 |
| Tarlatamab | Other | Phase PHASE2 | Relapsed/Refractory Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05060016 |
| Regorafenib | Other | Phase PHASE3 | Colorectal Cancer (CRC) | COMPLETED | NCT05198934 |
| Trifluridine and Tipiracil | Other | Phase PHASE3 | Colorectal Cancer (CRC) | COMPLETED | NCT05198934 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer (CRC) | COMPLETED | NCT05198934 |
| Sotorasib | Other | Phase PHASE3 | Colorectal Cancer (CRC) | COMPLETED | NCT05198934 |
| AMG 133 (liquid) | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT07717814 |
| AMG 133 (frozen liquid) | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT07717814 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07523711 |
| COC | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07523711 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | ACTIVE_NOT_RECRUITING | NCT06321601 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Evolocumab Drug Substance B (Reference) | Drug | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT07545226 |
| Evolocumab Drug Substance A (Test) | Drug | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT07545226 |
| Surgery | Procedure | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Neoadjuvant Radiation | Other | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Panitumumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| Pembrolizumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| AMG 410 | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| Pembrolizumab | Other | Phase PHASE2 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT03069378 |
| Talimogene Laherparepvec (T-VEC) | Other | Phase PHASE2 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT03069378 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT05111626 |
| Chemotherapy | Drug | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT05111626 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT05111626 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT05111626 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | TERMINATED | NCT05882877 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | TERMINATED | NCT05882877 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT07297979 |
| Bevacizumab-awwb | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Sotorasib | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| FOLFIRI Regimen | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Placebo | Other | Phase PHASE3 | Migraine | ACTIVE_NOT_RECRUITING | NCT03836040 |
| Erenumab Dose 3 | Other | Phase PHASE3 | Migraine | ACTIVE_NOT_RECRUITING | NCT03836040 |
| Erenumab Dose 2 | Other | Phase PHASE3 | Migraine | ACTIVE_NOT_RECRUITING | NCT03836040 |
| Erenumab Dose 1 | Other | Phase PHASE3 | Migraine | ACTIVE_NOT_RECRUITING | NCT03836040 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07203053 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT07313761 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Care Champion Intervention | Other | Approved | ASCVD | RECRUITING | NCT06471036 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07203053 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05565560 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Panitumumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| Pembrolizumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| AMG 410 | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Methotrexate | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Pegloticase | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Aflibercept (US) 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | RECRUITING | NCT07614776 |
| ABP 938 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | RECRUITING | NCT07614776 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07203053 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06502977 |
| Placebo | Other | Phase PHASE3 | Thyroid Eye Disease | ACTIVE_NOT_RECRUITING | NCT06248619 |
| Teprotumumab | Other | Phase PHASE3 | Thyroid Eye Disease | ACTIVE_NOT_RECRUITING | NCT06248619 |
| Dexamethasone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab 28 ug | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab 9ug | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Questionnaire Administration | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Electronic Health Record Review | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Echocardiography Test | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Computed Tomography | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Biospecimen Collection | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Aflibercept (US) 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | RECRUITING | NCT07614776 |
| ABP 938 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | RECRUITING | NCT07614776 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07684235 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07684235 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07684144 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07684144 |
| Methotrexate | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Pegloticase | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Obesity or Overweight | RECRUITING | NCT07575399 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Abiraterone | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Darolutamide | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT06376045 |
| Rocatinlimab | Other | Phase PHASE2 | Asthma | COMPLETED | NCT06376045 |
| Bevacizumab-awwb | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Sotorasib | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| FOLFIRI Regimen | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Methotrexate | Other | Phase PHASE4 | Gout | COMPLETED | NCT06229145 |
| Pegloticase | Other | Phase PHASE4 | Gout | COMPLETED | NCT06229145 |
| Pemetrexed | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05118854 |
| Carboplatin | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05118854 |
| Cisplatin | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05118854 |
| AMG 510 | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05118854 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07523711 |
| COC | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07523711 |
| Evolocumab Drug Substance B (Reference) | Drug | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07545226 |
| Evolocumab Drug Substance A (Test) | Drug | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07545226 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Midazolam | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | COMPLETED | NCT03600883 |
| Anti PD-1/L1 | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | COMPLETED | NCT03600883 |
| sotorasib | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | COMPLETED | NCT03600883 |
| Erwinia-asparaginase | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| PEG-asparaginase | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Ifosfamide | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Methotrexate | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Daunorubicin | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Vincrisitne | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Dexamethasone | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Blinatumomab | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05651711 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05651711 |
| Abiraterone | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Darolutamide | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Tarlatamab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | RECRUITING | NCT06598306 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Panitumumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| Pembrolizumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| AMG 410 | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| ABP 501-LCF | Other | Phase PHASE1 | Adalimumab | COMPLETED | NCT05909852 |
| ABP 501-HCF | Other | Phase PHASE1 | Adalimumab | COMPLETED | NCT05909852 |
| Placebo | Other | Phase PHASE3 | Coronary Heart Disease (CHD) | COMPLETED | NCT03872401 |
| Evolocumab | Other | Phase PHASE3 | Coronary Heart Disease (CHD) | COMPLETED | NCT03872401 |
| Abiraterone | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Darolutamide | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Evolocumab Drug Substance B | Drug | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT07422285 |
| Evolocumab Drug Substance A | Drug | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT07422285 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07590193 |
| Placebo | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| AMG 513 | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| Bemarituzumab | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05325866 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07203053 |
| Aflibercept (US) 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | RECRUITING | NCT07614776 |
| ABP 938 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | RECRUITING | NCT07614776 |
| Calcium | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT07366086 |
| Vitamin D | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT07366086 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| Methotrexate | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Pegloticase | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE2 | Granulomatosis With Polyangiitis | NOT_YET_RECRUITING | NCT07176546 |
| Avacopan | Other | Phase PHASE2 | Granulomatosis With Polyangiitis | NOT_YET_RECRUITING | NCT07176546 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | COMPLETED | NCT07226778 |
| Tarlatamab | Other | Phase PHASE2 | Metastatic Prostate Cancer | RECRUITING | NCT07111507 |
| Placebo | Other | Phase PHASE1 | Asthma | ACTIVE_NOT_RECRUITING | NCT06637371 |
| AMG 691 | Other | Phase PHASE1 | Asthma | ACTIVE_NOT_RECRUITING | NCT06637371 |
| Blinatumomab Injection | Other | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia | NOT_YET_RECRUITING | NCT07313852 |
| Denosumab | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT03839459 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Panitumumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| Pembrolizumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| AMG 410 | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| AMG 513 | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| Aflibercept (US) 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | RECRUITING | NCT07614776 |
| ABP 938 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | RECRUITING | NCT07614776 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | ACTIVE_NOT_RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | ACTIVE_NOT_RECRUITING | NCT07160257 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02332850 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02332850 |
| Isatuximab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02332850 |
| Xaluritamig | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT07297979 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Obesity or Overweight | RECRUITING | NCT07575399 |
| Methotrexate | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Pegloticase | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Placebo | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06376045 |
| Rocatinlimab | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06376045 |
| Bevacizumab-awwb | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Sotorasib | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| FOLFIRI Regimen | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Durvalumab | Other | Phase PHASE3 | Limited Stage Small-Cell Lung Cancer | NOT_YET_RECRUITING | NCT07637513 |
| Tarlatamab | Other | Phase PHASE3 | Limited Stage Small-Cell Lung Cancer | NOT_YET_RECRUITING | NCT07637513 |
| ABP 692 | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | ACTIVE_NOT_RECRUITING | NCT06700343 |
| Ocrelizumab (EU) | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | ACTIVE_NOT_RECRUITING | NCT06700343 |
| Ocrelizumab (US) | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | ACTIVE_NOT_RECRUITING | NCT06700343 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07203053 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04176718 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04176718 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04176718 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04176718 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Placebo | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| AMG 513 | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| Placebo Alendronate | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | WITHDRAWN | NCT06973109 |
| Placebo Romosozumab | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | WITHDRAWN | NCT06973109 |
| Alendronate (Fosamax) | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | WITHDRAWN | NCT06973109 |
| Romosozumab | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | WITHDRAWN | NCT06973109 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Ziftomenib | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Blinatumomab | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Methotrexate | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Mercaptopurine | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Vorinostat | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Bortezomib | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| PEG asparaginase | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Mitoxantrone | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Dexamethasone | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Dexamethasone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab 28 ug | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab 9ug | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04430894 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04430894 |
| Isatuximab | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04430894 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04430894 |
| RMC-6236 | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | ACTIVE_NOT_RECRUITING | NCT06360354 |
| Modified FOLFIRINOX | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | ACTIVE_NOT_RECRUITING | NCT06360354 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | ACTIVE_NOT_RECRUITING | NCT06360354 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | ACTIVE_NOT_RECRUITING | NCT06360354 |
| Anvumetostat | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | ACTIVE_NOT_RECRUITING | NCT06360354 |
| Aflibercept (US) 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | NOT_YET_RECRUITING | NCT07614776 |
| ABP 938 8 mg | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | NOT_YET_RECRUITING | NCT07614776 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| AB248 | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | RECRUITING | NCT07037758 |
| Tarlatamab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | RECRUITING | NCT07037758 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| ZL-1310 | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Tarlatamab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | RECRUITING | NCT06598306 |
| Enzalutamide | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| AMG 509 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| ABP 692 | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| Ocrelizumab (EU) | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| Ocrelizumab (US) | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| anvumetostat | Other | Phase PHASE2 | MTAP-deleted NSCLC | ACTIVE_NOT_RECRUITING | NCT06593522 |
| Blinatumomab | Other | Phase PHASE1 | B Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04521231 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06131398 |
| AMG 355 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06131398 |
| Sotorasib | Other | Phase PHASE1 | Thoracic Tumors | ACTIVE_NOT_RECRUITING | NCT06333951 |
| Pemetrexed | Other | Phase PHASE1 | Thoracic Tumors | ACTIVE_NOT_RECRUITING | NCT06333951 |
| Pembrolizumab | Other | Phase PHASE1 | Thoracic Tumors | ACTIVE_NOT_RECRUITING | NCT06333951 |
| Paclitaxel | Other | Phase PHASE1 | Thoracic Tumors | ACTIVE_NOT_RECRUITING | NCT06333951 |
| Carboplatin | Other | Phase PHASE1 | Thoracic Tumors | ACTIVE_NOT_RECRUITING | NCT06333951 |
| Anvumetostat | Other | Phase PHASE1 | Thoracic Tumors | ACTIVE_NOT_RECRUITING | NCT06333951 |
| Comparator Anvumetostat Test Tablet | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Docetaxel | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Anvumetostat | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| mFOLFOX6 | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06588153 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| mFOLFOX6 | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06588153 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| mFOLFOX6 | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06588153 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| mFOLFOX6 | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06588153 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| mFOLFOX6 | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06588153 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| mFOLFOX6 | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06588153 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| mFOLFOX6 | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | COMPLETED | NCT05052801 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06588153 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | ACTIVE_NOT_RECRUITING | NCT05972551 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | RECRUITING | NCT07438405 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Sotorasib | Other | Phase PHASE1 | Brain Tumor | RECRUITING | NCT06807619 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| ZL-1310 | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Sotorasib | Other | Phase PHASE1 | Brain Tumor | RECRUITING | NCT06807619 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| ZL-1310 | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Sotorasib | Other | Phase PHASE1 | Brain Tumor | RECRUITING | NCT06807619 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| ZL-1310 | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Sotorasib | Other | Phase PHASE1 | Brain Tumor | RECRUITING | NCT06807619 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| ZL-1310 | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Sotorasib | Other | Phase PHASE1 | Brain Tumor | RECRUITING | NCT06807619 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| ZL-1310 | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT07531095 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING | NCT07493512 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Standard of Care | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Placebo | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Inebilizumab | Other | Phase PHASE3 | Autoimmune Hepatitis | NOT_YET_RECRUITING | NCT07598825 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT04994717 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07153796 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Trifluridine | Other | Approved | Mycobacterium Avium-Intracellulare Infection | COMPLETED | NCT00002037 |
| Trifluridine | Other | Approved | Mycobacterium Avium-Intracellulare Infection | COMPLETED | NCT00002037 |
| Aranesp | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00245895 |
| Aranesp | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00245895 |
| Interferon gamma-1b | Other | Approved | HIV Infections | COMPLETED | NCT00002433 |
| Interferon gamma-1b | Other | Approved | HIV Infections | COMPLETED | NCT00002433 |
| Interferon gamma-1b | Other | Approved | HIV Infections | COMPLETED | NCT00002433 |
| Zidovudine | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Epoetin alfa | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Filgrastim | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Zidovudine | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Epoetin alfa | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Filgrastim | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Zidovudine | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Epoetin alfa | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Filgrastim | Other | Approved | HIV Infections | COMPLETED | NCT00002281 |
| Zidovudine | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Epoetin alfa | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Filgrastim | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Zidovudine | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Epoetin alfa | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Filgrastim | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Zidovudine | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Epoetin alfa | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Filgrastim | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002255 |
| Filgrastim | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002126 |
| Filgrastim | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002126 |
| Filgrastim | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002126 |
| 4 TXT q 2 weeks followed by 4 EC q 2 weeks | Other | Phase PHASE2 | Node Positive Breast Cancer | COMPLETED | NCT00189670 |
| 4 EC q 2 weeks followed by 4 TXT q 2 weeks | Other | Phase PHASE2 | Node Positive Breast Cancer | COMPLETED | NCT00189670 |
| 6 TEC q 3 weeks | Other | Phase PHASE2 | Node Positive Breast Cancer | COMPLETED | NCT00189670 |
| leptin | Other | Phase PHASE4 | Healthy | COMPLETED | NCT00121433 |
| leptin | Other | Phase PHASE4 | Healthy | COMPLETED | NCT00121433 |
| Darbepoetin Alfa | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT00122720 |
| Darbepoetin Alfa | Other | Phase PHASE4 | Colorectal Cancer | COMPLETED | NCT00122720 |
| recombinant human erythropoietin (rHuEPO) | Other | Phase PHASE2 | Gynecological Malignancies | COMPLETED | NCT00121030 |
| darbepoetin alfa | Other | Phase PHASE2 | Gynecological Malignancies | COMPLETED | NCT00121030 |
| recombinant human erythropoietin (rHuEPO) | Other | Phase PHASE2 | Gynecological Malignancies | COMPLETED | NCT00121030 |
| darbepoetin alfa | Other | Phase PHASE2 | Gynecological Malignancies | COMPLETED | NCT00121030 |
| Recombinant Human Erythropoietin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00120692 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00120692 |
| Recombinant Human Erythropoietin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00120692 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00120692 |
| recombinant human erythropoietin (rHuEPO) | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00120679 |
| darbepoetin alfa | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00120679 |
| recombinant human erythropoietin (rHuEPO) | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00120679 |
| darbepoetin alfa | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00120679 |
| Anakinra (Kineret®) | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00117091 |
| Anakinra (Kineret®) | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00117091 |
| carboplatin | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| paclitaxel | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| ABX-EGF | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| carboplatin | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| paclitaxel | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| ABX-EGF | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| carboplatin | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| paclitaxel | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| ABX-EGF | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00034346 |
| AMG 714 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00433875 |
| Sensipar after Post Transplant | Other | Preclinical | Kidney Tansplant | COMPLETED | NCT00395902 |
| Sensipar after Post Transplant | Other | Preclinical | Kidney Tansplant | COMPLETED | NCT00395902 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00095277 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00095277 |
| Sensipar® | Other | Preclinical | Nephrology | COMPLETED | NCT00189501 |
| Sensipar® | Other | Preclinical | Nephrology | COMPLETED | NCT00189501 |
| Sensipar® | Other | Preclinical | Nephrology | COMPLETED | NCT00189501 |
| darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00119587 |
| darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00117624 |
| epratuzumab | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00044902 |
| epratuzumab | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00044902 |
| Panitumumab with capecitabine and radiation | Other | Phase PHASE2 | Rectal Cancer | WITHDRAWN | NCT00346099 |
| Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by | Other | Phase PHASE2 | Rectal Cancer | WITHDRAWN | NCT00346099 |
| Panitumumab with capecitabine and radiation | Other | Phase PHASE2 | Rectal Cancer | WITHDRAWN | NCT00346099 |
| Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by | Other | Phase PHASE2 | Rectal Cancer | WITHDRAWN | NCT00346099 |
| Liatermin (r-metHuGDNF) | Other | Phase PHASE1 | Idiopathic Parkinson's Disease | COMPLETED | NCT00115427 |
| Liatermin (r-metHuGDNF) | Other | Phase PHASE1 | Idiopathic Parkinson's Disease | COMPLETED | NCT00115427 |
| placebo | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110916 |
| Intra-articular metHuIL-1ra (anakinra) | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110916 |
| placebo | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110916 |
| Intra-articular metHuIL-1ra (anakinra) | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110916 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00121602 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00121602 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00121602 |
| Darbepoetin alfa | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00111137 |
| rHuEPO | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00111137 |
| pegfilgrastim 6 mg | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| filgrastim | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| pegfilgrastim 12 mg | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| pegfilgrastim 6 mg | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| filgrastim | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| pegfilgrastim 12 mg | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| pegfilgrastim 6 mg | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| filgrastim | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| pegfilgrastim 12 mg | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00066092 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110942 |
| Systemic AMG 108 | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110942 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110942 |
| Systemic AMG 108 | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110942 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110942 |
| Systemic AMG 108 | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00110942 |
| cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| doxorubicin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| docetaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| pegfilgrastim | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| darbepoetin alfa | Other | Phase PHASE3 | Small Cell Lung Cancer | COMPLETED | NCT00119613 |
| placebo | Other | Phase PHASE3 | Small Cell Lung Cancer | COMPLETED | NCT00119613 |
| darbepoetin alfa | Other | Phase PHASE3 | Small Cell Lung Cancer | COMPLETED | NCT00119613 |
| placebo | Other | Phase PHASE3 | Small Cell Lung Cancer | COMPLETED | NCT00119613 |
| darbepoetin alfa | Other | Phase PHASE3 | Small Cell Lung Cancer | COMPLETED | NCT00119613 |
| placebo | Other | Phase PHASE3 | Small Cell Lung Cancer | COMPLETED | NCT00119613 |
| Aranesp® | Other | Phase PHASE4 | Chronic Renal Failure | COMPLETED | NCT00111995 |
| Aranesp® | Other | Phase PHASE4 | Chronic Renal Failure | COMPLETED | NCT00111995 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00111098 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00111098 |
| Panitumumab (ABX-EGF) | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00425204 |
| Darbepoetin alfa | Other | Approved | Hematologic Malignancies | COMPLETED | NCT00355407 |
| Darbepoetin alfa | Other | Approved | Hematologic Malignancies | COMPLETED | NCT00355407 |
| AMG 114 | Other | Phase PHASE1 | Anemia | TERMINATED | NCT00119600 |
| AMG 114 | Other | Phase PHASE1 | Anemia | TERMINATED | NCT00119600 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00115167 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00115167 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00115167 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00115167 |
| darbepoetin alfa | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00036023 |
| darbepoetin alfa | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00036023 |
| darbepoetin alfa | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00036023 |
| anakinra and PEG sTNF-R1 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00537667 |
| anakinra | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00537667 |
| anakinra and PEG sTNF-R1 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00537667 |
| anakinra | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00537667 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07134088 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07134088 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07134088 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07134088 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00293826 |
| AMG 108 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00293826 |
| Darbepoetin alfa | Other | Phase PHASE2 | Non-Myeloid Malignancies | COMPLETED | NCT00239239 |
| Darbepoetin alfa | Other | Phase PHASE2 | Non-Myeloid Malignancies | COMPLETED | NCT00239239 |
| Darbepoetin alfa | Other | Phase PHASE2 | Non-Myeloid Malignancies | COMPLETED | NCT00239239 |
| Neulasta (pegfilgrastim) | Other | Phase PHASE4 | Neutropenia | COMPLETED | NCT00277160 |
| Neulasta (pegfilgrastim) | Other | Phase PHASE4 | Neutropenia | COMPLETED | NCT00277160 |
| Placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00413400 |
| Etanercept | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00413400 |
| PI Discretion | Other | Phase PHASE4 | Neutropenia | COMPLETED | NCT00125723 |
| AMG 706 | Other | Phase PHASE1 | Histologically or Cytologically Documented Solid Tumors | COMPLETED | NCT01235416 |
| AMG 706 | Other | Phase PHASE1 | Histologically or Cytologically Documented Solid Tumors | COMPLETED | NCT01235416 |
| AMG 706 | Other | Phase PHASE1 | Histologically or Cytologically Documented Solid Tumors | COMPLETED | NCT01235416 |
| Placebo | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT00418665 |
| AMG 531 | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT00418665 |
| Placebo | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT00418665 |
| AMG 531 | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT00418665 |
| Denosumab | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00330460 |
| Alendronate | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00330460 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07134088 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07134088 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07134088 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT07134088 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06691984 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| AMG 127 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07590193 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Blood draw | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00439894 |
| Aranesp® | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00116701 |
| pegfilgrastim | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00117910 |
| filgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00117455 |
| pegfilgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00117455 |
| Placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00409318 |
| Etanercept | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00409318 |
| Placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00409318 |
| Etanercept | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00409318 |
| Pegfilgrastim (drug) | Drug | Phase PHASE2 | Solid Malignancies | TERMINATED | NCT00695370 |
| Pegfilgrastim (drug) | Drug | Phase PHASE2 | Solid Malignancies | TERMINATED | NCT00695370 |
| Aranesp® (darbepoetin alfa) | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00124098 |
| Aranesp® (darbepoetin alfa) | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00124098 |
| Epoetin alfa RB | Other | Phase PHASE3 | Chronic Kidney Disease | TERMINATED | NCT00156962 |
| Epoetin alfa DT | Other | Phase PHASE3 | Chronic Kidney Disease | TERMINATED | NCT00156962 |
| cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| doxorubicin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| docetaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| pegfilgrastim | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| doxorubicin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| docetaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| pegfilgrastim | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00115414 |
| rHuEPO | Other | Phase PHASE3 | Neoplasms | COMPLETED | NCT00038064 |
| Darbepoetin alfa | Other | Phase PHASE3 | Neoplasms | COMPLETED | NCT00038064 |
| rHuEPO | Other | Phase PHASE3 | Neoplasms | COMPLETED | NCT00038064 |
| Darbepoetin alfa | Other | Phase PHASE3 | Neoplasms | COMPLETED | NCT00038064 |
| Aranesp® | Other | Phase PHASE4 | Kidney Disease | COMPLETED | NCT00117078 |
| Aranesp® | Other | Phase PHASE4 | Kidney Disease | COMPLETED | NCT00117078 |
| Aranesp® | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00117039 |
| Aranesp® | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00117039 |
| Aranesp® | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00117039 |
| pegfilgrastim | Other | Phase PHASE2 | Myeloid Leukemia | COMPLETED | NCT00114764 |
| filgrastim | Other | Phase PHASE2 | Myeloid Leukemia | COMPLETED | NCT00114764 |
| pegfilgrastim | Other | Phase PHASE2 | Myeloid Leukemia | COMPLETED | NCT00114764 |
| filgrastim | Other | Phase PHASE2 | Myeloid Leukemia | COMPLETED | NCT00114764 |
| Kineret® | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00121056 |
| Enbrel® | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00121056 |
| Kineret® | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00121056 |
| Enbrel® | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00121056 |
| Kineret® | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00121056 |
| Enbrel® | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00121056 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00094341 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00094341 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00094341 |
| AMG 073 | Other | Phase PHASE3 | Hyperparathyroidism | COMPLETED | NCT00527267 |
| Placebo | Other | Phase PHASE3 | Hyperparathyroidism | COMPLETED | NCT00527267 |
| AMG 073 | Other | Phase PHASE3 | Hyperparathyroidism | COMPLETED | NCT00527267 |
| Placebo | Other | Phase PHASE3 | Hyperparathyroidism | COMPLETED | NCT00527267 |
| Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00413452 |
| Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00413452 |
| Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00413452 |
| Sensipar | Other | Phase PHASE4 | Kidney Disease | COMPLETED | NCT00132431 |
| Sensipar | Other | Phase PHASE4 | Kidney Disease | COMPLETED | NCT00132431 |
| PI Discretion | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00113789 |
| PI Discretion | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00113789 |
| PI Discretion | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00113789 |
| PI Discretion | Other | Preclinical | Lung Cancer | COMPLETED | NCT00094822 |
| PI Discretion | Other | Preclinical | Lung Cancer | COMPLETED | NCT00094822 |
| etanercept | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT00121615 |
| etanercept | Other | Phase PHASE3 | Inflammation | COMPLETED | NCT00121615 |
| Pegsunercept (PEG sTNF-RI) | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00111423 |
| Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC) | Drug | Phase PHASE2 | Lymphoma | COMPLETED | NCT00869284 |
| CEEP regimen | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00869284 |
| Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC) | Drug | Phase PHASE2 | Lymphoma | COMPLETED | NCT00869284 |
| CEEP regimen | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00869284 |
| darbepoetin alfa | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT00120705 |
| Aranesp | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00117117 |
| Aranesp | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00117117 |
| Aranesp | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00117117 |
| Neulasta® (pegfilgrastim) | Other | Phase PHASE4 | Non-Small Cell Lung Cancer | COMPLETED | NCT00115206 |
| Neulasta® (pegfilgrastim) | Other | Phase PHASE4 | Non-Small Cell Lung Cancer | COMPLETED | NCT00115206 |
| darbepoetin alfa | Other | Phase PHASE2 | Pre-Dialysis | COMPLETED | NCT00527215 |
| darbepoetin alfa | Other | Phase PHASE2 | Pre-Dialysis | COMPLETED | NCT00527215 |
| darbepoetin alfa | Other | Phase PHASE2 | Pre-Dialysis | COMPLETED | NCT00526929 |
| darbepoetin alfa | Other | Phase PHASE2 | Pre-Dialysis | COMPLETED | NCT00526929 |
| darbepoetin alfa | Other | Phase PHASE2 | Pre-Dialysis | COMPLETED | NCT00526929 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00096915 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00111111 |
| De Novo Administration of Darbepoetin Alfa | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT00112008 |
| De Novo Administration of Darbepoetin Alfa | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT00112008 |
| Panitumumab | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00091806 |
| panitumumab (ABX-EGF) | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00091806 |
| Panitumumab | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00091806 |
| panitumumab (ABX-EGF) | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00091806 |
| Filgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00117897 |
| pegfilgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00117897 |
| Filgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00117897 |
| pegfilgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00117897 |
| Filgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00117897 |
| pegfilgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00117897 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00049985 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00049985 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT00049985 |
| ABX-EGF (panitumumab) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00327119 |
| ABX-EGF (panitumumab) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00327119 |
| darbepoetin alfa | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00369772 |
| darbepoetin alfa | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00369772 |
| darbepoetin alfa | Other | Phase PHASE1 | Anemia | COMPLETED | NCT00117247 |
| darbepoetin alfa | Other | Phase PHASE1 | Anemia | COMPLETED | NCT00117247 |
| Aranesp® | Other | Phase PHASE4 | End Stage Renal Disease | COMPLETED | NCT00117104 |
| Aranesp® | Other | Phase PHASE4 | End Stage Renal Disease | COMPLETED | NCT00117104 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00099554 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00099554 |
| Peripheral blood stem cell transplantation | Other | Phase PHASE3 | Acute Leukemia | COMPLETED | NCT01020175 |
| Bone marrow transplantation | Other | Phase PHASE3 | Acute Leukemia | COMPLETED | NCT01020175 |
| Kineret® (Anakinra) | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00121043 |
| SimpleJectTM | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00121043 |
| Kineret® (Anakinra) | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00121043 |
| SimpleJectTM | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00121043 |
| pegsunercept | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00037700 |
| anakinra | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00037700 |
| pegsunercept | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00037700 |
| anakinra | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00037700 |
| Placebo | Other | Phase PHASE2 | Juvenile Chronic Arthritis | COMPLETED | NCT00037648 |
| Anakinra | Other | Phase PHASE2 | Juvenile Chronic Arthritis | COMPLETED | NCT00037648 |
| Placebo | Other | Phase PHASE2 | Juvenile Chronic Arthritis | COMPLETED | NCT00037648 |
| Anakinra | Other | Phase PHASE2 | Juvenile Chronic Arthritis | COMPLETED | NCT00037648 |
| Iron saccharate (Venofer) | Other | Phase PHASE2 | Hematological Malignancies | COMPLETED | NCT00557817 |
| Darbepoetin alpha (Aranesp) | Other | Phase PHASE2 | Hematological Malignancies | COMPLETED | NCT00557817 |
| Iron saccharate (Venofer) | Other | Phase PHASE2 | Hematological Malignancies | COMPLETED | NCT00557817 |
| Darbepoetin alpha (Aranesp) | Other | Phase PHASE2 | Hematological Malignancies | COMPLETED | NCT00557817 |
| darbopoeitin | Other | Phase PHASE4 | Kidney Transplantation | COMPLETED | NCT00204334 |
| darbopoeitin | Other | Phase PHASE4 | Kidney Transplantation | COMPLETED | NCT00204334 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00110955 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00110955 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00110955 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00110955 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT00095264 |
| Darbepoetin alfa | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00369733 |
| Epoetin alfa DT | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT00156949 |
| Aranesp | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00261313 |
| Neulasta | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00261313 |
| Epoetin alfa DT | Other | Phase PHASE3 | Nephrology | COMPLETED | NCT00146224 |
| Epoetin alfa RB | Other | Phase PHASE3 | Nephrology | COMPLETED | NCT00146224 |
| Epoetin alfa DT | Other | Phase PHASE3 | Nephrology | COMPLETED | NCT00146224 |
| Epoetin alfa RB | Other | Phase PHASE3 | Nephrology | COMPLETED | NCT00146224 |
| 5-fluorouracil | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00124111 |
| methotrexate | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00124111 |
| cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00124111 |
| pegfilgrastim | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00124111 |
| filgrastim | Other | Phase PHASE2 | Sarcoma | COMPLETED | NCT00035620 |
| pegfilgrastim | Other | Phase PHASE2 | Sarcoma | COMPLETED | NCT00035620 |
| filgrastim | Other | Phase PHASE2 | Sarcoma | COMPLETED | NCT00035620 |
| pegfilgrastim | Other | Phase PHASE2 | Sarcoma | COMPLETED | NCT00035620 |
| Darbepoetin alfa | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00368901 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT00902356 |
| AMG 167 | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT00902356 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT00902356 |
| AMG 167 | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT00902356 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT00902356 |
| AMG 167 | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT00902356 |
| AMG 073 | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT00110929 |
| etanercept | Other | Phase PHASE4 | Psoriasis | UNKNOWN | NCT01132235 |
| etanercept | Other | Phase PHASE4 | Psoriasis | UNKNOWN | NCT01132235 |
| etanercept | Other | Phase PHASE4 | Psoriasis | UNKNOWN | NCT01132235 |
| Injection of Filgrastim | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00794261 |
| Injection of Pegfilgrastim | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00794261 |
| Injection of Filgrastim | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00794261 |
| Injection of Pegfilgrastim | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00794261 |
| No Intervention for Observational Study | Other | Preclinical | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00861224 |
| No Intervention for Observational Study | Other | Preclinical | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00861224 |
| Enbrel liquid | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00249041 |
| 50 mg Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00249041 |
| Enbrel liquid | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00249041 |
| 50 mg Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00249041 |
| Enbrel liquid | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00249041 |
| 50 mg Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00249041 |
| AMG 386 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00102830 |
| AMG 386 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00102830 |
| ABX-EGF | Other | Phase PHASE2 | Non-small Cell Lung Cancer | COMPLETED | NCT00101920 |
| ABX-EGF | Other | Phase PHASE2 | Non-small Cell Lung Cancer | COMPLETED | NCT00101920 |
| Panitumumab + FOLFIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT01144195 |
| Panitumumab + FOLFIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT01144195 |
| Panitumumab + FOLFIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT01144195 |
| Panitumumab + FOLFIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT01144195 |
| darbepoetin alfa | Other | Approved | Congestive Heart Failure | COMPLETED | NCT00117234 |
| darbepoetin alfa | Other | Approved | Congestive Heart Failure | COMPLETED | NCT00117234 |
| Etanercept | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT00317499 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT00317499 |
| Etanercept | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT00317499 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT00317499 |
| Placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00091793 |
| AMG 162 | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00091793 |
| Placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00091793 |
| AMG 162 | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00091793 |
| Placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00091793 |
| AMG 162 | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00091793 |
| AMG 853 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01124279 |
| AMG 853 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01124279 |
| AMG 853 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01124279 |
| Pegfilgrastim (Neulasta, Amgen) | Other | Phase PHASE2 | Solid Malignancies | UNKNOWN | NCT00751894 |
| Pegfilgrastim (Neulasta, Amgen) | Other | Phase PHASE2 | Solid Malignancies | UNKNOWN | NCT00751894 |
| AMG 706 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00448786 |
| AMG 706 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00448786 |
| AMG 706 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00448786 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT00436995 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT00436995 |
| Placebo | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00132418 |
| Enbrel | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00132418 |
| Placebo | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00132418 |
| Enbrel | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00132418 |
| Aranesp® | Other | Phase PHASE4 | Kidney Disease | COMPLETED | NCT00117130 |
| Aranesp® | Other | Phase PHASE4 | Kidney Disease | COMPLETED | NCT00117130 |
| Aranesp® | Other | Phase PHASE4 | Kidney Disease | COMPLETED | NCT00117130 |
| ABX-EGF | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00113776 |
| ABX-EGF | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00113776 |
| ABX-EGF | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00113776 |
| Observations | Other | Preclinical | Kidney Transplantation | COMPLETED | NCT00110656 |
| placebo to AMG 719 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00038298 |
| AGM 719 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00038298 |
| AMG 719 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00038298 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00038298 |
| placebo to AMG 719 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00038298 |
| AGM 719 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00038298 |
| AMG 719 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00038298 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00038298 |
| AMG 162- 180 mg q 4 weeks | Other | Phase PHASE2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT00104650 |
| IV Bisphosphonate q 4 weeks | Other | Phase PHASE2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT00104650 |
| AMG 162 180 mg (SC) q 12 weeks | Other | Phase PHASE2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT00104650 |
| AMG 162- 180 mg q 4 weeks | Other | Phase PHASE2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT00104650 |
| IV Bisphosphonate q 4 weeks | Other | Phase PHASE2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT00104650 |
| AMG 162 180 mg (SC) q 12 weeks | Other | Phase PHASE2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT00104650 |
| carboplatin | Other | Phase PHASE2 | Testicular Neoplasms | COMPLETED | NCT00231582 |
| ifosfamide | Other | Phase PHASE2 | Testicular Neoplasms | COMPLETED | NCT00231582 |
| etoposide | Other | Phase PHASE2 | Testicular Neoplasms | COMPLETED | NCT00231582 |
| paclitaxel | Other | Phase PHASE2 | Testicular Neoplasms | COMPLETED | NCT00231582 |
| high-dose and autologous stem cell transplantation | Other | Phase PHASE2 | Testicular Neoplasms | COMPLETED | NCT00231582 |
| epirubicin | Other | Phase PHASE2 | Testicular Neoplasms | COMPLETED | NCT00231582 |
| cyclophosphamide | Other | Phase PHASE3 | Diffuse Large-Cell Lymphoma | COMPLETED | NCT00140595 |
| doxorubicin | Other | Phase PHASE3 | Diffuse Large-Cell Lymphoma | COMPLETED | NCT00140595 |
| rituximab | Other | Phase PHASE3 | Diffuse Large-Cell Lymphoma | COMPLETED | NCT00140595 |
| cyclophosphamide | Other | Phase PHASE3 | Diffuse Large-Cell Lymphoma | COMPLETED | NCT00140595 |
| doxorubicin | Other | Phase PHASE3 | Diffuse Large-Cell Lymphoma | COMPLETED | NCT00140595 |
| rituximab | Other | Phase PHASE3 | Diffuse Large-Cell Lymphoma | COMPLETED | NCT00140595 |
| Standard of care | Other | Phase PHASE4 | End Stage Renal Disease | COMPLETED | NCT00110890 |
| cinacalcet | Other | Phase PHASE4 | End Stage Renal Disease | COMPLETED | NCT00110890 |
| Standard of care | Other | Phase PHASE4 | End Stage Renal Disease | COMPLETED | NCT00110890 |
| cinacalcet | Other | Phase PHASE4 | End Stage Renal Disease | COMPLETED | NCT00110890 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00116181 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00116181 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | TERMINATED | NCT00534456 |
| Placebo | Other | Phase PHASE3 | Anemia | TERMINATED | NCT00534456 |
| ENBREL® | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00116727 |
| ENBREL® | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00116727 |
| DMARD | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT00116714 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Blinatumomab | Other | Phase PHASE1 | B-precursor Acute Lymphoblastic Leukemia | COMPLETED | NCT06649006 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Epratuzumab | Other | Approved | Lymphoma, Non-Hodgkin | COMPLETED | NCT00398372 |
| Rituximab | Other | Approved | Lymphoma, Non-Hodgkin | COMPLETED | NCT00398372 |
| Epratuzumab | Other | Approved | Lymphoma, Non-Hodgkin | COMPLETED | NCT00398372 |
| Rituximab | Other | Approved | Lymphoma, Non-Hodgkin | COMPLETED | NCT00398372 |
| Epratuzumab | Other | Approved | Lymphoma, Non-Hodgkin | COMPLETED | NCT00398372 |
| Rituximab | Other | Approved | Lymphoma, Non-Hodgkin | COMPLETED | NCT00398372 |
| AMG 531 | Other | Phase PHASE1 | Chemotherapy-Induced Thrombocytopenia | COMPLETED | NCT00283439 |
| AMG 531 | Other | Phase PHASE1 | Chemotherapy-Induced Thrombocytopenia | COMPLETED | NCT00283439 |
| Placebo | Other | Phase PHASE1 | Dermatomyositis | COMPLETED | NCT00112385 |
| Etanercept | Other | Phase PHASE1 | Dermatomyositis | COMPLETED | NCT00112385 |
| Denosumab (AMG 162) | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00377819 |
| alendronate | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00377819 |
| Denosumab (AMG 162) | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00377819 |
| alendronate | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00377819 |
| AMG 706 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01386866 |
| AMG 706 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01386866 |
| nbUVB | Other | Phase PHASE4 | Psoriasis Vulgaris | COMPLETED | NCT00640393 |
| Etanercept | Other | Phase PHASE4 | Psoriasis Vulgaris | COMPLETED | NCT00640393 |
| nbUVB | Other | Phase PHASE4 | Psoriasis Vulgaris | COMPLETED | NCT00640393 |
| Etanercept | Other | Phase PHASE4 | Psoriasis Vulgaris | COMPLETED | NCT00640393 |
| nbUVB | Other | Phase PHASE4 | Psoriasis Vulgaris | COMPLETED | NCT00640393 |
| Etanercept | Other | Phase PHASE4 | Psoriasis Vulgaris | COMPLETED | NCT00640393 |
| Etanercept | Other | Phase PHASE3 | Palmoplantaris Pustulosis | COMPLETED | NCT00353119 |
| Placebo comparator | Other | Phase PHASE3 | Palmoplantaris Pustulosis | COMPLETED | NCT00353119 |
| Etanercept | Other | Phase PHASE3 | Palmoplantaris Pustulosis | COMPLETED | NCT00353119 |
| Placebo comparator | Other | Phase PHASE3 | Palmoplantaris Pustulosis | COMPLETED | NCT00353119 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Blinatumomab | Other | Phase PHASE1 | B-precursor Acute Lymphoblastic Leukemia | COMPLETED | NCT06649006 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Vincristine sulfate | Other | Phase PHASE2 | Sarcoma, Kaposi | COMPLETED | NCT00001059 |
| Bleomycin sulfate | Other | Phase PHASE2 | Sarcoma, Kaposi | COMPLETED | NCT00001059 |
| Filgrastim | Other | Phase PHASE2 | Sarcoma, Kaposi | COMPLETED | NCT00001059 |
| Doxorubicin hydrochloride (liposomal) | Other | Phase PHASE2 | Sarcoma, Kaposi | COMPLETED | NCT00001059 |
| Vincristine sulfate | Other | Phase PHASE2 | Sarcoma, Kaposi | COMPLETED | NCT00001059 |
| Bleomycin sulfate | Other | Phase PHASE2 | Sarcoma, Kaposi | COMPLETED | NCT00001059 |
| Filgrastim | Other | Phase PHASE2 | Sarcoma, Kaposi | COMPLETED | NCT00001059 |
| Doxorubicin hydrochloride (liposomal) | Other | Phase PHASE2 | Sarcoma, Kaposi | COMPLETED | NCT00001059 |
| Placebo | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma or Hodgkin's Disease | WITHDRAWN | NCT00570999 |
| Palifermin | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma or Hodgkin's Disease | WITHDRAWN | NCT00570999 |
| Placebo | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma or Hodgkin's Disease | WITHDRAWN | NCT00570999 |
| Palifermin | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma or Hodgkin's Disease | WITHDRAWN | NCT00570999 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT01384994 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT01384994 |
| 5-FU | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT01384994 |
| Folic Acid | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT01384994 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT01384994 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT01384994 |
| 5-FU | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT01384994 |
| Folic Acid | Other | Phase PHASE2 | Colorectal Cancer | UNKNOWN | NCT01384994 |
| Apheresis | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00067639 |
| Pegfilgrastim (Neulasta) | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00067639 |
| Recombinant Human Keratinocyte Growth Factor | Other | Phase PHASE1 | Acute Graft Versus Host Disease | TERMINATED | NCT00038792 |
| Recombinant Human Keratinocyte Growth Factor | Other | Phase PHASE1 | Acute Graft Versus Host Disease | TERMINATED | NCT00038792 |
| Etanercept | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT00509600 |
| Etanercept | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT00509600 |
| Filgrastim | Other | Approved | Graft-Versus-Host Disease | TERMINATED | NCT00501228 |
| FOLFIRI | Other | Phase PHASE1 | Rectal Cancer | COMPLETED | NCT00101894 |
| Panitumumab (Part 1a only) | Other | Phase PHASE1 | Rectal Cancer | COMPLETED | NCT00101894 |
| AMG 706 | Other | Phase PHASE1 | Rectal Cancer | COMPLETED | NCT00101894 |
| FOLFOX-4 | Other | Phase PHASE1 | Rectal Cancer | COMPLETED | NCT00101894 |
| FOLFIRI | Other | Phase PHASE1 | Rectal Cancer | COMPLETED | NCT00101894 |
| Panitumumab (Part 1a only) | Other | Phase PHASE1 | Rectal Cancer | COMPLETED | NCT00101894 |
| AMG 706 | Other | Phase PHASE1 | Rectal Cancer | COMPLETED | NCT00101894 |
| FOLFOX-4 | Other | Phase PHASE1 | Rectal Cancer | COMPLETED | NCT00101894 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01568203 |
| AMG 579 | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01568203 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01568203 |
| AMG 579 | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01568203 |
| Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta | Drug | Phase PHASE2 | Unresectable Locally Advanced NSCLC | COMPLETED | NCT00682383 |
| Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta | Drug | Phase PHASE2 | Unresectable Locally Advanced NSCLC | COMPLETED | NCT00682383 |
| Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta | Drug | Phase PHASE2 | Unresectable Locally Advanced NSCLC | COMPLETED | NCT00682383 |
| Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta | Drug | Phase PHASE2 | Unresectable Locally Advanced NSCLC | COMPLETED | NCT00682383 |
| Cinacalcet | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00431496 |
| Cinacalcet | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00431496 |
| AMG 706 | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00089960 |
| AMG 706 | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00089960 |
| AMG 706 | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00089960 |
| cinacalcet | Other | Phase PHASE2 | Hyperparathyroidism, Primary | COMPLETED | NCT00936988 |
| darbepoetin alfa | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00135317 |
| darbepoetin alfa | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00135317 |
| AMG 557 or PLACEBO | Other | Phase PHASE1 | Psoriasis | TERMINATED | NCT01493518 |
| AMG 706 | Other | Phase PHASE2 | Advanced Gastrointestinal Stromal Tumor | COMPLETED | NCT00254267 |
| AMG 706 | Other | Phase PHASE2 | Advanced Gastrointestinal Stromal Tumor | COMPLETED | NCT00254267 |
| Blinatumomab | Other | Phase PHASE1 | B-precursor Acute Lymphoblastic Leukemia | COMPLETED | NCT06649006 |
| Blinatumomab | Other | Phase PHASE1 | B-precursor Acute Lymphoblastic Leukemia | COMPLETED | NCT06649006 |
| 5FU | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | TERMINATED | NCT01182610 |
| Carboplatin | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | TERMINATED | NCT01182610 |
| Paclitaxel | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | TERMINATED | NCT01182610 |
| Panitumumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | TERMINATED | NCT01182610 |
| Filgrastim-SD/01 | Other | Phase PHASE2 | Non-small Cell Lung Cancer | COMPLETED | NCT00050674 |
| Darbepoetin alfa | Other | Phase PHASE1 | Blood Cancer | COMPLETED | NCT00230321 |
| Denosumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00936897 |
| Ibandronate | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00936897 |
| Denosumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00936897 |
| Ibandronate | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00936897 |
| AMG 876 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT01492465 |
| AMG 876 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT01492465 |
| neoadjuvant therapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| adjuvant therapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| paclitaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| epirubicin hydrochloride | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| filgrastim | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| neoadjuvant therapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| adjuvant therapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| paclitaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| epirubicin hydrochloride | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| filgrastim | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00072319 |
| AMG 811 or Placebo | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT01510951 |
| AMG 557 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT00774943 |
| AMG 557 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT00774943 |
| AMG 557 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT00774943 |
| AMG 151 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT01755442 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT01755442 |
| AMG 151 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT01755442 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT01755442 |
| darbepoetin alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00540696 |
| darbepoetin alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00540696 |
| Aranesp® | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00117065 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00111436 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00111436 |
| Etanercept Liquid | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00110903 |
| Darbepoetin alfa - 500mcg | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00118638 |
| Darbepoetin alfa - 2.25 mcg/kg | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00118638 |
| Darbepoetin alfa - 500mcg | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00118638 |
| Darbepoetin alfa - 2.25 mcg/kg | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00118638 |
| Darbepoetin alfa - 500mcg | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00118638 |
| Darbepoetin alfa - 2.25 mcg/kg | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00118638 |
| cinacalcet | Other | Phase PHASE2 | Hyperparathyroidism, Primary | COMPLETED | NCT00936988 |
| cinacalcet | Other | Phase PHASE2 | Hyperparathyroidism, Primary | COMPLETED | NCT00936650 |
| placebo | Other | Phase PHASE2 | Hyperparathyroidism, Primary | COMPLETED | NCT00936650 |
| cinacalcet | Other | Phase PHASE2 | Hyperparathyroidism, Primary | COMPLETED | NCT00936650 |
| placebo | Other | Phase PHASE2 | Hyperparathyroidism, Primary | COMPLETED | NCT00936650 |
| cinacalcet | Other | Phase PHASE2 | Hyperparathyroidism, Primary | COMPLETED | NCT00936650 |
| placebo | Other | Phase PHASE2 | Hyperparathyroidism, Primary | COMPLETED | NCT00936650 |
| Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Other | Phase PHASE1 | Anemia | COMPLETED | NCT00540384 |
| Placebo | Other | Phase PHASE1 | Anemia | COMPLETED | NCT00540384 |
| Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Other | Phase PHASE1 | Anemia | COMPLETED | NCT00540384 |
| Placebo | Other | Phase PHASE1 | Anemia | COMPLETED | NCT00540384 |
| Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Other | Phase PHASE1 | Anemia | COMPLETED | NCT00540384 |
| Placebo | Other | Phase PHASE1 | Anemia | COMPLETED | NCT00540384 |
| rHuEPO | Other | Phase PHASE3 | Pre-dialysis | COMPLETED | NCT00527137 |
| darbepoetin alfa | Other | Phase PHASE3 | Pre-dialysis | COMPLETED | NCT00527137 |
| rHuEPO | Other | Phase PHASE3 | Pre-dialysis | COMPLETED | NCT00527137 |
| darbepoetin alfa | Other | Phase PHASE3 | Pre-dialysis | COMPLETED | NCT00527137 |
| Placebo | Other | Phase PHASE2 | Renal Osteodystrophy | COMPLETED | NCT00527085 |
| AMG 073 | Other | Phase PHASE2 | Renal Osteodystrophy | COMPLETED | NCT00527085 |
| Darbepoetin alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00111462 |
| Darbepoetin alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00111462 |
| Cinacalcet HCl | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00094484 |
| Cinacalcet HCl | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00094484 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00091858 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00091858 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00091858 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00091858 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00091858 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00091858 |
| AMG 073 | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00042653 |
| Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00042653 |
| AMG 073 | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00042653 |
| Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00042653 |
| AMG 073 | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00042653 |
| Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00042653 |
| Recombinant Human Keratinocyte Growth Factor | Other | Phase PHASE3 | Stomatitis | COMPLETED | NCT00041665 |
| Recombinant Human Keratinocyte Growth Factor | Other | Phase PHASE3 | Stomatitis | COMPLETED | NCT00041665 |
| Recombinant Human Keratinocyte Growth Factor | Other | Phase PHASE3 | Stomatitis | COMPLETED | NCT00041665 |
| Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00037635 |
| AMG 073 | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00037635 |
| Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00037635 |
| AMG 073 | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00037635 |
| AMG 073 | Other | Phase PHASE4 | Hyperparathyroidism | COMPLETED | NCT00037518 |
| AMG 073 | Other | Phase PHASE4 | Hyperparathyroidism | COMPLETED | NCT00037518 |
| pegfilgrastim | Other | Phase PHASE3 | Neutropenia | COMPLETED | NCT00035594 |
| pegfilgrastim | Other | Phase PHASE3 | Neutropenia | COMPLETED | NCT00035594 |
| Panitumumab (ABX-EGF) | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00425035 |
| Panitumumab (ABX-EGF) | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00425035 |
| pegfilgrastim | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00117442 |
| paclitaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00117442 |
| carboplatin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00117442 |
| pegfilgrastim | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00117442 |
| paclitaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00117442 |
| carboplatin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00117442 |
| filgrastim | Other | Preclinical | Normal PBPC Donors | COMPLETED | NCT00115128 |
| filgrastim | Other | Preclinical | Normal PBPC Donors | COMPLETED | NCT00115128 |
| Cinacalcet | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT00113958 |
| Cinacalcet | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT00113958 |
| Cinacalcet | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT00113958 |
| Cinacalcet | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT00113945 |
| cinacalcet (AMG 073) | Other | Phase PHASE2 | Secondary Hyperparathyroidism | COMPLETED | NCT00042432 |
| Darbepoetin alfa IV | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00035607 |
| Darbepoetin alfa SC | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00035607 |
| Darbepoetin alfa IV | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00035607 |
| Darbepoetin alfa SC | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00035607 |
| Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00356590 |
| Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00356590 |
| Etanercept | Other | Phase PHASE3 | Ankylosing Spondylitis | COMPLETED | NCT00356356 |
| Etanercept | Other | Phase PHASE3 | Ankylosing Spondylitis | COMPLETED | NCT00356356 |
| Etanercept | Other | Phase PHASE3 | Ankylosing Spondylitis | COMPLETED | NCT00356356 |
| ABX-EGF | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111774 |
| ABX-EGF | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111774 |
| ABX-EGF | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111774 |
| Enbrel® | Other | Preclinical | Juvenile Rheumatoid Arthritis | COMPLETED | NCT00078793 |
| Enbrel® | Other | Preclinical | Juvenile Rheumatoid Arthritis | COMPLETED | NCT00078793 |
| Darbepoetin alfa and Epoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00148421 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00111449 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00111449 |
| Enbrel® | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00111124 |
| Enbrel® | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00111124 |
| AMG 706 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00093873 |
| Anti-angiogenesis | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00093873 |
| AMG 706 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00093873 |
| Anti-angiogenesis | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00093873 |
| AMG 706 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00093873 |
| Anti-angiogenesis | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00093873 |
| cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00117052 |
| cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00117052 |
| Aranesp® | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00144131 |
| Aranesp® | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00144131 |
| Etanercept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00110981 |
| Etanerept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00110981 |
| NB-UVB | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00110981 |
| darbepoetin alfa SF | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00093977 |
| darbepoetin alfa SF | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00093977 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00115219 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00115219 |
| methotrexate - etanercept - prednisolone arm | Other | Phase PHASE4 | Juvenile Chronic Polyarthritis | COMPLETED | NCT00443430 |
| methotrexate | Other | Phase PHASE4 | Juvenile Chronic Polyarthritis | COMPLETED | NCT00443430 |
| methotrexate - etanercept - prednisolone arm | Other | Phase PHASE4 | Juvenile Chronic Polyarthritis | COMPLETED | NCT00443430 |
| methotrexate | Other | Phase PHASE4 | Juvenile Chronic Polyarthritis | COMPLETED | NCT00443430 |
| Epirubicine, Oxaliplatin, Capecitabine, Panitumumab | Other | Phase PHASE2 | KRAS Wild Type | TERMINATED | NCT01351038 |
| Placebo | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 14 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 60 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 100 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| Placebo | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 14 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 60 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 100 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| Placebo | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 14 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 60 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| 100 mg AMG 162 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00306189 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | WITHDRAWN | NCT01009879 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | WITHDRAWN | NCT01009879 |
| biopsy | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| pharmacological study | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| ganitumab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| biopsy | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| pharmacological study | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| ganitumab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| biopsy | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| pharmacological study | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| ganitumab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00562380 |
| Amg 181 | Other | Phase PHASE1 | Ulcerative Colitis | TERMINATED | NCT01164904 |
| Amg 181 | Other | Phase PHASE1 | Ulcerative Colitis | TERMINATED | NCT01164904 |
| Amg 181 | Other | Phase PHASE1 | Ulcerative Colitis | TERMINATED | NCT01164904 |
| AMG 706 | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| Paclitaxel | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| Docetaxel | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| AMG 706 | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| Paclitaxel | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| Docetaxel | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| AMG 706 | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| Paclitaxel | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| Docetaxel | Other | Phase PHASE1 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00322400 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01001208 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01001208 |
| Methotrexate | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01001208 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01001208 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01001208 |
| Methotrexate | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01001208 |
| pegfilgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00115193 |
| pegfilgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00115193 |
| pegfilgrastim | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00115193 |
| Panitumumab | Other | Phase PHASE2 | Malignant Glioma of Brain | TERMINATED | NCT01017653 |
| Irinotecan | Other | Phase PHASE2 | Malignant Glioma of Brain | TERMINATED | NCT01017653 |
| Panitumumab | Other | Phase PHASE2 | Malignant Glioma of Brain | TERMINATED | NCT01017653 |
| Irinotecan | Other | Phase PHASE2 | Malignant Glioma of Brain | TERMINATED | NCT01017653 |
| Panitumumab and CPT-11 | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00475293 |
| Etanercept | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00361634 |
| Alendronate | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00043186 |
| Denosumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00043186 |
| Placebo | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00043186 |
| Alendronate | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00043186 |
| Denosumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00043186 |
| Placebo | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00043186 |
| Etoposide | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| Mitozantrone | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| Topotecan | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| Etoposide | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| Mitozantrone | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| Topotecan | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| Etoposide | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| Mitozantrone | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| Topotecan | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00100477 |
| AMG 706 | Other | Phase PHASE2 | Thyroid Cancer | COMPLETED | NCT00121628 |
| AMG 706 | Other | Phase PHASE2 | Thyroid Cancer | COMPLETED | NCT00121628 |
| Cisplatin | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Carboplatin | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Gemcitabine | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Placebo | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Romiplostim | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Cisplatin | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Carboplatin | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Gemcitabine | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Placebo | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Romiplostim | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Cisplatin | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Carboplatin | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Gemcitabine | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Placebo | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| Romiplostim | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT00413283 |
| denosumab | Other | Phase PHASE3 | Low Bone Mineral Density | COMPLETED | NCT00515463 |
| Previous denosumab | Other | Phase PHASE2 | Low Bone Mass | COMPLETED | NCT00887965 |
| Previous denosumab | Other | Phase PHASE2 | Low Bone Mass | COMPLETED | NCT00887965 |
| Previous denosumab | Other | Phase PHASE2 | Low Bone Mass | COMPLETED | NCT00887965 |
| AMG 827 or Placebo | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT01395485 |
| AMG 827 or Placebo | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT01395485 |
| Physician Survey | Other | Preclinical | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00454857 |
| Patient-reported Outcome Questionnaires | Other | Preclinical | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00454857 |
| Retrospective Chart Review | Other | Preclinical | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00454857 |
| Physician Survey | Other | Preclinical | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00454857 |
| Patient-reported Outcome Questionnaires | Other | Preclinical | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00454857 |
| Retrospective Chart Review | Other | Preclinical | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00454857 |
| pain therapy | Drug | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| doxorubicin hydrochloride | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| docetaxel | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| cyclophosphamide | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| filgrastim | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| pain therapy | Drug | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| doxorubicin hydrochloride | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| docetaxel | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| cyclophosphamide | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| filgrastim | Other | Phase PHASE2 | Pain | UNKNOWN | NCT00005960 |
| vincristine sulfate | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| prednisone | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| doxorubicin hydrochloride | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| cyclophosphamide | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| rituximab | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| filgrastim | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| vincristine sulfate | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| prednisone | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| doxorubicin hydrochloride | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| cyclophosphamide | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| rituximab | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| filgrastim | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| vincristine sulfate | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| prednisone | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| doxorubicin hydrochloride | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| cyclophosphamide | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| rituximab | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| filgrastim | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| vincristine sulfate | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| prednisone | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| doxorubicin hydrochloride | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| cyclophosphamide | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| rituximab | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| filgrastim | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00005959 |
| gemcitabine hydrochloride | Other | Phase PHASE2 | Bladder Cancer | UNKNOWN | NCT00005958 |
| docetaxel | Other | Phase PHASE2 | Bladder Cancer | UNKNOWN | NCT00005958 |
| filgrastim | Other | Phase PHASE2 | Bladder Cancer | UNKNOWN | NCT00005958 |
| Placebo | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| Cisplatin | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| AMG 102 | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| Epirubicin | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| Capecitabine | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| Placebo | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| Cisplatin | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| AMG 102 | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| Epirubicin | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| Capecitabine | Other | Phase PHASE1 | Esophagogastric Junction Adenocarcinoma | COMPLETED | NCT00719550 |
| Leucovorin | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111761 |
| 5-Fluorouracil | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111761 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111761 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111761 |
| Leucovorin | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111761 |
| 5-Fluorouracil | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111761 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111761 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00111761 |
| Romiplostim | Other | Phase PHASE2 | Thrombocytopenia | COMPLETED | NCT00303472 |
| Romiplostim | Other | Phase PHASE2 | Thrombocytopenia | COMPLETED | NCT00303472 |
| Romiplostim | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00116688 |
| vinorelbine tartrate | Other | Phase PHASE2 | Lung Cancer | UNKNOWN | NCT00006215 |
| docetaxel | Other | Phase PHASE2 | Lung Cancer | UNKNOWN | NCT00006215 |
| filgrastim | Other | Phase PHASE2 | Lung Cancer | UNKNOWN | NCT00006215 |
| vinorelbine tartrate | Other | Phase PHASE2 | Lung Cancer | UNKNOWN | NCT00006215 |
| docetaxel | Other | Phase PHASE2 | Lung Cancer | UNKNOWN | NCT00006215 |
| filgrastim | Other | Phase PHASE2 | Lung Cancer | UNKNOWN | NCT00006215 |
| panitumumab | Other | Phase PHASE2 | Cancer of Pancreas | TERMINATED | NCT00613730 |
| Gemcitabine | Other | Phase PHASE2 | Cancer of Pancreas | TERMINATED | NCT00613730 |
| panitumumab | Other | Phase PHASE2 | Cancer of Pancreas | TERMINATED | NCT00613730 |
| Gemcitabine | Other | Phase PHASE2 | Cancer of Pancreas | TERMINATED | NCT00613730 |
| AMG 557 Placebo | Other | Phase PHASE1 | Cutaneous Lupus | TERMINATED | NCT01389895 |
| AMG 557 | Other | Phase PHASE1 | Cutaneous Lupus | TERMINATED | NCT01389895 |
| AMG 557 Placebo | Other | Phase PHASE1 | Cutaneous Lupus | TERMINATED | NCT01389895 |
| AMG 557 | Other | Phase PHASE1 | Cutaneous Lupus | TERMINATED | NCT01389895 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00083616 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00083616 |
| IV Bisphosphonates | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00091832 |
| Denosumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00091832 |
| IV Bisphosphonates | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00091832 |
| Denosumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00091832 |
| darbepoetin alfa | Other | Phase PHASE2 | Anemia | TERMINATED | NCT00989092 |
| darbepoetin alfa | Other | Phase PHASE2 | Anemia | TERMINATED | NCT00989092 |
| IV iron dextran | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00401544 |
| darbepoetin alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00401544 |
| Conatumumab | Other | Phase PHASE1 | Colon Cancer | COMPLETED | NCT00630786 |
| Panitumumab | Other | Phase PHASE1 | Colon Cancer | COMPLETED | NCT00630786 |
| amg 162 | Other | Phase PHASE3 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT00950911 |
| Vitamin D | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT00135304 |
| Sensipar® | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT00135304 |
| Vitamin D | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT00135304 |
| Sensipar® | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT00135304 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01137565 |
| AMG 853 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01137565 |
| Bortezomib | Other | Phase PHASE1 | Hodgkin's Lymphoma | COMPLETED | NCT00791011 |
| Vorinostat | Other | Phase PHASE1 | Hodgkin's Lymphoma | COMPLETED | NCT00791011 |
| AMG 655 | Other | Phase PHASE1 | Hodgkin's Lymphoma | COMPLETED | NCT00791011 |
| Bortezomib | Other | Phase PHASE1 | Hodgkin's Lymphoma | COMPLETED | NCT00791011 |
| Vorinostat | Other | Phase PHASE1 | Hodgkin's Lymphoma | COMPLETED | NCT00791011 |
| AMG 655 | Other | Phase PHASE1 | Hodgkin's Lymphoma | COMPLETED | NCT00791011 |
| Radiation | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Filgrastim | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Vinorelbine | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Paclitaxel | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Radiation | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Filgrastim | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Vinorelbine | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Paclitaxel | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Radiation | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Filgrastim | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Vinorelbine | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| Paclitaxel | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00724386 |
| ARM 1 | Other | Phase PHASE3 | Recurrent and/or Metastatic Head and Neck Cancer | COMPLETED | NCT00460265 |
| ARM 2 | Other | Phase PHASE3 | Recurrent and/or Metastatic Head and Neck Cancer | COMPLETED | NCT00460265 |
| ARM 1 | Other | Phase PHASE3 | Recurrent and/or Metastatic Head and Neck Cancer | COMPLETED | NCT00460265 |
| ARM 2 | Other | Phase PHASE3 | Recurrent and/or Metastatic Head and Neck Cancer | COMPLETED | NCT00460265 |
| Prednisone | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Placebo | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Mitoxantrone | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| AMG 102 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Prednisone | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Placebo | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Mitoxantrone | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| AMG 102 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Prednisone | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Placebo | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Mitoxantrone | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| AMG 102 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770848 |
| Cisplatin | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00101907 |
| Gemcitabine | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00101907 |
| Panitumumab | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00101907 |
| AMG 706 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00101907 |
| Placebo | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Denosumab | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Dual energy X-ray absorptiometry (DXA) | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| high-resolution peripheral quantitative computed tomography (HR-pQCT) | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Placebo | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Denosumab | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Dual energy X-ray absorptiometry (DXA) | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| high-resolution peripheral quantitative computed tomography (HR-pQCT) | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Placebo | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Denosumab | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Dual energy X-ray absorptiometry (DXA) | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| high-resolution peripheral quantitative computed tomography (HR-pQCT) | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00890981 |
| Placebo | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT01250405 |
| Cinacalcet | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT01250405 |
| Placebo | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT01250405 |
| Cinacalcet | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT01250405 |
| Epoetin alfa | Other | Phase PHASE4 | Anemia | TERMINATED | NCT01737879 |
| Peginesatide | Other | Phase PHASE4 | Anemia | TERMINATED | NCT01737879 |
| Epoetin alfa | Other | Phase PHASE4 | Anemia | TERMINATED | NCT01737879 |
| Peginesatide | Other | Phase PHASE4 | Anemia | TERMINATED | NCT01737879 |
| Epoetin alfa | Other | Phase PHASE4 | Anemia | TERMINATED | NCT01737879 |
| Peginesatide | Other | Phase PHASE4 | Anemia | TERMINATED | NCT01737879 |
| Placebo | Other | Phase PHASE1 | Asthma | TERMINATED | NCT01514981 |
| AMG 761 | Other | Phase PHASE1 | Asthma | TERMINATED | NCT01514981 |
| Placebo | Other | Phase PHASE1 | Asthma | TERMINATED | NCT01514981 |
| AMG 761 | Other | Phase PHASE1 | Asthma | TERMINATED | NCT01514981 |
| Etanercept | Other | Phase PHASE4 | Psoriatic Arthritis | COMPLETED | NCT00127842 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00625651 |
| Modified FOLFOX6 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00625651 |
| AMG 655 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00625651 |
| Placebo | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00625651 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00625651 |
| Modified FOLFOX6 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00625651 |
| AMG 655 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00625651 |
| Placebo | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00625651 |
| Docetaxel | Other | Phase PHASE2 | Urothelial Carcinoma | WITHDRAWN | NCT01907308 |
| AMG 386 | Other | Phase PHASE2 | Urothelial Carcinoma | WITHDRAWN | NCT01907308 |
| Docetaxel | Other | Phase PHASE2 | Urothelial Carcinoma | WITHDRAWN | NCT01907308 |
| AMG 386 | Other | Phase PHASE2 | Urothelial Carcinoma | WITHDRAWN | NCT01907308 |
| Docetaxel | Other | Phase PHASE2 | Urothelial Carcinoma | WITHDRAWN | NCT01907308 |
| AMG 386 | Other | Phase PHASE2 | Urothelial Carcinoma | WITHDRAWN | NCT01907308 |
| Capecitabine | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| Cisplatin | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 3mg/kg | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 10mg/kg | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 placebo | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| Capecitabine | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| Cisplatin | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 3mg/kg | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 10mg/kg | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 placebo | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| Capecitabine | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| Cisplatin | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 3mg/kg | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 10mg/kg | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| AMG 386 placebo | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT00583674 |
| Ifosfamide | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Adriamycin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Carboplatin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| AMG 531 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Ifosfamide | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Adriamycin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Carboplatin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| AMG 531 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Ifosfamide | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Adriamycin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Carboplatin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| AMG 531 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00147225 |
| Metformin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| AMG 151 | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| Metformin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| AMG 151 | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| Metformin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| AMG 151 | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01464437 |
| Capecitabine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00493636 |
| Placebo | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00493636 |
| Sorafenib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00493636 |
| Gemcitabine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00493636 |
| Capecitabine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00493636 |
| Placebo | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00493636 |
| Sorafenib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00493636 |
| Gemcitabine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00493636 |
| Placebo | Other | Phase PHASE3 | Anemia | TERMINATED | NCT00364845 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | TERMINATED | NCT00364845 |
| Etanercept | Other | Phase EARLY_PHASE1 | Inclusion Body Myositis | COMPLETED | NCT00802815 |
| Etanercept | Other | Phase EARLY_PHASE1 | Inclusion Body Myositis | COMPLETED | NCT00802815 |
| darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00925587 |
| darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00925587 |
| placebo | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00393822 |
| palifermin | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00393822 |
| placebo | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00393822 |
| palifermin | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00393822 |
| placebo | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00393822 |
| palifermin | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00393822 |
| etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| hydroxychloroquine | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| sulfasalazine | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| methotrexate | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| hydroxychloroquine | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| sulfasalazine | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| methotrexate | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| hydroxychloroquine | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| sulfasalazine | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| methotrexate | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00259610 |
| Sensipar (Cinacalcet HCl) | Other | Phase PHASE2 | Secondary Hyperparathyroidism | COMPLETED | NCT00261950 |
| Placebo | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00791765 |
| Etanercept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00791765 |
| Placebo | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00791765 |
| Etanercept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00791765 |
| Methotrexate | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00654368 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00654368 |
| cinacalcet | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00379899 |
| etanercept 50 mg | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00967538 |
| etanercept 50 mg | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00967538 |
| etanercept 50 mg | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00967538 |
| Observations | Other | Preclinical | Anemia | COMPLETED | NCT00727571 |
| Observations | Other | Preclinical | Anemia | COMPLETED | NCT00727571 |
| AMG 531 | Other | Phase PHASE1 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00515203 |
| Placebo | Other | Phase PHASE1 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00515203 |
| AMG 531 | Other | Phase PHASE1 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00515203 |
| Placebo | Other | Phase PHASE1 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00515203 |
| AMG 531 | Other | Phase PHASE1 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00515203 |
| Placebo | Other | Phase PHASE1 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00515203 |
| etanercept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00332332 |
| Placebo | Other | Phase PHASE2 | Postmenopausal Osteoporosis | COMPLETED | NCT00293813 |
| Denosumab | Other | Phase PHASE2 | Postmenopausal Osteoporosis | COMPLETED | NCT00293813 |
| Alendronate | Other | Phase PHASE2 | Postmenopausal Osteoporosis | COMPLETED | NCT00293813 |
| Placebo | Other | Phase PHASE2 | Postmenopausal Osteoporosis | COMPLETED | NCT00293813 |
| Denosumab | Other | Phase PHASE2 | Postmenopausal Osteoporosis | COMPLETED | NCT00293813 |
| Alendronate | Other | Phase PHASE2 | Postmenopausal Osteoporosis | COMPLETED | NCT00293813 |
| Radiation Therapy | Drug | Phase PHASE2 | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT01305772 |
| Surgery | Procedure | Phase PHASE2 | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT01305772 |
| Panitumumab | Other | Phase PHASE2 | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT01305772 |
| Radiation Therapy | Drug | Phase PHASE2 | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT01305772 |
| Surgery | Procedure | Phase PHASE2 | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT01305772 |
| Panitumumab | Other | Phase PHASE2 | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT01305772 |
| AMG 811 | Other | Phase PHASE1 | Nephritis | COMPLETED | NCT00818948 |
| AMG 811 | Other | Phase PHASE1 | Nephritis | COMPLETED | NCT00818948 |
| AMG811 Placebo | Other | Phase PHASE1 | Cutaneous Lupus | TERMINATED | NCT01164917 |
| AMG811 | Other | Phase PHASE1 | Cutaneous Lupus | TERMINATED | NCT01164917 |
| AMG811 Placebo | Other | Phase PHASE1 | Cutaneous Lupus | TERMINATED | NCT01164917 |
| AMG811 | Other | Phase PHASE1 | Cutaneous Lupus | TERMINATED | NCT01164917 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01992341 |
| AMG 386 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01992341 |
| R-CHOEP14x6+HD-AraC+HD-Mtx | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01502982 |
| R-CHOEP14x6+HD-AraC+HD-Mtx | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01502982 |
| Placebo | Other | Phase PHASE2 | Schizophrenia | TERMINATED | NCT01568229 |
| AMG 747 | Other | Phase PHASE2 | Schizophrenia | TERMINATED | NCT01568229 |
| Placebo | Other | Phase PHASE1 | Chronic Pain | COMPLETED | NCT02348879 |
| AMG 403 | Other | Phase PHASE1 | Chronic Pain | COMPLETED | NCT02348879 |
| Placebo | Other | Phase PHASE1 | Chronic Pain | COMPLETED | NCT02348879 |
| AMG 403 | Other | Phase PHASE1 | Chronic Pain | COMPLETED | NCT02348879 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02443506 |
| AMG 623 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02443506 |
| Etanercept (ENBREL®) via Manual injection | Other | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02588534 |
| etanercept (ENBREL®) via auto-injector device | Device | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02588534 |
| Etanercept (ENBREL®) via Manual injection | Other | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02588534 |
| etanercept (ENBREL®) via auto-injector device | Device | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02588534 |
| Cisplatin | Other | Phase PHASE3 | Squamous Cell Carcinoma | TERMINATED | NCT01161498 |
| Radiation | Other | Phase PHASE3 | Squamous Cell Carcinoma | TERMINATED | NCT01161498 |
| Talimogene Laherparepvec | Other | Phase PHASE3 | Squamous Cell Carcinoma | TERMINATED | NCT01161498 |
| Cisplatin | Other | Phase PHASE3 | Squamous Cell Carcinoma | TERMINATED | NCT01161498 |
| Radiation | Other | Phase PHASE3 | Squamous Cell Carcinoma | TERMINATED | NCT01161498 |
| Talimogene Laherparepvec | Other | Phase PHASE3 | Squamous Cell Carcinoma | TERMINATED | NCT01161498 |
| Reactive Skin Treatment | Drug | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| Pre-emptive Skin Treatment | Drug | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| FOLFIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| Panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| Paclitaxel | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Carboplatin | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Bevacizumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| AMG 951 (rhApo2L/TRAIL) | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Paclitaxel | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Carboplatin | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Bevacizumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| AMG 951 (rhApo2L/TRAIL) | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Matching Placebo | Other | Phase PHASE1 | Lupus Arthritis, Systemic Lupus Erythematosus | COMPLETED | NCT01683695 |
| AMG 557 | Other | Phase PHASE1 | Lupus Arthritis, Systemic Lupus Erythematosus | COMPLETED | NCT01683695 |
| cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim | Other | Approved | Breast Cancer | COMPLETED | NCT00615901 |
| Cisplatin | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00547157 |
| Panitumumab | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00547157 |
| Cisplatin | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00547157 |
| Panitumumab | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00547157 |
| Panitumumab | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01175733 |
| Panitumumab | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01175733 |
| Epoetin alfa | Other | Phase PHASE4 | Renal Insufficiency, Chronic | COMPLETED | NCT02253654 |
| Placebo | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00925600 |
| Denosumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00925600 |
| Placebo | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00925600 |
| Denosumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00925600 |
| Carfilzomib | Other | Phase PHASE2 | Relapse Multiple Myeloma | COMPLETED | NCT01775553 |
| Carfilzomib | Other | Phase PHASE2 | Relapse Multiple Myeloma | COMPLETED | NCT01775553 |
| Ferric carboxymaltose | Other | Phase PHASE3 | Tubular Breast Cancer Stage II | COMPLETED | NCT02125344 |
| Trastuzumab | Other | Phase PHASE3 | Tubular Breast Cancer Stage II | COMPLETED | NCT02125344 |
| Pertuzumab | Other | Phase PHASE3 | Tubular Breast Cancer Stage II | COMPLETED | NCT02125344 |
| Cyclophosphamide | Other | Phase PHASE3 | Tubular Breast Cancer Stage II | COMPLETED | NCT02125344 |
| Epirubicin | Other | Phase PHASE3 | Tubular Breast Cancer Stage II | COMPLETED | NCT02125344 |
| Paclitaxel | Other | Phase PHASE3 | Tubular Breast Cancer Stage II | COMPLETED | NCT02125344 |
| Carboplatin | Other | Phase PHASE3 | Tubular Breast Cancer Stage II | COMPLETED | NCT02125344 |
| non-pegylated liposomal doxorubicin | Other | Phase PHASE3 | Tubular Breast Cancer Stage II | COMPLETED | NCT02125344 |
| Etoposide | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| Carboplatin | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| Carfilzomib | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| Etanercept | Other | Phase PHASE3 | Pediatric Plaque Psoriasis | COMPLETED | NCT00141921 |
| etanercept | Other | Preclinical | Hidradenitis Suppurativa | COMPLETED | NCT00949546 |
| etanercept | Other | Preclinical | Hidradenitis Suppurativa | COMPLETED | NCT00949546 |
| Methotrexate | Other | Phase PHASE4 | Moderate to Severe Rheumatoid Arthritis | TERMINATED | NCT01927757 |
| Etanercept | Other | Phase PHASE4 | Moderate to Severe Rheumatoid Arthritis | TERMINATED | NCT01927757 |
| Methotrexate | Other | Phase PHASE4 | Moderate to Severe Rheumatoid Arthritis | TERMINATED | NCT01927757 |
| Etanercept | Other | Phase PHASE4 | Moderate to Severe Rheumatoid Arthritis | TERMINATED | NCT01927757 |
| Placebo (for denosumab) | Other | Phase PHASE4 | Hip Osteoarthritis | COMPLETED | NCT01926158 |
| Denosumb | Other | Phase PHASE4 | Hip Osteoarthritis | COMPLETED | NCT01926158 |
| Placebo (for denosumab) | Other | Phase PHASE4 | Hip Osteoarthritis | COMPLETED | NCT01926158 |
| Denosumb | Other | Phase PHASE4 | Hip Osteoarthritis | COMPLETED | NCT01926158 |
| Total Hip Replacement | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Demeclocycline | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Tetracycline | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Total Hip Replacement | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Demeclocycline | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Tetracycline | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Total Hip Replacement | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Demeclocycline | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Tetracycline | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02576652 |
| Placebo | Other | Phase PHASE3 | Osteoporosis in Men | COMPLETED | NCT02186171 |
| Romosozumab | Other | Phase PHASE3 | Osteoporosis in Men | COMPLETED | NCT02186171 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT01696396 |
| Abrilumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT01696396 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT01696396 |
| Abrilumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT01696396 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01694485 |
| Abrilumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01694485 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01694485 |
| Abrilumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01694485 |
| Denosumab | Other | Phase PHASE2 | Early Stage Breast Cancer | TERMINATED | NCT01545648 |
| Denosumab | Other | Phase PHASE2 | Early Stage Breast Cancer | TERMINATED | NCT01545648 |
| Apremilast | Other | Phase PHASE2 | Psoriasis-Type Psoriasis | COMPLETED | NCT00521339 |
| Apremilast | Other | Phase PHASE2 | Psoriasis-Type Psoriasis | COMPLETED | NCT00521339 |
| Blinatumomab | Other | Phase PHASE1 | B-precursor Acute Lymphoblastic Leukemia | COMPLETED | NCT06649006 |
| Vectibix® (panitumumab) | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00879385 |
| Dacogen™ (decitabine) | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00879385 |
| Denosumab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01869686 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02291588 |
| AMG 811 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02291588 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02291588 |
| AMG 811 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02291588 |
| Placebo | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01953341 |
| AMG 333 | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01953341 |
| Placebo | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01953341 |
| AMG 333 | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01953341 |
| AMG 208 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00813384 |
| Placebo | Other | Phase PHASE1 | Osteoarthritis | COMPLETED | NCT02318407 |
| AMG 403 | Other | Phase PHASE1 | Osteoarthritis | COMPLETED | NCT02318407 |
| Placebo | Other | Phase PHASE1 | Osteoarthritis | COMPLETED | NCT02318407 |
| AMG 403 | Other | Phase PHASE1 | Osteoarthritis | COMPLETED | NCT02318407 |
| Placebo | Other | Phase PHASE2 | PSORIASIS | COMPLETED | NCT01989689 |
| Etanercept | Other | Phase PHASE2 | PSORIASIS | COMPLETED | NCT01989689 |
| Placebo | Other | Phase PHASE2 | PSORIASIS | COMPLETED | NCT01989689 |
| Etanercept | Other | Phase PHASE2 | PSORIASIS | COMPLETED | NCT01989689 |
| Not applicable- observational study | Other | Preclinical | Birth Defect | TERMINATED | NCT02090088 |
| Not applicable- observational study | Other | Preclinical | Birth Defect | TERMINATED | NCT02090088 |
| pamidronate | Other | Phase PHASE4 | Solid Tumor | WITHDRAWN | NCT02101164 |
| denosumab | Other | Phase PHASE4 | Solid Tumor | WITHDRAWN | NCT02101164 |
| pamidronate | Other | Phase PHASE4 | Solid Tumor | WITHDRAWN | NCT02101164 |
| denosumab | Other | Phase PHASE4 | Solid Tumor | WITHDRAWN | NCT02101164 |
| Placebo | Other | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT01695876 |
| AMG 357 | Other | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT01695876 |
| Placebo | Other | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT01695876 |
| AMG 357 | Other | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT01695876 |
| AMG 780 | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT01137552 |
| AMG 780 | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT01137552 |
| Denosumab | Other | Phase PHASE3 | Castrate-resistant Prostate Cancer | COMPLETED | NCT01824342 |
| panitumumab + docetaxel + cisplatino | Other | Phase PHASE2 | Gastric Adenocarcinoma | UNKNOWN | NCT01379807 |
| panitumumab + docetaxel + cisplatino | Other | Phase PHASE2 | Gastric Adenocarcinoma | UNKNOWN | NCT01379807 |
| Placebo for AMG 181 | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01290042 |
| AMG 181 | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01290042 |
| Placebo for AMG 181 | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01290042 |
| AMG 181 | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01290042 |
| Placebo for AMG 181 | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01290042 |
| AMG 181 | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01290042 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01126112 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01126112 |
| Panitumumab+irinotecan | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00958386 |
| Panitumumab+irinotecan | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00958386 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02391259 |
| AMG 557 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02391259 |
| Placebo | Other | Phase PHASE1 | Migraine | TERMINATED | NCT02132429 |
| AMG 333 | Other | Phase PHASE1 | Migraine | TERMINATED | NCT02132429 |
| Placebo | Other | Phase PHASE1 | Migraine | TERMINATED | NCT02132429 |
| AMG 333 | Other | Phase PHASE1 | Migraine | TERMINATED | NCT02132429 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02411136 |
| AMG 623 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02411136 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02411136 |
| AMG 623 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02411136 |
| AMG 102 at 20 mg/kg | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00422019 |
| AMG 102 at 10 mg/kg | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00422019 |
| AMG 102 at 20 mg/kg | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00422019 |
| AMG 102 at 10 mg/kg | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00422019 |
| AMG 102 at 20 mg/kg | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00422019 |
| AMG 102 at 10 mg/kg | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00422019 |
| Questionnaire | Other | Phase PHASE2 | Prostate Cancer | WITHDRAWN | NCT02420587 |
| AMG 208 | Other | Phase PHASE2 | Prostate Cancer | WITHDRAWN | NCT02420587 |
| Questionnaire | Other | Phase PHASE2 | Prostate Cancer | WITHDRAWN | NCT02420587 |
| AMG 208 | Other | Phase PHASE2 | Prostate Cancer | WITHDRAWN | NCT02420587 |
| AMG 102 at 10 mg/kg | Other | Phase PHASE2 | Advanced Malignant Glioma | COMPLETED | NCT00427440 |
| AMG 102 at 20 mg/kg | Other | Phase PHASE2 | Advanced Malignant Glioma | COMPLETED | NCT00427440 |
| AMG 102 at 10 mg/kg | Other | Phase PHASE2 | Advanced Malignant Glioma | COMPLETED | NCT00427440 |
| AMG 102 at 20 mg/kg | Other | Phase PHASE2 | Advanced Malignant Glioma | COMPLETED | NCT00427440 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02443506 |
| AMG 623 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02443506 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02443506 |
| AMG 623 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02443506 |
| Doxorubicin | Other | Phase PHASE1 | Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma | COMPLETED | NCT00626704 |
| Placebo | Other | Phase PHASE1 | Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma | COMPLETED | NCT00626704 |
| AMG 655 | Other | Phase PHASE1 | Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma | COMPLETED | NCT00626704 |
| Doxorubicin | Other | Phase PHASE1 | Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma | COMPLETED | NCT00626704 |
| Placebo | Other | Phase PHASE1 | Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma | COMPLETED | NCT00626704 |
| AMG 655 | Other | Phase PHASE1 | Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma | COMPLETED | NCT00626704 |
| Database assessment of off-label XGEVA use | Other | Preclinical | XGEVA Off-label Use | COMPLETED | NCT02066805 |
| Database assessment of off-label XGEVA use | Other | Preclinical | XGEVA Off-label Use | COMPLETED | NCT02066805 |
| Database assessment of off-label XGEVA use | Other | Preclinical | XGEVA Off-label Use | COMPLETED | NCT02066805 |
| Placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | WITHDRAWN | NCT02429882 |
| Brodalumab 210 mg | Other | Phase PHASE2 | Axial Spondyloarthritis | WITHDRAWN | NCT02429882 |
| Placebo | Other | Phase PHASE2 | Axial Spondyloarthritis | WITHDRAWN | NCT02429882 |
| Brodalumab 210 mg | Other | Phase PHASE2 | Axial Spondyloarthritis | WITHDRAWN | NCT02429882 |
| Chemotherapy plus Filgrastim | Drug | Phase PHASE2 | Malignant Lymphoma | TERMINATED | NCT01016795 |
| r-metHuSCF and Filgrastim | Other | Phase PHASE2 | Malignant Lymphoma | TERMINATED | NCT01016795 |
| Chemotherapy plus Filgrastim | Drug | Phase PHASE2 | Malignant Lymphoma | TERMINATED | NCT01016795 |
| r-metHuSCF and Filgrastim | Other | Phase PHASE2 | Malignant Lymphoma | TERMINATED | NCT01016795 |
| Radiation Therapy (RT) | Drug | Phase PHASE1 | Cancer of the Esophagus | COMPLETED | NCT00578071 |
| Oxaliplatin | Other | Phase PHASE1 | Cancer of the Esophagus | COMPLETED | NCT00578071 |
| Capecitabine | Other | Phase PHASE1 | Cancer of the Esophagus | COMPLETED | NCT00578071 |
| Panitumumab | Other | Phase PHASE1 | Cancer of the Esophagus | COMPLETED | NCT00578071 |
| Radiation Therapy (RT) | Drug | Phase PHASE1 | Cancer of the Esophagus | COMPLETED | NCT00578071 |
| Oxaliplatin | Other | Phase PHASE1 | Cancer of the Esophagus | COMPLETED | NCT00578071 |
| Capecitabine | Other | Phase PHASE1 | Cancer of the Esophagus | COMPLETED | NCT00578071 |
| Panitumumab | Other | Phase PHASE1 | Cancer of the Esophagus | COMPLETED | NCT00578071 |
| high-dose leptin | Other | Approved | Type Two Diabetes Mellitus | COMPLETED | NCT01207934 |
| low-dose leptin | Other | Approved | Type Two Diabetes Mellitus | COMPLETED | NCT01207934 |
| placebo | Other | Approved | Type Two Diabetes Mellitus | COMPLETED | NCT01207934 |
| Placebo | Other | Phase PHASE2 | Schizophrenia | TERMINATED | NCT01568216 |
| AMG 747 | Other | Phase PHASE2 | Schizophrenia | TERMINATED | NCT01568216 |
| Placebo | Other | Phase PHASE2 | Schizophrenia | TERMINATED | NCT01568216 |
| AMG 747 | Other | Phase PHASE2 | Schizophrenia | TERMINATED | NCT01568216 |
| Intensity Modulated Radiation Therapy | Drug | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT01312493 |
| Panitumumab | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT01312493 |
| Intensity Modulated Radiation Therapy | Drug | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT01312493 |
| Panitumumab | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT01312493 |
| FOLFIRI | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| AMG 386 Placebo | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| AMG 386 | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| FOLFIRI | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| AMG 386 Placebo | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| AMG 386 | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| FOLFIRI | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| AMG 386 Placebo | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| AMG 386 | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00752570 |
| Darbepoetin alfa | Other | Phase PHASE3 | Diffuse Large Cell Lymphoma | COMPLETED | NCT00144755 |
| Darbepoetin alfa | Other | Phase PHASE3 | Diffuse Large Cell Lymphoma | COMPLETED | NCT00144755 |
| carboplatin | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| paclitaxel | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| AMG 706 | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| carboplatin | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| paclitaxel | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| AMG 706 | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| carboplatin | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| paclitaxel | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| AMG 706 | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00460317 |
| Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D | Other | Approved | Hyperparathyroidism, Secondary | UNKNOWN | NCT02273570 |
| standard care | Other | Approved | Hyperparathyroidism, Secondary | UNKNOWN | NCT02273570 |
| Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D | Other | Approved | Hyperparathyroidism, Secondary | UNKNOWN | NCT02273570 |
| standard care | Other | Approved | Hyperparathyroidism, Secondary | UNKNOWN | NCT02273570 |
| Percutaneous core needle breast biopsy | Other | Phase PHASE1 | Healthy Volunteer, Female, Breast | COMPLETED | NCT02099461 |
| Denosumab | Other | Phase PHASE1 | Healthy Volunteer, Female, Breast | COMPLETED | NCT02099461 |
| Percutaneous core needle breast biopsy | Other | Phase PHASE1 | Healthy Volunteer, Female, Breast | COMPLETED | NCT02099461 |
| Denosumab | Other | Phase PHASE1 | Healthy Volunteer, Female, Breast | COMPLETED | NCT02099461 |
| B3: AMG 386 15mg/kg + Topotecan | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770536 |
| B1: AMG 386 10 mg/kg + Topotecan | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770536 |
| A3: AMG 386 15mg/kg + Liposomal doxorubicin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770536 |
| A1: AMG 386 10 mg/kg + Liposomal doxorubicin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770536 |
| B3: AMG 386 15mg/kg + Topotecan | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770536 |
| B1: AMG 386 10 mg/kg + Topotecan | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770536 |
| A3: AMG 386 15mg/kg + Liposomal doxorubicin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770536 |
| A1: AMG 386 10 mg/kg + Liposomal doxorubicin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00770536 |
| AMG 386, paclitaxel and carboplatin | Other | Phase PHASE1 | Carcinoma | COMPLETED | NCT01253681 |
| AMG 386, paclitaxel and carboplatin | Other | Phase PHASE1 | Carcinoma | COMPLETED | NCT01253681 |
| AMG 386, paclitaxel and carboplatin | Other | Phase PHASE1 | Carcinoma | COMPLETED | NCT01253681 |
| AMG 706 | Other | Phase PHASE2 | Solid Tumors | TERMINATED | NCT00360867 |
| AMG 706 | Other | Phase PHASE2 | Solid Tumors | TERMINATED | NCT00360867 |
| Paclitaxel | Other | Phase PHASE2 | Breast Neoplasms | TERMINATED | NCT00356681 |
| AMG 706 | Other | Phase PHASE2 | Breast Neoplasms | TERMINATED | NCT00356681 |
| Bevacizumab | Other | Phase PHASE2 | Breast Neoplasms | TERMINATED | NCT00356681 |
| AMG 706 placebo | Other | Phase PHASE2 | Breast Neoplasms | TERMINATED | NCT00356681 |
| Paclitaxel | Other | Phase PHASE2 | Breast Neoplasms | TERMINATED | NCT00356681 |
| AMG 706 | Other | Phase PHASE2 | Breast Neoplasms | TERMINATED | NCT00356681 |
| Bevacizumab | Other | Phase PHASE2 | Breast Neoplasms | TERMINATED | NCT00356681 |
| AMG 706 placebo | Other | Phase PHASE2 | Breast Neoplasms | TERMINATED | NCT00356681 |
| Placebo | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02567370 |
| AMG 581 | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02567370 |
| Placebo | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02567370 |
| AMG 581 | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02567370 |
| Paclitaxel | Other | Phase PHASE2 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00511459 |
| Bevacizumab | Other | Phase PHASE2 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00511459 |
| AMG 386 | Other | Phase PHASE2 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00511459 |
| AMG 386 Placebo | Other | Phase PHASE2 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00511459 |
| Paclitaxel | Other | Phase PHASE2 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00511459 |
| Bevacizumab | Other | Phase PHASE2 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00511459 |
| AMG 386 | Other | Phase PHASE2 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00511459 |
| AMG 386 Placebo | Other | Phase PHASE2 | Locally Recurrent and Metastatic Breast Cancer | COMPLETED | NCT00511459 |
| AMG 876 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT01856881 |
| AMG 876 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT01856881 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT00381836 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT00381836 |
| Avastin | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT01113398 |
| AMG 102 | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT01113398 |
| Avastin | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT01113398 |
| AMG 102 | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT01113398 |
| caffeine, ephedrine, and leptin A | Other | Approved | Obesity | COMPLETED | NCT01710722 |
| Leptin A | Other | Approved | Obesity | COMPLETED | NCT01710722 |
| caffeine and ephedrine | Other | Approved | Obesity | COMPLETED | NCT01710722 |
| caffeine, ephedrine, and leptin A | Other | Approved | Obesity | COMPLETED | NCT01710722 |
| Leptin A | Other | Approved | Obesity | COMPLETED | NCT01710722 |
| caffeine and ephedrine | Other | Approved | Obesity | COMPLETED | NCT01710722 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | COMPLETED | NCT01953328 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | COMPLETED | NCT01953328 |
| Atorvastatin | Other | Phase PHASE3 | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | COMPLETED | NCT01953328 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | COMPLETED | NCT01953328 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | COMPLETED | NCT01953328 |
| Atorvastatin | Other | Phase PHASE3 | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | COMPLETED | NCT01953328 |
| epirubicin, cyclophosphamide, Paclitaxel, | Other | Approved | Breast Cancer | COMPLETED | NCT00617370 |
| epirubicin, cyclophosphamide, Paclitaxel, | Other | Approved | Breast Cancer | COMPLETED | NCT00617370 |
| epirubicin, cyclophosphamide, Paclitaxel, | Other | Approved | Breast Cancer | COMPLETED | NCT00617370 |
| Panitumumab | Other | Phase PHASE2 | Adenoma, Pleomorphic | WITHDRAWN | NCT00984217 |
| Radiation | Other | Phase PHASE2 | Adenoma, Pleomorphic | WITHDRAWN | NCT00984217 |
| Panitumumab | Other | Phase PHASE2 | Adenoma, Pleomorphic | WITHDRAWN | NCT00984217 |
| Radiation | Other | Phase PHASE2 | Adenoma, Pleomorphic | WITHDRAWN | NCT00984217 |
| AMG 655 placebo | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT00534027 |
| AMG 655 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT00534027 |
| AMG 655 placebo | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT00534027 |
| AMG 655 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT00534027 |
| AMG 714 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00443326 |
| AMG 714 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00443326 |
| AMG 714 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00443326 |
| Capecitabine | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Cisplatin | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Epirubicin | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Rilotumumab | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Capecitabine | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Cisplatin | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Epirubicin | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Rilotumumab | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Capecitabine | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Cisplatin | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Epirubicin | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| Rilotumumab | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT01697072 |
| radical cystectomy | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01916109 |
| Panitumumab | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01916109 |
| Carboplatin | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01916109 |
| Gemcitabine | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01916109 |
| radical cystectomy | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01916109 |
| Panitumumab | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01916109 |
| Carboplatin | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01916109 |
| Gemcitabine | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01916109 |
| FOLFIRI | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00411450 |
| Panitumumab | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00411450 |
| FOLFIRI | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00411450 |
| Panitumumab | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00411450 |
| Denosumab | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT01464931 |
| Reactive Skin Treatment | Drug | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| Pre-emptive Skin Treatment | Drug | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| FOLFIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| Panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00332163 |
| Rilotumumab | Other | Phase PHASE1 | Part 1- Advanced Solid Tumors | COMPLETED | NCT01791374 |
| Rilotumumab | Other | Phase PHASE1 | Part 1- Advanced Solid Tumors | COMPLETED | NCT01791374 |
| Rilotumumab | Other | Phase PHASE1 | Part 1- Advanced Solid Tumors | COMPLETED | NCT01791374 |
| Radiotherapy | Drug | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00375310 |
| Gemcitabine, Sorafenib | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00375310 |
| Radiotherapy | Drug | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00375310 |
| Gemcitabine, Sorafenib | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00375310 |
| Talimogene Laherparepvec | Other | Preclinical | Unresected Stage IIIb to IVM1c Melanoma | NO_LONGER_AVAILABLE | NCT02147951 |
| Midazolam | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02504476 |
| Placebo | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02504476 |
| AMG 581 | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02504476 |
| Midazolam | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02504476 |
| Placebo | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02504476 |
| AMG 581 | Other | Phase PHASE1 | Schizophrenia or Schizoaffective Disorder | COMPLETED | NCT02504476 |
| radiation therapy | Drug | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| therapeutic conventional surgery | Procedure | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| neoadjuvant therapy | Drug | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| docetaxel | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| cisplatin | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| panitumumab | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| radiation therapy | Drug | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| therapeutic conventional surgery | Procedure | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| neoadjuvant therapy | Drug | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| docetaxel | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| cisplatin | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| panitumumab | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| radiation therapy | Drug | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| therapeutic conventional surgery | Procedure | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| neoadjuvant therapy | Drug | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| docetaxel | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| cisplatin | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| panitumumab | Other | Phase PHASE2 | Adenocarcinoma of the Gastroesophageal Junction | COMPLETED | NCT00757172 |
| Placebo | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT00530114 |
| AMG 223 | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT00530114 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01018550 |
| AMG 853 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01018550 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01018550 |
| AMG 853 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01018550 |
| AMG 386 placebo IV | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00467025 |
| Sorafenib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00467025 |
| AMG 386 | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00467025 |
| AMG 386 placebo IV | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00467025 |
| Sorafenib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00467025 |
| AMG 386 | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00467025 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00436670 |
| AMG 317 300 mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00436670 |
| AMG 317 150 mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00436670 |
| AMG 317 75 mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00436670 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00436670 |
| AMG 317 300 mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00436670 |
| AMG 317 150 mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00436670 |
| AMG 317 75 mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00436670 |
| Carboplatin | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00094835 |
| Paclitaxel | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00094835 |
| Motesanib diphosphate | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00094835 |
| Panitumumab | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00094835 |
| Carboplatin | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00094835 |
| Paclitaxel | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00094835 |
| Motesanib diphosphate | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00094835 |
| Panitumumab | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00094835 |
| AMG 172 | Other | Phase PHASE1 | Renal Cell Adenocarcinoma | COMPLETED | NCT01497821 |
| Capecitabine | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT02137343 |
| Cisplatin | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT02137343 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT02137343 |
| Rilotumumab | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT02137343 |
| Capecitabine | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT02137343 |
| Cisplatin | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT02137343 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT02137343 |
| Rilotumumab | Other | Phase PHASE3 | Gastric Cancer | TERMINATED | NCT02137343 |
| Sorafenib | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT00872014 |
| AMG 386 | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT00872014 |
| Sorafenib | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT00872014 |
| AMG 386 | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT00872014 |
| Sorafenib | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT00872014 |
| AMG 386 | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT00872014 |
| Irinotecan | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00563316 |
| Panitumumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00563316 |
| Irinotecan | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00563316 |
| Panitumumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT00563316 |
| AMG 595 | Other | Phase PHASE1 | Advanced Malignant Glioma | COMPLETED | NCT01475006 |
| AMG 595 | Other | Phase PHASE1 | Advanced Malignant Glioma | COMPLETED | NCT01475006 |
| AMG 595 | Other | Phase PHASE1 | Advanced Malignant Glioma | COMPLETED | NCT01475006 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT02499315 |
| AMG 357 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT02499315 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT02499315 |
| AMG 357 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT02499315 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT02499315 |
| AMG 357 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT02499315 |
| Pharmacogenomic Studies | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Proteosome Inhibition Assessment | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Pharmacodynamic Studies | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Cytokine Assessment | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| carfilzomib | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Pharmacogenomic Studies | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Proteosome Inhibition Assessment | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Pharmacodynamic Studies | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Cytokine Assessment | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| carfilzomib | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Pharmacogenomic Studies | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Proteosome Inhibition Assessment | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Pharmacodynamic Studies | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Cytokine Assessment | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| carfilzomib | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | COMPLETED | NCT01212380 |
| Etanercept | Other | Approved | Psoriasis | TERMINATED | NCT00477191 |
| Etanercept | Other | Approved | Psoriasis | TERMINATED | NCT00477191 |
| Panitumumab | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00658658 |
| Panitumumab | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00658658 |
| Placebo | Other | Phase PHASE1 | Chronic Rhinosinusitis With Nasal Polyps | COMPLETED | NCT02170337 |
| AMG 282 | Other | Phase PHASE1 | Chronic Rhinosinusitis With Nasal Polyps | COMPLETED | NCT02170337 |
| Carboplatin | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT01666977 |
| Pemetrexed | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT01666977 |
| AMG 386 Placebo | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT01666977 |
| AMG 386 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT01666977 |
| Carboplatin | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT01666977 |
| Pemetrexed | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT01666977 |
| AMG 386 Placebo | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT01666977 |
| AMG 386 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT01666977 |
| Paclitaxel | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Carboplatin | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Bevacizumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| AMG 951 (rhApo2L/TRAIL) | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00508625 |
| Etanercept (ENBREL®) | Other | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Etanercept (ENBREL®) via Manual injection | Other | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Auto-injector device | Device | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Etanercept (ENBREL®) | Other | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Etanercept (ENBREL®) via Manual injection | Other | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Auto-injector device | Device | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Etanercept (ENBREL®) | Other | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Etanercept (ENBREL®) via Manual injection | Other | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Auto-injector device | Device | Phase PHASE1 | Healthy Men and Women | COMPLETED | NCT02799498 |
| Darbepoetin alfa | Other | Phase PHASE1 | Anemia | WITHDRAWN | NCT01428154 |
| Darbepoetin alfa | Other | Phase PHASE1 | Anemia | WITHDRAWN | NCT01428154 |
| Darbepoetin alfa | Other | Phase PHASE1 | Anemia | WITHDRAWN | NCT01428154 |
| Aranesp | Other | Preclinical | Chronic Kidney Disease, Receiving Dialysis | TERMINATED | NCT01890577 |
| Aranesp | Other | Preclinical | Chronic Kidney Disease, Receiving Dialysis | TERMINATED | NCT01890577 |
| GM-CSF | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT00769704 |
| Talimogene laherparepvec | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT00769704 |
| nonmyeloablative stem cell transplant | Other | Approved | Metastatic Solid Tumor | COMPLETED | NCT00997529 |
| nonmyeloablative stem cell transplant | Other | Approved | Metastatic Solid Tumor | COMPLETED | NCT00997529 |
| Anakinra (r-metHuIL-1ra) | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00111410 |
| Anakinra (r-metHuIL-1ra) | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00111410 |
| gemcitabine | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT01308840 |
| oxaliplatin | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT01308840 |
| Panitumumab | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT01308840 |
| Surgery | Procedure | Phase PHASE2 | Colorectal Cancer Metastatic | TERMINATED | NCT01508000 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer Metastatic | TERMINATED | NCT01508000 |
| Bevacizumab | Other | Phase PHASE2 | Colorectal Cancer Metastatic | TERMINATED | NCT01508000 |
| FOLFOX6 | Other | Phase PHASE2 | Colorectal Cancer Metastatic | TERMINATED | NCT01508000 |
| Surgery | Procedure | Phase PHASE2 | Colorectal Cancer Metastatic | TERMINATED | NCT01508000 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer Metastatic | TERMINATED | NCT01508000 |
| Bevacizumab | Other | Phase PHASE2 | Colorectal Cancer Metastatic | TERMINATED | NCT01508000 |
| FOLFOX6 | Other | Phase PHASE2 | Colorectal Cancer Metastatic | TERMINATED | NCT01508000 |
| Paclitaxel | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT01194869 |
| Cisplatin | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT01194869 |
| Sorafenib | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT01194869 |
| Paclitaxel | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT01194869 |
| Cisplatin | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT01194869 |
| Sorafenib | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT01194869 |
| Pegfilgrastim | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| cisplatin | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| vinblastine | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| Doxorubicin | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| Methotrexate | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| Pegfilgrastim | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| cisplatin | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| vinblastine | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| Doxorubicin | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| Methotrexate | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT00808639 |
| Trastuzumab | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01479179 |
| AMG 479 | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01479179 |
| Trastuzumab | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01479179 |
| AMG 479 | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01479179 |
| Trastuzumab | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01479179 |
| AMG 479 | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01479179 |
| Filgrastim | Other | Approved | Non Hodgkin Lymphoma | TERMINATED | NCT01541072 |
| Pegfilgrastim | Other | Approved | Non Hodgkin Lymphoma | TERMINATED | NCT01541072 |
| Irinotecan | Other | Phase PHASE2 | Esophageal Cancer | COMPLETED | NCT00836277 |
| Panitumumab | Other | Phase PHASE2 | Esophageal Cancer | COMPLETED | NCT00836277 |
| Adalimumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01970475 |
| ABP 501 | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01970475 |
| Adalimumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01970475 |
| ABP 501 | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01970475 |
| AMG 108 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00369473 |
| AMG 108 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00369473 |
| AMG 282 Matching Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01928368 |
| AMG 282 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01928368 |
| Paclitaxel | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| AMG 386 Placebo | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| AMG 386 | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| Paclitaxel | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| AMG 386 Placebo | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| AMG 386 | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| Paclitaxel | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| AMG 386 Placebo | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| AMG 386 | Other | Phase PHASE3 | Fallopian Tube Cancer | COMPLETED | NCT01204749 |
| Palifermin | Other | Phase PHASE3 | Head and Neck Cancer | COMPLETED | NCT00131638 |
| Placebo | Other | Phase PHASE3 | Head and Neck Cancer | COMPLETED | NCT00131638 |
| Etanercept | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT02274792 |
| Etanercept | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT02274792 |
| Matching Placebo | Other | Phase PHASE1 | Lupus Arthritis, Systemic Lupus Erythematosus | COMPLETED | NCT01683695 |
| AMG 557 | Other | Phase PHASE1 | Lupus Arthritis, Systemic Lupus Erythematosus | COMPLETED | NCT01683695 |
| Dexamethasone | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02257476 |
| Carfilzomib | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02257476 |
| Dexamethasone | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02257476 |
| Carfilzomib | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02257476 |
| Bevacizumab | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00861419 |
| Sunitinib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00861419 |
| AMG 386 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00861419 |
| AMG 706 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00861419 |
| Sorafenib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00861419 |
| Placebo | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT01444417 |
| Romiplostim | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT01444417 |
| Placebo | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT01444417 |
| Romiplostim | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT01444417 |
| DMARD Therapy | Drug | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT01313208 |
| Placebo | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT01313208 |
| etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT01313208 |
| AMG 319 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01300026 |
| AMG 319 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01300026 |
| Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00357903 |
| Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00357903 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Congestive Heart Failure | COMPLETED | NCT00086086 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Congestive Heart Failure | COMPLETED | NCT00086086 |
| Carboplatin | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01493505 |
| AMG 386 Placebo | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01493505 |
| Paclitaxel | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01493505 |
| AMG 386 | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01493505 |
| Carboplatin | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01493505 |
| AMG 386 Placebo | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01493505 |
| Paclitaxel | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01493505 |
| AMG 386 | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01493505 |
| Cisplatin | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Docetaxel | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| 5-Fluorouracil | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Intensity Modulated Radiation Therapy | Drug | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Paclitaxel | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Carboplatin | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Panitumumab | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Cisplatin | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Docetaxel | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| 5-Fluorouracil | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Intensity Modulated Radiation Therapy | Drug | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Paclitaxel | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Carboplatin | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| Panitumumab | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT00513383 |
| rituximab | Other | Phase PHASE3 | Diffuse Large Cell Lymphoma | TERMINATED | NCT00140660 |
| rituximab | Other | Phase PHASE3 | Diffuse Large Cell Lymphoma | TERMINATED | NCT00140660 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT01412957 |
| Best Supportive Care (BSC) | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT01412957 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT01412957 |
| Best Supportive Care (BSC) | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT01412957 |
| Topical agents | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01313221 |
| etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01313221 |
| Topical agents | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01313221 |
| etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01313221 |
| DENOSUMAB | Other | Phase PHASE2 | Relapsed or Plateau-Phase Multiple Myeloma | COMPLETED | NCT00259740 |
| DENOSUMAB | Other | Phase PHASE2 | Relapsed or Plateau-Phase Multiple Myeloma | COMPLETED | NCT00259740 |
| DENOSUMAB | Other | Phase PHASE2 | Relapsed or Plateau-Phase Multiple Myeloma | COMPLETED | NCT00259740 |
| Personalized Patient Counselling | Other | Phase PHASE4 | Persistence to Enbrel | TERMINATED | NCT02346877 |
| Personalized Patient Counselling | Other | Phase PHASE4 | Persistence to Enbrel | TERMINATED | NCT02346877 |
| G-CSF | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| methotrexate | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| cyclosporine | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| fludarabine | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| Cyclophosphamide | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| G-CSF | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| methotrexate | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| cyclosporine | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| fludarabine | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| Cyclophosphamide | Other | Phase PHASE2 | AML | COMPLETED | NCT00636909 |
| Intensive Care | Other | Approved | Psoriatic Arthritis (PsA) | WITHDRAWN | NCT01692912 |
| Intensive Care | Other | Approved | Psoriatic Arthritis (PsA) | WITHDRAWN | NCT01692912 |
| Intensive Care | Other | Approved | Psoriatic Arthritis (PsA) | WITHDRAWN | NCT01692912 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT01351623 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT01351623 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT01351623 |
| ABP 501 | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02114931 |
| ABP 501 | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02114931 |
| Sorafenib | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | WITHDRAWN | NCT02227914 |
| Oprozomib | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | WITHDRAWN | NCT02227914 |
| Sorafenib | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | WITHDRAWN | NCT02227914 |
| Oprozomib | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | WITHDRAWN | NCT02227914 |
| Sorafenib | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | WITHDRAWN | NCT02227914 |
| Oprozomib | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | WITHDRAWN | NCT02227914 |
| Prednisone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02072863 |
| Melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02072863 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02072863 |
| Prednisone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02072863 |
| Melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02072863 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02072863 |
| Carfilzomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01949545 |
| Carfilzomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01949545 |
| Carfilzomib | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT01949532 |
| Carfilzomib | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT01949532 |
| Carfilzomib | Other | Preclinical | Multiple Myeloma | APPROVED_FOR_MARKETING | NCT01410500 |
| Best Supportive Care | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01302392 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01302392 |
| Best Supportive Care | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01302392 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01302392 |
| Best Supportive Care | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01302392 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01302392 |
| Oprozomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01129349 |
| Oprozomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01129349 |
| Oprozomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01129349 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00721734 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00721734 |
| carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00530816 |
| carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00530816 |
| Dexamethasone | Other | Phase PHASE1 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00150462 |
| Carfilzomib | Other | Phase PHASE1 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00150462 |
| Placebo | Other | Phase PHASE2 | HAART-induced Lipodystrophy and Metabolic Syndrome | COMPLETED | NCT00140244 |
| r-metHuLeptin | Other | Phase PHASE2 | HAART-induced Lipodystrophy and Metabolic Syndrome | COMPLETED | NCT00140244 |
| Placebo | Other | Phase PHASE2 | HAART-induced Lipodystrophy and Metabolic Syndrome | COMPLETED | NCT00140244 |
| r-metHuLeptin | Other | Phase PHASE2 | HAART-induced Lipodystrophy and Metabolic Syndrome | COMPLETED | NCT00140244 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00842257 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00842257 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00842257 |
| Placebo | Other | Phase PHASE2 | Amenorrhea | COMPLETED | NCT00130117 |
| Oral Contraceptive Pills (OCPs) | Other | Phase PHASE2 | Amenorrhea | COMPLETED | NCT00130117 |
| r-metHuLeptin | Other | Phase PHASE2 | Amenorrhea | COMPLETED | NCT00130117 |
| Placebo | Other | Phase PHASE2 | Amenorrhea | COMPLETED | NCT00130117 |
| Oral Contraceptive Pills (OCPs) | Other | Phase PHASE2 | Amenorrhea | COMPLETED | NCT00130117 |
| r-metHuLeptin | Other | Phase PHASE2 | Amenorrhea | COMPLETED | NCT00130117 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01980589 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01980589 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01980589 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01980589 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01980589 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01980589 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT00603447 |
| Lenalidomide | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT00603447 |
| Carfilzomib | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT00603447 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT00603447 |
| Lenalidomide | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT00603447 |
| Carfilzomib | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT00603447 |
| placebo | Other | Phase PHASE1 | Fasting | COMPLETED | NCT00140231 |
| r-metHuLeptin | Other | Phase PHASE1 | Fasting | COMPLETED | NCT00140231 |
| Denosumab | Other | Phase PHASE1 | Postmenopausal | TERMINATED | NCT01294397 |
| Etanercept | Other | Phase PHASE1 | Postmenopausal | TERMINATED | NCT01294397 |
| Denosumab | Other | Phase PHASE1 | Postmenopausal | TERMINATED | NCT01294397 |
| Etanercept | Other | Phase PHASE1 | Postmenopausal | TERMINATED | NCT01294397 |
| Denosumab | Other | Phase PHASE1 | Postmenopausal | TERMINATED | NCT01294397 |
| Etanercept | Other | Phase PHASE1 | Postmenopausal | TERMINATED | NCT01294397 |
| AMG 102 and erlotinib | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT01233687 |
| AMG 102 and erlotinib | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT01233687 |
| AMG 102 and erlotinib | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT01233687 |
| AMG 337 | Other | Phase PHASE2 | Stomach Neoplasms | TERMINATED | NCT02016534 |
| AMG 337 | Other | Phase PHASE2 | Stomach Neoplasms | TERMINATED | NCT02016534 |
| Bevacizumab | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT01290263 |
| Amgen 386 | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT01290263 |
| Bevacizumab | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT01290263 |
| Amgen 386 | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT01290263 |
| Panitumumab+FOLFIRI | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00885885 |
| Panitumumab+FOLFOX-4 | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00885885 |
| Panitumumab+FOLFIRI | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00885885 |
| Panitumumab+FOLFOX-4 | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00885885 |
| Panitumumab+FOLFIRI | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00885885 |
| Panitumumab+FOLFOX-4 | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00885885 |
| methoxsalen | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| etanercept | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| mycophenolate (standard GVHD prophylaxis) | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| tacrolimus (standard GVHD prophylaxis) | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| stem cell transplant | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| methoxsalen | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| etanercept | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| mycophenolate (standard GVHD prophylaxis) | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| tacrolimus (standard GVHD prophylaxis) | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| stem cell transplant | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT00639717 |
| AMG 162 | Other | Phase PHASE3 | Low Bone Mineral Density | COMPLETED | NCT00325468 |
| AMG 162 | Other | Phase PHASE3 | Low Bone Mineral Density | COMPLETED | NCT00325468 |
| AMG 162 | Other | Phase PHASE3 | Low Bone Mineral Density | COMPLETED | NCT00325468 |
| Dexamethasone | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT00531284 |
| Carfilzomib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT00531284 |
| Dexamethasone | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT00531284 |
| Carfilzomib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT00531284 |
| Denosumab (CP4) | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02157948 |
| Denosumab (CP2) | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02157948 |
| Etoposide | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| Carboplatin | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| Carfilzomib | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| Etoposide | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| Carboplatin | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| Carfilzomib | Other | Phase PHASE1 | Extensive-Stage Small-Cell Lung Cancer | COMPLETED | NCT01987232 |
| carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00511238 |
| carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00511238 |
| Dexamethasone | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01926665 |
| Carfilzomib | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01926665 |
| Radiation Therapy | Drug | Phase PHASE2 | Cancer of Head | COMPLETED | NCT00798655 |
| Cisplatin | Other | Phase PHASE2 | Cancer of Head | COMPLETED | NCT00798655 |
| Panitumumab | Other | Phase PHASE2 | Cancer of Head | COMPLETED | NCT00798655 |
| Radiation Therapy | Drug | Phase PHASE2 | Cancer of Head | COMPLETED | NCT00798655 |
| Cisplatin | Other | Phase PHASE2 | Cancer of Head | COMPLETED | NCT00798655 |
| Panitumumab | Other | Phase PHASE2 | Cancer of Head | COMPLETED | NCT00798655 |
| Etanercept | Other | Phase PHASE3 | Pediatric Plaque Psoriasis | COMPLETED | NCT00141921 |
| Etanercept | Other | Phase PHASE3 | Pediatric Plaque Psoriasis | COMPLETED | NCT00141921 |
| Dexamethasone | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01789242 |
| Carfilzomib | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01789242 |
| Dexamethasone | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01789242 |
| Carfilzomib | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01789242 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01660750 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01660750 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01660750 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01660750 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01660750 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01660750 |
| Bevacizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer Metastatic | COMPLETED | NCT01966003 |
| ABP 215 | Other | Phase PHASE3 | Non-small Cell Lung Cancer Metastatic | COMPLETED | NCT01966003 |
| Paclitaxel | Other | Phase PHASE3 | Non-small Cell Lung Cancer Metastatic | COMPLETED | NCT01966003 |
| Carboplatin | Other | Phase PHASE3 | Non-small Cell Lung Cancer Metastatic | COMPLETED | NCT01966003 |
| Bevacizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer Metastatic | COMPLETED | NCT01966003 |
| ABP 215 | Other | Phase PHASE3 | Non-small Cell Lung Cancer Metastatic | COMPLETED | NCT01966003 |
| Paclitaxel | Other | Phase PHASE3 | Non-small Cell Lung Cancer Metastatic | COMPLETED | NCT01966003 |
| Carboplatin | Other | Phase PHASE3 | Non-small Cell Lung Cancer Metastatic | COMPLETED | NCT01966003 |
| Arm 2- Dose Expansion | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01380756 |
| Arm 1- Dose Escalation | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01380756 |
| Arm 2- Dose Expansion | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01380756 |
| Arm 1- Dose Escalation | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01380756 |
| AMG 386 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01331941 |
| AMG 386 + Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01331941 |
| AMG 386 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01331941 |
| AMG 386 + Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01331941 |
| AMG 386 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01331941 |
| AMG 386 + Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01331941 |
| AMG 386 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01331941 |
| AMG 386 + Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01331941 |
| CCX168 | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | TERMINATED | NCT02464891 |
| CCX168 | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | TERMINATED | NCT02464891 |
| CCX168 | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | TERMINATED | NCT02464891 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT02102204 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT02102204 |
| Pegfilgrastim | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Cytoxan | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Doxorubicin | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Temozolomide | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Vincristine | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Irinotecan | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Pegfilgrastim | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Cytoxan | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Doxorubicin | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Temozolomide | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Vincristine | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Irinotecan | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Pegfilgrastim | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Cytoxan | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Doxorubicin | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Temozolomide | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Vincristine | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Irinotecan | Other | Phase PHASE2 | Bone Cancer | TERMINATED | NCT01313884 |
| Placebo plus PLD | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01281254 |
| AMG386 plus PLD | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01281254 |
| Placebo plus PLD | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01281254 |
| AMG386 plus PLD | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01281254 |
| Placebo plus PLD | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01281254 |
| AMG386 plus PLD | Other | Phase PHASE3 | Fallopian Tube Cancer | TERMINATED | NCT01281254 |
| Placebo | Other | Phase PHASE3 | MDS | COMPLETED | NCT01362140 |
| Darbepoetin alfa | Other | Phase PHASE3 | MDS | COMPLETED | NCT01362140 |
| Placebo | Other | Phase PHASE3 | MDS | COMPLETED | NCT01362140 |
| Darbepoetin alfa | Other | Phase PHASE3 | MDS | COMPLETED | NCT01362140 |
| Placebo | Other | Phase PHASE3 | MDS | COMPLETED | NCT01362140 |
| Darbepoetin alfa | Other | Phase PHASE3 | MDS | COMPLETED | NCT01362140 |
| Denosumab CP2 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02053753 |
| Denosumab CP4 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02053753 |
| Denosumab CP2 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02053753 |
| Denosumab CP4 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02053753 |
| Etanercept | Other | Phase PHASE4 | Psoriasis | TERMINATED | NCT01543204 |
| Etanercept | Other | Phase PHASE4 | Psoriasis | TERMINATED | NCT01543204 |
| Standard Chemotherapy | Drug | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Bevacizumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Placebo | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Pegfilgrastim | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Standard Chemotherapy | Drug | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Bevacizumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Placebo | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Pegfilgrastim | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Standard Chemotherapy | Drug | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Bevacizumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Placebo | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Pegfilgrastim | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Standard Chemotherapy | Drug | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Bevacizumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Placebo | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Pegfilgrastim | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00911170 |
| Romiplostim (formerly AMG 531) | Other | Approved | Hematology | COMPLETED | NCT00472290 |
| Romiplostim (formerly AMG 531) | Other | Approved | Hematology | COMPLETED | NCT00472290 |
| Carboplatin | Other | Phase PHASE2 | Advanced Non-squamous NSCLC | TERMINATED | NCT00369070 |
| Paclitaxel | Other | Phase PHASE2 | Advanced Non-squamous NSCLC | TERMINATED | NCT00369070 |
| AMG 706 | Other | Phase PHASE2 | Advanced Non-squamous NSCLC | TERMINATED | NCT00369070 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Non-squamous NSCLC | TERMINATED | NCT00369070 |
| Carboplatin | Other | Phase PHASE2 | Advanced Non-squamous NSCLC | TERMINATED | NCT00369070 |
| Paclitaxel | Other | Phase PHASE2 | Advanced Non-squamous NSCLC | TERMINATED | NCT00369070 |
| AMG 706 | Other | Phase PHASE2 | Advanced Non-squamous NSCLC | TERMINATED | NCT00369070 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Non-squamous NSCLC | TERMINATED | NCT00369070 |
| Physician Survey | Other | Preclinical | Solid Tumours | COMPLETED | NCT01998607 |
| Physician Survey | Other | Preclinical | Solid Tumours | COMPLETED | NCT01998607 |
| Background Statin Therapy | Drug | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT02207634 |
| Placebo | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT02207634 |
| Evolocumab | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT02207634 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | WITHDRAWN | NCT03343847 |
| Romiplostim | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | WITHDRAWN | NCT03343847 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | WITHDRAWN | NCT03343847 |
| Romiplostim | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | WITHDRAWN | NCT03343847 |
| Epirubicin, Cisplatin, Capecitabine | Other | Phase PHASE2 | Stomach Neoplasms | COMPLETED | NCT01234324 |
| Epirubicin, Cisplatin, Capecitabine, Panitumumab | Other | Phase PHASE2 | Stomach Neoplasms | COMPLETED | NCT01234324 |
| Epirubicin, Cisplatin, Capecitabine | Other | Phase PHASE2 | Stomach Neoplasms | COMPLETED | NCT01234324 |
| Epirubicin, Cisplatin, Capecitabine, Panitumumab | Other | Phase PHASE2 | Stomach Neoplasms | COMPLETED | NCT01234324 |
| Chemotherapy | Drug | Phase PHASE2 | Bone Pain in Stage I - III Breast Cancer | COMPLETED | NCT01712009 |
| Pegfilgrastim | Other | Phase PHASE2 | Bone Pain in Stage I - III Breast Cancer | COMPLETED | NCT01712009 |
| Loratadine | Other | Phase PHASE2 | Bone Pain in Stage I - III Breast Cancer | COMPLETED | NCT01712009 |
| Naproxen | Other | Phase PHASE2 | Bone Pain in Stage I - III Breast Cancer | COMPLETED | NCT01712009 |
| Chemotherapy | Drug | Phase PHASE2 | Bone Pain in Stage I - III Breast Cancer | COMPLETED | NCT01712009 |
| Pegfilgrastim | Other | Phase PHASE2 | Bone Pain in Stage I - III Breast Cancer | COMPLETED | NCT01712009 |
| Loratadine | Other | Phase PHASE2 | Bone Pain in Stage I - III Breast Cancer | COMPLETED | NCT01712009 |
| Naproxen | Other | Phase PHASE2 | Bone Pain in Stage I - III Breast Cancer | COMPLETED | NCT01712009 |
| etanercept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT01053819 |
| etanercept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT01053819 |
| Panitumumab | Other | Phase PHASE3 | Esophageal Squamous Cell Cancer | TERMINATED | NCT01627379 |
| Cisplatin, 5-FU | Other | Phase PHASE3 | Esophageal Squamous Cell Cancer | TERMINATED | NCT01627379 |
| Panitumumab | Other | Phase PHASE3 | Esophageal Squamous Cell Cancer | TERMINATED | NCT01627379 |
| Cisplatin, 5-FU | Other | Phase PHASE3 | Esophageal Squamous Cell Cancer | TERMINATED | NCT01627379 |
| AMG 479 | Other | Phase PHASE2 | Neuroendocrine Tumor | COMPLETED | NCT01024387 |
| AMG 479 | Other | Phase PHASE2 | Neuroendocrine Tumor | COMPLETED | NCT01024387 |
| AMG 479 | Other | Phase PHASE2 | Neuroendocrine Tumor | COMPLETED | NCT01024387 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00884312 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00884312 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00884312 |
| Panitumumab + FOLFOX (no-DP) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01288339 |
| Panitumumab + FOLFOX (DP) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01288339 |
| Panitumumab + FOLFOX (no-DP) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01288339 |
| Panitumumab + FOLFOX (DP) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01288339 |
| panitumumab, mytomicin C, 5-FU, radiation | Other | Phase PHASE2 | Anal Squamous Cell Carcinoma | COMPLETED | NCT01285778 |
| Etanercept | Other | Preclinical | Psoriasis | COMPLETED | NCT00322439 |
| Etanercept | Other | Preclinical | Psoriasis | COMPLETED | NCT00322439 |
| teriparatide | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00926380 |
| denosumab | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00926380 |
| No intervention | Other | Preclinical | Non-Hodgkin's Lymphoma | COMPLETED | NCT00903812 |
| saline placebo | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00169104 |
| vinorelbine | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00169104 |
| trastuzumab | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00169104 |
| G-CSF | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00169104 |
| saline placebo | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00169104 |
| vinorelbine | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00169104 |
| trastuzumab | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00169104 |
| G-CSF | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00169104 |
| Placebo for denosumab | Other | Phase PHASE3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | COMPLETED | NCT01575873 |
| Risendronate | Other | Phase PHASE3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | COMPLETED | NCT01575873 |
| Placebo for risendronate | Other | Phase PHASE3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | COMPLETED | NCT01575873 |
| Denosumab | Other | Phase PHASE3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | COMPLETED | NCT01575873 |
| Placebo for denosumab | Other | Phase PHASE3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | COMPLETED | NCT01575873 |
| Risendronate | Other | Phase PHASE3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | COMPLETED | NCT01575873 |
| Placebo for risendronate | Other | Phase PHASE3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | COMPLETED | NCT01575873 |
| Denosumab | Other | Phase PHASE3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | COMPLETED | NCT01575873 |
| Cinacalcet | Other | Preclinical | Hyperparathyroidism, Primary | COMPLETED | NCT00928408 |
| Cinacalcet | Other | Preclinical | Hyperparathyroidism, Primary | COMPLETED | NCT00928408 |
| Melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01690143 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01690143 |
| Melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01690143 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01690143 |
| 2=Clobetasol propionate foam | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01235442 |
| 1=Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01235442 |
| 2=Clobetasol propionate foam | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01235442 |
| 1=Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01235442 |
| 2=Clobetasol propionate foam | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01235442 |
| 1=Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01235442 |
| Midazolam | Other | Phase PHASE1 | Postmenopausal Osteoporosis | COMPLETED | NCT01221727 |
| Denosumab | Other | Phase PHASE1 | Postmenopausal Osteoporosis | COMPLETED | NCT01221727 |
| Midazolam | Other | Phase PHASE1 | Postmenopausal Osteoporosis | COMPLETED | NCT01221727 |
| Denosumab | Other | Phase PHASE1 | Postmenopausal Osteoporosis | COMPLETED | NCT01221727 |
| Autologous stem cell transplant | Other | Phase PHASE2 | Untreated CD20-positive Large B-cell Lymphoma | COMPLETED | NCT00169143 |
| Rituximab + ACVBP regimen plus Pegfilgrastim | Other | Phase PHASE2 | Untreated CD20-positive Large B-cell Lymphoma | COMPLETED | NCT00169143 |
| Autologous stem cell transplant | Other | Phase PHASE2 | Untreated CD20-positive Large B-cell Lymphoma | COMPLETED | NCT00169143 |
| Rituximab + ACVBP regimen plus Pegfilgrastim | Other | Phase PHASE2 | Untreated CD20-positive Large B-cell Lymphoma | COMPLETED | NCT00169143 |
| Placebo | Other | Phase PHASE2 | Stable Angina | COMPLETED | NCT02575833 |
| Erenumab | Other | Phase PHASE2 | Stable Angina | COMPLETED | NCT02575833 |
| Placebo | Other | Phase PHASE2 | Stable Angina | COMPLETED | NCT02575833 |
| Erenumab | Other | Phase PHASE2 | Stable Angina | COMPLETED | NCT02575833 |
| denosumab | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00321620 |
| zoledronic acid | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00321620 |
| denosumab | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00321620 |
| zoledronic acid | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00321620 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02739984 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02739984 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02739984 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02739984 |
| [¹⁴C]Etelcalcetide | Other | Phase PHASE1 | Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis | COMPLETED | NCT02054572 |
| [¹⁴C]Etelcalcetide | Other | Phase PHASE1 | Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis | COMPLETED | NCT02054572 |
| Etanercept / Autoinjector A | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT01901185 |
| Etanercept / Autoinjector A | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT01901185 |
| Etanercept via Autoinjector B | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT01875991 |
| Etanercept via Autoinjector A | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT01875991 |
| AMG 167 | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101048 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101048 |
| AMG 167 | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101048 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101048 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | WITHDRAWN | NCT00661921 |
| AMG 108 | Other | Phase PHASE2 | Diabetes Mellitus | WITHDRAWN | NCT00661921 |
| AMG 954/Panitumumab | Other | Phase PHASE1 | Oncology | WITHDRAWN | NCT00352950 |
| AMG 954/Panitumumab | Other | Phase PHASE1 | Oncology | WITHDRAWN | NCT00352950 |
| Quality Improvement Intervention | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT02851732 |
| Quality Improvement Intervention | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT02851732 |
| Quality Improvement Intervention | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT02851732 |
| Placebo to Atorvastatin | Other | Phase PHASE3 | Primary Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT02189837 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Primary Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT02189837 |
| Atorvastatin | Other | Phase PHASE3 | Primary Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT02189837 |
| Evolocumab | Other | Phase PHASE3 | Primary Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT02189837 |
| Placebo to Atorvastatin | Other | Phase PHASE3 | Primary Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT02189837 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Primary Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT02189837 |
| Atorvastatin | Other | Phase PHASE3 | Primary Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT02189837 |
| Evolocumab | Other | Phase PHASE3 | Primary Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT02189837 |
| Placebo | Other | Phase PHASE2 | Age-associated Muscle Loss | WITHDRAWN | NCT00975104 |
| AMG 745 3.0 mg/kg | Other | Phase PHASE2 | Age-associated Muscle Loss | WITHDRAWN | NCT00975104 |
| AMG 745 1.0 mg/kg | Other | Phase PHASE2 | Age-associated Muscle Loss | WITHDRAWN | NCT00975104 |
| AMG 745 0.3 mg/kg | Other | Phase PHASE2 | Age-associated Muscle Loss | WITHDRAWN | NCT00975104 |
| Placebo | Other | Phase PHASE2 | Age-associated Muscle Loss | WITHDRAWN | NCT00975104 |
| AMG 745 3.0 mg/kg | Other | Phase PHASE2 | Age-associated Muscle Loss | WITHDRAWN | NCT00975104 |
| AMG 745 1.0 mg/kg | Other | Phase PHASE2 | Age-associated Muscle Loss | WITHDRAWN | NCT00975104 |
| AMG 745 0.3 mg/kg | Other | Phase PHASE2 | Age-associated Muscle Loss | WITHDRAWN | NCT00975104 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01932970 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01932970 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01932970 |
| Cinacalcet | Other | Phase PHASE4 | Hyperparathyroidism, Secondary | COMPLETED | NCT01181531 |
| Traditional Vitamin D Therapy | Drug | Phase PHASE4 | Hyperparathyroidism, Secondary | COMPLETED | NCT01181531 |
| Cinacalcet | Other | Phase PHASE4 | Hyperparathyroidism, Secondary | COMPLETED | NCT01181531 |
| Traditional Vitamin D Therapy | Drug | Phase PHASE4 | Hyperparathyroidism, Secondary | COMPLETED | NCT01181531 |
| Cinacalcet | Other | Phase PHASE4 | Hyperparathyroidism, Secondary | COMPLETED | NCT01181531 |
| Traditional Vitamin D Therapy | Drug | Phase PHASE4 | Hyperparathyroidism, Secondary | COMPLETED | NCT01181531 |
| Placebo | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00980174 |
| 60 mg denosumab | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00980174 |
| Placebo | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00980174 |
| 60 mg denosumab | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00980174 |
| Placebo | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00980174 |
| 60 mg denosumab | Other | Phase PHASE3 | Low Bone Mass | COMPLETED | NCT00980174 |
| Placebo | Other | Phase PHASE3 | Hyperparathyroidism, Primary | COMPLETED | NCT00975221 |
| Cinacalcet | Other | Phase PHASE3 | Hyperparathyroidism, Primary | COMPLETED | NCT00975221 |
| Placebo | Other | Phase PHASE3 | Chronic Allograft Nephropathy | COMPLETED | NCT00975000 |
| Cinacalcet | Other | Phase PHASE3 | Chronic Allograft Nephropathy | COMPLETED | NCT00975000 |
| Placebo | Other | Phase PHASE3 | Chronic Allograft Nephropathy | COMPLETED | NCT00975000 |
| Cinacalcet | Other | Phase PHASE3 | Chronic Allograft Nephropathy | COMPLETED | NCT00975000 |
| denosumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00896454 |
| Vitamin D | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00803712 |
| Cinacalcet | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00803712 |
| Vitamin D | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00803712 |
| Cinacalcet | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT00803712 |
| Panitumumab | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT00500760 |
| Standard Fractionation Radiotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT00500760 |
| Cisplatin | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT00500760 |
| Panitumumab | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT00500760 |
| Standard Fractionation Radiotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT00500760 |
| Cisplatin | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT00500760 |
| Docetaxel | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00454779 |
| Panitumumab | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00454779 |
| Cisplatin | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00454779 |
| Docetaxel | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00454779 |
| Panitumumab | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00454779 |
| Cisplatin | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00454779 |
| 5-Fluorouracil | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00418938 |
| Irinotecan | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00418938 |
| Leucovorin | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00418938 |
| Bevacizumab | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00418938 |
| Panitumumab | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00418938 |
| Decitabine | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Azacitidine | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| AMG 531 (Romiplostim) | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Placebo | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Decitabine | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Azacitidine | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| AMG 531 (Romiplostim) | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Placebo | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Decitabine | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Azacitidine | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| AMG 531 (Romiplostim) | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Placebo | Other | Phase PHASE2 | MDS | COMPLETED | NCT00321711 |
| Placebo | Other | Phase PHASE3 | Hormone Refractory Prostate Cancer | COMPLETED | NCT00286091 |
| Denosumab | Other | Phase PHASE3 | Hormone Refractory Prostate Cancer | COMPLETED | NCT00286091 |
| Placebo | Other | Phase PHASE3 | Hormone Refractory Prostate Cancer | COMPLETED | NCT00286091 |
| Denosumab | Other | Phase PHASE3 | Hormone Refractory Prostate Cancer | COMPLETED | NCT00286091 |
| Placebo | Other | Phase PHASE3 | Hormone Refractory Prostate Cancer | COMPLETED | NCT00286091 |
| Denosumab | Other | Phase PHASE3 | Hormone Refractory Prostate Cancer | COMPLETED | NCT00286091 |
| Bevacizumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Irinotecan Based Chemotherapy | Drug | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Oxaliplatin Based Chemotherapy | Drug | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Bevacizumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Irinotecan Based Chemotherapy | Drug | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Oxaliplatin Based Chemotherapy | Drug | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Bevacizumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Irinotecan Based Chemotherapy | Drug | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Oxaliplatin Based Chemotherapy | Drug | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00115765 |
| Pegfilgrastim | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00094809 |
| Placebo | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00094809 |
| Pegfilgrastim | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00094809 |
| Placebo | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00094809 |
| Pegfilgrastim | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00094809 |
| Placebo | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00094809 |
| Placebo | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT00089674 |
| AMG 162 | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT00089674 |
| AMG 162 / Denosumab | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00089661 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00089661 |
| AMG 162 / Denosumab | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00089661 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00089661 |
| Denosumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00838201 |
| Denosumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT00838201 |
| denosumab | Other | Preclinical | Osteoporosis | COMPLETED | NCT02435147 |
| denosumab | Other | Preclinical | Osteoporosis | COMPLETED | NCT02435147 |
| denosumab | Other | Preclinical | Osteoporosis | COMPLETED | NCT02435147 |
| Placebo | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01133522 |
| Evolocumab | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01133522 |
| Placebo | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01133522 |
| Evolocumab | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01133522 |
| r-metHuLeptin | Other | Phase PHASE1 | Energy Deficiency Due to Short-term Fasting | COMPLETED | NCT00140205 |
| r-metHuLeptin | Other | Phase PHASE1 | Energy Deficiency Due to Short-term Fasting | COMPLETED | NCT00140205 |
| Ifosfamide | Other | Approved | Sarcoma | COMPLETED | NCT00283621 |
| Adriamycin | Other | Approved | Sarcoma | COMPLETED | NCT00283621 |
| Neulasta (pegfilgrastim) | Other | Approved | Sarcoma | COMPLETED | NCT00283621 |
| Aranesp (darbepoetin alfa) | Other | Approved | Sarcoma | COMPLETED | NCT00283621 |
| Ifosfamide | Other | Approved | Sarcoma | COMPLETED | NCT00283621 |
| Adriamycin | Other | Approved | Sarcoma | COMPLETED | NCT00283621 |
| Neulasta (pegfilgrastim) | Other | Approved | Sarcoma | COMPLETED | NCT00283621 |
| Aranesp (darbepoetin alfa) | Other | Approved | Sarcoma | COMPLETED | NCT00283621 |
| Placebo 70 mg/mL | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02016716 |
| Romosozumab 70 mg/mL | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02016716 |
| Placebo 90 mg/mL | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02016716 |
| Romosozumab 90 mg/mL | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02016716 |
| Placebo 70 mg/mL | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02016716 |
| Romosozumab 70 mg/mL | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02016716 |
| Placebo 90 mg/mL | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02016716 |
| Romosozumab 90 mg/mL | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02016716 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Myelodysplastic Syndrome (MDS) | COMPLETED | NCT02175277 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Myelodysplastic Syndrome (MDS) | COMPLETED | NCT02175277 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Myelodysplastic Syndrome (MDS) | COMPLETED | NCT02175277 |
| 5FU | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00756444 |
| Cisplatin | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00756444 |
| Panitumumab | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT00756444 |
| Ivabradine | Other | Phase PHASE3 | Heart Transplantation, Elevated Resting Heart Rate | WITHDRAWN | NCT03619187 |
| Ivabradine | Other | Phase PHASE3 | Heart Transplantation, Elevated Resting Heart Rate | WITHDRAWN | NCT03619187 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Carfilzomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Dexamethasone | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Carfilzomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Dexamethasone | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Carfilzomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Dexamethasone | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT01470196 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia and High Risk for Cardiovascular Events | COMPLETED | NCT01652703 |
| Evolocumab | Other | Phase PHASE2 | Hypercholesterolemia and High Risk for Cardiovascular Events | COMPLETED | NCT01652703 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia and High Risk for Cardiovascular Events | COMPLETED | NCT01652703 |
| Evolocumab | Other | Phase PHASE2 | Hypercholesterolemia and High Risk for Cardiovascular Events | COMPLETED | NCT01652703 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Placebo to Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Placebo to Atorvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Atorvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Placebo to Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Placebo to Atorvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Atorvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01984424 |
| Evolocumab AI/pen | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT01849497 |
| Evolocumab Pre-filled Syringe | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT01849497 |
| Placebo | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT01588496 |
| Evolocumab | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT01588496 |
| Placebo | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT01588496 |
| Evolocumab | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT01588496 |
| Placebo | Other | Phase PHASE2 | Primary Hyperparathyroidism | COMPLETED | NCT03774771 |
| Cinacalcet | Other | Phase PHASE2 | Primary Hyperparathyroidism | COMPLETED | NCT03774771 |
| Placebo | Other | Phase PHASE2 | Primary Hyperparathyroidism | COMPLETED | NCT03776058 |
| Cinacalcet | Other | Phase PHASE2 | Primary Hyperparathyroidism | COMPLETED | NCT03776058 |
| Placebo | Other | Phase PHASE2 | Primary Hyperparathyroidism | COMPLETED | NCT03776058 |
| Cinacalcet | Other | Phase PHASE2 | Primary Hyperparathyroidism | COMPLETED | NCT03776058 |
| Acyclovir | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Dexamethasone | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Carfilzomib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Acyclovir | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Dexamethasone | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Carfilzomib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Acyclovir | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Dexamethasone | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Carfilzomib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02047253 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT03776032 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT03776032 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT03776032 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT03776032 |
| Placebo | Other | Phase PHASE3 | Anemia | COMPLETED | NCT03776032 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT03776032 |
| Ethynil Estradiol/Norgestimate Oral Contraceptive | Other | Phase PHASE1 | Headache, Migraine | COMPLETED | NCT02792517 |
| Erenumab | Other | Phase PHASE1 | Headache, Migraine | COMPLETED | NCT02792517 |
| Ethynil Estradiol/Norgestimate Oral Contraceptive | Other | Phase PHASE1 | Headache, Migraine | COMPLETED | NCT02792517 |
| Erenumab | Other | Phase PHASE1 | Headache, Migraine | COMPLETED | NCT02792517 |
| Placebo | Other | Phase PHASE3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | COMPLETED | NCT02662569 |
| Atorvastatin | Other | Phase PHASE3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | COMPLETED | NCT02662569 |
| Evolocumab | Other | Phase PHASE3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | COMPLETED | NCT02662569 |
| Placebo | Other | Phase PHASE3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | COMPLETED | NCT02662569 |
| Atorvastatin | Other | Phase PHASE3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | COMPLETED | NCT02662569 |
| Evolocumab | Other | Phase PHASE3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | COMPLETED | NCT02662569 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms; Hot Flashes | COMPLETED | NCT01890109 |
| Erenumab | Other | Phase PHASE1 | Vasomotor Symptoms; Hot Flashes | COMPLETED | NCT01890109 |
| Placebo | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01723514 |
| Erenumab | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01723514 |
| Placebo | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01723514 |
| Erenumab | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01723514 |
| Placebo | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01688739 |
| Erenumab | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01688739 |
| Placebo | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01688739 |
| Erenumab | Other | Phase PHASE1 | Migraine | COMPLETED | NCT01688739 |
| MTX based chemotherapy | Drug | Phase PHASE2 | Primary Central Nervous System Lymphoma | ACTIVE_NOT_RECRUITING | NCT00863460 |
| intensive chemotherapy and hematopoietic stem cell rescue | Drug | Phase PHASE2 | Primary Central Nervous System Lymphoma | ACTIVE_NOT_RECRUITING | NCT00863460 |
| cranial radiotherapy | Drug | Phase PHASE2 | Primary Central Nervous System Lymphoma | ACTIVE_NOT_RECRUITING | NCT00863460 |
| MTX based chemotherapy | Drug | Phase PHASE2 | Primary Central Nervous System Lymphoma | ACTIVE_NOT_RECRUITING | NCT00863460 |
| intensive chemotherapy and hematopoietic stem cell rescue | Drug | Phase PHASE2 | Primary Central Nervous System Lymphoma | ACTIVE_NOT_RECRUITING | NCT00863460 |
| cranial radiotherapy | Drug | Phase PHASE2 | Primary Central Nervous System Lymphoma | ACTIVE_NOT_RECRUITING | NCT00863460 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01813422 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01813422 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01813422 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01813422 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01813422 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01813422 |
| Phone Calls | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02269085 |
| Carfilzomib | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02269085 |
| Ibrutinib | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02269085 |
| Phone Calls | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02269085 |
| Carfilzomib | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02269085 |
| Ibrutinib | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02269085 |
| Denosumab | Other | Preclinical | Osteoporosis, Postmenopausal | COMPLETED | NCT01652690 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02304484 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02304484 |
| Placebo | Other | Phase PHASE2 | Postmenopausal Osteoporosis (PMO) | COMPLETED | NCT01992159 |
| Romosozumab | Other | Phase PHASE2 | Postmenopausal Osteoporosis (PMO) | COMPLETED | NCT01992159 |
| Placebo | Other | Phase PHASE2 | Postmenopausal Osteoporosis (PMO) | COMPLETED | NCT01992159 |
| Romosozumab | Other | Phase PHASE2 | Postmenopausal Osteoporosis (PMO) | COMPLETED | NCT01992159 |
| Placebo | Other | Phase PHASE2 | Postmenopausal Osteoporosis (PMO) | COMPLETED | NCT01992159 |
| Romosozumab | Other | Phase PHASE2 | Postmenopausal Osteoporosis (PMO) | COMPLETED | NCT01992159 |
| Romosozumab | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT01588509 |
| Romosozumab | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT01588509 |
| Romosozumab | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT01588509 |
| Erenumab | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02741310 |
| Sumatriptan | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02741310 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02741310 |
| ABP 501 | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01970488 |
| Adalimumab | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01970488 |
| ABP 501 | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01970488 |
| Adalimumab | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01970488 |
| ABP 501 | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01970488 |
| Adalimumab | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01970488 |
| ABP 501 | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01970488 |
| Adalimumab | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01970488 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01785875 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01785875 |
| Panitumumab + paclitaxel | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01264328 |
| Panitumumab + paclitaxel | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01264328 |
| Panitumumab + paclitaxel | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01264328 |
| Questionnaires | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Placebo | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Loratadine | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Pegfilgrastim | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Questionnaires | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Placebo | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Loratadine | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Pegfilgrastim | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Questionnaires | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Placebo | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Loratadine | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Pegfilgrastim | Other | Phase EARLY_PHASE1 | Lymphoma | TERMINATED | NCT02392039 |
| Arm 1- Dose Expansion | Other | Phase PHASE1 | Advanced Malignancy | COMPLETED | NCT00858377 |
| Arm 1- Dose Escalation | Other | Phase PHASE1 | Advanced Malignancy | COMPLETED | NCT00858377 |
| Placebo | Other | Phase PHASE4 | Heart Failure | UNKNOWN | NCT03387605 |
| Ivabradine | Other | Phase PHASE4 | Heart Failure | UNKNOWN | NCT03387605 |
| Placebo | Other | Phase PHASE3 | Osteoporosis in Men | COMPLETED | NCT02186171 |
| Romosozumab | Other | Phase PHASE3 | Osteoporosis in Men | COMPLETED | NCT02186171 |
| PACAP-38 Challenge Agent | Other | Phase PHASE1 | Migraine | COMPLETED | NCT02542605 |
| Placebo | Other | Phase PHASE1 | Migraine | COMPLETED | NCT02542605 |
| Erenumab | Other | Phase PHASE1 | Migraine | COMPLETED | NCT02542605 |
| PACAP-38 Challenge Agent | Other | Phase PHASE1 | Migraine | COMPLETED | NCT02542605 |
| Placebo | Other | Phase PHASE1 | Migraine | COMPLETED | NCT02542605 |
| Erenumab | Other | Phase PHASE1 | Migraine | COMPLETED | NCT02542605 |
| Standard of Care | Other | Phase PHASE3 | Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT01854918 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT01854918 |
| Standard of Care | Other | Phase PHASE3 | Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT01854918 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia and Mixed Dyslipidemia | COMPLETED | NCT01854918 |
| Placebo | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763918 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763918 |
| Placebo | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763918 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763918 |
| Kyprolis | Other | Preclinical | Multiple Myeloma | UNKNOWN | NCT04004338 |
| Placebo | Other | Phase PHASE1 | Cardiovascular | COMPLETED | NCT03170193 |
| AMG 529 | Other | Phase PHASE1 | Cardiovascular | COMPLETED | NCT03170193 |
| Placebo | Other | Phase PHASE1 | Cardiovascular | COMPLETED | NCT03170193 |
| AMG 529 | Other | Phase PHASE1 | Cardiovascular | COMPLETED | NCT03170193 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01059435 |
| Romosozumab | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01059435 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT00950950 |
| Romosozumab | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT00950950 |
| Etelcalcetide | Other | Phase PHASE1 | Chronic Kidney Disease, Secondary Hyperparathyroidism | COMPLETED | NCT02833857 |
| Etelcalcetide | Other | Phase PHASE1 | Chronic Kidney Disease, Secondary Hyperparathyroidism | COMPLETED | NCT02833857 |
| New Formulation Etanercept | Other | Phase PHASE3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | COMPLETED | NCT02986139 |
| Commercial Formulation Etanercept | Other | Phase PHASE3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | COMPLETED | NCT02986139 |
| New Formulation Etanercept | Other | Phase PHASE3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | COMPLETED | NCT02986139 |
| Commercial Formulation Etanercept | Other | Phase PHASE3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | COMPLETED | NCT02986139 |
| New Formulation Etanercept | Other | Phase PHASE3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | COMPLETED | NCT02986139 |
| Commercial Formulation Etanercept | Other | Phase PHASE3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | COMPLETED | NCT02986139 |
| Intravenous Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT01896232 |
| Oral Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT01896232 |
| Cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT01896232 |
| Etelcalcetide | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT01896232 |
| Denosumab | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT03822078 |
| Placebo | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT03822078 |
| 5-FU | Other | Phase PHASE2 | Treatment Related Cancer | NOT_YET_RECRUITING | NCT04034173 |
| Folinic acid | Other | Phase PHASE2 | Treatment Related Cancer | NOT_YET_RECRUITING | NCT04034173 |
| Irinotecan | Other | Phase PHASE2 | Treatment Related Cancer | NOT_YET_RECRUITING | NCT04034173 |
| Panitumumab | Other | Phase PHASE2 | Treatment Related Cancer | NOT_YET_RECRUITING | NCT04034173 |
| 5-FU | Other | Phase PHASE2 | Treatment Related Cancer | NOT_YET_RECRUITING | NCT04034173 |
| Folinic acid | Other | Phase PHASE2 | Treatment Related Cancer | NOT_YET_RECRUITING | NCT04034173 |
| Irinotecan | Other | Phase PHASE2 | Treatment Related Cancer | NOT_YET_RECRUITING | NCT04034173 |
| Panitumumab | Other | Phase PHASE2 | Treatment Related Cancer | NOT_YET_RECRUITING | NCT04034173 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00078819 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00078819 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00078819 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00078819 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101061 |
| Romosozumab | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101061 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101061 |
| Romosozumab | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101061 |
| Placebo | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101061 |
| Romosozumab | Other | Phase PHASE1 | Osteopenia | COMPLETED | NCT01101061 |
| Methotrexate | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT03781375 |
| Placebo to Etanerceot | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT03781375 |
| Etanercept | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT03781375 |
| Methotrexate | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT03781375 |
| Placebo to Etanerceot | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT03781375 |
| Etanercept | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT03781375 |
| Placebo | Other | Phase PHASE2 | Juvenile Rheumatoid Arthritis | COMPLETED | NCT03780959 |
| Etanercept | Other | Phase PHASE2 | Juvenile Rheumatoid Arthritis | COMPLETED | NCT03780959 |
| Placebo | Other | Phase PHASE2 | Juvenile Rheumatoid Arthritis | COMPLETED | NCT03780959 |
| Etanercept | Other | Phase PHASE2 | Juvenile Rheumatoid Arthritis | COMPLETED | NCT03780959 |
| Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT01901146 |
| Paclitaxel | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT01901146 |
| Trastuzumab | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT01901146 |
| ABP 980 | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT01901146 |
| Placebo | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT03287609 |
| Evolocumab 140 mg/mL | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT03287609 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | ENROLLING_BY_INVITATION | NCT03815279 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | ENROLLING_BY_INVITATION | NCT03815279 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | ENROLLING_BY_INVITATION | NCT03815279 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | ENROLLING_BY_INVITATION | NCT03815279 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | ENROLLING_BY_INVITATION | NCT03815279 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | ENROLLING_BY_INVITATION | NCT03815279 |
| Placebo | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01788046 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01788046 |
| Placebo | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01788046 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01788046 |
| Denosumab | Other | Phase PHASE2 | Aneurysmal Bone Cysts | UNKNOWN | NCT03605199 |
| Denosumab | Other | Phase PHASE2 | Aneurysmal Bone Cysts | UNKNOWN | NCT03605199 |
| Prednisone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01818752 |
| Melphalan | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01818752 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01818752 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01818752 |
| Prednisone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01818752 |
| Melphalan | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01818752 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01818752 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01818752 |
| Placebo | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01785849 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01785849 |
| Placebo | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01785849 |
| Etelcalcetide | Other | Phase PHASE3 | Hyperparathyroidism, Secondary | COMPLETED | NCT01785849 |
| Infliximab | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02937701 |
| ABP 710 | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02937701 |
| Infliximab | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02937701 |
| ABP 710 | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02937701 |
| Denosumab | Other | Phase PHASE3 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT01419717 |
| Denosumab | Other | Phase PHASE3 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | COMPLETED | NCT01419717 |
| Placebo | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT00078806 |
| Etanercept | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT00078806 |
| Placebo | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT00078806 |
| Etanercept | Other | Phase PHASE3 | Juvenile Rheumatoid Arthritis | TERMINATED | NCT00078806 |
| Usual Care | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT02827500 |
| ivabradine | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT02827500 |
| Usual Care | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT02827500 |
| ivabradine | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT02827500 |
| Placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02791516 |
| Romosozumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT02791516 |
| Fasting mimicking diet | Other | Phase PHASE2 | Fasting Mimicking Diet | COMPLETED | NCT02126449 |
| Fasting mimicking diet | Other | Phase PHASE2 | Fasting Mimicking Diet | COMPLETED | NCT02126449 |
| Talimogene Laherparepvec | Other | Preclinical | Unresected Stage IIIB to IVM1c Melanoma | NO_LONGER_AVAILABLE | NCT02297529 |
| Talimogene Laherparepvec | Other | Preclinical | Unresected Stage IIIB to IVM1c Melanoma | NO_LONGER_AVAILABLE | NCT02297529 |
| Talimogene Laherparepvec | Other | Preclinical | Unresected Stage IIIB to IVM1c Melanoma | NO_LONGER_AVAILABLE | NCT02297529 |
| FOLFIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00508404 |
| Panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00508404 |
| FOLFIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00508404 |
| Panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT00508404 |
| Talimogene laherparepvec | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT02014441 |
| Talimogene laherparepvec | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT02014441 |
| Denosumab | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT01952054 |
| Docetaxel | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Vinorelbine | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Pertuzumab | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Trastuzumab | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Docetaxel | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Vinorelbine | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Pertuzumab | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Trastuzumab | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Docetaxel | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Vinorelbine | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Pertuzumab | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| Trastuzumab | Other | Phase PHASE3 | Advanced Breast Cancer | WITHDRAWN | NCT03811418 |
| docetaxel + cyclophosphamide + pegfilgrastim | Other | Phase PHASE2 | Female Breast Cancer | COMPLETED | NCT01671319 |
| docetaxel + cyclophosphamide + pegfilgrastim | Other | Phase PHASE2 | Female Breast Cancer | COMPLETED | NCT01671319 |
| Gluten Challenge | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT02637141 |
| Placebo Gluten Challenge | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT02637141 |
| Placebo | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT02637141 |
| AMG 714 | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT02637141 |
| denosumab | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00518531 |
| alendronate | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00518531 |
| denosumab | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00518531 |
| alendronate | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00518531 |
| Panitumumab | Other | Phase PHASE1 | Cancer | TERMINATED | NCT01128387 |
| Pre-filled syringe | Other | Approved | Non Hodgkin Lymphoma | COMPLETED | NCT03619993 |
| On-body injector | Other | Approved | Non Hodgkin Lymphoma | COMPLETED | NCT03619993 |
| AMG 386 Placebo | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00479817 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00479817 |
| AMG 386 | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00479817 |
| AMG 386 Placebo | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00479817 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00479817 |
| AMG 386 | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00479817 |
| Placebo | Other | Phase PHASE2 | Type II Refractory Celiac Disease (RCD-II) | COMPLETED | NCT02633020 |
| AMG 714 | Other | Phase PHASE2 | Type II Refractory Celiac Disease (RCD-II) | COMPLETED | NCT02633020 |
| Placebo | Other | Phase PHASE2 | Type II Refractory Celiac Disease (RCD-II) | COMPLETED | NCT02633020 |
| AMG 714 | Other | Phase PHASE2 | Type II Refractory Celiac Disease (RCD-II) | COMPLETED | NCT02633020 |
| Placebo | Other | Phase PHASE2 | Type II Refractory Celiac Disease (RCD-II) | COMPLETED | NCT02633020 |
| AMG 714 | Other | Phase PHASE2 | Type II Refractory Celiac Disease (RCD-II) | COMPLETED | NCT02633020 |
| Education and inform the optimal threshold of LDL-C levels | Other | Preclinical | Dyslipidemias | UNKNOWN | NCT04220164 |
| Education and inform the optimal threshold of LDL-C levels | Other | Preclinical | Dyslipidemias | RECRUITING | NCT04220164 |
| Placebo | Other | Phase PHASE2 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00111475 |
| Romiplostim | Other | Phase PHASE2 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00111475 |
| Placebo | Other | Phase PHASE2 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00111475 |
| Romiplostim | Other | Phase PHASE2 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00111475 |
| Denosumab 60 mg | Other | Phase PHASE2 | Breast Neoplasms | WITHDRAWN | NCT03532087 |
| Denosumab 120 mg | Other | Phase PHASE2 | Breast Neoplasms | WITHDRAWN | NCT03532087 |
| Denosumab 60 mg | Other | Phase PHASE2 | Breast Neoplasms | WITHDRAWN | NCT03532087 |
| Denosumab 120 mg | Other | Phase PHASE2 | Breast Neoplasms | WITHDRAWN | NCT03532087 |
| Romiplostim | Other | Phase PHASE3 | Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP | COMPLETED | NCT01071954 |
| Romiplostim | Other | Phase PHASE3 | Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP | COMPLETED | NCT01071954 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00346294 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00346294 |
| Etanercept | Other | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00346294 |
| survey | Other | Preclinical | Dyslipidemia | COMPLETED | NCT02537535 |
| AMG 301 | Other | Phase PHASE2 | Chronic Migraine or Episodic Migraine | COMPLETED | NCT03238781 |
| Placebo | Other | Phase PHASE2 | Chronic Migraine or Episodic Migraine | COMPLETED | NCT03238781 |
| Placebo | Other | Phase PHASE1 | Secondary Hyperparathyroidism | COMPLETED | NCT03283098 |
| Etelcalcetide | Other | Phase PHASE1 | Secondary Hyperparathyroidism | COMPLETED | NCT03283098 |
| Placebo | Other | Phase PHASE1 | Secondary Hyperparathyroidism | COMPLETED | NCT03283098 |
| Etelcalcetide | Other | Phase PHASE1 | Secondary Hyperparathyroidism | COMPLETED | NCT03283098 |
| Placebo | Other | Phase PHASE1 | Secondary Hyperparathyroidism | COMPLETED | NCT03283098 |
| Etelcalcetide | Other | Phase PHASE1 | Secondary Hyperparathyroidism | COMPLETED | NCT03283098 |
| Panitumumab | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT01202409 |
| Panitumumab | Other | Phase PHASE2 | Gastrointestinal Cancer | COMPLETED | NCT01202409 |
| liposomal cytarabine | Other | Phase PHASE2 | Primary Disease | COMPLETED | NCT01325194 |
| etanercept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT01971346 |
| etanercept | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT01971346 |
| Placebo to Zoledronic Acid | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT01732770 |
| Placebo to Denosumab | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT01732770 |
| Zoledronic Acid | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT01732770 |
| Denosumab | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT01732770 |
| Placebo to Zoledronic Acid | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT01732770 |
| Placebo to Denosumab | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT01732770 |
| Zoledronic Acid | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT01732770 |
| Denosumab | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT01732770 |
| Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months. | Other | Phase PHASE4 | Peripheral Arterial Disease | UNKNOWN | NCT04306081 |
| Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months. | Other | Phase PHASE4 | Peripheral Arterial Disease | UNKNOWN | NCT04306081 |
| Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months. | Other | Phase PHASE4 | Peripheral Arterial Disease | UNKNOWN | NCT04306081 |
| Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months. | Other | Phase PHASE4 | Peripheral Arterial Disease | UNKNOWN | NCT04306081 |
| Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months | Other | Phase PHASE4 | Critical Limb Ischemia | UNKNOWN | NCT04306471 |
| Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. | Other | Phase PHASE4 | Critical Limb Ischemia | UNKNOWN | NCT04306471 |
| Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months | Other | Phase PHASE4 | Critical Limb Ischemia | UNKNOWN | NCT04306471 |
| Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. | Other | Phase PHASE4 | Critical Limb Ischemia | UNKNOWN | NCT04306471 |
| Doxycycline 50Mg Tablet | Other | Phase PHASE2 | Skin Toxicity | COMPLETED | NCT03448731 |
| Doxycycline 50Mg Tablet | Other | Phase PHASE2 | Skin Toxicity | COMPLETED | NCT03448731 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00606450 |
| CC-10004 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00606450 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00606450 |
| CC-10004 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00606450 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00606450 |
| CC-10004 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00606450 |
| CC10004 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00604682 |
| Apremilast | Other | Preclinical | Psoriasis | COMPLETED | NCT03097003 |
| Apremilast | Other | Preclinical | Psoriasis | COMPLETED | NCT03097003 |
| Apremilast | Other | Preclinical | Psoriasis | COMPLETED | NCT03097003 |
| Other | Other | Preclinical | Relapsed/Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT02783651 |
| Other | Other | Preclinical | Relapsed/Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT02783651 |
| CC-10004 | Other | Preclinical | Bechet's Disease | NO_LONGER_AVAILABLE | NCT03740516 |
| CC-10004 | Other | Preclinical | Bechet's Disease | NO_LONGER_AVAILABLE | NCT03740516 |
| CC-10004 | Other | Preclinical | Bechet's Disease | NO_LONGER_AVAILABLE | NCT03740516 |
| apremilast | Other | Preclinical | Arthritis, Psoriatic | COMPLETED | NCT03096990 |
| Other: not applicable - observational study | Other | Preclinical | B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303522 |
| Other: not applicable - observational study | Other | Preclinical | B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303522 |
| Other: not applicable - observational study | Other | Preclinical | B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303522 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Apremilast 30mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Apremilast 20mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Apremilast 30mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Apremilast 20mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Apremilast 30mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Apremilast 20mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212770 |
| Placebo + 30 mg Apremilast | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212757 |
| Placebo + 20 mg Apremilast | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212757 |
| Apremilast 30mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212757 |
| Apremilast 20mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01212757 |
| Apremilast | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02576678 |
| Apremilast | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02576678 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT02289417 |
| Apremilast | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT02289417 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT02289417 |
| Apremilast | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT02289417 |
| Placebo | Other | Phase PHASE2 | Dermatitis, Atopic Dermatitis | COMPLETED | NCT02087943 |
| Apremilast | Other | Phase PHASE2 | Dermatitis, Atopic Dermatitis | COMPLETED | NCT02087943 |
| Placebo | Other | Phase PHASE2 | Dermatitis, Atopic Dermatitis | COMPLETED | NCT02087943 |
| Apremilast | Other | Phase PHASE2 | Dermatitis, Atopic Dermatitis | COMPLETED | NCT02087943 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT01988103 |
| Apremilast | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT01988103 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT01988103 |
| Apremilast | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT01988103 |
| Apremilast 30mg | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Apremilast 30 mg | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Apremilast 20mg | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Apremilast 10mg | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Apremilast 30mg | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Apremilast 30 mg | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Apremilast 20mg | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Apremilast 10mg | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00773734 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01285310 |
| Apremilast 20 mg | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01285310 |
| Apremilast 30 mg | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01285310 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01285310 |
| Apremilast 20 mg | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01285310 |
| Apremilast 30 mg | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01285310 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01925768 |
| Apremilast 30 mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01925768 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01925768 |
| Apremilast 30 mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01925768 |
| Placebo | Other | Phase PHASE3 | Ankylosing Spondyloarthritis | COMPLETED | NCT01583374 |
| Apremilast tablet 30 mg BID | Other | Phase PHASE3 | Ankylosing Spondyloarthritis | COMPLETED | NCT01583374 |
| Apremilast tablet 20 mg | Other | Phase PHASE3 | Ankylosing Spondyloarthritis | COMPLETED | NCT01583374 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03123471 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03123471 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03123471 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03123471 |
| Etanercept | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT02749370 |
| Etanercept | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT02749370 |
| Darbepoetin alfa | Other | Preclinical | Cardiomyopathy | COMPLETED | NCT00883415 |
| Darbepoetin alfa | Other | Preclinical | Cardiomyopathy | COMPLETED | NCT00883415 |
| Darbepoetin alfa | Other | Preclinical | Cardiomyopathy | COMPLETED | NCT00883415 |
| lung ultrasound | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT03182699 |
| Body composition monitoring | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT03182699 |
| Laboratory tests | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT03182699 |
| echocardiography with strain | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT03182699 |
| cardiac MRI | Other | Phase PHASE4 | Secondary Hyperparathyroidism | COMPLETED | NCT03182699 |
| Laboratory Biomarker Analysis | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Quality-of-Life Assessment | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Capecitabine | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Fluorouracil | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Leucovorin Calcium | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Oxaliplatin | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Laboratory Biomarker Analysis | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Quality-of-Life Assessment | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Capecitabine | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Fluorouracil | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Leucovorin Calcium | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Oxaliplatin | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Adenocarcinoma | TERMINATED | NCT03300609 |
| Standard of Care | Other | Phase PHASE2 | Chronic Kidney Disease | TERMINATED | NCT01439867 |
| Cinacalcet hydrochloride | Other | Phase PHASE2 | Chronic Kidney Disease | TERMINATED | NCT01439867 |
| Standard of Care | Other | Phase PHASE2 | Chronic Kidney Disease | TERMINATED | NCT01439867 |
| Cinacalcet hydrochloride | Other | Phase PHASE2 | Chronic Kidney Disease | TERMINATED | NCT01439867 |
| Cinacalcet | Other | Phase PHASE1 | Chronic Kidney Disease | COMPLETED | NCT01290029 |
| Cinacalcet | Other | Phase PHASE1 | Chronic Kidney Disease | COMPLETED | NCT01290029 |
| Placebo + 30 mg Apremilast | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01172938 |
| Placebo + 20 mg Apremilast | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01172938 |
| Apremilast 30mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01172938 |
| Apremilast 20mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01172938 |
| Placebo + 30 mg Apremilast | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01172938 |
| Placebo + 20 mg Apremilast | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01172938 |
| Apremilast 30mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01172938 |
| Apremilast 20mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01172938 |
| Placebo | Other | Phase PHASE2 | Behcet Syndrome | COMPLETED | NCT00866359 |
| Apremilast (CC-10004) | Other | Phase PHASE2 | Behcet Syndrome | COMPLETED | NCT00866359 |
| Placebo | Other | Phase PHASE2 | Behcet Syndrome | COMPLETED | NCT00866359 |
| Apremilast (CC-10004) | Other | Phase PHASE2 | Behcet Syndrome | COMPLETED | NCT00866359 |
| Placebo | Other | Phase PHASE2 | Psoriatic Arthritis | COMPLETED | NCT00456092 |
| Apremilast | Other | Phase PHASE2 | Psoriatic Arthritis | COMPLETED | NCT00456092 |
| CC-11050 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04139226 |
| CC-11050 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04139226 |
| Placebo | Other | Phase PHASE2 | Cutaneous Lupus Erythematosus | COMPLETED | NCT01300208 |
| CC-11050 | Other | Phase PHASE2 | Cutaneous Lupus Erythematosus | COMPLETED | NCT01300208 |
| Placebo | Other | Phase PHASE2 | Cutaneous Lupus Erythematosus | COMPLETED | NCT01300208 |
| CC-11050 | Other | Phase PHASE2 | Cutaneous Lupus Erythematosus | COMPLETED | NCT01300208 |
| Placebos | Other | Phase PHASE2 | Osteoporosis | WITHDRAWN | NCT04231682 |
| Denosumab Injection | Other | Phase PHASE2 | Osteoporosis | WITHDRAWN | NCT04231682 |
| Placebos | Other | Phase PHASE2 | Osteoporosis | WITHDRAWN | NCT04231682 |
| Denosumab Injection | Other | Phase PHASE2 | Osteoporosis | WITHDRAWN | NCT04231682 |
| Placebos | Other | Phase PHASE2 | Osteoporosis | WITHDRAWN | NCT04231682 |
| Denosumab Injection | Other | Phase PHASE2 | Osteoporosis | WITHDRAWN | NCT04231682 |
| Cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism, Chronic Kidney Disease | COMPLETED | NCT02341417 |
| Cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism, Chronic Kidney Disease | COMPLETED | NCT02341417 |
| Standard of Care | Other | Phase PHASE3 | Chronic Kidney Disease, Secondary Hyperparathyroidism | TERMINATED | NCT02138838 |
| Cinacalcet HCl | Other | Phase PHASE3 | Chronic Kidney Disease, Secondary Hyperparathyroidism | TERMINATED | NCT02138838 |
| Standard of Care | Other | Phase PHASE3 | Chronic Kidney Disease, Secondary Hyperparathyroidism | TERMINATED | NCT02138838 |
| Cinacalcet HCl | Other | Phase PHASE3 | Chronic Kidney Disease, Secondary Hyperparathyroidism | TERMINATED | NCT02138838 |
| Standard of Care | Other | Phase PHASE3 | Chronic Kidney Disease | TERMINATED | NCT01277510 |
| placebo | Other | Phase PHASE3 | Chronic Kidney Disease | TERMINATED | NCT01277510 |
| cinacalcet capsule | Other | Phase PHASE3 | Chronic Kidney Disease | TERMINATED | NCT01277510 |
| Standard of Care | Other | Phase PHASE3 | Chronic Kidney Disease | TERMINATED | NCT01277510 |
| placebo | Other | Phase PHASE3 | Chronic Kidney Disease | TERMINATED | NCT01277510 |
| cinacalcet capsule | Other | Phase PHASE3 | Chronic Kidney Disease | TERMINATED | NCT01277510 |
| Rituximab | Other | Phase PHASE1 | Transplants and Implants | UNKNOWN | NCT02442648 |
| Carfilzomib | Other | Phase PHASE1 | Transplants and Implants | UNKNOWN | NCT02442648 |
| Rituximab | Other | Phase PHASE1 | Transplants and Implants | UNKNOWN | NCT02442648 |
| Carfilzomib | Other | Phase PHASE1 | Transplants and Implants | UNKNOWN | NCT02442648 |
| Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging | Other | Approved | Renal Cell Carcinoma | TERMINATED | NCT00953446 |
| Trebananib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00853372 |
| Sunitinib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00853372 |
| Trebananib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00853372 |
| Sunitinib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00853372 |
| Trebananib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00853372 |
| Sunitinib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT00853372 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01832727 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01832727 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01832727 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01832727 |
| Placebo to Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763905 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763905 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763905 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763905 |
| Placebo to Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763905 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763905 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763905 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763905 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7 | WITHDRAWN | NCT03430687 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7 | WITHDRAWN | NCT03430687 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7 | WITHDRAWN | NCT03430687 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7 | WITHDRAWN | NCT03430687 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7 | WITHDRAWN | NCT03430687 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7 | WITHDRAWN | NCT03430687 |
| Denosumab | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00919711 |
| Actonel® | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00919711 |
| Denosumab | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00919711 |
| Actonel® | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00919711 |
| epoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00070382 |
| darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00070382 |
| epoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00070382 |
| darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00070382 |
| epoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00070382 |
| darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT00070382 |
| Blinatumomab | Other | Phase PHASE2 | High-risk Diffuse Large B-cell Lymphoma | TERMINATED | NCT03298412 |
| Blinatumomab | Other | Phase PHASE2 | High-risk Diffuse Large B-cell Lymphoma | TERMINATED | NCT03298412 |
| Dexamethasone | Other | Phase PHASE2 | High-risk Diffuse Large B-Cell Lymphoma | COMPLETED | NCT03023878 |
| Investigator's Choice Chemotherapy | Drug | Phase PHASE2 | High-risk Diffuse Large B-Cell Lymphoma | COMPLETED | NCT03023878 |
| Blinatumomab | Other | Phase PHASE2 | High-risk Diffuse Large B-Cell Lymphoma | COMPLETED | NCT03023878 |
| Dexamethasone | Other | Phase PHASE2 | High-risk Diffuse Large B-Cell Lymphoma | COMPLETED | NCT03023878 |
| Investigator's Choice Chemotherapy | Drug | Phase PHASE2 | High-risk Diffuse Large B-Cell Lymphoma | COMPLETED | NCT03023878 |
| Blinatumomab | Other | Phase PHASE2 | High-risk Diffuse Large B-Cell Lymphoma | COMPLETED | NCT03023878 |
| Etanercept | Other | Phase EARLY_PHASE1 | Fanconi Anemia | COMPLETED | NCT00965666 |
| Etanercept | Other | Phase EARLY_PHASE1 | Fanconi Anemia | COMPLETED | NCT00965666 |
| Rituximab (EU) | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02792699 |
| Rituximab (US) | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02792699 |
| ABP 798 | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02792699 |
| Rituximab (EU) | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02792699 |
| Rituximab (US) | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02792699 |
| ABP 798 | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02792699 |
| etanercept | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT00833729 |
| etanercept | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT00833729 |
| Trametinib | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Dabrafenib | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Talimogene Laherparep 100 Mil Pfu/Ml 1Ml | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Trametinib | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Dabrafenib | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Talimogene Laherparep 100 Mil Pfu/Ml 1Ml | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Trametinib | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Dabrafenib | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Talimogene Laherparep 100 Mil Pfu/Ml 1Ml | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil | Other | Phase PHASE1 | Melanoma | UNKNOWN | NCT03088176 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02335983 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02335983 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02335983 |
| Placebo Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02634580 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02634580 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02634580 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02634580 |
| romosozumab self-administration with AI/Pen | Other | Phase PHASE3 | Post-Menopausal Osteoporosis | COMPLETED | NCT03432533 |
| romosozumab HCP administration with PFS | Other | Phase PHASE3 | Post-Menopausal Osteoporosis | COMPLETED | NCT03432533 |
| romosozumab self-administration with AI/Pen | Other | Phase PHASE3 | Post-Menopausal Osteoporosis | COMPLETED | NCT03432533 |
| romosozumab HCP administration with PFS | Other | Phase PHASE3 | Post-Menopausal Osteoporosis | COMPLETED | NCT03432533 |
| evolocumab | Other | Preclinical | Hypercholesterolemia; ASCVD; Pregnancy | TERMINATED | NCT02957604 |
| evolocumab | Other | Preclinical | Hypercholesterolemia; ASCVD; Pregnancy | TERMINATED | NCT02957604 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Other | Phase PHASE2 | Bone Giant Cell Tumor | TERMINATED | NCT03620149 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Other | Phase PHASE2 | Bone Giant Cell Tumor | TERMINATED | NCT03620149 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Other | Phase PHASE2 | Bone Giant Cell Tumor | TERMINATED | NCT03620149 |
| Carfilzomib | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT03512353 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT03512353 |
| Carfilzomib | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT03512353 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT03512353 |
| Carfilzomib | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT03512353 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT03512353 |
| Blinatumomab | Other | Phase PHASE2 | B-Cell Non Hodgkin Lymphoma | COMPLETED | NCT02910063 |
| Blinatumomab | Other | Phase PHASE2 | B-Cell Non Hodgkin Lymphoma | COMPLETED | NCT02910063 |
| Blinatumomab | Other | Phase PHASE2 | B-Cell Non Hodgkin Lymphoma | COMPLETED | NCT02910063 |
| Pertuzumab | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Carboplatin | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Cyclophosphamide | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Epirubicin | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| nab-Paclitaxel | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Denosumab | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Pertuzumab | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Carboplatin | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Cyclophosphamide | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Epirubicin | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| nab-Paclitaxel | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Denosumab | Other | Phase PHASE2 | Breast Cancer Female NOS | COMPLETED | NCT02682693 |
| Liquid biopsy sampling | Other | Approved | Metastatic Colorectal Cancer | UNKNOWN | NCT04735900 |
| Liquid biopsy sampling | Other | Approved | Metastatic Colorectal Cancer | UNKNOWN | NCT04735900 |
| Zoledronic Acid | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT03087851 |
| Zoledronic Acid | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT03087851 |
| Zoledronic Acid | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT03087851 |
| Midazolam | Other | Phase PHASE1 | Advanced Non-Central Nervous System (CNS) Malignancies | TERMINATED | NCT02244112 |
| Oprozomib | Other | Phase PHASE1 | Advanced Non-Central Nervous System (CNS) Malignancies | TERMINATED | NCT02244112 |
| Midazolam | Other | Phase PHASE1 | Advanced Non-Central Nervous System (CNS) Malignancies | TERMINATED | NCT02244112 |
| Oprozomib | Other | Phase PHASE1 | Advanced Non-Central Nervous System (CNS) Malignancies | TERMINATED | NCT02244112 |
| Midazolam | Other | Phase PHASE1 | Advanced Non-Central Nervous System (CNS) Malignancies | TERMINATED | NCT02244112 |
| Oprozomib | Other | Phase PHASE1 | Advanced Non-Central Nervous System (CNS) Malignancies | TERMINATED | NCT02244112 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Solid Tumors | COMPLETED | NCT01327612 |
| Ganitumab | Other | Phase PHASE2 | Advanced Solid Tumors | COMPLETED | NCT01327612 |
| Conatumumab | Other | Phase PHASE2 | Advanced Solid Tumors | COMPLETED | NCT01327612 |
| Modified FOLFOX6 | Other | Phase PHASE2 | Advanced Solid Tumors | COMPLETED | NCT01327612 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Solid Tumors | COMPLETED | NCT01327612 |
| Ganitumab | Other | Phase PHASE2 | Advanced Solid Tumors | COMPLETED | NCT01327612 |
| Conatumumab | Other | Phase PHASE2 | Advanced Solid Tumors | COMPLETED | NCT01327612 |
| Modified FOLFOX6 | Other | Phase PHASE2 | Advanced Solid Tumors | COMPLETED | NCT01327612 |
| AMG 211 | Other | Phase PHASE1 | GI Adenocarcinoma | TERMINATED | NCT02291614 |
| AMG 211 | Other | Phase PHASE1 | GI Adenocarcinoma | TERMINATED | NCT02291614 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis RA | TERMINATED | NCT03410056 |
| Efavaleukin alfa | Other | Phase PHASE1 | Rheumatoid Arthritis RA | TERMINATED | NCT03410056 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis RA | TERMINATED | NCT03410056 |
| Efavaleukin alfa | Other | Phase PHASE1 | Rheumatoid Arthritis RA | TERMINATED | NCT03410056 |
| Apremilast XL | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02777554 |
| Apremilast IR | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02777554 |
| Apremilast XL | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02777554 |
| Apremilast IR | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02777554 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Other | Phase EARLY_PHASE1 | Breast Neoplasm Female | UNKNOWN | NCT03691311 |
| AMG 827 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01059448 |
| AMG 827 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01059448 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04448834 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04448834 |
| Blinatumomab for Injection | Other | Phase PHASE1 | Pediatric ALL, B Cell | UNKNOWN | NCT04604691 |
| Blinatumomab for Injection | Other | Phase PHASE1 | Pediatric ALL, B Cell | UNKNOWN | NCT04604691 |
| Placebo to Methotrexate | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02376790 |
| Placebo to Etanercept | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02376790 |
| Methotrexate | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02376790 |
| Etanercept | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02376790 |
| Placebo to Methotrexate | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02376790 |
| Placebo to Etanercept | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02376790 |
| Methotrexate | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02376790 |
| Etanercept | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT02376790 |
| Brodalumab | Other | Phase PHASE2 | Asthma | TERMINATED | NCT01902290 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT01902290 |
| Brodalumab | Other | Phase PHASE2 | Asthma | TERMINATED | NCT01902290 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT01902290 |
| Placebo | Other | Phase PHASE2 | Treatment for Prevention of Chronic Migraine | COMPLETED | NCT02066415 |
| Erenumab | Other | Phase PHASE2 | Treatment for Prevention of Chronic Migraine | COMPLETED | NCT02066415 |
| Placebo | Other | Phase PHASE2 | Treatment for Prevention of Chronic Migraine | COMPLETED | NCT02066415 |
| Erenumab | Other | Phase PHASE2 | Treatment for Prevention of Chronic Migraine | COMPLETED | NCT02066415 |
| Evolocumab | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT02275156 |
| AMG 228 | Other | Phase PHASE1 | Advanced Malignancy | TERMINATED | NCT02437916 |
| AMG 228 | Other | Phase PHASE1 | Advanced Malignancy | TERMINATED | NCT02437916 |
| Placebo | Other | Phase PHASE3 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT02392559 |
| Evolocumab | Other | Phase PHASE3 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT02392559 |
| Placebo | Other | Phase PHASE3 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT02392559 |
| Evolocumab | Other | Phase PHASE3 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT02392559 |
| Simvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Rosuvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Atorvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Placebo to Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Simvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Rosuvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Atorvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Placebo to Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763866 |
| Placebo to Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763827 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763827 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763827 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763827 |
| Placebo to Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763827 |
| Placebo to Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763827 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763827 |
| Evolocumab | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT01763827 |
| Low-density Lipoprotein Cholesterol (LDL-C) Apheresis | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02585895 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02585895 |
| Patient Experience | Other | Approved | Fracture of Femur | UNKNOWN | NCT05669040 |
| Training in the use of MyPlan Aplication | Other | Approved | Fracture of Femur | UNKNOWN | NCT05669040 |
| Pharmacological education | Other | Approved | Fracture of Femur | UNKNOWN | NCT05669040 |
| Patient Experience | Other | Approved | Fracture of Femur | UNKNOWN | NCT05669040 |
| Training in the use of MyPlan Aplication | Other | Approved | Fracture of Femur | UNKNOWN | NCT05669040 |
| Pharmacological education | Other | Approved | Fracture of Femur | UNKNOWN | NCT05669040 |
| Dexamthasone | Other | Phase PHASE3 | Acute Lymphoblastic Leukemia | COMPLETED | NCT03476239 |
| Blinatumomab | Other | Phase PHASE3 | Acute Lymphoblastic Leukemia | COMPLETED | NCT03476239 |
| Dexamthasone | Other | Phase PHASE3 | Acute Lymphoblastic Leukemia | COMPLETED | NCT03476239 |
| Blinatumomab | Other | Phase PHASE3 | Acute Lymphoblastic Leukemia | COMPLETED | NCT03476239 |
| Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Carfilzomib + Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Blinatumomab | Other | Phase PHASE1 | B-precursor Acute Lymphoblastic Leukemia | COMPLETED | NCT06649006 |
| Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Carfilzomib + Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Placebo | Other | Phase PHASE2 | HFrEF | COMPLETED | NCT04956809 |
| Dapagliflozin 10Mg Tab | Other | Phase PHASE2 | HFrEF | COMPLETED | NCT04956809 |
| Placebo | Other | Phase PHASE2 | HFrEF | COMPLETED | NCT04956809 |
| Dapagliflozin 10Mg Tab | Other | Phase PHASE2 | HFrEF | COMPLETED | NCT04956809 |
| Dexamethasone | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Daratumumab | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Lenalidomide | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Carfilzomib | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Dexamethasone | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Daratumumab | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Lenalidomide | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Carfilzomib | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Dexamethasone | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Daratumumab | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Lenalidomide | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Carfilzomib | Other | Phase PHASE2 | Smoldering Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03289299 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT03812224 |
| Erenumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT03812224 |
| Apremilast | Other | Preclinical | Plaque Psoriasis | COMPLETED | NCT04031027 |
| Dexamethasone Premedication | Drug | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04524455 |
| AMG 404 | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04524455 |
| Blinatumomab | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04524455 |
| Dexamethasone Premedication | Drug | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04524455 |
| AMG 404 | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04524455 |
| Blinatumomab | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04524455 |
| evolocumab | Other | Phase PHASE4 | Homozygous Familial Hypercholesterolemia HoFH | COMPLETED | NCT03403374 |
| Inebilzumab+VIB4920 | Other | Phase PHASE2 | Highly Sensitized Patients on Waiting List for Kidney Transplantation | WITHDRAWN | NCT04174677 |
| VIB4920 | Other | Phase PHASE2 | Highly Sensitized Patients on Waiting List for Kidney Transplantation | WITHDRAWN | NCT04174677 |
| Inebilizumab | Other | Phase PHASE2 | Highly Sensitized Patients on Waiting List for Kidney Transplantation | WITHDRAWN | NCT04174677 |
| Inebilzumab+VIB4920 | Other | Phase PHASE2 | Highly Sensitized Patients on Waiting List for Kidney Transplantation | WITHDRAWN | NCT04174677 |
| VIB4920 | Other | Phase PHASE2 | Highly Sensitized Patients on Waiting List for Kidney Transplantation | WITHDRAWN | NCT04174677 |
| Inebilizumab | Other | Phase PHASE2 | Highly Sensitized Patients on Waiting List for Kidney Transplantation | WITHDRAWN | NCT04174677 |
| NaPBA | Other | Phase PHASE4 | Urea Cycle Disorder | COMPLETED | NCT03335488 |
| RAVICTI | Other | Phase PHASE4 | Urea Cycle Disorder | COMPLETED | NCT03335488 |
| HPN-100 | Other | Phase PHASE4 | Urea Cycle Disorders | COMPLETED | NCT01257737 |
| Denosumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02613416 |
| Denosumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02613416 |
| Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Carfilzomib + Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Evolocumab | Other | Phase PHASE4 | Familial Hypercholesterolemia | TERMINATED | NCT03331666 |
| Evolocumab | Other | Phase PHASE4 | Familial Hypercholesterolemia | TERMINATED | NCT03331666 |
| Apremilast | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01634191 |
| Apremilast | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01634191 |
| Nivolumab | Other | Phase PHASE1 | Malignant Pleural Effusion | TERMINATED | NCT03597009 |
| Talimogene laherparepvec (TVEC) | Other | Phase PHASE1 | Malignant Pleural Effusion | TERMINATED | NCT03597009 |
| Apremilast | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01634178 |
| Apremilast | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01634178 |
| Melphalan IV | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Busulfan IV | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Melphalan IV | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Busulfan IV | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Melphalan IV | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Busulfan IV | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03795597 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01999335 |
| Cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT03299244 |
| Etelcalcetide | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT03299244 |
| Cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT03299244 |
| Etelcalcetide | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT03299244 |
| Standard care in a hip fracture | Other | Approved | Hip Fractures | UNKNOWN | NCT04859309 |
| ActiveHip+ mobile application | Other | Approved | Hip Fractures | UNKNOWN | NCT04859309 |
| Standard care in a hip fracture | Other | Approved | Hip Fractures | UNKNOWN | NCT04859309 |
| ActiveHip+ mobile application | Other | Approved | Hip Fractures | UNKNOWN | NCT04859309 |
| Apremilast Modified Release 14 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 13 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 12 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 11 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 9 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 8 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 6 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 5 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 4 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 3 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 2 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Modified Release 1 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Apremilast Immediate Release | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02236988 |
| Panitumumab | Other | Phase PHASE2 | Advanced Colorectal Cancer | TERMINATED | NCT03311750 |
| Rifampin IV Solution | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01561963 |
| Rifampin Oral Capsules | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01561963 |
| Apremilast | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01561963 |
| Rifampin IV Solution | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01561963 |
| Rifampin Oral Capsules | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01561963 |
| Apremilast | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01561963 |
| 5-FU | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Folinic acid | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| 5-FU | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Folinic acid | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| 5-FU | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Folinic acid | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT03142516 |
| Maintenance - CFZ-R(T)-D | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Consolidation - CFZ-TD-PACE | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic) | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Inter-Therapy - MEL-20+CFZ-TD-PACE (75%) | Drug | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic) | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Induction 1 - MEL-10+CFZ-TD-PACE | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| myPRS | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Maintenance - CFZ-R(T)-D | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Consolidation - CFZ-TD-PACE | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic) | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Inter-Therapy - MEL-20+CFZ-TD-PACE (75%) | Drug | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic) | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Induction 1 - MEL-10+CFZ-TD-PACE | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| myPRS | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02128230 |
| Placebo | Other | Phase PHASE3 | Postural Orthostatic Tachycardia Syndrome | COMPLETED | NCT03182725 |
| Ivabradine | Other | Phase PHASE3 | Postural Orthostatic Tachycardia Syndrome | COMPLETED | NCT03182725 |
| Placebo | Other | Phase PHASE3 | Postural Orthostatic Tachycardia Syndrome | COMPLETED | NCT03182725 |
| Ivabradine | Other | Phase PHASE3 | Postural Orthostatic Tachycardia Syndrome | COMPLETED | NCT03182725 |
| 5-FU | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT03751176 |
| Folinic acid | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT03751176 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT03751176 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT03751176 |
| 5-FU | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT03751176 |
| Folinic acid | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT03751176 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT03751176 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT03751176 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02802735 |
| Apremilast | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02802735 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02802735 |
| Apremilast | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02802735 |
| Placebo | Other | Phase PHASE2 | End Stage Renal Disease | TERMINATED | NCT00293202 |
| Etanercept | Other | Phase PHASE2 | End Stage Renal Disease | TERMINATED | NCT00293202 |
| Placebo | Other | Phase PHASE2 | End Stage Renal Disease | TERMINATED | NCT00293202 |
| Etanercept | Other | Phase PHASE2 | End Stage Renal Disease | TERMINATED | NCT00293202 |
| Placebo | Other | Phase PHASE3 | Behçet's Syndrome | COMPLETED | NCT02307513 |
| Apremilast | Other | Phase PHASE3 | Behçet's Syndrome | COMPLETED | NCT02307513 |
| Placebo | Other | Phase PHASE3 | Behçet's Syndrome | COMPLETED | NCT02307513 |
| Apremilast | Other | Phase PHASE3 | Behçet's Syndrome | COMPLETED | NCT02307513 |
| Placebo | Other | Phase PHASE3 | Behçet's Syndrome | COMPLETED | NCT02307513 |
| Apremilast | Other | Phase PHASE3 | Behçet's Syndrome | COMPLETED | NCT02307513 |
| Apremilast Oral Suspension | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02641353 |
| Apremilast Tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02641353 |
| Apremilast Oral Suspension | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02641353 |
| Apremilast Tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02641353 |
| Pembrolizumab | Other | Phase PHASE1 | Carcinoma of the Head and Neck | COMPLETED | NCT02626000 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Carcinoma of the Head and Neck | COMPLETED | NCT02626000 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT04746209 |
| Alpha/Beta T-cell and B-cell depleted HCT | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT04746209 |
| Placebo | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Cytarabine | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Methotrexate | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Dexamethasone | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Doxorubicin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Vincristine | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| AMG 531 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Placebo | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Cytarabine | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Methotrexate | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Dexamethasone | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Doxorubicin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Vincristine | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| Rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| AMG 531 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00299182 |
| darbepoetin alfa | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00153868 |
| darbepoetin alfa | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00153868 |
| darbepoetin alfa | Other | Phase PHASE4 | Anemia | COMPLETED | NCT00153868 |
| Denosumab | Other | Phase PHASE3 | Breast Cancer | TERMINATED | NCT01077154 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | TERMINATED | NCT01077154 |
| Information collection | Other | Preclinical | Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial | COMPLETED | NCT02173171 |
| Information collection | Other | Preclinical | Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial | COMPLETED | NCT02173171 |
| Placebo to Zoledronic Acid | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Standard Chemotherapy | Drug | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Placebo to Denosumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Zoledronic acid | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Denosumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Placebo to Zoledronic Acid | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Standard Chemotherapy | Drug | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Placebo to Denosumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Zoledronic acid | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| Denosumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01951586 |
| denosumab | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00095498 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00095498 |
| denosumab | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00095498 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00095498 |
| Doxorubicin hydrochloride | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00000626 |
| Bleomycin sulfate | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00000626 |
| Filgrastim | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00000626 |
| Dacarbazine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00000626 |
| Vinblastine sulfate | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00000626 |
| Ivabradine | Other | Phase PHASE4 | Heart Failure (HF) | COMPLETED | NCT03456856 |
| Ivabradine | Other | Phase PHASE4 | Heart Failure (HF) | COMPLETED | NCT03456856 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Other | Phase EARLY_PHASE1 | Breast Neoplasm Female | UNKNOWN | NCT03691311 |
| Vitamin D | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03520231 |
| Calcium | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03520231 |
| Cisplatin | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03520231 |
| Carboplatin | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03520231 |
| Gemcitabine | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03520231 |
| Denosumab Placebo | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03520231 |
| Denosumab | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03520231 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01199289 |
| AMG 827 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01199289 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01199289 |
| AMG 827 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01199289 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771030 |
| Brodalumab | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771030 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771030 |
| Brodalumab | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771030 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Unresected Stage IIIb to IVM1c Melanoma | COMPLETED | NCT02366195 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Unresected Stage IIIb to IVM1c Melanoma | COMPLETED | NCT02366195 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Unresected Stage IIIb to IVM1c Melanoma | COMPLETED | NCT02366195 |
| Apremilast | Other | Preclinical | Psoriasis | COMPLETED | NCT03757013 |
| folic acid | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Brodalumab | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| folic acid | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Brodalumab | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| folic acid | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| Brodalumab | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00950989 |
| AMG 337 | Other | Phase PHASE1 | Stomach Neoplasms | COMPLETED | NCT02096666 |
| AMG 337 | Other | Phase PHASE1 | Stomach Neoplasms | COMPLETED | NCT02096666 |
| Brodalumab | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT01199302 |
| Brodalumab | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT01199302 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT01150890 |
| Brodalumab | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT01150890 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT01150890 |
| Brodalumab | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT01150890 |
| OCT | Other | Phase PHASE4 | Psoriasis | UNKNOWN | NCT05135312 |
| Etanercept | Other | Phase PHASE4 | Psoriasis | UNKNOWN | NCT05135312 |
| Topical Therapy | Drug | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03930186 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03930186 |
| Topical Therapy | Drug | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03930186 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03930186 |
| Topical Therapy | Drug | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03930186 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03930186 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT03137537 |
| Ivabradine | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT03137537 |
| Placebo | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00594620 |
| Flav-ein capsules | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00594620 |
| Placebo | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00594620 |
| Flav-ein capsules | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00594620 |
| Placebo | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT03096288 |
| Evolocumab | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT03096288 |
| Placebo | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT03096288 |
| Evolocumab | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT03096288 |
| Placebo | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT03096288 |
| Evolocumab | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT03096288 |
| blinatumomab | Other | Phase PHASE2 | B-cell Adult Acute Lymphoblastic Leukemia | TERMINATED | NCT04044560 |
| blinatumomab | Other | Phase PHASE2 | B-cell Adult Acute Lymphoblastic Leukemia | TERMINATED | NCT04044560 |
| blinatumomab | Other | Phase PHASE2 | B-cell Adult Acute Lymphoblastic Leukemia | TERMINATED | NCT04044560 |
| AMG 827 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01059448 |
| AMG 827 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01059448 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | TERMINATED | NCT03809663 |
| Tezepelumab | Other | Phase PHASE2 | Atopic Dermatitis | TERMINATED | NCT03809663 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| rituximab | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| methylprednisolone | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| leucovorin calcium | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| cytarabine | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| methotrexate | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| dexamethasone | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| doxorubicin hydrochloride | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| vincristine sulfate | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| cyclophosphamide | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| carfilzomib | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| rituximab | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| methylprednisolone | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| leucovorin calcium | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| cytarabine | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| methotrexate | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| dexamethasone | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| doxorubicin hydrochloride | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| vincristine sulfate | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| cyclophosphamide | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| carfilzomib | Other | Phase PHASE1 | Contiguous Stage II Adult Lymphoblastic Lymphoma | COMPLETED | NCT02293109 |
| Placebo injection | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Placebo tablet | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Placebo injection | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Placebo tablet | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Placebo injection | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Placebo tablet | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Etanercept | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01690299 |
| Topical or Phototherapy Therapy | Drug | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01232283 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01232283 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01232283 |
| Topical treatments or phototherapy | Drug | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Topical treatments or phototherapy | Drug | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Topical treatments or phototherapy | Drug | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT01194219 |
| Leucovorin | Other | Phase PHASE2 | Rectal Cancer | COMPLETED | NCT03000374 |
| Oxaliplatin | Other | Phase PHASE2 | Rectal Cancer | COMPLETED | NCT03000374 |
| 5Fluorouracil | Other | Phase PHASE2 | Rectal Cancer | COMPLETED | NCT03000374 |
| Panitumumab | Other | Phase PHASE2 | Rectal Cancer | COMPLETED | NCT03000374 |
| Leucovorin | Other | Phase PHASE2 | Rectal Cancer | COMPLETED | NCT03000374 |
| Oxaliplatin | Other | Phase PHASE2 | Rectal Cancer | COMPLETED | NCT03000374 |
| 5Fluorouracil | Other | Phase PHASE2 | Rectal Cancer | COMPLETED | NCT03000374 |
| Panitumumab | Other | Phase PHASE2 | Rectal Cancer | COMPLETED | NCT03000374 |
| Etelcalcetide | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT03795558 |
| Etelcalcetide | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT03795558 |
| Etelcalcetide | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT03795558 |
| Evolocumab | Other | Phase PHASE4 | Carotid Artery Stenosis | UNKNOWN | NCT04539223 |
| Evolocumab | Other | Phase PHASE4 | Carotid Artery Stenosis | UNKNOWN | NCT04539223 |
| Statin therapy | Drug | Phase PHASE3 | Coronary Artery Disease (CAD) | COMPLETED | NCT03570697 |
| Placebo | Other | Phase PHASE3 | Coronary Artery Disease (CAD) | COMPLETED | NCT03570697 |
| Evolocumab | Other | Phase PHASE3 | Coronary Artery Disease (CAD) | COMPLETED | NCT03570697 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01307423 |
| Apremilast 30mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01307423 |
| Apremilast 20mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01307423 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01307423 |
| Apremilast 30mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01307423 |
| Apremilast 20mg | Other | Phase PHASE3 | Psoriatic Arthritis | COMPLETED | NCT01307423 |
| AMG 986 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT03318809 |
| AMG 986 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT03318809 |
| Romiplostim | Other | Phase PHASE3 | Immune Thrombocytopenia | COMPLETED | NCT02279173 |
| Romiplostim | Other | Phase PHASE3 | Immune Thrombocytopenia | COMPLETED | NCT02279173 |
| Zilucoplan placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Zilucoplan | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Lanadelumab placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Lanadelumab | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Apremilast placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Apremilast | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Standard of care | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Zilucoplan placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Zilucoplan | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Lanadelumab placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Lanadelumab | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Apremilast placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Apremilast | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Standard of care | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04590586 |
| Placebo | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | COMPLETED | NCT02833844 |
| Evolocumab | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | COMPLETED | NCT02833844 |
| Placebo | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | COMPLETED | NCT02833844 |
| Evolocumab | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | COMPLETED | NCT02833844 |
| Romosozumab | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT01833754 |
| Romosozumab | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT01833754 |
| Diet Only | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Diet Only | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Evolocumab | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01516879 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01464034 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01464034 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01464034 |
| Placebo IV | Other | Phase PHASE1 | Heart Failure | TERMINATED | NCT03276728 |
| Placebo PO | Other | Phase PHASE1 | Heart Failure | TERMINATED | NCT03276728 |
| AMG 986 PO | Other | Phase PHASE1 | Heart Failure | TERMINATED | NCT03276728 |
| AMG 986 IV | Other | Phase PHASE1 | Heart Failure | TERMINATED | NCT03276728 |
| Dexamethasone | Other | Preclinical | Multiple Myeloma in Relapse | UNKNOWN | NCT05495620 |
| Lenalidomide | Other | Preclinical | Multiple Myeloma in Relapse | UNKNOWN | NCT05495620 |
| Carfilzomib | Other | Preclinical | Multiple Myeloma in Relapse | UNKNOWN | NCT05495620 |
| Romiplostim | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | COMPLETED | NCT01516619 |
| Romiplostim | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | COMPLETED | NCT01516619 |
| Placebo | Other | Phase PHASE2 | Revision Surgery of Total Hip Arthroplasty | COMPLETED | NCT01358669 |
| Denosumab | Other | Phase PHASE2 | Revision Surgery of Total Hip Arthroplasty | COMPLETED | NCT01358669 |
| Placebo | Other | Phase PHASE2 | Revision Surgery of Total Hip Arthroplasty | COMPLETED | NCT01358669 |
| Denosumab | Other | Phase PHASE2 | Revision Surgery of Total Hip Arthroplasty | COMPLETED | NCT01358669 |
| Physician Survey | Other | Preclinical | Metastatic Colorectal Cancer | COMPLETED | NCT01652833 |
| Physician Survey | Other | Preclinical | Metastatic Colorectal Cancer | COMPLETED | NCT01652833 |
| Rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin | COMPLETED | NCT02747043 |
| ABP 798 | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin | COMPLETED | NCT02747043 |
| Rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin | COMPLETED | NCT02747043 |
| ABP 798 | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin | COMPLETED | NCT02747043 |
| Other | Other | Preclinical | Metastatic Colorectal Cancer | COMPLETED | NCT01791361 |
| Other | Other | Preclinical | Metastatic Colorectal Cancer | COMPLETED | NCT01791361 |
| pharmacological study | Other | Phase PHASE1 | Adult Acute Megakaryoblastic Leukemia (M7) | COMPLETED | NCT01555268 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Adult Acute Megakaryoblastic Leukemia (M7) | COMPLETED | NCT01555268 |
| cytarabine | Other | Phase PHASE1 | Adult Acute Megakaryoblastic Leukemia (M7) | COMPLETED | NCT01555268 |
| trebananib | Other | Phase PHASE1 | Adult Acute Megakaryoblastic Leukemia (M7) | COMPLETED | NCT01555268 |
| pharmacological study | Other | Phase PHASE1 | Adult Acute Megakaryoblastic Leukemia (M7) | COMPLETED | NCT01555268 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Adult Acute Megakaryoblastic Leukemia (M7) | COMPLETED | NCT01555268 |
| cytarabine | Other | Phase PHASE1 | Adult Acute Megakaryoblastic Leukemia (M7) | COMPLETED | NCT01555268 |
| trebananib | Other | Phase PHASE1 | Adult Acute Megakaryoblastic Leukemia (M7) | COMPLETED | NCT01555268 |
| Brodalumab | Other | Phase PHASE2 | Asthma | TERMINATED | NCT01902290 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT01902290 |
| Placebo | Other | Phase PHASE3 | Anemia in Chronic Kidney Disease Patients Not on Dialysis | COMPLETED | NCT01652872 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia in Chronic Kidney Disease Patients Not on Dialysis | COMPLETED | NCT01652872 |
| Placebo | Other | Phase PHASE3 | Anemia in Chronic Kidney Disease Patients Not on Dialysis | COMPLETED | NCT01652872 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia in Chronic Kidney Disease Patients Not on Dialysis | COMPLETED | NCT01652872 |
| Standard of care | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01439880 |
| Evolocumab | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01439880 |
| Standard of care | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01439880 |
| Evolocumab | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01439880 |
| Romiplostim | Other | Phase PHASE2 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT01143038 |
| Romiplostim | Other | Phase PHASE2 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT01143038 |
| Romosozumab | Other | Phase PHASE2 | Fracture Healing | COMPLETED | NCT01081678 |
| Placebo | Other | Phase PHASE2 | Fracture Healing | COMPLETED | NCT01081678 |
| Romosozumab | Other | Phase PHASE2 | Fracture Healing | COMPLETED | NCT01081678 |
| Placebo | Other | Phase PHASE2 | Fracture Healing | COMPLETED | NCT01081678 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01080391 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01080391 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01080391 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01080391 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01080391 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01080391 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT01001377 |
| Cetuximab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT01001377 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT01001377 |
| Cetuximab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT01001377 |
| Tezepelumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00972179 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00972179 |
| Tezepelumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00972179 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00972179 |
| romiplostim | Other | Phase PHASE4 | Thrombocytopenia | COMPLETED | NCT00907478 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT00757042 |
| Tezepelumab | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT00757042 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT00757042 |
| Tezepelumab | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT00757042 |
| application | Other | Preclinical | Secondary Prevention | UNKNOWN | NCT05542719 |
| application | Other | Preclinical | Secondary Prevention | UNKNOWN | NCT05542719 |
| application | Other | Preclinical | Secondary Prevention | UNKNOWN | NCT05542719 |
| Placebo | Other | Phase PHASE2 | Fracture Healing | COMPLETED | NCT00907296 |
| Romosozumab | Other | Phase PHASE2 | Fracture Healing | COMPLETED | NCT00907296 |
| Zoledronic acid | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Placebo to Denosumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Denosumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Romosozumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Teriparatide | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Alendronate | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Placebo to Romosozumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Zoledronic acid | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Placebo to Denosumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Denosumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Romosozumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Teriparatide | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Alendronate | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Placebo to Romosozumab | Other | Phase PHASE2 | Low Bone Mineral Density | COMPLETED | NCT00896532 |
| Denosumab | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00680992 |
| Placebo | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia | COMPLETED | NCT02729025 |
| Evolocumab | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia | COMPLETED | NCT02729025 |
| Placebo | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia | COMPLETED | NCT02729025 |
| Evolocumab | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia | COMPLETED | NCT02729025 |
| Placebo | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia | COMPLETED | NCT02729025 |
| Evolocumab | Other | Phase PHASE3 | Subjects With Hyperlipidemia, Dyslipidemia | COMPLETED | NCT02729025 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02412878 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02412878 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02412878 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02412878 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01677858 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01677858 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01677858 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01677858 |
| FOLFIRI | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT00339183 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT00339183 |
| FOLFIRI | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT00339183 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT00339183 |
| AMG 701 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | WITHDRAWN | NCT04998747 |
| Panitumumab | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00446446 |
| Panitumumab | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00446446 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05571163 |
| Erenumab | Other | Phase PHASE2 | Migraine | COMPLETED | NCT02630459 |
| Placebo | Other | Phase PHASE2 | Migraine | COMPLETED | NCT02630459 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02483585 |
| Erenumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02483585 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02483585 |
| Erenumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02483585 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02456740 |
| Erenumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02456740 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02456740 |
| Erenumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02456740 |
| Erenumab | Other | Phase PHASE2 | Treatment for Prevention of Chronic Migraine | COMPLETED | NCT02174861 |
| Erenumab | Other | Phase PHASE2 | Treatment for Prevention of Chronic Migraine | COMPLETED | NCT02174861 |
| Erenumab AI/Pen | Other | Phase PHASE2 | Migraine | COMPLETED | NCT01952574 |
| Erenumab PFS | Other | Phase PHASE2 | Migraine | COMPLETED | NCT01952574 |
| Placebo | Other | Phase PHASE2 | Migraine | COMPLETED | NCT01952574 |
| Erenumab | Other | Phase PHASE2 | Migraine | COMPLETED | NCT01952574 |
| Erenumab AI/Pen | Other | Phase PHASE2 | Migraine | COMPLETED | NCT01952574 |
| Erenumab PFS | Other | Phase PHASE2 | Migraine | COMPLETED | NCT01952574 |
| Placebo | Other | Phase PHASE2 | Migraine | COMPLETED | NCT01952574 |
| Erenumab | Other | Phase PHASE2 | Migraine | COMPLETED | NCT01952574 |
| Tezepelumab | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01405963 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01405963 |
| Tezepelumab | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01405963 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01405963 |
| Placebo | Other | Phase PHASE4 | Primary Hyperparathyroidism | TERMINATED | NCT01558115 |
| Denosumab | Other | Phase PHASE4 | Primary Hyperparathyroidism | TERMINATED | NCT01558115 |
| Placebo | Other | Phase PHASE4 | Primary Hyperparathyroidism | TERMINATED | NCT01558115 |
| Denosumab | Other | Phase PHASE4 | Primary Hyperparathyroidism | TERMINATED | NCT01558115 |
| AMG 510 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT05578859 |
| Evolocumab | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT02275156 |
| Not applicable - observational study | Other | Preclinical | Acute Lymphoblastic Leukemia | COMPLETED | NCT02003612 |
| Not applicable - observational study | Other | Preclinical | Acute Lymphoblastic Leukemia | COMPLETED | NCT02003612 |
| Placebo to Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| Ezetimibe | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| Placebo to Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| Ezetimibe | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| Placebo to Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| Ezetimibe | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375764 |
| AMG 337 | Other | Phase PHASE1 | Advanced Malignancy | COMPLETED | NCT01253707 |
| AMG 337 | Other | Phase PHASE1 | Advanced Malignancy | COMPLETED | NCT01253707 |
| Romiplostim | Other | Phase PHASE2 | MDS | COMPLETED | NCT00614523 |
| Placebo | Other | Phase PHASE2 | MDS | COMPLETED | NCT00614523 |
| Romiplostim | Other | Phase PHASE2 | MDS | COMPLETED | NCT00614523 |
| Placebo | Other | Phase PHASE2 | MDS | COMPLETED | NCT00614523 |
| Denosumab | Other | Phase PHASE3 | Osteopenia | COMPLETED | NCT00523341 |
| Denosumab | Other | Phase PHASE3 | Osteopenia | COMPLETED | NCT00523341 |
| FOLFOX regimen | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT00364013 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT00364013 |
| FOLFOX regimen | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT00364013 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | COMPLETED | NCT00364013 |
| Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00345839 |
| Cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00345839 |
| Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00345839 |
| Cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00345839 |
| Placebo | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00345839 |
| Cinacalcet | Other | Phase PHASE3 | Secondary Hyperparathyroidism | COMPLETED | NCT00345839 |
| Zoledronic Acid | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00330759 |
| Denosumab | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00330759 |
| Zoledronic Acid | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00330759 |
| Denosumab | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00330759 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00113763 |
| Best supportive care | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00113763 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00113763 |
| Best supportive care | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT00113763 |
| AMG 531 | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00102323 |
| Placebo | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00102323 |
| AMG 531 | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00102323 |
| Placebo | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00102323 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00089635 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00089635 |
| Panitumumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00089635 |
| Panitumumab + Chemotherapy | Drug | Preclinical | Wild-type RAS Metastatic Colorectal Cancer | COMPLETED | NCT01732783 |
| Panitumumab + Chemotherapy | Drug | Preclinical | Wild-type RAS Metastatic Colorectal Cancer | COMPLETED | NCT01732783 |
| Panitumumab + Chemotherapy | Drug | Preclinical | Wild-type RAS Metastatic Colorectal Cancer | COMPLETED | NCT01732783 |
| oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01416428 |
| oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01416428 |
| Placebo to Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375777 |
| Ezetimibe | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375777 |
| Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01375777 |
| Denosumab (for the open-label treatment phase) | Drug | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Placebo to zoledronic acid | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Placebo to Denosumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Zoledronic acid | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Denosumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Denosumab (for the open-label treatment phase) | Drug | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Placebo to zoledronic acid | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Placebo to Denosumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Zoledronic acid | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| Denosumab | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01345019 |
| AMG 386 10 mg/kg, Capecitabine and Lapatinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00807859 |
| AMG 386 10 mgkg, Paclitaxel and Trastuzumab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00807859 |
| AMG 386 30 mg/kg, Capecitabine and Lapatinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00807859 |
| AMG 386 30 mg/kg, Paclitaxel and Trastuzumab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00807859 |
| AMG 386 10 mg/kg, Capecitabine and Lapatinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00807859 |
| AMG 386 10 mgkg, Paclitaxel and Trastuzumab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00807859 |
| AMG 386 30 mg/kg, Capecitabine and Lapatinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00807859 |
| AMG 386 30 mg/kg, Paclitaxel and Trastuzumab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00807859 |
| AMG 531 | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00603642 |
| Placebo | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00603642 |
| AMG 531 | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00603642 |
| Placebo | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00603642 |
| Romiplostim | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00415532 |
| Medical Standard of Care for ITP | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00415532 |
| Romiplostim | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00415532 |
| Medical Standard of Care for ITP | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00415532 |
| Romiplostim | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00415532 |
| Medical Standard of Care for ITP | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00415532 |
| Calcium/Vitamin D | Other | Phase PHASE2 | GCT | COMPLETED | NCT00396279 |
| Denosumab | Other | Phase PHASE2 | GCT | COMPLETED | NCT00396279 |
| Calcium/Vitamin D | Other | Phase PHASE2 | GCT | COMPLETED | NCT00396279 |
| Denosumab | Other | Phase PHASE2 | GCT | COMPLETED | NCT00396279 |
| Placebo | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00358215 |
| Darbepoetin alfa | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00358215 |
| Zoledronic Acid | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00321464 |
| Denosumab | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00321464 |
| Zoledronic Acid | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00321464 |
| Denosumab | Other | Phase PHASE3 | Bone Metastases | COMPLETED | NCT00321464 |
| Placebo | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00102336 |
| AMG 531 | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00102336 |
| darbepoetin alfa | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00093015 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00093015 |
| darbepoetin alfa | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00093015 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00093015 |
| darbepoetin alfa | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00093015 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | COMPLETED | NCT00093015 |
| Denosumab | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00089791 |
| placebo | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00089791 |
| Denosumab | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00089791 |
| placebo | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00089791 |
| AMG 162 - Prolia | Other | Preclinical | Post Menopausal Osteoporosis | COMPLETED | NCT02347865 |
| AMG 162 - Prolia | Other | Preclinical | Post Menopausal Osteoporosis | COMPLETED | NCT02347865 |
| Placebo | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT02263508 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT02263508 |
| Talimogene Laherparepvec | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT02263508 |
| Placebo | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT02263508 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT02263508 |
| Talimogene Laherparepvec | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT02263508 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Oprozomib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01881789 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01568866 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01568866 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01568866 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01568866 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01568866 |
| Carfilzomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01568866 |
| Romiplostim | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00508820 |
| Romiplostim | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00508820 |
| Placebo to Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01380730 |
| Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01380730 |
| Placebo to Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01380730 |
| Evolocumab | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01380730 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia, Familial | COMPLETED | NCT01375751 |
| Evolocumab | Other | Phase PHASE2 | Hypercholesterolemia, Familial | COMPLETED | NCT01375751 |
| Teriparatide | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01796301 |
| Romozosumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01796301 |
| Teriparatide | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01796301 |
| Romozosumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01796301 |
| Teriparatide | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01796301 |
| Romozosumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01796301 |
| Bone Pain Education DVD | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01752907 |
| General Education DVD | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01752907 |
| Bone Pain Education DVD | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01752907 |
| General Education DVD | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01752907 |
| Placebo | Other | Phase PHASE3 | Anemia | TERMINATED | NCT00436748 |
| Darbepoetin Alfa | Other | Phase PHASE3 | Anemia | TERMINATED | NCT00436748 |
| Evolocumab AI/pen | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT01879319 |
| Evolocumab AMD | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT01879319 |
| Evolocumab AI/pen | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT01879319 |
| Evolocumab AMD | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT01879319 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00858364 |
| Darbepoetin alfa | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | TERMINATED | NCT00858364 |
| Care As Usual | Other | Preclinical | Postmenopausal Osteoporosis | COMPLETED | NCT03970902 |
| Integrated Osteoporosis Care | Other | Preclinical | Postmenopausal Osteoporosis | COMPLETED | NCT03970902 |
| Care As Usual | Other | Preclinical | Postmenopausal Osteoporosis | COMPLETED | NCT03970902 |
| Integrated Osteoporosis Care | Other | Preclinical | Postmenopausal Osteoporosis | COMPLETED | NCT03970902 |
| Care As Usual | Other | Preclinical | Postmenopausal Osteoporosis | COMPLETED | NCT03970902 |
| Integrated Osteoporosis Care | Other | Preclinical | Postmenopausal Osteoporosis | COMPLETED | NCT03970902 |
| mFOLFOX6 | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00819780 |
| Bevacizumab | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00819780 |
| Panitumumab | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00819780 |
| mFOLFOX6 | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00819780 |
| Bevacizumab | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00819780 |
| Panitumumab | Other | Phase PHASE2 | Colon Cancer | COMPLETED | NCT00819780 |
| Alternative osteoporosis medications | Drug | Phase PHASE3 | Osteogenesis Imperfecta (OI) | TERMINATED | NCT03638128 |
| Denosumab | Other | Phase PHASE3 | Osteogenesis Imperfecta (OI) | TERMINATED | NCT03638128 |
| Alternative osteoporosis medications | Drug | Phase PHASE3 | Osteogenesis Imperfecta (OI) | TERMINATED | NCT03638128 |
| Denosumab | Other | Phase PHASE3 | Osteogenesis Imperfecta (OI) | TERMINATED | NCT03638128 |
| Denosumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | TERMINATED | NCT02352753 |
| Denosumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | TERMINATED | NCT02352753 |
| Folic acid (non-investigational product) | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| Placebo for methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| Placebo for etanercept subcutaneous injection | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| Oral methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| etanercept pre-filled syringe subcutaneous injection | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| Folic acid (non-investigational product) | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| Placebo for methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| Placebo for etanercept subcutaneous injection | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| Oral methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| etanercept pre-filled syringe subcutaneous injection | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02373813 |
| Hematopoietic Cell Transplantation | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02807883 |
| Blinatumomab | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02807883 |
| Hematopoietic Cell Transplantation | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02807883 |
| Blinatumomab | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02807883 |
| Phase I: Fumaric acid esters. Phase II: Apremilast | Other | Preclinical | Psoriasis | COMPLETED | NCT02954081 |
| Phase I: Fumaric acid esters. Phase II: Apremilast | Other | Preclinical | Psoriasis | COMPLETED | NCT02954081 |
| Nivolumab | Other | Phase PHASE2 | Hematopoietic/Lymphoid Cancer | TERMINATED | NCT03121534 |
| Ibrutinib | Other | Phase PHASE2 | Hematopoietic/Lymphoid Cancer | TERMINATED | NCT03121534 |
| Dexamethasone | Other | Phase PHASE2 | Hematopoietic/Lymphoid Cancer | TERMINATED | NCT03121534 |
| Blinatumomab | Other | Phase PHASE2 | Hematopoietic/Lymphoid Cancer | TERMINATED | NCT03121534 |
| Evolocumab | Other | Phase PHASE4 | Atherosclerotic Vascular Disease | COMPLETED | NCT03829046 |
| Placebo | Other | Phase PHASE4 | Atherosclerotic Vascular Disease | COMPLETED | NCT03829046 |
| Evolocumab | Other | Phase PHASE4 | Atherosclerotic Vascular Disease | COMPLETED | NCT03829046 |
| Placebo | Other | Phase PHASE4 | Atherosclerotic Vascular Disease | COMPLETED | NCT03829046 |
| Repatha | Other | Phase PHASE4 | Ischemic Stroke | TERMINATED | NCT04573777 |
| placebo | Other | Phase PHASE3 | Primary Hypercholesterolemia | TERMINATED | NCT03433755 |
| evolocumab | Other | Phase PHASE3 | Primary Hypercholesterolemia | TERMINATED | NCT03433755 |
| Evolocumab | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT02867813 |
| Evolocumab | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT02867813 |
| Azacitidine | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03465540 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03465540 |
| AMG 397 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03465540 |
| Azacitidine | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03465540 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03465540 |
| AMG 397 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03465540 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes | COMPLETED | NCT00730392 |
| Etanercept | Other | Phase PHASE1 | Type 1 Diabetes | COMPLETED | NCT00730392 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes | COMPLETED | NCT00730392 |
| Etanercept | Other | Phase PHASE1 | Type 1 Diabetes | COMPLETED | NCT00730392 |
| Placebo | Other | Phase PHASE2 | Mucocutaneous Lymph Node Syndrome | COMPLETED | NCT00841789 |
| Etanercept | Other | Phase PHASE2 | Mucocutaneous Lymph Node Syndrome | COMPLETED | NCT00841789 |
| Placebo | Other | Phase PHASE2 | Mucocutaneous Lymph Node Syndrome | COMPLETED | NCT00841789 |
| Etanercept | Other | Phase PHASE2 | Mucocutaneous Lymph Node Syndrome | COMPLETED | NCT00841789 |
| Nab paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Gemcitabine (GEM) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Leucovorin (LV) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| 5 Fluorouracil (5FU) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Liposomal Irinotecan (nal-IRI) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Sotorasib | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Nab paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Gemcitabine (GEM) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Leucovorin (LV) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| 5 Fluorouracil (5FU) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Liposomal Irinotecan (nal-IRI) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Sotorasib | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Nab paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Gemcitabine (GEM) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Leucovorin (LV) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| 5 Fluorouracil (5FU) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Liposomal Irinotecan (nal-IRI) | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Sotorasib | Other | Phase PHASE1 | Pancreatic Cancer | WITHDRAWN | NCT05251038 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03818607 |
| ABP 959 | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03818607 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03818607 |
| ABP 959 | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03818607 |
| Placebo | Other | Phase PHASE1 | Chronic Graft-versus-host Disease (cGVHD) | COMPLETED | NCT05873907 |
| AMG 592 | Other | Phase PHASE1 | Chronic Graft-versus-host Disease (cGVHD) | COMPLETED | NCT05873907 |
| Placebo | Other | Phase PHASE1 | Chronic Graft-versus-host Disease (cGVHD) | COMPLETED | NCT05873907 |
| AMG 592 | Other | Phase PHASE1 | Chronic Graft-versus-host Disease (cGVHD) | COMPLETED | NCT05873907 |
| Romiplostim | Other | Phase PHASE2 | First Progression of MGMT Promoter-methylated Glioblastoma | WITHDRAWN | NCT04933942 |
| Lomustine | Other | Phase PHASE2 | First Progression of MGMT Promoter-methylated Glioblastoma | WITHDRAWN | NCT04933942 |
| Blinatumomab | Other | Phase PHASE2 | Richter Syndrome | COMPLETED | NCT03931642 |
| RCHOP | Other | Phase PHASE2 | Richter Syndrome | COMPLETED | NCT03931642 |
| Blinatumomab | Other | Phase PHASE2 | Richter Syndrome | COMPLETED | NCT03931642 |
| RCHOP | Other | Phase PHASE2 | Richter Syndrome | COMPLETED | NCT03931642 |
| Placebo | Other | Phase PHASE1 | Chronic Graft-versus-Host Disease (cGVHD) | COMPLETED | NCT05885451 |
| AMG 592 | Other | Phase PHASE1 | Chronic Graft-versus-Host Disease (cGVHD) | COMPLETED | NCT05885451 |
| Placebo | Other | Phase PHASE1 | Chronic Graft-versus-Host Disease (cGVHD) | COMPLETED | NCT05885451 |
| AMG 592 | Other | Phase PHASE1 | Chronic Graft-versus-Host Disease (cGVHD) | COMPLETED | NCT05885451 |
| Placebo-Apremilast | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Placebo | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Apremilast | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Placebo-Apremilast | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Placebo | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Apremilast | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Placebo-Apremilast | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Placebo | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Apremilast | Other | Phase PHASE4 | Parapsoriasis | COMPLETED | NCT02425826 |
| Immediate surgical resection of melanoma lesion(s) | Other | Phase PHASE2 | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma | COMPLETED | NCT02211131 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma | COMPLETED | NCT02211131 |
| Immediate surgical resection of melanoma lesion(s) | Other | Phase PHASE2 | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma | COMPLETED | NCT02211131 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma | COMPLETED | NCT02211131 |
| Immediate surgical resection of melanoma lesion(s) | Other | Phase PHASE2 | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma | COMPLETED | NCT02211131 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma | COMPLETED | NCT02211131 |
| AMG 553 | Other | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia | WITHDRAWN | NCT03904069 |
| AMG 553 | Other | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia | WITHDRAWN | NCT03904069 |
| Panitumumab (Within re-induction phase) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01991873 |
| mFOLFOX6 (Within re-induction phase) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01991873 |
| Panitumumab (Within maintenance phase) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01991873 |
| Maintenance Chemotherapy | Drug | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01991873 |
| Panitumumab (Within re-induction phase) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01991873 |
| mFOLFOX6 (Within re-induction phase) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01991873 |
| Panitumumab (Within maintenance phase) | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01991873 |
| Maintenance Chemotherapy | Drug | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01991873 |
| FOLFOXIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01328171 |
| FOLFOXIRI + Panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01328171 |
| FOLFOXIRI | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01328171 |
| FOLFOXIRI + Panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01328171 |
| ABP 501-LCF | Other | Phase PHASE1 | Adalimumab | COMPLETED | NCT05909852 |
| ABP 501-HCF | Other | Phase PHASE1 | Adalimumab | COMPLETED | NCT05909852 |
| ABP 501-LCF | Other | Phase PHASE1 | Adalimumab | COMPLETED | NCT05909852 |
| ABP 501-HCF | Other | Phase PHASE1 | Adalimumab | COMPLETED | NCT05909852 |
| FPA144 | Other | Phase PHASE1 | Gastric or Gastroesophageal Cancer | COMPLETED | NCT05913115 |
| FPA144 | Other | Phase PHASE1 | Gastric or Gastroesophageal Cancer | COMPLETED | NCT05913115 |
| Romiplostim | Other | Phase PHASE1 | Thrombocytopenic Purpura | COMPLETED | NCT00117143 |
| Romiplostim | Other | Phase PHASE1 | Thrombocytopenic Purpura | COMPLETED | NCT00117143 |
| Carboplatin | Other | Phase PHASE3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04466917 |
| Paclitaxel | Other | Phase PHASE3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04466917 |
| Bevacizumab | Other | Phase PHASE3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04466917 |
| ABP 215 | Other | Phase PHASE3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04466917 |
| Carboplatin | Other | Phase PHASE3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04466917 |
| Paclitaxel | Other | Phase PHASE3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04466917 |
| Bevacizumab | Other | Phase PHASE3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04466917 |
| ABP 215 | Other | Phase PHASE3 | Metastatic Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04466917 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03451422 |
| Efavaleukin Alfa | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03451422 |
| Statins (Cardiovascular Agents) | Other | Phase PHASE4 | Hyperlipidemias | UNKNOWN | NCT04608474 |
| Evolocumab | Other | Phase PHASE4 | Hyperlipidemias | UNKNOWN | NCT04608474 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT04169347 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer Metastatic | UNKNOWN | NCT04169347 |
| filgrastim, TBO-filgrastim or pegfilgrastim | Other | Preclinical | Breast Cancer | COMPLETED | NCT02921191 |
| Standard of Care | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00556374 |
| Zoledronic Acid | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00556374 |
| Non-steroidal aromatase inhibitor therapy | Drug | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00556374 |
| Denosumab | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00556374 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00556374 |
| Standard of Care | Other | Approved | Heart Failure | TERMINATED | NCT04292275 |
| Biobeat Wrist Watch | Other | Approved | Heart Failure | TERMINATED | NCT04292275 |
| Placebo | Other | Phase PHASE1 | Vasculitis | COMPLETED | NCT05984251 |
| CCX168 | Other | Phase PHASE1 | Vasculitis | COMPLETED | NCT05984251 |
| Placebo | Other | Phase PHASE1 | Vasculitis | COMPLETED | NCT05984251 |
| CCX168 | Other | Phase PHASE1 | Vasculitis | COMPLETED | NCT05984251 |
| Placebo | Other | Phase PHASE1 | Vasculitis | COMPLETED | NCT05984251 |
| CCX168 | Other | Phase PHASE1 | Vasculitis | COMPLETED | NCT05984251 |
| Talimogene laherparepvec | Other | Phase PHASE1 | Unresectable Stage IIIB-IV Malignant Melanoma | COMPLETED | NCT03064763 |
| Talimogene laherparepvec | Other | Phase PHASE1 | Unresectable Stage IIIB-IV Malignant Melanoma | COMPLETED | NCT03064763 |
| Placebo for moxifloxacin | Other | Phase PHASE1 | Electrocardiography | COMPLETED | NCT05988034 |
| Placebo for avacopan | Other | Phase PHASE1 | Electrocardiography | COMPLETED | NCT05988034 |
| Moxifloxacin | Other | Phase PHASE1 | Electrocardiography | COMPLETED | NCT05988034 |
| Avacopan | Other | Phase PHASE1 | Electrocardiography | COMPLETED | NCT05988034 |
| CCX168 | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT05988021 |
| CCX168 | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT05988021 |
| Placebo | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT05988008 |
| CCX168 | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT05988008 |
| Placebo | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT05988008 |
| CCX168 | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT05988008 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05045638 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05045638 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05045638 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05045638 |
| Adalimumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995691 |
| ABP 501 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995691 |
| Adalimumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995691 |
| ABP 501 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995691 |
| Placebo injections | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00585650 |
| Etanercept | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00585650 |
| Placebo injections | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00585650 |
| Etanercept | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00585650 |
| [14C]CCX168 | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004960 |
| [14C]CCX168 | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004960 |
| Rifampicin | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| Itraconazole | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| Celecoxib | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| Midazolam | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| CCX168 | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| Rifampicin | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| Itraconazole | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| Celecoxib | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| Midazolam | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| CCX168 | Other | Phase PHASE1 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | COMPLETED | NCT06004947 |
| Avacopan | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06004934 |
| Avacopan | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06004934 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02597062 |
| Cyclophosphamide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02597062 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02597062 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02597062 |
| Cyclophosphamide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02597062 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02597062 |
| Placebo | Other | Phase PHASE1 | Postmenopausal | COMPLETED | NCT01825785 |
| Romosozumab | Other | Phase PHASE1 | Postmenopausal | COMPLETED | NCT01825785 |
| Placebo | Other | Phase PHASE1 | Postmenopausal | COMPLETED | NCT01825785 |
| Romosozumab | Other | Phase PHASE1 | Postmenopausal | COMPLETED | NCT01825785 |
| Emerfetamab | Other | Phase EARLY_PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT03224819 |
| Emerfetamab | Other | Phase EARLY_PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT03224819 |
| Liraglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03757130 |
| Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03757130 |
| AMG 598 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03757130 |
| Liraglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03757130 |
| Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03757130 |
| AMG 598 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03757130 |
| T-Vec | Other | Phase PHASE2 | Melanoma | SUSPENDED | NCT04427306 |
| T-Vec | Other | Phase PHASE2 | Melanoma | SUSPENDED | NCT04427306 |
| T-Vec | Other | Phase PHASE2 | Melanoma | SUSPENDED | NCT04427306 |
| carfilzomib | Other | Phase PHASE1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | COMPLETED | NCT01336920 |
| carfilzomib | Other | Phase PHASE1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | COMPLETED | NCT01336920 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05048784 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05048784 |
| Global gene expression profiles obtained from synovial biopsies. | Other | Approved | Psoriatic Arthritis | COMPLETED | NCT04645420 |
| Global gene expression profiles obtained from synovial biopsies. | Other | Approved | Psoriatic Arthritis | COMPLETED | NCT04645420 |
| Standard of care | Other | Preclinical | Psoriatic Arthritis | COMPLETED | NCT03620188 |
| Standard of care | Other | Preclinical | Psoriatic Arthritis | COMPLETED | NCT03620188 |
| Standard of care | Other | Preclinical | Psoriatic Arthritis | COMPLETED | NCT03620188 |
| AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P) | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00591851 |
| AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P) | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00591851 |
| AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P) | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00591851 |
| Cyclosporine A | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Antithymocyte Globulin | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Romiplostim | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Cyclosporine A | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Antithymocyte Globulin | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Romiplostim | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Cyclosporine A | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Antithymocyte Globulin | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Romiplostim | Other | Phase PHASE2 | Severe Aplastic Anemia (SAA) | WITHDRAWN | NCT05323617 |
| Etanercept | Other | Preclinical | Pregnancy | COMPLETED | NCT00116272 |
| Etanercept | Other | Preclinical | Pregnancy | COMPLETED | NCT00116272 |
| MVASI | Other | Phase PHASE1 | Non Small Cell Lung Cancer | WITHDRAWN | NCT05180422 |
| AMG 510 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | WITHDRAWN | NCT05180422 |
| MVASI | Other | Phase PHASE1 | Non Small Cell Lung Cancer | WITHDRAWN | NCT05180422 |
| AMG 510 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | WITHDRAWN | NCT05180422 |
| Triamcinolone Acetonide | Other | Phase PHASE4 | Gout Attack | TERMINATED | NCT03636373 |
| Etanercept | Other | Phase PHASE4 | Gout Attack | TERMINATED | NCT03636373 |
| Triamcinolone Acetonide | Other | Phase PHASE4 | Gout Attack | TERMINATED | NCT03636373 |
| Etanercept | Other | Phase PHASE4 | Gout Attack | TERMINATED | NCT03636373 |
| Placebo | Other | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT04857606 |
| AMG 609 | Other | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT04857606 |
| Temporary Stopping | Other | Phase PHASE1 | Non-small Cell Lung Cancer Metastatic | RECRUITING | NCT06127940 |
| Stereotactic body radiation therapy (SBRT) | Drug | Phase PHASE1 | Non-small Cell Lung Cancer Metastatic | RECRUITING | NCT06127940 |
| Evolocumab | Other | Phase EARLY_PHASE1 | Acute Metabolic Effects of Evolocumab and Atorvastatin | NOT_YET_RECRUITING | NCT06140095 |
| Evolocumab | Other | Phase EARLY_PHASE1 | Acute Metabolic Effects of Evolocumab and Atorvastatin | UNKNOWN | NCT06140095 |
| Efavaleukin Alfa | Other | Phase PHASE1 | Chronic Graft Versus Host Disease cGVHD | TERMINATED | NCT03422627 |
| KRdD only | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03224507 |
| KRdD followed by auto-HCT | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03224507 |
| Peripheral blood draws | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Melphalan | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Cytarabine | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Etoposide | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Carmustine | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Autologous stem cell transplant | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Blinatumomab | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Peripheral blood draws | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Melphalan | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Cytarabine | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Etoposide | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Carmustine | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Autologous stem cell transplant | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Blinatumomab | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT03072771 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05327491 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05327491 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05327491 |
| ABP 654 | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT04761627 |
| Ustekinumab | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT04761627 |
| ABP 654 | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT04761627 |
| Ustekinumab | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT04761627 |
| Blinatumomab | Other | Phase PHASE2 | ALL, Childhood | TERMINATED | NCT04785547 |
| Simvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06207682 |
| Avacopan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06207682 |
| Simvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06207682 |
| Avacopan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06207682 |
| Simvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06207682 |
| Avacopan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06207682 |
| Sotorasib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05497557 |
| Omeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05497557 |
| Sotorasib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05497557 |
| Omeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05497557 |
| Sotorasib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05497557 |
| Omeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05497557 |
| AMG 910 | Other | Phase PHASE1 | Gastric and Gastroesophageal Junction Adenocarcinoma | TERMINATED | NCT04260191 |
| AMG 910 | Other | Phase PHASE1 | Gastric and Gastroesophageal Junction Adenocarcinoma | TERMINATED | NCT04260191 |
| AMG 224 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02561962 |
| AMG 224 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02561962 |
| AMG 224 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02561962 |
| blinatumomab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT02961881 |
| blinatumomab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT02961881 |
| ABP 501 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT05073315 |
| Adalimumab | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT05073315 |
| ABP 501 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT05073315 |
| Adalimumab | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT05073315 |
| ABP 501 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT05073315 |
| Adalimumab | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT05073315 |
| Romiplostim | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT04478123 |
| Romiplostim | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT04478123 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Advanced Non CNS Tumors | COMPLETED | NCT02756845 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Advanced Non CNS Tumors | COMPLETED | NCT02756845 |
| Apremilast | Other | Preclinical | Plaque Psoriasis | COMPLETED | NCT04031027 |
| Patient questionnaire | Other | Preclinical | Psoriasis | COMPLETED | NCT02740218 |
| Patient questionnaire | Other | Preclinical | Psoriasis | COMPLETED | NCT02740218 |
| Standard of Care Chemotherapy | Drug | Phase PHASE3 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | TERMINATED | NCT02013167 |
| Blinatumomab | Other | Phase PHASE3 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | TERMINATED | NCT02013167 |
| Pembrolizumab | Other | Phase PHASE1 | Relapsed or Refractory Acute Myeloid Leukemia | TERMINATED | NCT04478695 |
| AMG 330 | Other | Phase PHASE1 | Relapsed or Refractory Acute Myeloid Leukemia | TERMINATED | NCT04478695 |
| Pembrolizumab | Other | Phase PHASE1 | Relapsed or Refractory Acute Myeloid Leukemia | TERMINATED | NCT04478695 |
| AMG 330 | Other | Phase PHASE1 | Relapsed or Refractory Acute Myeloid Leukemia | TERMINATED | NCT04478695 |
| Blinatumomab in combination with donor lymphocyte infusion | Other | Phase PHASE2 | B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation | WITHDRAWN | NCT03982992 |
| Blinatumomab in combination with donor lymphocyte infusion | Other | Phase PHASE2 | B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation | WITHDRAWN | NCT03982992 |
| Denosumab | Other | Phase PHASE2 | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | COMPLETED | NCT03925532 |
| Denosumab | Other | Phase PHASE2 | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | COMPLETED | NCT03925532 |
| Placebo | Other | Phase PHASE2 | Trigeminal Neuropathy | TERMINATED | NCT05142228 |
| Erenumab-Aooe | Other | Phase PHASE2 | Trigeminal Neuropathy | TERMINATED | NCT05142228 |
| Placebo | Other | Phase PHASE2 | Trigeminal Neuropathy | TERMINATED | NCT05142228 |
| Erenumab-Aooe | Other | Phase PHASE2 | Trigeminal Neuropathy | TERMINATED | NCT05142228 |
| AMG 562 | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma(DLBCL) | TERMINATED | NCT03571828 |
| AMG 562 | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma(DLBCL) | TERMINATED | NCT03571828 |
| Efavaleukin alfa | Other | Phase PHASE1 | Inflammatory Diseases | COMPLETED | NCT04987333 |
| Efavaleukin alfa | Other | Phase PHASE1 | Inflammatory Diseases | COMPLETED | NCT04987333 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02891811 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02891811 |
| Thalidomide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02891811 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02891811 |
| Placebo | Other | Phase PHASE2 | Temporomandibular Disorders | TERMINATED | NCT05162027 |
| Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe | Other | Phase PHASE2 | Temporomandibular Disorders | TERMINATED | NCT05162027 |
| Placebo | Other | Phase PHASE2 | Temporomandibular Disorders | TERMINATED | NCT05162027 |
| Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe | Other | Phase PHASE2 | Temporomandibular Disorders | TERMINATED | NCT05162027 |
| N/A - observational study. | Other | Preclinical | Cardiovascular Diseases | TERMINATED | NCT04128475 |
| N/A - observational study. | Other | Preclinical | Cardiovascular Diseases | TERMINATED | NCT04128475 |
| N/A - observational study. | Other | Preclinical | Cardiovascular Diseases | TERMINATED | NCT04128475 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | WITHDRAWN | NCT06061523 |
| Sotorasib | Other | Phase PHASE1 | Healthy Participants | WITHDRAWN | NCT06061523 |
| Vitamin D | Other | Phase PHASE1 | Osteogenesis Imperfecta | COMPLETED | NCT04545554 |
| Calcium | Other | Phase PHASE1 | Osteogenesis Imperfecta | COMPLETED | NCT04545554 |
| Romosozumab | Other | Phase PHASE1 | Osteogenesis Imperfecta | COMPLETED | NCT04545554 |
| Sotorasib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT04887064 |
| Sotorasib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT04887064 |
| Apremilast | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT04306965 |
| Apremilast | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT04306965 |
| Apremilast | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT04306965 |
| Panitumumab | Other | Preclinical | Metastatic Colorectal Cancer | COMPLETED | NCT03043950 |
| Panitumumab | Other | Preclinical | Metastatic Colorectal Cancer | COMPLETED | NCT03043950 |
| Sotorasib 960mg | Other | Phase PHASE4 | Drug Drug Interaction Study | COMPLETED | NCT06314763 |
| Rivaroxaban 20mg | Other | Phase PHASE4 | Drug Drug Interaction Study | COMPLETED | NCT06314763 |
| Sotorasib 960mg | Other | Phase PHASE4 | Drug Drug Interaction Study | COMPLETED | NCT06314763 |
| Rivaroxaban 20mg | Other | Phase PHASE4 | Drug Drug Interaction Study | COMPLETED | NCT06314763 |
| Zoledronic Acid | Other | Phase PHASE2 | IOP | COMPLETED | NCT03396315 |
| Alendronate | Other | Phase PHASE2 | IOP | COMPLETED | NCT03396315 |
| Zoledronic Acid | Other | Phase PHASE2 | IOP | COMPLETED | NCT03396315 |
| Alendronate | Other | Phase PHASE2 | IOP | COMPLETED | NCT03396315 |
| Extension of LTFU as per ProtocolAmendment7 7Jun18 | Other | Preclinical | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | NO_LONGER_AVAILABLE | NCT02187354 |
| Blinatumomab | Other | Preclinical | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | NO_LONGER_AVAILABLE | NCT02187354 |
| Extension of LTFU as per ProtocolAmendment7 7Jun18 | Other | Preclinical | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | NO_LONGER_AVAILABLE | NCT02187354 |
| Blinatumomab | Other | Preclinical | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | NO_LONGER_AVAILABLE | NCT02187354 |
| Extension of LTFU as per ProtocolAmendment7 7Jun18 | Other | Preclinical | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | NO_LONGER_AVAILABLE | NCT02187354 |
| Blinatumomab | Other | Preclinical | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | NO_LONGER_AVAILABLE | NCT02187354 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03777436 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03777436 |
| Atezolizumab | Other | Phase PHASE1 | Metastatic Triple Negative Breast Cancer | COMPLETED | NCT03256344 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Metastatic Triple Negative Breast Cancer | COMPLETED | NCT03256344 |
| Atezolizumab | Other | Phase PHASE1 | Metastatic Triple Negative Breast Cancer | COMPLETED | NCT03256344 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Metastatic Triple Negative Breast Cancer | COMPLETED | NCT03256344 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT03156023 |
| Rozibafusp Alfa | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT03156023 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT03156023 |
| Rozibafusp Alfa | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT03156023 |
| AMG 570 Matching Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02618967 |
| AMG 570 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02618967 |
| AMG 570 Matching Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02618967 |
| AMG 570 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02618967 |
| AMG 570 Matching Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02618967 |
| AMG 570 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02618967 |
| Ipilimumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01740297 |
| Talimogene laherparepvec | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01740297 |
| Ipilimumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01740297 |
| Talimogene laherparepvec | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01740297 |
| Denosumab | Other | Phase PHASE4 | Giant Cell Tumor of Bone | COMPLETED | NCT03301857 |
| Denosumab | Other | Phase PHASE4 | Giant Cell Tumor of Bone | COMPLETED | NCT03301857 |
| Denosumab | Other | Phase PHASE4 | Giant Cell Tumor of Bone | COMPLETED | NCT03301857 |
| AMG 334 Dose 3 | Other | Phase PHASE1 | Migraine | COMPLETED | NCT03499119 |
| AMG 334 Dose 2 | Other | Phase PHASE1 | Migraine | COMPLETED | NCT03499119 |
| AMG 334 Dose 1 | Other | Phase PHASE1 | Migraine | COMPLETED | NCT03499119 |
| AMG 334 Dose 3 | Other | Phase PHASE1 | Migraine | COMPLETED | NCT03499119 |
| AMG 334 Dose 2 | Other | Phase PHASE1 | Migraine | COMPLETED | NCT03499119 |
| AMG 334 Dose 1 | Other | Phase PHASE1 | Migraine | COMPLETED | NCT03499119 |
| Blinatumomab | Other | Phase PHASE2 | Relapsed/Refractory Philadelphia Positive B-precursor ALL | COMPLETED | NCT02000427 |
| Blinatumomab | Other | Phase PHASE2 | Relapsed/Refractory Philadelphia Positive B-precursor ALL | COMPLETED | NCT02000427 |
| Placebo | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT01764633 |
| Evolocumab | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT01764633 |
| Placebo | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT01764633 |
| Evolocumab | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT01764633 |
| Placebo | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT01764633 |
| Evolocumab | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT01764633 |
| Evolocumab | Other | Phase PHASE2 | Severe Familial Hypercholesterolemia | COMPLETED | NCT01624142 |
| Evolocumab | Other | Phase PHASE2 | Severe Familial Hypercholesterolemia | COMPLETED | NCT01624142 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03721172 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03721172 |
| evolocumab | Other | Phase PHASE4 | Homozygous Familial Hypercholesterolemia HoFH | COMPLETED | NCT03403374 |
| Evolocumab | Other | Phase PHASE3 | Dyslipidemia | TERMINATED | NCT03080935 |
| Evolocumab | Other | Phase PHASE3 | Dyslipidemia | TERMINATED | NCT03080935 |
| Evolocumab | Other | Phase PHASE3 | Familial Hypercholesterolemia | COMPLETED | NCT02624869 |
| Evolocumab | Other | Phase PHASE3 | Familial Hypercholesterolemia | COMPLETED | NCT02624869 |
| Evolocumab | Other | Phase PHASE3 | Familial Hypercholesterolemia | COMPLETED | NCT02624869 |
| Erwinia-asparaginase | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| PEG-asparaginase | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Ifosfamide | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Methotrexate | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Daunorubicin | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Vincrisitne | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Dexamethasone | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Blinatumomab | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Erwinia-asparaginase | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| PEG-asparaginase | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Ifosfamide | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Methotrexate | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Daunorubicin | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Vincrisitne | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Dexamethasone | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Blinatumomab | Other | Phase PHASE3 | Leukemia, Acute Lymphoblastic | COMPLETED | NCT02393859 |
| Evolocumab | Other | Phase PHASE2 | Heart Transplant | COMPLETED | NCT03944577 |
| Evolocumab | Other | Phase PHASE2 | Heart Transplant | COMPLETED | NCT03944577 |
| Apremilast | Other | Preclinical | Arthritis, Psoriatic | COMPLETED | NCT03828045 |
| Apremilast | Other | Preclinical | Arthritis, Psoriatic | COMPLETED | NCT03828045 |
| Apremilast | Other | Preclinical | Arthritis, Psoriatic | COMPLETED | NCT03608657 |
| Erenumab | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04265755 |
| Erenumab | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04265755 |
| Teprotumumab | Other | Preclinical | Thyroid Eye Disease | APPROVED_FOR_MARKETING | NCT04040894 |
| Teprotumumab | Other | Preclinical | Thyroid Eye Disease | APPROVED_FOR_MARKETING | NCT04040894 |
| Teprotumumab | Other | Preclinical | Thyroid Eye Disease | APPROVED_FOR_MARKETING | NCT04040894 |
| Radiotherapy | Drug | Phase PHASE1 | Soft Tissue Sarcoma | COMPLETED | NCT02453191 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Soft Tissue Sarcoma | COMPLETED | NCT02453191 |
| Radiotherapy | Drug | Phase PHASE1 | Soft Tissue Sarcoma | COMPLETED | NCT02453191 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Soft Tissue Sarcoma | COMPLETED | NCT02453191 |
| Moxifloxacin | Other | Phase PHASE1 | Drug Toxicity | COMPLETED | NCT01135680 |
| Placebo | Other | Phase PHASE1 | Drug Toxicity | COMPLETED | NCT01135680 |
| HPN-100 or Placebo | Other | Phase PHASE1 | Drug Toxicity | COMPLETED | NCT01135680 |
| HPN-100 | Other | Phase PHASE1 | Drug Toxicity | COMPLETED | NCT01135680 |
| Moxifloxacin | Other | Phase PHASE1 | Drug Toxicity | COMPLETED | NCT01135680 |
| Placebo | Other | Phase PHASE1 | Drug Toxicity | COMPLETED | NCT01135680 |
| HPN-100 or Placebo | Other | Phase PHASE1 | Drug Toxicity | COMPLETED | NCT01135680 |
| HPN-100 | Other | Phase PHASE1 | Drug Toxicity | COMPLETED | NCT01135680 |
| HPN-100 | Other | Phase PHASE1 | Hepatic Encephalopathy | COMPLETED | NCT00986895 |
| Buphenyl | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00977600 |
| Ammonul | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00977600 |
| HPN-100 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00977600 |
| Buphenyl | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00977600 |
| Ammonul | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00977600 |
| HPN-100 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00977600 |
| Teprotumumab | Other | Phase PHASE1 | Thyroid Eye Disease | COMPLETED | NCT06389578 |
| Teprotumumab | Other | Phase PHASE1 | Thyroid Eye Disease | COMPLETED | NCT06389578 |
| Teprotumumab | Other | Phase PHASE1 | Thyroid Eye Disease | COMPLETED | NCT06389578 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04087720 |
| methylprednisolone | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| acetaminophen | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| fexofenadine | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| gout flare prophylaxis regimen | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| folic acid | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| placebo | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| methotrexate | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| Pegloticase | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| methylprednisolone | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| acetaminophen | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| fexofenadine | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| gout flare prophylaxis regimen | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| folic acid | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| placebo | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| methotrexate | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| Pegloticase | Other | Phase PHASE4 | Gout | COMPLETED | NCT03994731 |
| Folic Acid | Other | Phase PHASE4 | Gout | COMPLETED | NCT03635957 |
| Infusion Reaction (IR) Prophylaxis | Other | Phase PHASE4 | Gout | COMPLETED | NCT03635957 |
| Standard Gout Flare Prophylaxis | Other | Phase PHASE4 | Gout | COMPLETED | NCT03635957 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Gout | COMPLETED | NCT03635957 |
| Pegloticase | Other | Phase PHASE4 | Gout | COMPLETED | NCT03635957 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04772313 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04772313 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04772313 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04772313 |
| Standard of Care | Other | Phase PHASE2 | Active Systemic Lupus Erythematosus | TERMINATED | NCT04680637 |
| Placebo | Other | Phase PHASE2 | Active Systemic Lupus Erythematosus | TERMINATED | NCT04680637 |
| Efavaleukin Alfa | Other | Phase PHASE2 | Active Systemic Lupus Erythematosus | TERMINATED | NCT04680637 |
| Standard of Care | Other | Phase PHASE2 | Active Systemic Lupus Erythematosus | TERMINATED | NCT04680637 |
| Placebo | Other | Phase PHASE2 | Active Systemic Lupus Erythematosus | TERMINATED | NCT04680637 |
| Efavaleukin Alfa | Other | Phase PHASE2 | Active Systemic Lupus Erythematosus | TERMINATED | NCT04680637 |
| Placebo | Other | Phase PHASE1 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04478994 |
| TEPEZZA | Other | Phase PHASE1 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04478994 |
| Placebo | Other | Phase PHASE1 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04478994 |
| TEPEZZA | Other | Phase PHASE1 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04478994 |
| Teprotumumab | Other | Phase PHASE3 | Thyroid Eye Disease | COMPLETED | NCT03461211 |
| Placebo | Other | Phase PHASE4 | Thyroid Eye Disease | COMPLETED | NCT04583735 |
| TEPEZZA | Other | Phase PHASE4 | Thyroid Eye Disease | COMPLETED | NCT04583735 |
| NaPBA | Other | Phase PHASE4 | Urea Cycle Disorder | COMPLETED | NCT03335488 |
| RAVICTI | Other | Phase PHASE4 | Urea Cycle Disorder | COMPLETED | NCT03335488 |
| RAVICTI | Other | Phase PHASE4 | Urea Cycle Disorder | COMPLETED | NCT02246218 |
| RAVICTI | Other | Phase PHASE4 | Urea Cycle Disorder | COMPLETED | NCT02246218 |
| AMG 160 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT04822298 |
| AMG 160 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT04822298 |
| AMG 160 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT04822298 |
| Buphenyl (NaPBA) | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT00992459 |
| HPN-100 | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT00992459 |
| Buphenyl (NaPBA) | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT00992459 |
| HPN-100 | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT00992459 |
| Buphenyl (NaPBA) | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT00992459 |
| HPN-100 | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT00992459 |
| Placebo | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT00999167 |
| HPN-100 | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT00999167 |
| Placebo | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT00999167 |
| HPN-100 | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT00999167 |
| Placebo | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT00999167 |
| HPN-100 | Other | Phase PHASE2 | Cirrhosis | COMPLETED | NCT00999167 |
| HPN-100 | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT00947297 |
| HPN-100 | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT00947297 |
| BUPHENYL® | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00551200 |
| HPN-100 | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00551200 |
| BUPHENYL® | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00551200 |
| HPN-100 | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00551200 |
| BUPHENYL® | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00551200 |
| HPN-100 | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00551200 |
| Placebo | Other | Phase PHASE3 | Thyroid Eye Disease | COMPLETED | NCT03298867 |
| Teprotumumab | Other | Phase PHASE3 | Thyroid Eye Disease | COMPLETED | NCT03298867 |
| Placebo | Other | Phase PHASE3 | Thyroid Eye Disease | COMPLETED | NCT03298867 |
| Teprotumumab | Other | Phase PHASE3 | Thyroid Eye Disease | COMPLETED | NCT03298867 |
| HPN-100 | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT01347073 |
| HPN-100 | Other | Phase PHASE3 | Urea Cycle Disorders | COMPLETED | NCT01347073 |
| NaPBA | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00947544 |
| HPN-100 | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00947544 |
| NaPBA | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00947544 |
| HPN-100 | Other | Phase PHASE2 | Urea Cycle Disorders | COMPLETED | NCT00947544 |
| Placebo | Other | Phase PHASE2 | Palmoplantaris Pustulosis | COMPLETED | NCT04057937 |
| Apremilast | Other | Phase PHASE2 | Palmoplantaris Pustulosis | COMPLETED | NCT04057937 |
| Placebo | Other | Phase PHASE2 | Palmoplantaris Pustulosis | COMPLETED | NCT04057937 |
| Apremilast | Other | Phase PHASE2 | Palmoplantaris Pustulosis | COMPLETED | NCT04057937 |
| Nitroglycerin | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| Metoprolol | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| Omnipaque | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| CCTA | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| 18F-NaF PET | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| Evolocumab | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| Nitroglycerin | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| Metoprolol | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| Omnipaque | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| CCTA | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| 18F-NaF PET | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| Evolocumab | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT03689946 |
| Placebo | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04141579 |
| Evolocumab 140 MG/ML [Repatha] | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04141579 |
| Placebo | Other | Phase PHASE3 | Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With | COMPLETED | NCT03164928 |
| Denosumab | Other | Phase PHASE3 | Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With | COMPLETED | NCT03164928 |
| Placebo | Other | Phase PHASE3 | Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With | COMPLETED | NCT03164928 |
| Denosumab | Other | Phase PHASE3 | Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With | COMPLETED | NCT03164928 |
| Placebo | Other | Phase PHASE2 | Lupus Erythematosus, Systemic | COMPLETED | NCT04925934 |
| VIB7734 | Other | Phase PHASE2 | Lupus Erythematosus, Systemic | COMPLETED | NCT04925934 |
| Placebo | Other | Phase PHASE2 | Lupus Erythematosus, Systemic | COMPLETED | NCT04925934 |
| VIB7734 | Other | Phase PHASE2 | Lupus Erythematosus, Systemic | COMPLETED | NCT04925934 |
| Romiplostim | Other | Phase EARLY_PHASE1 | Bone Marrow Failure Disorders | COMPLETED | NCT04478227 |
| Romiplostim | Other | Phase EARLY_PHASE1 | Bone Marrow Failure Disorders | COMPLETED | NCT04478227 |
| AMG 330 | Other | Phase PHASE1 | Relapsed/Refractory AML | TERMINATED | NCT02520427 |
| AMG 330 | Other | Phase PHASE1 | Relapsed/Refractory AML | TERMINATED | NCT02520427 |
| AMG 330 | Other | Phase PHASE1 | Relapsed/Refractory AML | TERMINATED | NCT02520427 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT02509507 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT02509507 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT02509507 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT02509507 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT03859427 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT03859427 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT03859427 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT03859427 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT03859427 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT03859427 |
| EDP | Other | Phase PHASE1 | Bioavailability | COMPLETED | NCT06563856 |
| TEPEZZA | Other | Phase PHASE1 | Bioavailability | COMPLETED | NCT06563856 |
| EDP | Other | Phase PHASE1 | Bioavailability | COMPLETED | NCT06563856 |
| TEPEZZA | Other | Phase PHASE1 | Bioavailability | COMPLETED | NCT06563856 |
| Prosthetic treatment | Drug | Preclinical | Missing Teeth | RECRUITING | NCT04741906 |
| Dental implant surgery | Procedure | Preclinical | Missing Teeth | RECRUITING | NCT04741906 |
| Prosthetic treatment | Drug | Preclinical | Missing Teeth | RECRUITING | NCT04741906 |
| Dental implant surgery | Procedure | Preclinical | Missing Teeth | RECRUITING | NCT04741906 |
| survey | Other | Preclinical | Dyslipidemia | COMPLETED | NCT03861533 |
| survey | Other | Preclinical | Dyslipidemia | COMPLETED | NCT03861533 |
| HPN-100 | Other | Phase PHASE4 | Urea Cycle Disorders | COMPLETED | NCT01257737 |
| HPN-100 | Other | Phase PHASE4 | Urea Cycle Disorders | COMPLETED | NCT01257737 |
| Placebo for Rozibafusp Alfa | Other | Phase PHASE2 | Systemic Lupus Erythematosus (SLE) | COMPLETED | NCT04058028 |
| Rozibafusp Alfa | Other | Phase PHASE2 | Systemic Lupus Erythematosus (SLE) | COMPLETED | NCT04058028 |
| Placebo for Rozibafusp Alfa | Other | Phase PHASE2 | Systemic Lupus Erythematosus (SLE) | COMPLETED | NCT04058028 |
| Rozibafusp Alfa | Other | Phase PHASE2 | Systemic Lupus Erythematosus (SLE) | COMPLETED | NCT04058028 |
| 800 mg ibuprofen/26.6 mg famotidine | Other | Phase PHASE4 | Juvenile Idiopathic Arthritis | COMPLETED | NCT01563185 |
| 800 mg ibuprofen/26.6 mg famotidine | Other | Phase PHASE4 | Juvenile Idiopathic Arthritis | COMPLETED | NCT01563185 |
| VIMOVO 500/20 | Other | Phase PHASE4 | Juvenile Idiopathic Arthritis (JIA) | COMPLETED | NCT01544114 |
| VIMOVO 375/20 | Other | Phase PHASE4 | Juvenile Idiopathic Arthritis (JIA) | COMPLETED | NCT01544114 |
| VIMOVO 250/20 | Other | Phase PHASE4 | Juvenile Idiopathic Arthritis (JIA) | COMPLETED | NCT01544114 |
| Cortancyl | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00686335 |
| Lodotra | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00686335 |
| Cortancyl | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00686335 |
| Lodotra | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00686335 |
| Cortancyl | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00686335 |
| Lodotra | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00686335 |
| Ibuprofen | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00613106 |
| HZT-501 | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00613106 |
| Cysteamine Bitartrate Delayed-release Capsules (RP103) | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01000961 |
| Cystagon® (Cysteamine Bitartrate) | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01000961 |
| Cysteamine Bitartrate Delayed-release Capsules (RP103) | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01000961 |
| Cystagon® (Cysteamine Bitartrate) | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01000961 |
| Cysteamine Bitartrate Delayed-release Capsules (RP103) | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01000961 |
| Cystagon® (Cysteamine Bitartrate) | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01000961 |
| Cysteamine Bitartrate | Other | Phase PHASE2 | Mitochondrial Diseases | TERMINATED | NCT02473445 |
| CCX168 | Other | Phase PHASE2 | Immunoglobulin A Nephropathy | COMPLETED | NCT02384317 |
| CCX168 | Other | Phase PHASE2 | Immunoglobulin A Nephropathy | COMPLETED | NCT02384317 |
| Omeprazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05581992 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05581992 |
| Rifampin | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05577624 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05577624 |
| therascreen® KRAS RGQ PCR Kit | Other | Approved | Colo-rectal Cancer | COMPLETED | NCT05347745 |
| therascreen® KRAS RGQ PCR Kit | Other | Approved | Colo-rectal Cancer | COMPLETED | NCT05347745 |
| AMG 794 | Other | Phase PHASE1 | Non-squamous Non-small Cell Lung Cancer | TERMINATED | NCT05317078 |
| AMG 794 | Other | Phase PHASE1 | Non-squamous Non-small Cell Lung Cancer | TERMINATED | NCT05317078 |
| Olpasiran | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05481411 |
| Romosozumab | Other | Phase PHASE4 | Postmenopausal Osteoporosis | COMPLETED | NCT06079476 |
| Romosozumab | Other | Phase PHASE4 | Postmenopausal Osteoporosis | COMPLETED | NCT06079476 |
| Romosozumab | Other | Phase PHASE4 | Postmenopausal Osteoporosis | COMPLETED | NCT06079476 |
| Pegfilgrastim | Other | Phase PHASE2 | HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03571633 |
| Trastuzumab + Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03571633 |
| Pegfilgrastim | Other | Phase PHASE2 | HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03571633 |
| Trastuzumab + Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03571633 |
| Rocatinlimab prefilled syringe | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06268860 |
| Rocatinlimab vial injection | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06268860 |
| Rocatinlimab prefilled syringe | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06268860 |
| Rocatinlimab vial injection | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06268860 |
| Rocatinlimab prefilled syringe | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06268860 |
| Rocatinlimab vial injection | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06268860 |
| Nivolumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06054555 |
| ABP 206 | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06054555 |
| Nivolumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06054555 |
| ABP 206 | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06054555 |
| standard of care second-line chemotherapy (FOLFIRI) | Drug | Phase PHASE2 | Advanced Neuroendocrine Carcinomas of The Digestive System | RECRUITING | NCT07061080 |
| Tarlatamab | Other | Phase PHASE2 | Advanced Neuroendocrine Carcinomas of The Digestive System | RECRUITING | NCT07061080 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | RECRUITING | NCT04994717 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | COMPLETED | NCT03362177 |
| Romiplostim | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | COMPLETED | NCT03362177 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | COMPLETED | NCT03362177 |
| Romiplostim | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | COMPLETED | NCT03362177 |
| Palbociclib | Other | Phase PHASE2 | Cancer of the Colon | COMPLETED | NCT03446157 |
| Cetuximab | Other | Phase PHASE2 | Cancer of the Colon | COMPLETED | NCT03446157 |
| Pembrolizumab | Other | Phase PHASE3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06430866 |
| ABP 234 | Other | Phase PHASE3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06430866 |
| Pembrolizumab | Other | Phase PHASE3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06430866 |
| ABP 234 | Other | Phase PHASE3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06430866 |
| Inebilizumab | Other | Phase PHASE2 | Generalized Myasthenia Gravis | RECRUITING | NCT06987539 |
| methotrexate | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04329325 |
| dexamethasone | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04329325 |
| dasatinib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04329325 |
| Blinatumomab | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04329325 |
| methotrexate | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04329325 |
| dexamethasone | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04329325 |
| dasatinib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04329325 |
| Blinatumomab | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT04329325 |
| Standard of care (SOC) | Other | Phase PHASE4 | STEMI - ST Elevation Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04951856 |
| Evolocumab 140 MG/ML | Other | Phase PHASE4 | STEMI - ST Elevation Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04951856 |
| Standard of care (SOC) | Other | Phase PHASE4 | STEMI - ST Elevation Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04951856 |
| Evolocumab 140 MG/ML | Other | Phase PHASE4 | STEMI - ST Elevation Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04951856 |
| Blinatumomab Injection | Other | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia | NOT_YET_RECRUITING | NCT07313852 |
| Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Carfilzomib + Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Denosumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01575834 |
| Placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01575834 |
| Romosozumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01575834 |
| Denosumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01575834 |
| Placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01575834 |
| Romosozumab | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT01575834 |
| UPLIZNA | Other | Preclinical | — | AVAILABLE | NCT06590051 |
| Daxdilimab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT05430854 |
| Daxdilimab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT05430854 |
| Erenumab | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04825678 |
| Erenumab | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04825678 |
| Placebo | Other | Phase PHASE1 | Obesity | TERMINATED | NCT04199351 |
| AMG 171 | Other | Phase PHASE1 | Obesity | TERMINATED | NCT04199351 |
| Placebo | Other | Phase PHASE1 | Obesity | TERMINATED | NCT04199351 |
| AMG 171 | Other | Phase PHASE1 | Obesity | TERMINATED | NCT04199351 |
| Placebo | Other | Phase PHASE1 | Obesity | TERMINATED | NCT04199351 |
| AMG 171 | Other | Phase PHASE1 | Obesity | TERMINATED | NCT04199351 |
| None, standard chemotherapy only | Drug | Phase PHASE3 | Lung Cancer Non-small Cell Stage IV | TERMINATED | NCT02129699 |
| Denosumab | Other | Phase PHASE3 | Lung Cancer Non-small Cell Stage IV | TERMINATED | NCT02129699 |
| None, standard chemotherapy only | Drug | Phase PHASE3 | Lung Cancer Non-small Cell Stage IV | TERMINATED | NCT02129699 |
| Denosumab | Other | Phase PHASE3 | Lung Cancer Non-small Cell Stage IV | TERMINATED | NCT02129699 |
| AMG 701 | Other | Preclinical | — | NO_LONGER_AVAILABLE | NCT05256446 |
| AMG 701 | Other | Preclinical | — | NO_LONGER_AVAILABLE | NCT05256446 |
| Placebo | Other | Phase PHASE4 | Facial Pain | COMPLETED | NCT04249427 |
| Erenumab Prefilled Syringe | Other | Phase PHASE4 | Facial Pain | COMPLETED | NCT04249427 |
| Placebo | Other | Phase PHASE4 | Facial Pain | COMPLETED | NCT04249427 |
| Erenumab Prefilled Syringe | Other | Phase PHASE4 | Facial Pain | COMPLETED | NCT04249427 |
| Placebo | Other | Phase PHASE4 | Facial Pain | COMPLETED | NCT04249427 |
| Erenumab Prefilled Syringe | Other | Phase PHASE4 | Facial Pain | COMPLETED | NCT04249427 |
| Questionnaire | Other | Preclinical | Psoriatic Arthritis | COMPLETED | NCT05171270 |
| Questionnaire | Other | Preclinical | Psoriatic Arthritis | COMPLETED | NCT05171270 |
| Calcium/Vit D supplementation | Other | Phase PHASE2 | Hand Osteoarthritis | COMPLETED | NCT02771860 |
| Placebo | Other | Phase PHASE2 | Hand Osteoarthritis | COMPLETED | NCT02771860 |
| denosumab | Other | Phase PHASE2 | Hand Osteoarthritis | COMPLETED | NCT02771860 |
| Calcium/Vit D supplementation | Other | Phase PHASE2 | Hand Osteoarthritis | COMPLETED | NCT02771860 |
| Placebo | Other | Phase PHASE2 | Hand Osteoarthritis | COMPLETED | NCT02771860 |
| denosumab | Other | Phase PHASE2 | Hand Osteoarthritis | COMPLETED | NCT02771860 |
| Pomalidomide | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT02939183 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT02939183 |
| Gastro-Retentive (GR) Formulation | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT02939183 |
| Immediate Release (IR) Formulation | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT02939183 |
| Pomalidomide | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT02939183 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT02939183 |
| Gastro-Retentive (GR) Formulation | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT02939183 |
| Immediate Release (IR) Formulation | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT02939183 |
| Injection of TVEC into target lesions 2wks after 3rd injection | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03714828 |
| Injection of TVEC into target lesions 2wks after 2nd injection | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03714828 |
| Injection of TVEC into target lesions 3wks after 1st injection | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03714828 |
| Injection of TVEC into target lesions - week 1-2 | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03714828 |
| Injection of TVEC into target lesions 2wks after 3rd injection | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03714828 |
| Injection of TVEC into target lesions 2wks after 2nd injection | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03714828 |
| Injection of TVEC into target lesions 3wks after 1st injection | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03714828 |
| Injection of TVEC into target lesions - week 1-2 | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03714828 |
| AMG 427 | Other | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | TERMINATED | NCT03541369 |
| AMG 427 | Other | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | TERMINATED | NCT03541369 |
| AMG 427 | Other | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | TERMINATED | NCT03541369 |
| Pembrolizumab | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | COMPLETED | NCT03340766 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | COMPLETED | NCT03340766 |
| Pembrolizumab | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | COMPLETED | NCT03340766 |
| Blinatumomab | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | COMPLETED | NCT03340766 |
| FOLFIRI regimen | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT03635021 |
| Bevacizumab | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT03635021 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT03635021 |
| FOLFOX regimen | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT03635021 |
| FOLFIRI regimen | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT03635021 |
| Bevacizumab | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT03635021 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT03635021 |
| FOLFOX regimen | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT03635021 |
| Apremilast (CC-10004) Placebo | Other | Phase PHASE4 | Arthritis, Psoriatic | COMPLETED | NCT03747939 |
| Apremilast (CC-10004) | Other | Phase PHASE4 | Arthritis, Psoriatic | COMPLETED | NCT03747939 |
| Apremilast (CC-10004) Placebo | Other | Phase PHASE4 | Arthritis, Psoriatic | COMPLETED | NCT03747939 |
| Apremilast (CC-10004) | Other | Phase PHASE4 | Arthritis, Psoriatic | COMPLETED | NCT03747939 |
| AMG 404 | Other | Phase PHASE1 | Glioblastoma or Malignant Glioma | TERMINATED | NCT03296696 |
| AMG 596 | Other | Phase PHASE1 | Glioblastoma or Malignant Glioma | TERMINATED | NCT03296696 |
| AMG 404 | Other | Phase PHASE1 | Glioblastoma or Malignant Glioma | TERMINATED | NCT03296696 |
| AMG 596 | Other | Phase PHASE1 | Glioblastoma or Malignant Glioma | TERMINATED | NCT03296696 |
| AMG 404 | Other | Phase PHASE1 | Glioblastoma or Malignant Glioma | TERMINATED | NCT03296696 |
| AMG 596 | Other | Phase PHASE1 | Glioblastoma or Malignant Glioma | TERMINATED | NCT03296696 |
| therascreen® KRAS RGQ PCR Kit | Other | Preclinical | Non Small Cell Lung Cancer | COMPLETED | NCT05360225 |
| therascreen® KRAS RGQ PCR Kit | Other | Approved | Non-Small Cell Lung Cancer | COMPLETED | NCT05348187 |
| therascreen® KRAS RGQ PCR Kit | Other | Approved | Non-Small Cell Lung Cancer | COMPLETED | NCT05348187 |
| therascreen® KRAS RGQ PCR Kit | Other | Approved | Non-small Cell Lung Cancer | COMPLETED | NCT05347797 |
| therascreen® KRAS RGQ PCR Kit | Other | Approved | Non-small Cell Lung Cancer | COMPLETED | NCT05347797 |
| bisphosphonate | Other | Preclinical | Osteoporosis | COMPLETED | NCT02520362 |
| denosumab | Other | Preclinical | Osteoporosis | COMPLETED | NCT02520362 |
| bisphosphonate | Other | Preclinical | Osteoporosis | COMPLETED | NCT02520362 |
| denosumab | Other | Preclinical | Osteoporosis | COMPLETED | NCT02520362 |
| bisphosphonate | Other | Preclinical | Osteoporosis | COMPLETED | NCT02520362 |
| denosumab | Other | Preclinical | Osteoporosis | COMPLETED | NCT02520362 |
| Teprotumumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06674941 |
| Teprotumumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06674941 |
| Teprotumumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06674941 |
| Lenvatinib | Other | Phase PHASE2 | Metastatic Non Small Cell Lung Cancer | WITHDRAWN | NCT06068153 |
| Sotorasib | Other | Phase PHASE2 | Metastatic Non Small Cell Lung Cancer | WITHDRAWN | NCT06068153 |
| Lenvatinib | Other | Phase PHASE2 | Metastatic Non Small Cell Lung Cancer | WITHDRAWN | NCT06068153 |
| Sotorasib | Other | Phase PHASE2 | Metastatic Non Small Cell Lung Cancer | WITHDRAWN | NCT06068153 |
| No intervention | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT02808403 |
| No intervention | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT02808403 |
| Talimogene laherparepvec | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT03086642 |
| Talimogene laherparepvec | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT03086642 |
| MP-376 (Levofloxacin solution for Inhalation) | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00840333 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00752414 |
| MP-376 (Levofloxacin solution for Inhalation) | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00752414 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00752414 |
| MP-376 (Levofloxacin solution for Inhalation) | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00752414 |
| placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00503490 |
| MP-376 (Levofloxacin solution for Inhalation) | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00503490 |
| placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00503490 |
| MP-376 (Levofloxacin solution for Inhalation) | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00503490 |
| placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00503490 |
| MP-376 (Levofloxacin solution for Inhalation) | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00503490 |
| Consolidation with 4 cycles of CarCyDex | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02315716 |
| Autologous Stem Cell Transplant (ASCT) | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02315716 |
| Consolidation with 4 cycles of CarCyDex | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02315716 |
| Autologous Stem Cell Transplant (ASCT) | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02315716 |
| Consolidation with 4 cycles of CarCyDex | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02315716 |
| Autologous Stem Cell Transplant (ASCT) | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02315716 |
| DMAB Discontinuation and Switching | Other | Phase PHASE4 | Osteoporosis | ACTIVE_NOT_RECRUITING | NCT04177940 |
| interferon γ-1b | Other | Phase PHASE3 | Friedreich's Ataxia | COMPLETED | NCT02797080 |
| interferon γ-1b | Other | Phase PHASE3 | Friedreich's Ataxia | COMPLETED | NCT02797080 |
| Famotidine | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| Omeprazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| Famotidine | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| Omeprazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| Famotidine | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| Omeprazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05599828 |
| Ustekinumab | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT04607980 |
| ABP 654 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT04607980 |
| Ustekinumab | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT04607980 |
| ABP 654 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT04607980 |
| Placebo | Other | Phase PHASE1 | Dendritic Cell -Mediated Rheumatic Diseases | COMPLETED | NCT04948099 |
| VIB1116 | Other | Phase PHASE1 | Dendritic Cell -Mediated Rheumatic Diseases | COMPLETED | NCT04948099 |
| Placebo | Other | Phase PHASE1 | Dendritic Cell -Mediated Rheumatic Diseases | COMPLETED | NCT04948099 |
| VIB1116 | Other | Phase PHASE1 | Dendritic Cell -Mediated Rheumatic Diseases | COMPLETED | NCT04948099 |
| Alendronate Effervescent Oral Tablet | Other | Phase PHASE2 | Erosive Osteoarthritis | COMPLETED | NCT04403698 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03817424 |
| VIB7734 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03817424 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03817424 |
| VIB7734 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03817424 |
| Placebos | Other | Phase PHASE1 | Safety Issues | TERMINATED | NCT03621605 |
| VIB9600 | Other | Phase PHASE1 | Safety Issues | TERMINATED | NCT03621605 |
| Placebo | Other | Phase PHASE1 | Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc | COMPLETED | NCT02780674 |
| MEDI7734 | Other | Phase PHASE1 | Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc | COMPLETED | NCT02780674 |
| Placebo | Other | Phase PHASE1 | Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc | COMPLETED | NCT02780674 |
| MEDI7734 | Other | Phase PHASE1 | Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc | COMPLETED | NCT02780674 |
| TIS (Tobramycin Inhalation Solution) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01270347 |
| MP-376 (Levofloxacin Solution for Inhalation) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01270347 |
| TIS (Tobramycin Inhalation Solution) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01270347 |
| MP-376 (Levofloxacin Solution for Inhalation) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01270347 |
| TIS (Tobramycin Inhalation Solution) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01270347 |
| MP-376 (Levofloxacin Solution for Inhalation) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01270347 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03701763 |
| Apremilast (CC-10004) | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03701763 |
| Placebo | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03701763 |
| Apremilast (CC-10004) | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT03701763 |
| Ibuprofen | Other | Phase PHASE3 | Peptic Ulcer | COMPLETED | NCT00450658 |
| HZT-501 | Other | Phase PHASE3 | Peptic Ulcer | COMPLETED | NCT00450658 |
| Ibuprofen | Other | Phase PHASE3 | Peptic Ulcer | COMPLETED | NCT00450658 |
| HZT-501 | Other | Phase PHASE3 | Peptic Ulcer | COMPLETED | NCT00450658 |
| Ibuprofen | Other | Phase PHASE3 | Ulcer | COMPLETED | NCT00450216 |
| Ibuprofen/famotidine | Other | Phase PHASE3 | Ulcer | COMPLETED | NCT00450216 |
| Ibuprofen | Other | Phase PHASE3 | Ulcer | COMPLETED | NCT00450216 |
| Ibuprofen/famotidine | Other | Phase PHASE3 | Ulcer | COMPLETED | NCT00450216 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT04163991 |
| VIB4920 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT04163991 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT04163991 |
| VIB4920 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT04163991 |
| normal saline | Other | Phase PHASE2 | Thyroid Associated Ophthalmopathies | COMPLETED | NCT01868997 |
| teprotumumab | Other | Phase PHASE2 | Thyroid Associated Ophthalmopathies | COMPLETED | NCT01868997 |
| normal saline | Other | Phase PHASE2 | Thyroid Associated Ophthalmopathies | COMPLETED | NCT01868997 |
| teprotumumab | Other | Phase PHASE2 | Thyroid Associated Ophthalmopathies | COMPLETED | NCT01868997 |
| VIMOVO 500/20 | Other | Phase PHASE4 | Juvenile Idiopathic Arthritis (JIA) | COMPLETED | NCT01544114 |
| VIMOVO 375/20 | Other | Phase PHASE4 | Juvenile Idiopathic Arthritis (JIA) | COMPLETED | NCT01544114 |
| VIMOVO 250/20 | Other | Phase PHASE4 | Juvenile Idiopathic Arthritis (JIA) | COMPLETED | NCT01544114 |
| Ibuprofen | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00613106 |
| HZT-501 | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00613106 |
| placebo solution (10% dextrose) | Other | Phase PHASE2 | Hepatic Encephalopathy | TERMINATED | NCT00597909 |
| sodium phenylacetate and sodium benzoate injection 10% / 10% | Other | Phase PHASE2 | Hepatic Encephalopathy | TERMINATED | NCT00597909 |
| placebo solution (10% dextrose) | Other | Phase PHASE2 | Hepatic Encephalopathy | TERMINATED | NCT00597909 |
| sodium phenylacetate and sodium benzoate injection 10% / 10% | Other | Phase PHASE2 | Hepatic Encephalopathy | TERMINATED | NCT00597909 |
| RAYOS (delayed-release prednisone) | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT02287610 |
| RAYOS (delayed-release prednisone) | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT02287610 |
| Placebo | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01180634 |
| Aeroquin | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01180634 |
| Placebo | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01180634 |
| Aeroquin | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01180634 |
| HZT-501 | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00984815 |
| HZT-501 | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00984815 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00650078 |
| MR prednisone | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00650078 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00650078 |
| MR prednisone | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00650078 |
| Interferon γ-1b | Other | Phase PHASE3 | Friedreich's Ataxia | COMPLETED | NCT02593773 |
| Interferon γ-1b | Other | Phase PHASE3 | Friedreich's Ataxia | COMPLETED | NCT02593773 |
| Placebo | Other | Phase PHASE3 | Friedreich's Ataxia | COMPLETED | NCT02415127 |
| Interferon γ-1b | Other | Phase PHASE3 | Friedreich's Ataxia | COMPLETED | NCT02415127 |
| Placebo | Other | Phase PHASE3 | Friedreich's Ataxia | COMPLETED | NCT02415127 |
| Interferon γ-1b | Other | Phase PHASE3 | Friedreich's Ataxia | COMPLETED | NCT02415127 |
| RP103 | Other | Phase PHASE1 | Cystinosis | COMPLETED | NCT00872729 |
| Cystagon® | Other | Phase PHASE1 | Cystinosis | COMPLETED | NCT00872729 |
| RP103 | Other | Phase PHASE1 | Cystinosis | COMPLETED | NCT00872729 |
| Cystagon® | Other | Phase PHASE1 | Cystinosis | COMPLETED | NCT00872729 |
| RP103 | Other | Phase PHASE1 | Cystinosis | COMPLETED | NCT00872729 |
| Cystagon® | Other | Phase PHASE1 | Cystinosis | COMPLETED | NCT00872729 |
| Methylprednisolone | Other | Phase PHASE2 | Allografts | COMPLETED | NCT04046549 |
| Thymoglobulin | Other | Phase PHASE2 | Allografts | COMPLETED | NCT04046549 |
| VIB4920 | Other | Phase PHASE2 | Allografts | COMPLETED | NCT04046549 |
| Belatacept | Other | Phase PHASE2 | Allografts | COMPLETED | NCT04046549 |
| Methylprednisolone | Other | Phase PHASE2 | Allografts | COMPLETED | NCT04046549 |
| Thymoglobulin | Other | Phase PHASE2 | Allografts | COMPLETED | NCT04046549 |
| VIB4920 | Other | Phase PHASE2 | Allografts | COMPLETED | NCT04046549 |
| Belatacept | Other | Phase PHASE2 | Allografts | COMPLETED | NCT04046549 |
| Placebo | Other | Phase PHASE1 | Adult Onset Rheumatoid Arthritis | COMPLETED | NCT02780388 |
| VIB4920 | Other | Phase PHASE1 | Adult Onset Rheumatoid Arthritis | COMPLETED | NCT02780388 |
| romiplostim | Other | Phase PHASE2 | Isolated Chemotherapy-induced Thrombocytopenia | COMPLETED | NCT02052882 |
| romiplostim | Other | Phase PHASE2 | Isolated Chemotherapy-induced Thrombocytopenia | COMPLETED | NCT02052882 |
| Cysteamine Bitartrate | Other | Phase PHASE2 | Inherited Mitochondrial Disease, Including Leigh Syndrome | COMPLETED | NCT02023866 |
| RP103 | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01744782 |
| RP103 | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01744782 |
| Cystagon® | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01733316 |
| RP103 | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01733316 |
| Cysteamine Bitartrate Delayed-release Capsules | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01197378 |
| Cysteamine Bitartrate Delayed-release Capsules | Other | Phase PHASE3 | Cystinosis | COMPLETED | NCT01197378 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00739648 |
| MP-376 | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00739648 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00739648 |
| MP-376 | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00739648 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00739648 |
| MP-376 | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00739648 |
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis (CF) | COMPLETED | NCT00677365 |
| MP-376 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | COMPLETED | NCT00677365 |
| Ethanol | Other | Phase PHASE2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | COMPLETED | NCT00661141 |
| Placebo | Other | Phase PHASE2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | COMPLETED | NCT00661141 |
| Antizol | Other | Phase PHASE2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | COMPLETED | NCT00661141 |
| Ethanol | Other | Phase PHASE2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | COMPLETED | NCT00661141 |
| Placebo | Other | Phase PHASE2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | COMPLETED | NCT00661141 |
| Antizol | Other | Phase PHASE2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | COMPLETED | NCT00661141 |
| AMG 404 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04727554 |
| AMG 994 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04727554 |
| AMG 404 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04727554 |
| AMG 994 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04727554 |
| Daxdilimab | Other | Phase PHASE2 | Alopecia Areata | COMPLETED | NCT05368103 |
| Daxdilimab | Other | Phase PHASE2 | Alopecia Areata | COMPLETED | NCT05368103 |
| Pembrolizumab | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT04068181 |
| Talimogene laherparepvec | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT04068181 |
| Pembrolizumab | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT04068181 |
| Talimogene laherparepvec | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT04068181 |
| TAP® Micro Select Device (Touch Activated Phlebotomy) | Device | Preclinical | Obesity | COMPLETED | NCT06761703 |
| TAP® Micro Select Device (Touch Activated Phlebotomy) | Device | Preclinical | Obesity | COMPLETED | NCT06761703 |
| Hypofractionated Radiotherapy | Drug | Phase PHASE2 | Melanoma | COMPLETED | NCT02819843 |
| TALIMOGENE LAHERPAREPVEC (TVEC) | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT02819843 |
| Hypofractionated Radiotherapy | Drug | Phase PHASE2 | Melanoma | COMPLETED | NCT02819843 |
| TALIMOGENE LAHERPAREPVEC (TVEC) | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT02819843 |
| Haplo-Mismatched Cell Therapy (HMCT) | Drug | Phase PHASE1 | B-Cell Acute Lymphoblastic Leukaemia | COMPLETED | NCT03751709 |
| Blinatumomab | Other | Phase PHASE1 | B-Cell Acute Lymphoblastic Leukaemia | COMPLETED | NCT03751709 |
| Haplo-Mismatched Cell Therapy (HMCT) | Drug | Phase PHASE1 | B-Cell Acute Lymphoblastic Leukaemia | COMPLETED | NCT03751709 |
| Blinatumomab | Other | Phase PHASE1 | B-Cell Acute Lymphoblastic Leukaemia | COMPLETED | NCT03751709 |
| leucovorin calcium | Other | Phase PHASE2 | Mucinous Adenocarcinoma of the Colon | COMPLETED | NCT01814501 |
| fluorouracil | Other | Phase PHASE2 | Mucinous Adenocarcinoma of the Colon | COMPLETED | NCT01814501 |
| irinotecan hydrochloride | Other | Phase PHASE2 | Mucinous Adenocarcinoma of the Colon | COMPLETED | NCT01814501 |
| panitumumab | Other | Phase PHASE2 | Mucinous Adenocarcinoma of the Colon | COMPLETED | NCT01814501 |
| Blood Red Cell Transfusion | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT01196715 |
| Filgrastim | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT01196715 |
| Darbepoetin alpha | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT01196715 |
| Blood Red Cell Transfusion | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT01196715 |
| Filgrastim | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT01196715 |
| Darbepoetin alpha | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT01196715 |
| Tarlatamab | Other | Phase PHASE2 | Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | NOT_YET_RECRUITING | NCT06816394 |
| Tarlatamab | Other | Phase PHASE2 | Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | NOT_YET_RECRUITING | NCT06816394 |
| Olpasiran | Other | Phase PHASE1 | Elevated Serum Lipoprotein(a) | COMPLETED | NCT04987320 |
| Olpasiran | Other | Phase PHASE1 | Elevated Serum Lipoprotein(a) | COMPLETED | NCT04987320 |
| Placebo 1.7 ml Subcutaneous Solution | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03792763 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03792763 |
| Placebo 1.7 ml Subcutaneous Solution | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03792763 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03792763 |
| Aflibercept | Other | Phase PHASE3 | Chorioretinal Vascular Disease | COMPLETED | NCT05704725 |
| ABP 938 | Other | Phase PHASE3 | Chorioretinal Vascular Disease | COMPLETED | NCT05704725 |
| Aflibercept | Other | Phase PHASE3 | Chorioretinal Vascular Disease | COMPLETED | NCT05704725 |
| ABP 938 | Other | Phase PHASE3 | Chorioretinal Vascular Disease | COMPLETED | NCT05704725 |
| Apremilast | Other | Phase PHASE4 | Psoriatic Arthritis | COMPLETED | NCT03783026 |
| Apremilast | Other | Phase PHASE4 | Psoriatic Arthritis | COMPLETED | NCT03783026 |
| Placebo to Alendronate | Other | Phase PHASE3 | Postmenopausal Women With Osteoporosis | COMPLETED | NCT01631214 |
| Placebo to Romosozumab | Other | Phase PHASE3 | Postmenopausal Women With Osteoporosis | COMPLETED | NCT01631214 |
| Alendronate | Other | Phase PHASE3 | Postmenopausal Women With Osteoporosis | COMPLETED | NCT01631214 |
| Romosozumab | Other | Phase PHASE3 | Postmenopausal Women With Osteoporosis | COMPLETED | NCT01631214 |
| Placebo to Alendronate | Other | Phase PHASE3 | Postmenopausal Women With Osteoporosis | COMPLETED | NCT01631214 |
| Placebo to Romosozumab | Other | Phase PHASE3 | Postmenopausal Women With Osteoporosis | COMPLETED | NCT01631214 |
| Alendronate | Other | Phase PHASE3 | Postmenopausal Women With Osteoporosis | COMPLETED | NCT01631214 |
| Romosozumab | Other | Phase PHASE3 | Postmenopausal Women With Osteoporosis | COMPLETED | NCT01631214 |
| AMG 133 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05056246 |
| AMG 133 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05056246 |
| CCX872-B | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02345408 |
| CCX872-B | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02345408 |
| CCX140-B | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT01447147 |
| Placebo | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT01447147 |
| CCX140-B | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT01447147 |
| Placebo | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT01447147 |
| CCX140-B | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT01440257 |
| Placebo | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT01440257 |
| CCX140-B | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT01440257 |
| Placebo | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT01440257 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05581758 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05581758 |
| Itraconazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05568082 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05568082 |
| Itraconazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05568082 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05568082 |
| Metformin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05550129 |
| AMG 510 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05550129 |
| Metformin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05550129 |
| AMG 510 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05550129 |
| CCX354-C | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01242917 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01242917 |
| CCX-354-C | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01242917 |
| CCX354-C | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01242917 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01242917 |
| CCX-354-C | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01242917 |
| CCX140-B | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01028963 |
| pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01028963 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01028963 |
| CCX140-B | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01028963 |
| pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01028963 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01028963 |
| CCX 354-C | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01027728 |
| Placebo | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT00540657 |
| CCX282-B | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT00540657 |
| Placebo | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT00540657 |
| CCX282-B | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT00540657 |
| CCX282-B | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00306215 |
| CCX282-B | Other | Phase PHASE2 | Crohn Disease | COMPLETED | NCT00102921 |
| CCX282-B | Other | Phase PHASE2 | Crohn Disease | COMPLETED | NCT00102921 |
| Tarlatamab | Other | Preclinical | Small Cell Lung Cancer | APPROVED_FOR_MARKETING | NCT06064500 |
| Tarlatamab | Other | Preclinical | Small Cell Lung Cancer | APPROVED_FOR_MARKETING | NCT06064500 |
| T-VEC | Other | Phase PHASE2 | Melanoma Stage III | COMPLETED | NCT04330430 |
| T-VEC | Other | Phase PHASE2 | Melanoma Stage III | COMPLETED | NCT04330430 |
| CCX140-B | Other | Phase PHASE2 | FSGS | COMPLETED | NCT03536754 |
| Placebo | Other | Phase PHASE2 | FSGS | COMPLETED | NCT03536754 |
| CCX140-B | Other | Phase PHASE2 | FSGS | COMPLETED | NCT03536754 |
| Placebo | Other | Phase PHASE2 | FSGS | COMPLETED | NCT03536754 |
| Avacopan Matching Placebo | Other | Phase PHASE2 | C3 Glomerulopathy (C3G) | COMPLETED | NCT03301467 |
| Avacopan | Other | Phase PHASE2 | C3 Glomerulopathy (C3G) | COMPLETED | NCT03301467 |
| Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids | Other | Phase PHASE2 | ANCA-associated Vasculitis | COMPLETED | NCT02222155 |
| CCX168 | Other | Phase PHASE2 | Vasculitis | COMPLETED | NCT01363388 |
| Placebo | Other | Phase PHASE2 | Vasculitis | COMPLETED | NCT01363388 |
| CCX168 | Other | Phase PHASE2 | Vasculitis | COMPLETED | NCT01363388 |
| Placebo | Other | Phase PHASE2 | Vasculitis | COMPLETED | NCT01363388 |
| CCX168 | Other | Phase PHASE2 | Vasculitis | COMPLETED | NCT01363388 |
| Placebo | Other | Phase PHASE2 | Vasculitis | COMPLETED | NCT01363388 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT03852472 |
| Avacopan | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT03852472 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT03852472 |
| Avacopan | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT03852472 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT03852472 |
| Avacopan | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT03852472 |
| CCX140-B | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | TERMINATED | NCT03703908 |
| Placebo (Normal Saline) | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT05540665 |
| Daxdilimab | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT05540665 |
| Azathioprine | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Rituximab | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Cyclophosphamide | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Prednisone | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Avacopan | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Azathioprine | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Rituximab | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Cyclophosphamide | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Prednisone | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Avacopan | Other | Phase PHASE3 | ANCA-Associated Vasculitis | COMPLETED | NCT02994927 |
| Nab-paclitaxel | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Paclitaxel | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Carboplatin | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Pembrolizumab | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Docetaxel | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Bemarituzumab | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Nab-paclitaxel | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Paclitaxel | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Carboplatin | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Pembrolizumab | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Docetaxel | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Bemarituzumab | Other | Phase PHASE1 | Squamous-Cell Non-Small-Cell Lung Cancer | TERMINATED | NCT05267470 |
| Digoxin | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05598281 |
| AMG 510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05598281 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05651711 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05651711 |
| Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Carfilzomib + Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Carfilzomib + Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Placebo | Other | Phase PHASE3 | Palmoplantar Pustulosis | COMPLETED | NCT05174065 |
| Apremilast | Other | Phase PHASE3 | Palmoplantar Pustulosis | COMPLETED | NCT05174065 |
| Placebo | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT04833855 |
| Omalizumab | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT04833855 |
| Tezepelumab Dose 2 | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT04833855 |
| Tezepelumab Dose 1 | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT04833855 |
| Placebo | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT04833855 |
| Omalizumab | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT04833855 |
| Tezepelumab Dose 2 | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT04833855 |
| Tezepelumab Dose 1 | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT04833855 |
| Placebo | Other | Phase PHASE2 | Sjögren's Syndrome | COMPLETED | NCT04129164 |
| VIB4920 | Other | Phase PHASE2 | Sjögren's Syndrome | COMPLETED | NCT04129164 |
| Placebo | Other | Phase PHASE2 | Sjögren's Syndrome | COMPLETED | NCT04129164 |
| VIB4920 | Other | Phase PHASE2 | Sjögren's Syndrome | COMPLETED | NCT04129164 |
| Pomalidomide | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03756896 |
| Dexamethasone | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03756896 |
| Carfilzomib | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03756896 |
| Motesanib | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01349088 |
| Capecitabine | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01349088 |
| Ixabepilone | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01349088 |
| Motesanib | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01349088 |
| Capecitabine | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01349088 |
| Ixabepilone | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT01349088 |
| AMG 714 | Other | Preclinical | Celiac Disease | NO_LONGER_AVAILABLE | NCT03439475 |
| AMG 714 | Other | Preclinical | Celiac Disease | NO_LONGER_AVAILABLE | NCT03439475 |
| AMG 714 | Other | Preclinical | Celiac Disease | NO_LONGER_AVAILABLE | NCT03439475 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT03158688 |
| Daratumumab | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT03158688 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT03158688 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT03158688 |
| Daratumumab | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT03158688 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT03158688 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | TERMINATED | NCT04556084 |
| Current Wearable Heatlth Monitoring System (CWHMS) | Other | Phase PHASE4 | B-precursor Acute Lymphoblastic Leukemia | TERMINATED | NCT04506086 |
| Blinatumomab | Other | Phase PHASE4 | B-precursor Acute Lymphoblastic Leukemia | TERMINATED | NCT04506086 |
| Carboplatin | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Gemcitabine | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Nab paclitaxel | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Tamoxifen | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Paclitaxel | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Letrozole | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Fulvestrant | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Exemestane | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Anastrozole | Other | Phase PHASE1 | Anatomic Stage III Breast Cancer AJCC v8 | COMPLETED | NCT03554044 |
| Sotorasib | Other | Phase PHASE1 | Brain Tumor | RECRUITING | NCT06807619 |
| Sotorasib | Other | Phase PHASE1 | Brain Tumor | RECRUITING | NCT06807619 |
| Dexamethasone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab 28 ug | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab 9ug | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT03114865 |
| Blinatumomab | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT02811679 |
| Extended Consultation for apremilast | Other | Phase EARLY_PHASE1 | Psoriasis | WITHDRAWN | NCT05601492 |
| Reminder Text Intervention with apremilast | Other | Phase EARLY_PHASE1 | Psoriasis | WITHDRAWN | NCT05601492 |
| Otezla - Standard Care | Other | Phase EARLY_PHASE1 | Psoriasis | WITHDRAWN | NCT05601492 |
| Extended Consultation for apremilast | Other | Phase EARLY_PHASE1 | Psoriasis | WITHDRAWN | NCT05601492 |
| Reminder Text Intervention with apremilast | Other | Phase EARLY_PHASE1 | Psoriasis | WITHDRAWN | NCT05601492 |
| Otezla - Standard Care | Other | Phase EARLY_PHASE1 | Psoriasis | WITHDRAWN | NCT05601492 |
| AMG 340 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04740034 |
| AMG 340 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04740034 |
| Teprotumumab | Other | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT02103283 |
| Teprotumumab | Other | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT02103283 |
| FOLFOX + panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT03584711 |
| Itraconazole | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT02675452 |
| Azacitidine | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT02675452 |
| AMG 176 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT02675452 |
| Itraconazole | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT02675452 |
| Azacitidine | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT02675452 |
| AMG 176 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | TERMINATED | NCT02675452 |
| Placebo | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT03774875 |
| Apremilast | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT03774875 |
| Azacitidine | Other | Phase PHASE1 | Higher Risk Myelodysplastic Syndrome | TERMINATED | NCT05209152 |
| AMG 176 | Other | Phase PHASE1 | Higher Risk Myelodysplastic Syndrome | TERMINATED | NCT05209152 |
| Azacitidine | Other | Phase PHASE1 | Higher Risk Myelodysplastic Syndrome | TERMINATED | NCT05209152 |
| AMG 176 | Other | Phase PHASE1 | Higher Risk Myelodysplastic Syndrome | TERMINATED | NCT05209152 |
| AMG 404 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03853109 |
| AMG 404 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03853109 |
| Olpasiran | Other | Preclinical | — | AVAILABLE | NCT07079267 |
| Olpasiran | Other | Preclinical | — | AVAILABLE | NCT07079267 |
| Care Champion Intervention | Other | Approved | ASCVD | RECRUITING | NCT06471036 |
| Drug: Carfilzomib + Lenalidomide + Dexamethasone | Drug | Phase PHASE4 | Relapsed Refractory Multiple Myeloma | COMPLETED | NCT03934684 |
| Drug: Carfilzomib + Dexamethasone | Drug | Phase PHASE4 | Relapsed Refractory Multiple Myeloma | COMPLETED | NCT03934684 |
| Drug: Carfilzomib + Lenalidomide + Dexamethasone | Drug | Phase PHASE4 | Relapsed Refractory Multiple Myeloma | COMPLETED | NCT03934684 |
| Drug: Carfilzomib + Dexamethasone | Drug | Phase PHASE4 | Relapsed Refractory Multiple Myeloma | COMPLETED | NCT03934684 |
| AMG 510 | Other | Preclinical | Non Small-cell Lung Cancer | NO_LONGER_AVAILABLE | NCT04667234 |
| AMG 510 | Other | Preclinical | Non Small-cell Lung Cancer | NO_LONGER_AVAILABLE | NCT04667234 |
| AMG 510 | Other | Preclinical | Non Small-cell Lung Cancer | NO_LONGER_AVAILABLE | NCT04667234 |
| Early Intervention | Other | Approved | Cardiovascular Diseases | RECRUITING | NCT05325034 |
| Opportunistic screening for low BMD | Other | Approved | Low Bone Density | COMPLETED | NCT05245851 |
| Opportunistic screening for low BMD | Other | Approved | Low Bone Density | COMPLETED | NCT05245851 |
| Opportunistic screening for low BMD | Other | Approved | Low Bone Density | COMPLETED | NCT05245851 |
| Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments | Drug | Phase PHASE2 | Temporomandibular Disorder | COMPLETED | NCT04884763 |
| Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments | Drug | Phase PHASE2 | Temporomandibular Disorder | COMPLETED | NCT04884763 |
| Bloods and urine | Other | Preclinical | Myeloma | COMPLETED | NCT03951220 |
| DXA scan | Other | Preclinical | Myeloma | COMPLETED | NCT03951220 |
| Diffusion Weighted Magnetic Resonance Imaging (DWMRI) | Other | Preclinical | Myeloma | COMPLETED | NCT03951220 |
| Bloods and urine | Other | Preclinical | Myeloma | COMPLETED | NCT03951220 |
| DXA scan | Other | Preclinical | Myeloma | COMPLETED | NCT03951220 |
| Diffusion Weighted Magnetic Resonance Imaging (DWMRI) | Other | Preclinical | Myeloma | COMPLETED | NCT03951220 |
| Romiplostim | Other | Phase PHASE2 | Lymphoma Patients | ACTIVE_NOT_RECRUITING | NCT04673266 |
| Pomalidomide | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT04191616 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT04191616 |
| Carfilzomib | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT04191616 |
| Pomalidomide | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT04191616 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT04191616 |
| Carfilzomib | Other | Phase PHASE2 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT04191616 |
| Teprotumumab | Other | Preclinical | Thyroid Eye Disease | COMPLETED | NCT07085117 |
| Teprotumumab | Other | Preclinical | Thyroid Eye Disease | COMPLETED | NCT07085117 |
| Atezolizumab | Other | Phase EARLY_PHASE1 | Breast Cancer | COMPLETED | NCT03802604 |
| Talimogene laherparepvec | Other | Phase EARLY_PHASE1 | Breast Cancer | COMPLETED | NCT03802604 |
| Atezolizumab | Other | Phase EARLY_PHASE1 | Breast Cancer | COMPLETED | NCT03802604 |
| Talimogene laherparepvec | Other | Phase EARLY_PHASE1 | Breast Cancer | COMPLETED | NCT03802604 |
| Aflibercept | Other | Phase PHASE3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | COMPLETED | NCT04270747 |
| ABP 938 | Other | Phase PHASE3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | COMPLETED | NCT04270747 |
| AMG 420 | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT03836053 |
| AMG 420 | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT03836053 |
| Tarlatamab | Other | Phase PHASE1 | Neuroendocrine Prostate Cancer | COMPLETED | NCT04702737 |
| Tarlatamab | Other | Phase PHASE1 | Neuroendocrine Prostate Cancer | COMPLETED | NCT04702737 |
| Placebo | Other | Phase PHASE2 | Granulomatosis With Polyangiitis | NOT_YET_RECRUITING | NCT07176546 |
| Avacopan | Other | Phase PHASE2 | Granulomatosis With Polyangiitis | NOT_YET_RECRUITING | NCT07176546 |
| Placebo | Other | Phase PHASE2 | Granulomatosis With Polyangiitis | NOT_YET_RECRUITING | NCT07176546 |
| Avacopan | Other | Phase PHASE2 | Granulomatosis With Polyangiitis | NOT_YET_RECRUITING | NCT07176546 |
| Placebo | Other | Phase PHASE2 | Granulomatosis With Polyangiitis | NOT_YET_RECRUITING | NCT07176546 |
| Avacopan | Other | Phase PHASE2 | Granulomatosis With Polyangiitis | NOT_YET_RECRUITING | NCT07176546 |
| Tarlatamab | Other | Phase PHASE2 | Astrocytic Tumor | RECRUITING | NCT06776250 |
| Tarlatamab | Other | Phase PHASE2 | Astrocytic Tumor | RECRUITING | NCT06776250 |
| Tarlatamab | Other | Phase PHASE2 | Astrocytic Tumor | RECRUITING | NCT06776250 |
| Placebo | Other | Phase PHASE4 | Migraine Headache | COMPLETED | NCT03971071 |
| Erenumab 140 mg | Other | Phase PHASE4 | Migraine Headache | COMPLETED | NCT03971071 |
| Erenumab 70 mg | Other | Phase PHASE4 | Migraine Headache | COMPLETED | NCT03971071 |
| Placebo | Other | Phase PHASE4 | Migraine Headache | COMPLETED | NCT03971071 |
| Erenumab 140 mg | Other | Phase PHASE4 | Migraine Headache | COMPLETED | NCT03971071 |
| Erenumab 70 mg | Other | Phase PHASE4 | Migraine Headache | COMPLETED | NCT03971071 |
| Peer Support Program | Other | Approved | Rheumatoid Arthritis | TERMINATED | NCT01525654 |
| Peer Support Program | Other | Approved | Rheumatoid Arthritis | TERMINATED | NCT01525654 |
| AMG 404 | Other | Phase PHASE1 | Small Cell Lung Cancer | COMPLETED | NCT04885998 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | COMPLETED | NCT04885998 |
| AMG 404 | Other | Phase PHASE1 | Small Cell Lung Cancer | COMPLETED | NCT04885998 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | COMPLETED | NCT04885998 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Methotrexate (MTX) | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| Pegloticase | Other | Phase PHASE4 | Uncontrolled Gout | COMPLETED | NCT04762498 |
| XGEVA® | Other | Phase PHASE4 | Giant Cell Tumor of Bone | ACTIVE_NOT_RECRUITING | NCT04586660 |
| Dexamethasone | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT03500445 |
| Lenalidomide | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT03500445 |
| Carfilzomib | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT03500445 |
| Daratumumab | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT03500445 |
| Routine Lipid Management | Other | Phase PHASE4 | Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05284747 |
| Evolocumab | Other | Phase PHASE4 | Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05284747 |
| Routine Lipid Management | Other | Phase PHASE4 | Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05284747 |
| Evolocumab | Other | Phase PHASE4 | Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05284747 |
| AMG 404 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04631601 |
| Abiraterone | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04631601 |
| Enzalutamide | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04631601 |
| Acapatamab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04631601 |
| AMG 404 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04631601 |
| Abiraterone | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04631601 |
| Enzalutamide | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04631601 |
| Acapatamab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04631601 |
| AMG 256 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04362748 |
| AMG 256 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04362748 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT04176718 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT04176718 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT04176718 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT04176718 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT04176718 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT04176718 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT04176718 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT04176718 |
| AMG 133 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT06976372 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| Pomalidomide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| AMG 701 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| Pomalidomide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| AMG 701 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| Pomalidomide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| AMG 701 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03287908 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Sequential Radiation therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Concurrent Radiation Therapy | Drug | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Tarlatamab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06814496 |
| Randomization to No Panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01312857 |
| panitumumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT01312857 |
| Panitumumab | Other | Phase PHASE2 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT02876107 |
| Paclitaxel | Other | Phase PHASE2 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT02876107 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT02876107 |
| Carboplatin | Other | Phase PHASE2 | Breast Carcinoma | ACTIVE_NOT_RECRUITING | NCT02876107 |
| Donor Leukocyte Infusion (DLI) | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06529731 |
| Interferon gamma-1b | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06529731 |
| Donor Leukocyte Infusion (DLI) | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06529731 |
| Interferon gamma-1b | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT06529731 |
| AMG 199 | Other | Phase PHASE1 | MUC17-positive Solid Tumors | TERMINATED | NCT04117958 |
| AMG 199 | Other | Phase PHASE1 | MUC17-positive Solid Tumors | TERMINATED | NCT04117958 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT05672199 |
| Efavaleukin alfa | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT05672199 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT05672199 |
| Efavaleukin alfa | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT05672199 |
| AMG 119 | Other | Phase PHASE1 | Small Cell Lung Cancer | SUSPENDED | NCT03392064 |
| AMG 119 | Other | Phase PHASE1 | Small Cell Lung Cancer | SUSPENDED | NCT03392064 |
| AMG 119 | Other | Phase PHASE1 | Small Cell Lung Cancer | SUSPENDED | NCT03392064 |
| Cytochrome P450 (CYP) Cocktail | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Etanercept | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Pembrolizumab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| acapatamab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Cytochrome P450 (CYP) Cocktail | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Etanercept | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Pembrolizumab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| acapatamab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Cytochrome P450 (CYP) Cocktail | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Etanercept | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Pembrolizumab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| acapatamab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT03792841 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06858839 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06858839 |
| Pegloticase with MTX | Other | Phase PHASE4 | Chronic Uncontrolled Gout | COMPLETED | NCT04511702 |
| Pemetrexed | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05118854 |
| Carboplatin | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05118854 |
| Cisplatin | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05118854 |
| AMG 510 | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05118854 |
| Pemetrexed | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05118854 |
| Carboplatin | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05118854 |
| Cisplatin | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05118854 |
| AMG 510 | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05118854 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Daxdilimab | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Placebo | Other | Phase PHASE2 | Discoid Lupus Erythematosus | TERMINATED | NCT05591222 |
| Sotorasib | Other | Phase PHASE2 | Non-small Cell Lung Cancer | COMPLETED | NCT04933695 |
| Sotorasib | Other | Phase PHASE2 | Non-small Cell Lung Cancer | COMPLETED | NCT04933695 |
| Sotorasib | Other | Phase PHASE2 | Non-small Cell Lung Cancer | COMPLETED | NCT04933695 |
| Sotorasib | Other | Phase PHASE2 | Non-small Cell Lung Cancer | COMPLETED | NCT04933695 |
| Everolimus | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| AMG 404 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| BI 1701963 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| IV Chemotherapy (Regimen 2) | Drug | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| IV Chemotherapy (Regimen 1) | Drug | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| TNO155 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| MVASI® (bevacizumab-awwb) | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Palbociclib | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Carboplatin, pemetrexed, docetaxel, paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Panitumumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| RMC-4630 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Trametinib | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Sotorasib | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Everolimus | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| AMG 404 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| BI 1701963 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| IV Chemotherapy (Regimen 2) | Drug | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| IV Chemotherapy (Regimen 1) | Drug | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| TNO155 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| MVASI® (bevacizumab-awwb) | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Palbociclib | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Carboplatin, pemetrexed, docetaxel, paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Panitumumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| RMC-4630 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Trametinib | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Sotorasib | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04185883 |
| Placebos | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT04082442 |
| Evolocumab | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT04082442 |
| Placebos | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT04082442 |
| Evolocumab | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT04082442 |
| Placebo | Other | Phase PHASE2 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06312020 |
| HZN-1116 | Other | Phase PHASE2 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06312020 |
| Placebo | Other | Phase PHASE2 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06312020 |
| HZN-1116 | Other | Phase PHASE2 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06312020 |
| Moxifloxacin | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Olpasiran | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Placebo | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Moxifloxacin | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Olpasiran | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Placebo | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Moxifloxacin | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Olpasiran | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Placebo | Other | Phase PHASE1 | Basic Science | COMPLETED | NCT06411860 |
| Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05406115 |
| AMG 786 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05406115 |
| Lp(a) Screening | Other | Approved | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT05378529 |
| Lp(a) Screening | Other | Approved | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT05378529 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06502977 |
| Pembrolizumab | Other | Phase PHASE2 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT03069378 |
| Talimogene Laherparepvec (T-VEC) | Other | Phase PHASE2 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT03069378 |
| Pembrolizumab | Other | Phase PHASE2 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT03069378 |
| Talimogene Laherparepvec (T-VEC) | Other | Phase PHASE2 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT03069378 |
| Pembrolizumab | Other | Phase PHASE2 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT03069378 |
| Talimogene Laherparepvec (T-VEC) | Other | Phase PHASE2 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT03069378 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT05882877 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT05882877 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Placebo | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| Daxdilimab | Other | Phase PHASE2 | Idiopathic Inflammatory Myositis | COMPLETED | NCT05669014 |
| erenumab-aooe | Other | Preclinical | Migraine | RECRUITING | NCT06150781 |
| erenumab-aooe | Other | Preclinical | Migraine | RECRUITING | NCT06150781 |
| Alendronate 70Mg Tab | Other | Phase PHASE3 | Bone Density | COMPLETED | NCT03292146 |
| Placebo Injection | Other | Phase PHASE3 | Bone Density | COMPLETED | NCT03292146 |
| Denosumab 60 MG [Prolia] | Other | Phase PHASE3 | Bone Density | COMPLETED | NCT03292146 |
| Alendronate 70Mg Tab | Other | Phase PHASE3 | Bone Density | COMPLETED | NCT03292146 |
| Placebo Injection | Other | Phase PHASE3 | Bone Density | COMPLETED | NCT03292146 |
| Denosumab 60 MG [Prolia] | Other | Phase PHASE3 | Bone Density | COMPLETED | NCT03292146 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05899816 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05899816 |
| Placebo | Other | Phase PHASE3 | Coronary Heart Disease (CHD) | COMPLETED | NCT03872401 |
| Evolocumab | Other | Phase PHASE3 | Coronary Heart Disease (CHD) | COMPLETED | NCT03872401 |
| Placebo | Other | Phase PHASE3 | Coronary Heart Disease (CHD) | COMPLETED | NCT03872401 |
| Evolocumab | Other | Phase PHASE3 | Coronary Heart Disease (CHD) | COMPLETED | NCT03872401 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06088199 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06088199 |
| CRS Mitigation Strategies | Other | Phase PHASE1 | Small Cell Lung Carcinoma | ACTIVE_NOT_RECRUITING | NCT03319940 |
| Pembrolizumab | Other | Phase PHASE1 | Small Cell Lung Carcinoma | ACTIVE_NOT_RECRUITING | NCT03319940 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Carcinoma | ACTIVE_NOT_RECRUITING | NCT03319940 |
| CRS Mitigation Strategies | Other | Phase PHASE1 | Small Cell Lung Carcinoma | ACTIVE_NOT_RECRUITING | NCT03319940 |
| Pembrolizumab | Other | Phase PHASE1 | Small Cell Lung Carcinoma | ACTIVE_NOT_RECRUITING | NCT03319940 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Carcinoma | ACTIVE_NOT_RECRUITING | NCT03319940 |
| Inebilizumab | Other | Phase PHASE4 | Neuromyelitis Optica Spectrum Disorder | ACTIVE_NOT_RECRUITING | NCT06180278 |
| Blood tests | Other | Phase PHASE4 | Neuromyelitis Optica Spectrum Disorder | ACTIVE_NOT_RECRUITING | NCT06180278 |
| Inebilizumab | Other | Phase PHASE4 | Neuromyelitis Optica Spectrum Disorder | ACTIVE_NOT_RECRUITING | NCT06180278 |
| Blood tests | Other | Phase PHASE4 | Neuromyelitis Optica Spectrum Disorder | ACTIVE_NOT_RECRUITING | NCT06180278 |
| Inebilizumab | Other | Phase PHASE4 | Neuromyelitis Optica Spectrum Disorder | ACTIVE_NOT_RECRUITING | NCT06180278 |
| Blood tests | Other | Phase PHASE4 | Neuromyelitis Optica Spectrum Disorder | ACTIVE_NOT_RECRUITING | NCT06180278 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05724199 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05724199 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05398445 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05398445 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05398445 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05398445 |
| Usual Care | Other | Approved | Hip Fractures | COMPLETED | NCT04748354 |
| Otago Exercise Program | Other | Approved | Hip Fractures | COMPLETED | NCT04748354 |
| Usual Care | Other | Approved | Hip Fractures | COMPLETED | NCT04748354 |
| Otago Exercise Program | Other | Approved | Hip Fractures | COMPLETED | NCT04748354 |
| Placebo | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT03515304 |
| Evolocumab | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT03515304 |
| Placebo | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT03515304 |
| Evolocumab | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT03515304 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | ACTIVE_NOT_RECRUITING | NCT06660173 |
| Maridebart Cafraglutide | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | ACTIVE_NOT_RECRUITING | NCT06660173 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | ACTIVE_NOT_RECRUITING | NCT06660173 |
| Maridebart Cafraglutide | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | ACTIVE_NOT_RECRUITING | NCT06660173 |
| Carfilzomib | Other | Preclinical | Multiple Myeloma in Relapse | COMPLETED | NCT02970747 |
| Carfilzomib | Other | Preclinical | Multiple Myeloma in Relapse | COMPLETED | NCT02970747 |
| Tarlatamab | Other | Phase PHASE2 | Metastatic/Locally Advanced Small-Cell Lung Cancer | RECRUITING | NCT07016230 |
| Olpasiran | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05489614 |
| Olpasiran | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05489614 |
| Olpasiran | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05489614 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| Maridebart cafraglutide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | RECRUITING | NCT07160257 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| GnRH Antagonist | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06613100 |
| Apremilast | Other | Phase PHASE3 | Behçet's Disease | RECRUITING | NCT05767047 |
| Apremilast | Other | Phase PHASE3 | Behçet's Disease | RECRUITING | NCT05767047 |
| Placebo | Other | Phase PHASE3 | Behçet Disease | RECRUITING | NCT04528082 |
| Apremilast | Other | Phase PHASE3 | Behçet Disease | RECRUITING | NCT04528082 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT05032066 |
| HZN-825 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT05032066 |
| Inebilizumab | Other | Phase PHASE2 | Neuromyelitis Optica Spectrum Disorder | RECRUITING | NCT05549258 |
| Inebilizumab | Other | Phase PHASE2 | Neuromyelitis Optica Spectrum Disorder | RECRUITING | NCT05549258 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05322577 |
| SOX | Other | Phase PHASE1 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05322577 |
| CAPOX | Other | Phase PHASE1 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05322577 |
| Bemarituzumab | Other | Phase PHASE1 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05322577 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05322577 |
| SOX | Other | Phase PHASE1 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05322577 |
| CAPOX | Other | Phase PHASE1 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05322577 |
| Bemarituzumab | Other | Phase PHASE1 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05322577 |
| nbUVB phototherapy | Drug | Phase PHASE2 | Vitiligo | COMPLETED | NCT04338581 |
| Placebo | Other | Phase PHASE2 | Vitiligo | COMPLETED | NCT04338581 |
| AMG 714 | Other | Phase PHASE2 | Vitiligo | COMPLETED | NCT04338581 |
| Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04478708 |
| maridebart cafraglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04478708 |
| Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04478708 |
| maridebart cafraglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04478708 |
| Placebo | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06376045 |
| Rocatinlimab | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06376045 |
| Placebo | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06376045 |
| Rocatinlimab | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06376045 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05633355 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05633355 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05633355 |
| Placebo | Other | Phase PHASE3 | IgG4 Related Disease | ACTIVE_NOT_RECRUITING | NCT04540497 |
| Inebilizumab | Other | Phase PHASE3 | IgG4 Related Disease | ACTIVE_NOT_RECRUITING | NCT04540497 |
| Placebo | Other | Phase PHASE3 | IgG4 Related Disease | ACTIVE_NOT_RECRUITING | NCT04540497 |
| Inebilizumab | Other | Phase PHASE3 | IgG4 Related Disease | ACTIVE_NOT_RECRUITING | NCT04540497 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Chemotherapy | Drug | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Chemotherapy | Drug | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Chemotherapy | Drug | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05111626 |
| Zoledronic acid 5 mg | Other | Phase PHASE3 | Bone Density, Low | COMPLETED | NCT04779216 |
| Placebo | Other | Phase PHASE3 | Bone Density, Low | COMPLETED | NCT04779216 |
| Romosozumab Prefilled Syringe | Other | Phase PHASE3 | Bone Density, Low | COMPLETED | NCT04779216 |
| Zoledronic acid 5 mg | Other | Phase PHASE3 | Bone Density, Low | COMPLETED | NCT04779216 |
| Placebo | Other | Phase PHASE3 | Bone Density, Low | COMPLETED | NCT04779216 |
| Romosozumab Prefilled Syringe | Other | Phase PHASE3 | Bone Density, Low | COMPLETED | NCT04779216 |
| Placebo | Other | Phase PHASE3 | Obesity Disease | ACTIVE_NOT_RECRUITING | NCT06987695 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity Disease | ACTIVE_NOT_RECRUITING | NCT06987695 |
| Durvalumab | Other | Phase PHASE3 | Extensive-Stage Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06211036 |
| Tarlatamab | Other | Phase PHASE3 | Extensive-Stage Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06211036 |
| Durvalumab | Other | Phase PHASE3 | Extensive-Stage Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06211036 |
| Tarlatamab | Other | Phase PHASE3 | Extensive-Stage Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06211036 |
| Standard of care (SOC) | Other | Phase PHASE4 | STEMI - ST Elevation Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04951856 |
| Evolocumab 140 MG/ML | Other | Phase PHASE4 | STEMI - ST Elevation Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04951856 |
| Blinatumomab | Other | Phase PHASE2 | Phase 2 Study | NOT_YET_RECRUITING | NCT07192237 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | NOT_YET_RECRUITING | NCT07293260 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | NOT_YET_RECRUITING | NCT07293260 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05565560 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05565560 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05565560 |
| Inebilizumab | Other | Phase PHASE2 | Immunoglobulin G4-related Disease | NOT_YET_RECRUITING | NCT07222553 |
| Inebilizumab | Other | Phase PHASE2 | Immunoglobulin G4-related Disease | NOT_YET_RECRUITING | NCT07222553 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06131398 |
| AMG 355 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06131398 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06131398 |
| AMG 355 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06131398 |
| Tarlatamab | Other | Phase PHASE2 | Relapsed/Refractory Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05060016 |
| Tarlatamab | Other | Phase PHASE2 | Relapsed/Refractory Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05060016 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT04175613 |
| Apremilast | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT04175613 |
| Rocatinlimab | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Omeprazole | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Vitamin K | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Warfarin | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Midazolam | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Metoprolol | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Caffeine | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Rocatinlimab | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Omeprazole | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Vitamin K | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Warfarin | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Midazolam | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Metoprolol | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Caffeine | Other | Phase EARLY_PHASE1 | Atopic Dermatitis | COMPLETED | NCT05891119 |
| Treatment with blinatumomab given subcutaneously. | Drug | Phase PHASE2 | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | NOT_YET_RECRUITING | NCT07301424 |
| Treatment with blinatumomab given subcutaneously. | Drug | Phase PHASE2 | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | NOT_YET_RECRUITING | NCT07301424 |
| Treatment with blinatumomab given subcutaneously. | Drug | Phase PHASE2 | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | NOT_YET_RECRUITING | NCT07301424 |
| Ondansetron | Other | Phase PHASE1 | Overweight | COMPLETED | NCT07310563 |
| AMG 133 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT07310563 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | ACTIVE_NOT_RECRUITING | NCT06858878 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | ACTIVE_NOT_RECRUITING | NCT06858878 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | ACTIVE_NOT_RECRUITING | NCT06858878 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | ACTIVE_NOT_RECRUITING | NCT06858878 |
| Methotrexate | Other | Phase PHASE4 | Gout | ACTIVE_NOT_RECRUITING | NCT06229145 |
| Pegloticase | Other | Phase PHASE4 | Gout | ACTIVE_NOT_RECRUITING | NCT06229145 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06122649 |
| apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06122649 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06122649 |
| apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06122649 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06122649 |
| apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06122649 |
| Amrubicin | Other | Phase PHASE3 | Small Cell Lung Cancer (SCLC) | ACTIVE_NOT_RECRUITING | NCT05740566 |
| Topotecan | Other | Phase PHASE3 | Small Cell Lung Cancer (SCLC) | ACTIVE_NOT_RECRUITING | NCT05740566 |
| Lurbinectedin | Other | Phase PHASE3 | Small Cell Lung Cancer (SCLC) | ACTIVE_NOT_RECRUITING | NCT05740566 |
| Tarlatamab | Other | Phase PHASE3 | Small Cell Lung Cancer (SCLC) | ACTIVE_NOT_RECRUITING | NCT05740566 |
| HZN-825 | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT05626751 |
| HZN-825 | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT05626751 |
| bemarituzumab, trifluridine/tipiracil | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| bemarituzumab, irinotecan | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| bemarituzumab, paclitaxel, ramucirumab | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| bemarituzumab, trifluridine/tipiracil | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| bemarituzumab, irinotecan | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| bemarituzumab, paclitaxel, ramucirumab | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| bemarituzumab, trifluridine/tipiracil | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| bemarituzumab, irinotecan | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| bemarituzumab, paclitaxel, ramucirumab | Other | Phase PHASE2 | Metastatic Gastro-esophageal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06680622 |
| Rocatinlimab | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06214481 |
| Rocatinlimab | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06214481 |
| Rocatinlimab | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06214481 |
| Blinatumomab | Other | Phase PHASE1 | B-precursor Acute Lymphoblastic Leukemia | COMPLETED | NCT06649006 |
| Blinatumomab | Other | Phase PHASE1 | B-precursor Acute Lymphoblastic Leukemia | COMPLETED | NCT06649006 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06352892 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06352892 |
| Placebo | Other | Phase PHASE3 | Sjögren's Syndrome (SS) | ACTIVE_NOT_RECRUITING | NCT06245408 |
| Dazodalibep | Other | Phase PHASE3 | Sjögren's Syndrome (SS) | ACTIVE_NOT_RECRUITING | NCT06245408 |
| Placebo | Other | Phase PHASE3 | Sjögren's Syndrome (SS) | ACTIVE_NOT_RECRUITING | NCT06245408 |
| Dazodalibep | Other | Phase PHASE3 | Sjögren's Syndrome (SS) | ACTIVE_NOT_RECRUITING | NCT06245408 |
| Placebo | Other | Phase PHASE3 | Sjögren's Syndrome (SS) | ACTIVE_NOT_RECRUITING | NCT06245408 |
| Dazodalibep | Other | Phase PHASE3 | Sjögren's Syndrome (SS) | ACTIVE_NOT_RECRUITING | NCT06245408 |
| Placebo | Other | Phase EARLY_PHASE1 | Abdominal Aortic Aneurysm | NOT_YET_RECRUITING | NCT06081153 |
| Evolocumab | Other | Phase EARLY_PHASE1 | Abdominal Aortic Aneurysm | NOT_YET_RECRUITING | NCT06081153 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT04987307 |
| Efavaleukin alfa | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT04987307 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT04987307 |
| Efavaleukin alfa | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT04987307 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT04987307 |
| Efavaleukin alfa | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT04987307 |
| Surgery | Procedure | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Neoadjuvant Radiation | Other | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Surgery | Procedure | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Neoadjuvant Radiation | Other | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Surgery | Procedure | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Neoadjuvant Radiation | Other | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Talimogene Laherparepvec | Other | Phase PHASE2 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06660810 |
| Placebo | Other | Phase PHASE4 | Thyroid Eye Disease | COMPLETED | NCT05002998 |
| Teprotumumab | Other | Phase PHASE4 | Thyroid Eye Disease | COMPLETED | NCT05002998 |
| Placebo | Other | Phase PHASE3 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06104124 |
| Dazodalibep | Other | Phase PHASE3 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06104124 |
| Placebo | Other | Phase PHASE3 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06104124 |
| Dazodalibep | Other | Phase PHASE3 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06104124 |
| Placebo | Other | Phase PHASE3 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06104124 |
| Dazodalibep | Other | Phase PHASE3 | Sjogren's Syndrome | ACTIVE_NOT_RECRUITING | NCT06104124 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05704738 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05704738 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05704738 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05704738 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05704738 |
| Rocatinlimab | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05704738 |
| Placebo | Other | Phase PHASE3 | Prurigo Nodularis | ACTIVE_NOT_RECRUITING | NCT06527404 |
| Rocatinlimab | Other | Phase PHASE3 | Prurigo Nodularis | ACTIVE_NOT_RECRUITING | NCT06527404 |
| Rocatinlimab | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06438263 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT05669599 |
| Maridebart Cafraglutide | Other | Phase PHASE2 | Obesity | COMPLETED | NCT05669599 |
| Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT04822337 |
| AI-Detected CAC Notification and Care Facilitation | Other | Approved | Atherosclerotic Cardiovascular Disease (ASCVD) | NOT_YET_RECRUITING | NCT07355894 |
| Subcutaneous Blinatumomab | Other | Phase PHASE2 | CD19 Positive | RECRUITING | NCT07222579 |
| Placebo for Moxifloxacin | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07229157 |
| Placebo for Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07229157 |
| Moxifloxacin | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07229157 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07229157 |
| Placebo for Moxifloxacin | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07229157 |
| Placebo for Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07229157 |
| Moxifloxacin | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07229157 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07229157 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06555796 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06555796 |
| Xaluritamig | Other | Phase PHASE1 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06555796 |
| Pembrolizumab (EU) | Other | Phase PHASE3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06311721 |
| Pembrolizumab (US) | Other | Phase PHASE3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06311721 |
| ABP 234 | Other | Phase PHASE3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06311721 |
| Blinatumomab | Other | Phase PHASE2 | B Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT06054113 |
| Blinatumomab | Other | Phase PHASE2 | B Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT06054113 |
| Blinatumomab | Other | Phase PHASE2 | B Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT06054113 |
| Blinatumomab | Other | Phase PHASE2 | B Precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT06054113 |
| UPLIZNA | Other | Preclinical | Neuromyelitis Optica Spectrum Disorder | RECRUITING | NCT05909761 |
| UPLIZNA | Other | Preclinical | Neuromyelitis Optica Spectrum Disorder | RECRUITING | NCT05909761 |
| UPLIZNA | Other | Preclinical | Neuromyelitis Optica Spectrum Disorder | RECRUITING | NCT05909761 |
| Placebo | Other | Phase PHASE3 | Thyroid Eye Disease | ACTIVE_NOT_RECRUITING | NCT06248619 |
| Teprotumumab | Other | Phase PHASE3 | Thyroid Eye Disease | ACTIVE_NOT_RECRUITING | NCT06248619 |
| Denosumab | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT03839459 |
| Denosumab | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT03839459 |
| Placebo | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT03626662 |
| AMG 890 | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT03626662 |
| Placebo | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT03626662 |
| AMG 890 | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT03626662 |
| Placebo | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT03626662 |
| AMG 890 | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT03626662 |
| Rituximab | Other | Phase PHASE1 | CD20 Positive | ACTIVE_NOT_RECRUITING | NCT01959698 |
| Pharmacological Study | Other | Phase PHASE1 | CD20 Positive | ACTIVE_NOT_RECRUITING | NCT01959698 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | CD20 Positive | ACTIVE_NOT_RECRUITING | NCT01959698 |
| Ifosfamide | Other | Phase PHASE1 | CD20 Positive | ACTIVE_NOT_RECRUITING | NCT01959698 |
| Etoposide | Other | Phase PHASE1 | CD20 Positive | ACTIVE_NOT_RECRUITING | NCT01959698 |
| Carfilzomib | Other | Phase PHASE1 | CD20 Positive | ACTIVE_NOT_RECRUITING | NCT01959698 |
| Carboplatin | Other | Phase PHASE1 | CD20 Positive | ACTIVE_NOT_RECRUITING | NCT01959698 |
| Sotorasib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT06333678 |
| Durvalumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT06333678 |
| Sotorasib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT06333678 |
| Durvalumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT06333678 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Standard of Care | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Placebo | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Avacopan | Other | Phase PHASE4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | RECRUITING | NCT06072482 |
| Radiotherapy | Drug | Phase PHASE1 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT04599062 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT04599062 |
| Radiotherapy | Drug | Phase PHASE1 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT04599062 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT04599062 |
| Radiotherapy | Drug | Phase PHASE1 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT04599062 |
| Talimogene Laherparepvec | Other | Phase PHASE1 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT04599062 |
| Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04113018 |
| Blinatumomab Injection | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | NOT_YET_RECRUITING | NCT07313852 |
| Bemarituzumab | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05325866 |
| Bemarituzumab | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05325866 |
| Bemarituzumab | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05325866 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT06898957 |
| Atezolizumab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | RECRUITING | NCT06898957 |
| Placebo | Other | Phase PHASE3 | Active Juvenile Psoriatic Arthritis | RECRUITING | NCT04804553 |
| Apremilast | Other | Phase PHASE3 | Active Juvenile Psoriatic Arthritis | RECRUITING | NCT04804553 |
| Regorafenib | Other | Phase PHASE3 | Colorectal Cancer (CRC) | ACTIVE_NOT_RECRUITING | NCT05198934 |
| Trifluridine and Tipiracil | Other | Phase PHASE3 | Colorectal Cancer (CRC) | ACTIVE_NOT_RECRUITING | NCT05198934 |
| Panitumumab | Other | Phase PHASE3 | Colorectal Cancer (CRC) | ACTIVE_NOT_RECRUITING | NCT05198934 |
| Sotorasib | Other | Phase PHASE3 | Colorectal Cancer (CRC) | ACTIVE_NOT_RECRUITING | NCT05198934 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07226778 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | ACTIVE_NOT_RECRUITING | NCT07226778 |
| Panitumumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| Pembrolizumab | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| AMG 410 | Other | Phase PHASE1 | KRAS Altered Advanced or Metastatic Solid Tumors | RECRUITING | NCT07094113 |
| Prolia | Other | Phase PHASE4 | Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06332014 |
| Abiraterone | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Darolutamide | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Abiraterone | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Darolutamide | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | RECRUITING | NCT07140900 |
| Placebo | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| AMG 513 | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| Placebo | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| AMG 513 | Other | Phase PHASE1 | Cardiometabolic Disease | RECRUITING | NCT06585462 |
| AMG 305 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT05800964 |
| AMG 305 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT05800964 |
| AMG 305 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT05800964 |
| Denosumab Q4W | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02833610 |
| Denosumab Q4W | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02833610 |
| Denosumab Q4W | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02833610 |
| Placebo | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05052801 |
| mFOLFOX6 | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05052801 |
| Bemarituzumab | Other | Phase PHASE3 | Gastric Cancer | ACTIVE_NOT_RECRUITING | NCT05052801 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Questionnaire Administration | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Electronic Health Record Review | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Echocardiography Test | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Computed Tomography | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Biospecimen Collection | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Questionnaire Administration | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Electronic Health Record Review | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Echocardiography Test | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Computed Tomography | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Biospecimen Collection | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT07423585 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| MTX/ARA-C | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| Mini-CVD | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| Blinatumomab | Other | Phase PHASE2 | B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT07153796 |
| AMG 133 | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT07429045 |
| AMG 133 | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT07429045 |
| Acetaminophen | Other | Phase PHASE1 | Overweight or Obesity | COMPLETED | NCT07429032 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | COMPLETED | NCT07429032 |
| AMG 133 | Other | Phase PHASE1 | Overweight or Obesity | COMPLETED | NCT07429032 |
| Acetaminophen | Other | Phase PHASE1 | Overweight or Obesity | COMPLETED | NCT07429032 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | COMPLETED | NCT07429032 |
| AMG 133 | Other | Phase PHASE1 | Overweight or Obesity | COMPLETED | NCT07429032 |
| Blinatumomab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | RECRUITING | NCT06570798 |
| Inebilizumab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | RECRUITING | NCT06570798 |
| Blinatumomab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | RECRUITING | NCT06570798 |
| Inebilizumab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | RECRUITING | NCT06570798 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Ponatinib | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Methotrexate | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Cytarabine | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Blinatumomab | Other | Phase PHASE2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | RECRUITING | NCT03263572 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07142642 |
| Teprotumumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07142642 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07142642 |
| Teprotumumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07142642 |
| Placebo | Other | Phase PHASE3 | Limited Stage Small Cell Lung Cancer | RECRUITING | NCT06117774 |
| Tarlatamab | Other | Phase PHASE3 | Limited Stage Small Cell Lung Cancer | RECRUITING | NCT06117774 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Olpasiran | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05581303 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05581303 |
| Olpasiran | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05581303 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05581303 |
| Olpasiran | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05581303 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05581303 |
| Denosumab 60 MG/ML Prefilled Syringe [Prolia] | Other | Phase PHASE2 | Premenopausal Idiopathic Osteoporosis | ACTIVE_NOT_RECRUITING | NCT04800367 |
| Romosozumab Prefilled Syringe [Evenity] | Other | Phase PHASE2 | Premenopausal Idiopathic Osteoporosis | ACTIVE_NOT_RECRUITING | NCT04800367 |
| Denosumab 60 MG/ML Prefilled Syringe [Prolia] | Other | Phase PHASE2 | Premenopausal Idiopathic Osteoporosis | ACTIVE_NOT_RECRUITING | NCT04800367 |
| Romosozumab Prefilled Syringe [Evenity] | Other | Phase PHASE2 | Premenopausal Idiopathic Osteoporosis | ACTIVE_NOT_RECRUITING | NCT04800367 |
| Standard of Care | Other | Phase PHASE3 | Secondary Hyperparathyroidism | RECRUITING | NCT03633708 |
| Etelcalcetide | Other | Phase PHASE3 | Secondary Hyperparathyroidism | RECRUITING | NCT03633708 |
| Standard of Care | Other | Phase PHASE3 | Secondary Hyperparathyroidism | RECRUITING | NCT03633708 |
| Etelcalcetide | Other | Phase PHASE3 | Secondary Hyperparathyroidism | RECRUITING | NCT03633708 |
| focus groups and individual interviews as well as filling out questionnaires | Other | Preclinical | Thyroid Eye Disease, TED | COMPLETED | NCT07444190 |
| focus groups and individual interviews as well as filling out questionnaires | Other | Preclinical | Thyroid Eye Disease, TED | COMPLETED | NCT07444190 |
| focus groups and individual interviews as well as filling out questionnaires | Other | Preclinical | Thyroid Eye Disease, TED | COMPLETED | NCT07444190 |
| Tarlatamab | Other | Phase PHASE2 | Small Cell Lung Cancer (SCLC) | ACTIVE_NOT_RECRUITING | NCT06745323 |
| Tarlatamab | Other | Phase PHASE2 | Small Cell Lung Cancer (SCLC) | ACTIVE_NOT_RECRUITING | NCT06745323 |
| Durvalumab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Atezolizumab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Etoposide | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Carboplatin | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Tarlatamab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Durvalumab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Atezolizumab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Etoposide | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Carboplatin | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| Tarlatamab | Other | Phase PHASE1 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05361395 |
| HyperCVAD | Other | Phase PHASE3 | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | NOT_YET_RECRUITING | NCT07223190 |
| Blinatumomab | Other | Phase PHASE3 | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | NOT_YET_RECRUITING | NCT07223190 |
| HyperCVAD | Other | Phase PHASE3 | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | NOT_YET_RECRUITING | NCT07223190 |
| Blinatumomab | Other | Phase PHASE3 | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | NOT_YET_RECRUITING | NCT07223190 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06691984 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06691984 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06691984 |
| Abiraterone | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06691984 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06691984 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Avacopan | Other | Phase PHASE3 | Vasculitis | RECRUITING | NCT06321601 |
| Placebo Alendronate | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | NOT_YET_RECRUITING | NCT06973109 |
| Placebo Romosozumab | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | NOT_YET_RECRUITING | NCT06973109 |
| Alendronate (Fosamax) | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | NOT_YET_RECRUITING | NCT06973109 |
| Romosozumab | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | NOT_YET_RECRUITING | NCT06973109 |
| Placebo Alendronate | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | NOT_YET_RECRUITING | NCT06973109 |
| Placebo Romosozumab | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | NOT_YET_RECRUITING | NCT06973109 |
| Alendronate (Fosamax) | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | NOT_YET_RECRUITING | NCT06973109 |
| Romosozumab | Other | Phase PHASE2 | Osteoporosis, Post-menopausal | NOT_YET_RECRUITING | NCT06973109 |
| IV Placebo | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| inebilizumab | Other | Phase PHASE3 | Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT04524273 |
| Palbociclib | Other | Phase PHASE2 | Cancer of the Colon | COMPLETED | NCT03446157 |
| Cetuximab | Other | Phase PHASE2 | Cancer of the Colon | COMPLETED | NCT03446157 |
| Paclitaxel | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02779855 |
| Talimogene laherparepvec | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02779855 |
| AMG 133 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT07428525 |
| AMG 133 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT07428525 |
| Xaluritamig | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT07297979 |
| Midazolam | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03600883 |
| Anti PD-1/L1 | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03600883 |
| sotorasib | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03600883 |
| Midazolam | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03600883 |
| Anti PD-1/L1 | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03600883 |
| sotorasib | Other | Phase PHASE1 | KRAS p.G12C Mutant Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03600883 |
| Evolocumab Drug Substance B | Drug | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07422285 |
| Evolocumab Drug Substance A | Drug | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07422285 |
| Corrie Lipids Digital Health Program | Other | Approved | Cardiovascular Risk | RECRUITING | NCT07478887 |
| Corrie Lipids Digital Health Program | Other | Approved | Cardiovascular Risk | RECRUITING | NCT07478887 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight and Obesity | ACTIVE_NOT_RECRUITING | NCT07313761 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight and Obesity | ACTIVE_NOT_RECRUITING | NCT07313761 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| Tarlatamab treatment | Drug | Phase PHASE2 | DLL3-expressing Tumors | RECRUITING | NCT06788938 |
| HZN-825 QD | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04781543 |
| Placebo | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04781543 |
| HZN-825 BID | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04781543 |
| HZN-825 QD | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04781543 |
| Placebo | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04781543 |
| HZN-825 BID | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT04781543 |
| Etelcalcetide | Other | Phase PHASE3 | Secondary Hyperparathyroidism | RECRUITING | NCT03969329 |
| Etelcalcetide | Other | Phase PHASE3 | Secondary Hyperparathyroidism | RECRUITING | NCT03969329 |
| Autologous Stem Cell Transplant (ASCT) | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Montelukast | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Diphenhydramine | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Acetaminophen | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Autologous Stem Cell Transplant (ASCT) | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Montelukast | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Diphenhydramine | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Acetaminophen | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04268498 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07493512 |
| Xaluritamig | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07493512 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | NOT_YET_RECRUITING | NCT07203053 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | RECRUITING | NCT06588153 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | RECRUITING | NCT06588153 |
| Prolia® | Other | Phase PHASE4 | Glucocorticoid-induced Osteoporosis | RECRUITING | NCT06588153 |
| Avacopan | Other | Phase PHASE1 | End-Stage Renal Disease (ESRD) | COMPLETED | NCT06468826 |
| Avacopan | Other | Phase PHASE1 | End-Stage Renal Disease (ESRD) | COMPLETED | NCT06468826 |
| Rocatinlimab AI | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT06224192 |
| Rocatinlimab Prefilled Syringe | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT06224192 |
| Rocatinlimab AI | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT06224192 |
| Rocatinlimab Prefilled Syringe | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT06224192 |
| AMG 510 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation | COMPLETED | NCT04380753 |
| AMG 510 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation | COMPLETED | NCT04380753 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Placebo | Other | Phase PHASE1 | Asthma | RECRUITING | NCT06637371 |
| AMG 691 | Other | Phase PHASE1 | Asthma | RECRUITING | NCT06637371 |
| EU-authorized Nivolumab | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT05907122 |
| FDA-licensed Nivolumab | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT05907122 |
| ABP 206 | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT05907122 |
| EU-authorized Nivolumab | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT05907122 |
| FDA-licensed Nivolumab | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT05907122 |
| ABP 206 | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT05907122 |
| Docetaxel | Other | Phase PHASE3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT04303780 |
| AMG 510 | Other | Phase PHASE3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT04303780 |
| Docetaxel | Other | Phase PHASE3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT04303780 |
| AMG 510 | Other | Phase PHASE3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT04303780 |
| Nivolumab | Other | Phase PHASE2 | Melanoma Stage Iii | COMPLETED | NCT03620019 |
| Pembrolizumab | Other | Phase PHASE2 | Melanoma Stage Iii | COMPLETED | NCT03620019 |
| Denosumab | Other | Phase PHASE2 | Melanoma Stage Iii | COMPLETED | NCT03620019 |
| Nivolumab | Other | Phase PHASE2 | Melanoma Stage Iii | COMPLETED | NCT03620019 |
| Pembrolizumab | Other | Phase PHASE2 | Melanoma Stage Iii | COMPLETED | NCT03620019 |
| Denosumab | Other | Phase PHASE2 | Melanoma Stage Iii | COMPLETED | NCT03620019 |
| ABP 692 | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| Ocrelizumab (EU) | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| Ocrelizumab (US) | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| Enzalutamide | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| AMG 509 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| Enzalutamide | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| AMG 509 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT04221542 |
| Methotrexate | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Pegloticase | Other | Phase PHASE3 | Uncontrolled Gout | RECRUITING | NCT07388498 |
| Calcium | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT07366086 |
| Vitamin D | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT07366086 |
| Calcium | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT07366086 |
| Vitamin D | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT07366086 |
| RMC-6236 | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Modified FOLFIRINOX | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Anvumetostat | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| RMC-6236 | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Modified FOLFIRINOX | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Anvumetostat | Other | Phase PHASE1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | RECRUITING | NCT06360354 |
| Comparator Anvumetostat Test Tablet | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Docetaxel | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Anvumetostat | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Comparator Anvumetostat Test Tablet | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Docetaxel | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Anvumetostat | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Comparator Anvumetostat Test Tablet | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Docetaxel | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Anvumetostat | Other | Phase PHASE1 | Advanced MTAP-null Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05094336 |
| Placebo | Other | Phase PHASE2 | Cardiovascular Disease | COMPLETED | NCT04270760 |
| Olpasiran | Other | Phase PHASE2 | Cardiovascular Disease | COMPLETED | NCT04270760 |
| Placebo | Other | Phase PHASE2 | Cardiovascular Disease | COMPLETED | NCT04270760 |
| Olpasiran | Other | Phase PHASE2 | Cardiovascular Disease | COMPLETED | NCT04270760 |
| Placebo | Other | Phase PHASE2 | Cardiovascular Disease | COMPLETED | NCT04270760 |
| Olpasiran | Other | Phase PHASE2 | Cardiovascular Disease | COMPLETED | NCT04270760 |
| Placebo | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04252742 |
| Erenumab | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04252742 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT06910709 |
| AMG 378 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT06910709 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT06910709 |
| AMG 378 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT06910709 |
| Placebo | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| AMG 732 | Other | Phase PHASE1 | Thyroid Eye Disease | RECRUITING | NCT06401044 |
| Bevacizumab-awwb | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Sotorasib | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| FOLFIRI Regimen | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | NOT_YET_RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | NOT_YET_RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | NOT_YET_RECRUITING | NCT07438405 |
| AMG 732 | Other | Phase PHASE2 | Thyroid Eye Disease | NOT_YET_RECRUITING | NCT07438405 |
| Tarlatamab | Other | Phase PHASE2 | Metastatic Prostate Cancer | RECRUITING | NCT07111507 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT05972551 |
| Bisphosphonate | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT05972551 |
| Romosozumab | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT05972551 |
| Sotorasib | Other | Preclinical | Non-Small Cell Lung Cancer | COMPLETED | NCT07143513 |
| Sotorasib | Other | Preclinical | Non-Small Cell Lung Cancer | COMPLETED | NCT07143513 |
| Dazodalibep | Other | Phase PHASE3 | Sjögren's Syndrome | RECRUITING | NCT06747949 |
| anvumetostat | Other | Phase PHASE2 | MTAP-deleted NSCLC | RECRUITING | NCT06593522 |
| anvumetostat | Other | Phase PHASE2 | MTAP-deleted NSCLC | RECRUITING | NCT06593522 |
| Sotorasib | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Pemetrexed | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Pembrolizumab | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Paclitaxel | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Carboplatin | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Anvumetostat | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| IDE397 | Other | Phase PHASE1 | MTAP-null Non-Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05975073 |
| Anvumetostat | Other | Phase PHASE1 | MTAP-null Non-Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05975073 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | ACTIVE_NOT_RECRUITING | NCT03937154 |
| Romiplostim | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | ACTIVE_NOT_RECRUITING | NCT03937154 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | ACTIVE_NOT_RECRUITING | NCT03937154 |
| Romiplostim | Other | Phase PHASE3 | Chemotherapy-induced Thrombocytopenia | ACTIVE_NOT_RECRUITING | NCT03937154 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02302495 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02302495 |
| Panitumumab | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Sotorasib | Other | Phase PHASE2 | Advanced Solid Tumors | RECRUITING | NCT07172919 |
| Placebo | Other | Phase PHASE1 | Asthma | RECRUITING | NCT06637371 |
| AMG 691 | Other | Phase PHASE1 | Asthma | RECRUITING | NCT06637371 |
| Methotrexate | Other | Phase PHASE4 | Gout | COMPLETED | NCT06229145 |
| Pegloticase | Other | Phase PHASE4 | Gout | COMPLETED | NCT06229145 |
| Immunological Factors | Other | Preclinical | Neuromyelitis Optica Spectrum Disorders | NOT_YET_RECRUITING | NCT07526298 |
| MRI | Other | Preclinical | Neuromyelitis Optica Spectrum Disorders | NOT_YET_RECRUITING | NCT07526298 |
| Maridebart Cafraglutide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07523711 |
| COC | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07523711 |
| ABP 692 | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| Ocrelizumab (EU) | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| Ocrelizumab (US) | Other | Phase PHASE3 | Relapsing-remitting Multiple Sclerosis (RRMS) | RECRUITING | NCT06700343 |
| Sotorasib | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Pemetrexed | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Pembrolizumab | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Paclitaxel | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Carboplatin | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Anvumetostat | Other | Phase PHASE1 | Thoracic Tumors | RECRUITING | NCT06333951 |
| Dexamethasone | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT03500445 |
| Lenalidomide | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT03500445 |
| Carfilzomib | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT03500445 |
| Daratumumab | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT03500445 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07531095 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07531095 |
| ZL-1310 | Other | Phase PHASE1 | Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07531095 |
| Tarlatamab | Other | Phase PHASE2 | Metastatic Prostate Cancer | RECRUITING | NCT07111507 |
| Tarlatamab | Other | Phase PHASE2 | Metastatic Prostate Cancer | RECRUITING | NCT07111507 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06502977 |
| Placebo | Other | Phase PHASE3 | Limited Stage Small Cell Lung Cancer | RECRUITING | NCT06117774 |
| Tarlatamab | Other | Phase PHASE3 | Limited Stage Small Cell Lung Cancer | RECRUITING | NCT06117774 |
| Evolocumab Drug Substance B | Drug | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07422285 |
| Evolocumab Drug Substance A | Drug | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07422285 |
| Xaluritamig | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT07297979 |
| Xaluritamig | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT07297979 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07293260 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07293260 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| SOC chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | RECRUITING | NCT04994717 |
| Low-intensity chemotherapy regimen | Drug | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | RECRUITING | NCT04994717 |
| Blinatumomab | Other | Phase PHASE3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | RECRUITING | NCT04994717 |
| Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04822337 |
| Evolocumab | Other | Phase PHASE4 | Hyperlipidemias | COMPLETED | NCT04608474 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| AMG 436 | Other | Phase PHASE1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | RECRUITING | NCT07403721 |
| Placebo | Other | Phase EARLY_PHASE1 | Abdominal Aortic Aneurysm | NOT_YET_RECRUITING | NCT06081153 |
| Evolocumab | Other | Phase EARLY_PHASE1 | Abdominal Aortic Aneurysm | NOT_YET_RECRUITING | NCT06081153 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07203053 |
| Tarlatamab | Other | Phase PHASE2 | Extensive Stage Lung Small Cell Cancer | RECRUITING | NCT07203053 |
| nbUVB phototherapy | Drug | Phase PHASE2 | Vitiligo | COMPLETED | NCT04338581 |
| Placebo | Other | Phase PHASE2 | Vitiligo | COMPLETED | NCT04338581 |
| AMG 714 | Other | Phase PHASE2 | Vitiligo | COMPLETED | NCT04338581 |
| Evolocumab Drug Substance B (Reference) | Drug | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07545226 |
| Evolocumab Drug Substance A (Test) | Drug | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07545226 |
| Evolocumab Drug Substance B (Reference) | Drug | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07545226 |
| Evolocumab Drug Substance A (Test) | Drug | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07545226 |
| AI-Detected CAC Notification and Care Facilitation | Other | Approved | Atherosclerotic Cardiovascular Disease (ASCVD) | NOT_YET_RECRUITING | NCT07355894 |
| AI-Detected CAC Notification and Care Facilitation | Other | Approved | Atherosclerotic Cardiovascular Disease (ASCVD) | NOT_YET_RECRUITING | NCT07355894 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Tarlatamab | Other | Phase PHASE1 | Glioma | RECRUITING | NCT07243470 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Atezolizumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Durvalumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Atezolizumab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| Tarlatamab | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| YL201 | Other | Phase PHASE1 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06898957 |
| IDE397 | Other | Phase PHASE1 | MTAP-null Non-Small-Cell Lung Cancer | COMPLETED | NCT05975073 |
| Anvumetostat | Other | Phase PHASE1 | MTAP-null Non-Small-Cell Lung Cancer | COMPLETED | NCT05975073 |
| DMAB Discontinuation and Switching | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT04177940 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Maridebart cafraglutide | Other | Phase PHASE2 | Overweight or Obesity and Elevated Liver Fat | RECRUITING | NCT07441252 |
| Calcium | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT07366086 |
| Vitamin D | Other | Phase PHASE3 | Osteogenesis Imperfecta | RECRUITING | NCT07366086 |
| Placebo | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obstructive Sleep Apnea | RECRUITING | NCT07226765 |
| Placebo | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07225686 |
| Cabazitaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Docetaxel | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Xaluritamig | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT07213674 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Olpasiran | Other | Phase PHASE3 | Cardiovascular Disease | RECRUITING | NCT07136012 |
| Placebo | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Maridebart cafraglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT07037459 |
| Placebo | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Maridebart Cafraglutide | Other | Phase PHASE3 | Atherosclerotic Cardiovascular Disease | RECRUITING | NCT07037433 |
| Etoposide | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Carboplatin | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Durvalumab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Tarlatamab | Other | Phase PHASE3 | Small-cell Lung Cancer | RECRUITING | NCT07005128 |
| Bevacizumab-awwb | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Panitumumab | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Sotorasib | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| FOLFIRI Regimen | Other | Phase PHASE3 | Metastatic Colorectal Cancer | RECRUITING | NCT06252649 |
| Pembrolizumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Sotorasib | Other | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05920356 |
| Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
| Carfilzomib + Ibrutinib | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT04263480 |
Total products: 6773